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Photoredox-Mediated Metal-Free C–h Alkylation And Dual Catalysis
Abstract
Over the past decade, a resurgence of interest in photo-induced electron transfer has resulted in a new class of
organic transformations. The ability to harness over 60 kcal/mol of visible light energy to activate redox-labile
substrates—via the intermediacy of a photoredox catalyst—has enabled reactions under extraordinarily mild
conditions compared to alternative two-electron modes of activation.
Recent research efforts have broadened the scope of trifluoroborate coupling partners, employed
1,4-dihydropyridines (DHPs) in mono- and dual-catalytic manifolds, and accessed new chemical space via
C–H functionalization pathways. First, the development of alkyltrifluoroborates as latent radicals for C–H
alkylation of heteroarenes under photocatalytic conditions is described. Notably, the catalytic generation of
carbon-centered radicals and the BF3 byproduct accomplishes a regioselective and atom-economical
approach to the classical Minisci reaction. Subsequent reports disclose DHPs as unique radical precursors that
do not require the use of a photocatalyst to effect a single-electron oxidation. Instead, DHPs are oxidized in
the presence persulfate, facilitated by their low oxidation potentials.
Furthermore, photoredox/Ni dual catalysis protocols have been developed to overcome several inherent
limitations of palladium-catalyzed cross-couplings [i.e., forcing reaction conditions, limited scope for
C(sp3)–C(sp2) bond formation] by invoking a single-electron transmetalation pathway. Within the area of
photoredox/Ni catalysis, a library of natural and unnatural aryl chromanones are accessed from the
corresponding trifluoroboratochromanones and aryl bromides. In an effort to expand the radical toolbox by
utilizing feedstock chemicals (e.g., aldehydes) to access radicals inspired the exploration of DHPs as radical
partners in the dual catalytic paradigm. Exploiting the one-step procedure to access highly functionalized
DHPs, a library of monosaccharide DHPs were synthesized and employed in the dual catalytic cross-coupling
procedure with aryl bromides.
In summary, the mild, photoredox-mediated C–H alkylation of heteroarenes represents a late-stage
functionalization strategy to rapidly access highly functionalized motifs. Additionally, photoredox/Ni dual
catalysis has enabled the modular synthesis of functionalized aryl chromanones and monosaccharides.
Throughout these reported studies, it is clear the controlled and catalytic nature of photoredox catalysis
enables previously challenging transformations and is primed for significant advancements in the near future.
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ABSTRACT 
PHOTOREDOX-MEDIATED METAL-FREE C–H ALKYLATION AND DUAL CATALYSIS 
 
Jennifer K. Matsui 
Gary A. Molander 
 
 Over the past decade, a resurgence of interest in photo-induced electron transfer has 
resulted in a new class of organic transformations.   The ability to harness over 60 kcal/mol of 
visible light energy to activate redox-labile substrates—via the intermediacy of a photoredox 
catalyst—has enabled reactions under extraordinarily mild conditions compared to alternative two-
electron modes of activation. 
Recent research efforts have broadened the scope of trifluoroborate coupling partners, 
employed 1,4-dihydropyridines (DHPs) in mono- and dual-catalytic manifolds, and accessed new 
chemical space via C–H functionalization pathways. First, the development of alkyltrifluoroborates 
as latent radicals for C–H alkylation of heteroarenes under photocatalytic conditions is described. 
Notably, the catalytic generation of carbon-centered radicals and the BF3 byproduct accomplishes 
a regioselective and atom-economical approach to the classical Minisci reaction. Subsequent 
reports disclose DHPs as unique radical precursors that do not require the use of a photocatalyst to 
effect a single-electron oxidation. Instead, DHPs are oxidized in the presence persulfate, facilitated 
by their low oxidation potentials. 
Furthermore, photoredox/Ni dual catalysis protocols have been developed to overcome 
several inherent limitations of palladium-catalyzed cross-couplings [i.e., forcing reaction 
conditions, limited scope for C(sp3)–C(sp2) bond formation] by invoking a single-electron 
transmetalation pathway. Within the area of photoredox/Ni catalysis, a library of natural and 
unnatural aryl chromanones are accessed from the corresponding trifluoroboratochromanones and 
  vi 
aryl bromides. In an effort to expand the radical toolbox by utilizing feedstock chemicals (e.g., 
aldehydes) to access radicals inspired the exploration of DHPs as radical partners in the dual 
catalytic paradigm. Exploiting the one-step procedure to access highly functionalized DHPs, a 
library of monosaccharide DHPs were synthesized and employed in the dual catalytic cross-
coupling procedure with aryl bromides. 
In summary, the mild, photoredox-mediated C–H alkylation of heteroarenes represents a 
late-stage functionalization strategy to rapidly access highly functionalized motifs. Additionally, 
photoredox/Ni dual catalysis has enabled the modular synthesis of functionalized aryl chromanones 
and monosaccharides. Throughout these reported studies, it is clear the controlled and catalytic 
nature of photoredox catalysis enables previously challenging transformations and is primed for 
significant advancements in the near future. 
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Chapter 1.  Photoredox Catalysis: A Rapidly Growing Field in Synthetic Organic Chemistry 
 
1.1 Introduction 
 Over the past decade, a resurgence of interest in photo-induced electron transfer has 
resulted in a new class of organic transformations.1  The ability to harness over 60 kcal/mol of 
visible light energy to activate redox-labile substrates—via the intermediacy of a photoredox 
catalyst—has enabled reactions under extraordinarily mild conditions compared to alternative two-
electron modes of activation.† Since the 1970s, the properties of transition metal photocatalysts 
(PC) have been studied, revealing that photoexcited transition metal catalysts can either undergo a 
single-electron oxidation or reduction (Figure 1.1). 
 
Figure 1.1. Oxidative and reductive quenching pathways. 
 
One of the first synthetic applications of a photoredox catalyst was reported by Deronzier, 
wherein a ruthenium photocatalyst was used in a Pschorr-type transformation via a single-electron 
 
 
 
† Reproduced in part from Matsui, J. K.; Lang, S. B.; Heitz, D. R.; Molander, G. A. ACS Catal. 2017, 7, 
2563. 
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reduction of an aryl diazonium moiety (Figure 1.2).2 Through the reported experiments, Deronzier 
successfully demonstrated how a photocatalyst excited by visible light can catalytically orchestrate 
single-electron transfer events to perform synthetically useful transformations. 
 
Figure 1.2. Photoredox mediated Pschorr cyclization. 
In subsequent reports, Deronzier and coworkers conducted Stern-Volmer plots to confirm 
the presence of a single-electron transfer event between the photocatalyst and diazonium salt. As 
expected, a linear trend was observed during the quenching studies, strongly suggesting the 
diazonium decomposes to the aryl radical in the presence of irradiated ruthenium photocatalyst. 
Once the aryl radical forms, intramolecular cyclization occurs, albeit in a significantly slower rate 
(given the rigid biaryl backbone). After the cyclization, the reduction of Ru(bpy)33+ is accomplished 
during the formation of aryl cation with rapid rearomatization, affording the tricyclic scaffold 
(Figure 1.3). 
 
Figure 1.3. Proposed mechanism. 
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More recently, Yoon,3 MacMillan,4 and Stephenson5 employed Ru(bpy)3 to perform 
cycloadditions, a-alkylation of aldehydes, and dehalogenation, respectively, through both 
oxidative and reductive quenching pathways. Following these seminal reports, numerous groups 
have developed creative applications with a variety of photocatalysts to effect a myriad of mono-
catalytic and dual catalytic reactions.6 
1.2 Merging Photoredox and Nickel Catalysis 
Our group became interested in photoredox catalysis as a tool to generate alkyl radicals for 
use in cross-coupling reactions. In 2014, we disclosed the first example of photoredox/Ni dual 
catalysis to forge C(sp2)–C(sp3) bonds under unusually mild reaction conditions.7  In this 
transformation, photoredox/Ni dual catalysis proceeds via the single-electron oxidative 
fragmentation of radical precursors and alkyl radical addition to a nickel catalyst, a process we refer 
to as single-electron transmetalation (Figure 1.4). The addition of the radical to the nickel complex 
using this protocol is the synthetic equivalent of the more traditional two-electron transmetalation, 
and the activation energy for this process is extraordinarily low.8  This paradigm is in stark contrast 
to typical Pd- or Ni-catalyzed processes, where transmetalation from an organometallic nucleophile 
to a metal center is often the rate-determining step with a high energy of activation.9 
 This Chapter details the efforts of our laboratory to expand the scope of photocatalytic 
routes to radicals by targeting three major components of the dual catalytic cycle for improvement 
(Scheme 2):  the radical precursor (A), the electrophilic coupling partner (B), and the photocatalyst 
(C). Beyond trifluoroborate and hypervalent silicate reagents previously exploited,1a we sought 
complementary radical precursors derived from feedstock chemicals (e.g., aldehydes), to engage in 
single-electron transmetalation processes. Furthermore, the development of protocols for the 
inclusion of electrophiles other than hetero(aryl)bromides is discussed. Additionally, our efforts in 
the arylation of alkyl C(sp3)–H bonds using photoredox/Ni dual catalysis are detailed. 
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Figure 1.4. Photoredox/Ni dual catalytic cross-coupling cycle. 
Another important accomplishment was the inclusion of competent, inexpensive, and 
sustainable organic photoredox catalysts (Figure 1.5) in many of the developed protocols.10 
Building upon Zhang’s report that 4CzIPN (4) can serve as a surrogate of transition metal-based 
photocatalysts within the photoredox/Ni manifold, we began to incorporate it into newly developed 
cross-couplings.11 We have also exploited the favorable properties of the mesityl acridinium dye 
(5)12 and Eosin Y (6) to effect metal-free couplings. 
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Figure 1.5. Metal-based photocatalysts and organophotocatalysts. 
An overarching theme that has evolved is the catalytic generation of radicals via 
photoredox processes that enables transformations that would be challenging, if not impossible, to 
carry out under conditions in which stoichiometric reagents were utilized to generate these same 
radicals. 
The many challenges of transition metal-catalyzed cross-coupling of sp3-hybridized 
nucleophilic species with sp2-hybridized electrophiles led our group6 and others to develop cross-
coupling protocols based upon single-electron transformations (Figure 1.4). The major advantage 
of using radical intermediates in such catalytic cycles derived from the extraordinarily rapid capture 
of these open-shell species by the transition metal cross-coupling catalysts in an event we termed 
“single-electron transmetalation.”  The success of these processes derived ultimately from the fact 
that these radicals were generated catalytically in a process that was tightly regulated and innately 
controlled by the intertwinement of the photoredox cycle and the cross-coupling cycle. Thus, 
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adjustment of the electronic nature and concentration of the individual catalysts are used to regulate 
the concentration of the radicals generated.  The tuning is critical to the success of the overall 
process because such highly reactive intermediates, left to themselves, are subject to a variety of 
deleterious side-reactions, including dimerization and disproportionation.  Catalytic generation of 
the key reactive intermediates was thus critical for the success of these intricately fused cycles, and 
provided the crucial, enabling transformations that could not be accomplished using stoichiometric 
methods based, for example, in tin hydride or electrochemical processes. 
The many challenges of transition metal-catalyzed cross-coupling of sp3-hybridized 
nucleophilic species with sp2-hybridized electrophiles led our group6 and others4i to develop cross-
coupling protocols based upon single-electron transformations. The major advantage of using 
radical intermediates in such catalytic cycles derived from the extraordinarily rapid capture of these 
open-shell species by the transition metal cross-coupling catalysts in an event we termed “single-
electron transmetalation”.  The success of these processes derived ultimately from the fact that 
these radicals were generated catalytically in a process that was tightly regulated and innately 
controlled by the intertwinement of the photoredox cycle and the cross-coupling cycle. Thus, 
adjustment of the electronic nature and concentration of the individual catalysts are used to regulate 
the concentration of the radicals generated.  This is critical to the success of the overall process 
because such highly reactive intermediates, left to themselves, are subject to a variety of deleterious 
side-reactions, including dimerization and disproportionation.  Catalytic generation of the key 
reactive intermediates was thus critical for the success of these intricately fused cycles, and 
provided the crucial, enabling transformations that could not be accomplished using stoichiometric 
methods based, for example, in tin hydride or electrochemical processes. 
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1.2 Photoredox/Ni Dual Catalysis 
Alkyltrifluoroborates are exceptional reagents for photoredox processes, primarily because 
of their low oxidation potentials, benchtop stability, and commercial availability.13 Additionally, 
complex alkyltrifluoroborates can be accessed via a variety of complementary pathways, including 
β-borylation of conjugated carbonyl substrates,14 substitution of halomethyltrifluoroborates, and so 
on.15 From the seminal cross-coupling of benzyltrifluoroborates, the exploration of different classes 
of trifluoroborates has led to the fruitful incorporation of secondary alkyl,16 α-alkoxy,17 α-amino,18 
and α-trifluoromethyl19 subunits into similar manifolds. To expand the scope of radical precursors 
with complementary reactivity, the compatibility of bis(catecholato)-alkylsilicates was evaluated 
in photoredox-/Ni-catalyzed crosscouplings. Hypervalent silicon compounds have been shown to 
be readily oxidized, affording the corresponding alkyl radicals as initially demonstrated by 
Nishigaichi and co-workers.20 The groups of Goddard, Ollivier, and Fensterbank also demonstrated 
that radicals derived from photooxidation of pentavalent bis(catecholato)silicates readily 
participated in allylation, vinylation/alkynylation, conjugate addition, and nickel-catalyzed cross-
coupling reactions.21 With an improved synthetic route to access alkyl ammonium 
bis(catecholato)silicates, our group built a library of silicate radical precursors containing epoxide, 
amine, and chloride functional groups from the corresponding trimethoxysilanes (Figure 1.6).22 
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Figure 1.6. Conversion of trimethoxysilanes to alkylsilicates. 
As with alkyltrifluoroborates, alkylsilicates are crystalline solids or free-flowing powders 
that are indefinitely bench-stable. Alkylsilicates have the added advantage of avoiding formation 
of the deleterious byproduct BF3, which requires the use of basic sequestering agents in cross-
coupling protocols.  Furthermore, the lower oxidation potentials (Ered = +0.75 V vs SCE) allowed 
the transition from iridium photocatalysts to the significantly less expensive Ru(bpy)3(2PF6)1b and 
even organic photocatalysts. Additionally, alkylsilicates tend to be more soluble than 
trifluoroborate salts, which can be an important consideration in their adaptation to photoflow 
conditions. These advantages enabled photoredox/Ni dual cross-coupling with exquisite functional 
group tolerance (e.g., substrates containing amines and protic functional groups). 
In 2011, our group reported the  b-borylation of α,β-unsaturated amide and carbonyl 
compounds using a readily available copper catalyst with bisboronic acid.14 Subsequently, we 
successfully engaged secondary alkyltrifluoroboratoamides in palladium-catalyzed cross-
couplings.23  Unfortunately, efforts to couple alkyl β-trifluoroborato ketones or -esters under similar 
conditions primarily resulted in β-hydride elimination. Other routes to similar synthons include the 
generation of organozinc and –lithium reagents, which also result in unproductive side reactions, 
specifically an intramolecular attack on the carbonyl to afford the corresponding 
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cyclopropanolates.24  Therefore, we hypothesized that coupling the secondary alkyl β-
trifluoroboratoketones and -esters via single-electron transmetalation using photoredox/Ni dual 
catalysis could address this unsolved challenge.25 
Optimization of reaction conditions revealed that the Ir[dFCF3ppy]2(bpy)PF6 photocatalyst 
(2.5 mol %), NiCl2 (2.5 mol %), dtbbpy (2.5 mol %) cross-coupling catalyst, Cs2CO3 (0.5 equiv), 
and 2,6-lutidine (0.5 equiv) in dioxane afforded the highest conversion to product. Impressively, 
this coupling tolerated a wide range of potentially sensitive functional groups (e.g., aldehydes, 
ketones, esters, nitriles) and heteroaryl partners (e.g., pyridine, pyrimidine, azaindole) as shown in 
Scheme 5. 
Tackling another challenging substrate class in palladium-catalyzed Suzuki cross-
couplings, we sought to utilize α-alkoxyalkyltrifluoroborates in the dual catalytic manifold. 
Previous palladium-catalyzed approaches toward the coupling of α-alkoxyalkyltrifluoroborates via 
two-electron transmetalation pathways were limited by the need for excess base (>5 equiv Cs2CO3) 
and elevated temperatures (>100 °C), which resulted in extremely narrow functional group 
tolerance.26  In fact, only a benzylic ether was compatible with the reaction conditions.20 We 
postulated that single-electron transmetalation would facilitate a more general synthesis of 
protected secondary alcohol derivatives.27  The mild, optimized reaction conditions associated with 
the dual catalytic cross-coupling manifold readily lent themselves toward a protecting group-
independent and functional group-tolerant strategy to access a broad range of protected benzylic 
alcohol derivatives (Figure 1.7). Notably, a fully unprotected carbohydrate was readily coupled in 
a synthetically useful 68% yield. 
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Figure 1.7. Protected secondary a–alkyoxytrifluoroborate coupling with aryl bromides. 
In an effort to merge the β-trifluoroborato ketones and secondary α-
alkoxyalkyltrifluoroborates, we next targeted the biologically significant chromanone core, found 
in myriad plant metabolites.28  Although there have been a multitude of synthetic routes to access 
functionalized chromanones,29 most disconnections involve a chalcone intermediate, making 
derivatization of the C2-aryl ring difficult. Conjugate addition of various arylmetallics to 
chromones constitutes another logical approach, but from a diversity point of view this tactic is less 
than ideal because it requires the synthesis of organometallic reagents, many of which are air- and 
moisture sensitive.  We envisioned an alternate route where a trifluoroboratochromanone serves as 
a radical precursor to access a wide array of 2-(hetero)aryl chromanones rapidly using the 
corresponding aryl or heteroaryl halide directly as coupling partners.30  This strategy would take 
advantage of having access to thousands of commercially available, structurally diverse aryl- and 
heteroaryl halides to elaborate the chromanone core.  The requisite 2-trifluoroboratochromanones 
were prepared via the β-borylation of commercially available chromone using an inexpensive 
copper catalyst and bisboronic acid on gram-scale (Figure 1.8).14 
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Figure 1.8. b–borylation of chromone. 
A variety of 2-(hetero)aryl-substituted flavanones were synthesized in one step under the 
operationally simple and mild reaction conditions (Figure 1.9). Aryl bromides bearing electron-
withdrawing substituents in the meta- and para- positions that may also subsequently serve as 
building blocks were well-tolerated. Additionally, a variety of heteroaryl bromides provided the 
desired flavanones in good yields. Lastly, chromones substituted on the aryl subunit were also 
readily borylated and then subsequently arylated, providing additional opportunities for 
diversification of the flavanone core. 
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Figure 1.9. Coupling of trifluoroboratochromanones with aryl bromide. 
Although we demonstrated that several reactive functional groups were untouched in the 
photoredox dual cross-couplings (e.g., aldehydes, chlorides), our laboratory sought to determine if 
boronate groups would also remain intact for iterative cross-couplings.31  The combination of 
photoredox/Ni dual catalysis at room temperature indeed allowed the differentiation of reactivity 
sites based on the preferential tendencies for tetracoordinate, C(sp3)-hybridized organoboron 
reagents to engage in single-electron transmetalation, in contrast to their tricoordinate, C(sp2)-
hybridized counterparts. Thus, reactive, tricoordinate, C(sp2)-hybridized organoboron reagents that 
succumb to decomposition pathways such as oxidation and protodeboronation during traditional 
Pd-mediated coupling conditions remained intact using the orthogonal photoredox/Ni cross-
coupling protocols (Figure 1.10).32 
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Initially, benzyltrifluoroborate was coupled with aryl bromides bearing the C(sp2)-
hybridized organoboron N-methyliminodiacetic acid (BMIDA) and 1,8-diaminonaphthalene 
(BDAN) subunits to afford the desired products in 59% and 73% yields, respectively. Tricoordinate 
boronate reagents were also successfully coupled and then immediately oxidized to the 
corresponding alcohol, because the intermediates were found to be unstable when subjected to 
column chromatography. 
 
Figure 1.10. Cross-coupling with boronate aryl bromides for further derivatization. 
 To demonstrate the utility of this orthogonal cross-coupling strategy, 2-(4-bromo-3-
chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was subjected to a series of modular 
functionalizations, beginning with photoredox/Ni dual-catalytic cross-coupling, to provide the 
C(sp3)–C(sp2) coupled product. The crude product was then directly diverted into either Suzuki or 
1,4-addition manifolds that chemoselectively activated the sp2-hybridized organoboron lynchpin. 
Additional elaboration of the aryl chloride by Buchwald-Hartwig or Suzuki cross-couplings 
provided expedient access to diversified products without the need for protecting group 
manipulations (Figure 1.11). 
Ph BF3K +
Br
BY2
Ir[dFCF3ppy]2(bpy)PF6 (3 mol %)
Ni(cod)2 (5 mol %), dtbbpy (5 mol %)
HTMP (3.0 equiv)
THF, 24 h, 26 W CFL
Ph
BY2
Ph
OH
[O]
BY2 =
Bpin
BNeop
B(OH)2
76%
61%
54%
BY2 =
BMIDA
BDAN
59%
73%
 14 
 
Figure 1.11. Iterative cross-coupling with aryl boronate. 
A similar, iterative strategy was pursued with ammonium silicates to provide alkylated 
aryl- and heteroaryl boronates, providing a complementary approach (Figure 1.12).33  
[Ru(bpy)2](PF6)2, a significantly less expensive photocatalyst ($138/g) than the commonly used 
Ir[dFCF3ppy]2(bpy)PF6  (>$1,000/g), was chosen because alkyl ammonium silicates possess lower 
oxidation potentials (Ered = +0.75 V vs SCE).  Comparable yields were also obtained when the 
organophotocatalyst 4CzIPN ($6/gram) was utilized, which further improved the sustainability of 
the reaction. An additional advantage to employing ammonium silicate radical precursors with 
lower oxidation potentials is the incorporation of primary, non-benzylic radicals into the dual cross-
coupling manifold.  Examination of the scope of the electrophilic, iterative cross-coupling partners 
revealed that a variety of C(sp2)-hybridized boronate esters were tolerated under the optimized 
reaction conditions, providing the target products in moderate to excellent yields. 
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Figure 1.12. Alkylsilicate coupling with aryl boronates. 
The standard conditions for silicate coupling also proved to be fruitful for iterative C(sp3)–
C(sp2) Suzuki cross-couplings. The crude, alkylated material could be carried directly on to the 
next step to provide multi-functionalized molecules in good yields (Figure 1.13). When a bromo-
substituted arylboronic acid was used, the catechol boronate ester that formed during the alkylation 
step could also be carried directly into a subsequent Suzuki reaction without purification. 
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Figure 1.13. One-pot iterative cross-coupling. 
Alternatives to aryl halide electrophiles were also pursued for incorporation into dual 
catalytic cross-coupling.34  Aryl sulfonates, which are derived from different chemical feedstocks 
(phenols) than the corresponding halides, were examined because of their ability to undergo low-
temperature oxidative addition toward ligated nickel species.35  Preliminary screening revealed that 
4-acetylphenyltrifluoromethanesulfonate readily participated in C(sp2)–C(sp3) cross-coupling with 
a variety of primary and secondary alkylbis(catecholato)silicates under conditions similar to those 
previously reported.14 Exploration of the aryl triflate scope revealed that although electron-neutral 
and electron–poor triflates provided product in acceptable yields, the use of electron-rich triflates 
resulted in lower reactivity (Figure 1.14). 
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Figure 1.14. Alkysilicate coupling with aryl triflates. 
Aryl tosylates and -mesylates, which display improved bench stability compared to aryl 
triflates, were also successfully coupled, although lower yields were observed. Additionally, the 
relative rates of oxidative addition of aryl bromides and aryl triflates onto Ni(I) was also 
investigated using 8 (Figure 1.15). In difunctionalized substrates, alkylation occurred exclusively 
at the position bearing the bromide, indicating that oxidative addition of aryl bromides is more 
rapid. This enables chemoselective transformations of poly-functionalized starting materials using 
dual catalysis. 
 
Figure 1.15. Chemoselective cross-coupling of alkysilicates with aryl bromides. 
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Further efforts to expand the scope of halide electrophiles in the dual catalytic manifold 
beyond aryl/heteroaryl moieties led to the examination of acyl chlorides. Although acyl halides are 
known to react with organoboron “ate” complexes in an intermolecular fashion, either air-sensitive 
trialkylboranes or pyrophoric/toxic additives under forcing conditions were required.36  In contrast, 
we recognized that the extremely mild conditions required to activate alkyltrifluoroborates for 
incorporation into Ni-catalyzed cross-coupling would allow the direct synthesis of alkyl ketones 
containing sensitive functional groups from bench stable starting materials.37 
A variety of α-alkoxymethyltrifluoroborates containing versatile synthetic lynchpins (i.e., 
alkenes, alkynes, amines) and heterocycles were readily coupled under the optimized reaction 
conditions to provide aliphatic α-alkoxy ketones and amides (Figure 1.16).39a Secondary 
alkyltrifluoroborates were also readily transformed into the corresponding ketones under similar 
reaction conditions.39b For both sets of trifluoroborate coupling partners, the acyl chloride was also 
varied to afford access to various dialkyl ketones. Lastly, it was demonstrated that the use of (4R)-
4-benzyl-2-oxazoline for the cross-coupling led to the formation of an enantioenriched ketone in 
modest er (81:19).  
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Figure 1.16. Alkylation of acyl chlorides. 
Our group hoped to access additional chemical space via the development and 
implementation of novel radical precursors. Recognizing several potential drawbacks of 
alkyltrifluoroborates (e.g., formation of BF3) and silicates (poor atom economy, limited commercial 
availability of silanes), we initially focused our attention on the incorporation of readily available 
feedstock chemicals bearing desirable functional groups (Figure 1.17). 
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Figure 1.17. Exploring new radical precursors. 
Currently, there are 12,000+ commercially available aldehydes, underlining their potential 
as an important chemical feedstock for the generation of radical precursors.38  Nishibayashi and co-
workers reported the synthesis of 4-alkyl-1,4-dihydropyridines for use as latent radicals from 
various aldehydes.39  As shown in Figure 1.18, the Hantzsch ester presumably undergoes a single-
electron oxidation to the radical cation followed by homolysis of the C–C bond to form an alkyl 
radical. The resulting benzylic radicals were then captured by a variety of 1,4-dicyanobenzenes. 
Additionally, the Nishibayashi group moved beyond benzylic radicals to heteroatom-stabilized, 
carbon-centered radicals (i.e., a-alkoxy, a-amino subunits). 
 
Figure 1.18. Alkylating dicyanobenzene with 1,4-dihydropyridines. 
We surmised that the alkyl 1,4-dihydropyridines (DHPs) could also serve as an alternative 
radical source in a Ni/photoredox dual catalytic manifold.40  A plausible mechanism is outlined in 
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Figure 1.19.  To initiate the cycle, the DHP undergoes a single-electron oxidation followed by 
concomitant C–C bond cleavage, forming a radical intermediate. As described above, the radical 
is captured by ligated Ni(0), which then undergoes oxidative addition toward the aryl bromide to 
provide a Ni(III) intermediate. Reductive elimination to provide the product and Ni(I) is followed 
by reduction of Ni(I) to Ni(0), closing both catalytic cycles. 
 
Figure 1.19. Proposed mechanism with 1,4-dihydropyridines as latent radicals. 
During the optimization process, we discovered that acetone was a suitable solvent for the 
reaction, and additives were not required because the DHP pyridine byproduct is unreactive under 
the dual catalytic conditions. Additionally, the iridium photocatalyst was replaced with the 
inexpensive organophotocatalyst 4CzIPN. To simplify the reaction conditions even further, 
NiCl2 dme was pre-complexed with dtbbpy to form the bench- and air-stable nickel pre-catalyst 
Ni(dtbbpy)Cl2 4H2O on multi-gram scale. 
With dioxolane DHP in hand, a wide variety of aryl and heteroaryl bromides was 
examined. A few notable examples are showcased in Figure 1.20.  A variety of DHPs and 
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(hetero)aryl bromides were also explored. Benzothiophenes proved to be robust partners with 
unstabilized secondary radicals. Electron-poor furans were also successfully coupled in decent 
yield with cyclohexyl DHP. Surprisingly, alkene-containing DHPs afforded excellent yields with 
acyclic and cyclic systems. 3-Bromo-5-chloropyridine was coupled with benzyl DHP in 42% yield, 
affording the chloride functional group for further derivatization.  
 
Figure 1.20. Photoredox/Ni cross-coupling with 1,4-dihydropyridines. 
The robust nature of the transformation was demonstrated by using a protected 
carbohydrate derivative. This particular example, in which the product was isolated in 70% yield, 
demonstrates the complementarity between the single electron protocol and processes based on 
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traditional organometallic species.  In the latter, any metalation on the carbohydrate core would 
lead to rapid b-elimination of the neighboring alkoxide.  Photoredox/Ni dual catalysis thus provides 
rapid entry to novel chemical space. Finally, unprotected glycoside moieties were tolerated, albeit 
in modest yield.  Previous methods based on organometallic nucleophiles would typically require 
protection of the free hydroxyl groups before coupling, followed by a global deprotection. 
Alkyltrifluoroborates, -silicates, and -DHPs exhibit many desirable traits as partners in 
photoredox/Ni dual catalysis, but the coupling of pre-functionalized, redox-active substrates is 
inherently limited by atom, step, and redox economy. For example, one must adjust the redox 
profile of unreactive species (e.g., boronic acids, silanes, or aldehydes) into their active forms, 
adding mass and molecular complexity that is ultimately lost upon coupling. In principle, direct 
functionalization of a C(sp3)–H bond would provide optimal atom economy while reducing step 
and redox inefficiency en route to C(sp3)–C(sp2) coupling products.41  Efforts toward general 
approaches to Ni-catalyzed C(sp3)–H arylation in the literature are limited by extreme conditions 
(greater than 100 °C), peroxide reagents/oxidants that often lead to unwanted byproducts, and the 
need for directing groups.42  Given that photoredox catalysis is a powerful tool for accessing 
reactive intermediates demonstrated by numerous synthetic groups,43  we sought to apply 
photoredox/Ni dual catalysis to the difficult challenge of effecting C(sp3)–H arylation at room 
temperature.44 
In the context of photoredox catalysis, C(sp3)–H functionalization has been achieved 
through oxidation of N,N-dialkylanilines,4i,45 because the formation of a nitrogen-centered radical 
cation significantly weakens the adjacent C(sp3)–H bond. Our group envisioned targeting redox-
inactive C(sp3)–H bonds, from which we hoped to form alkyl radicals that could participate in dual 
catalytic systems. For a C–H bond to replace a stoichiometric, redox-active radical precursor within 
the established mechanism, an additive would need to serve two roles: (1) act as a single-electron 
reductant of the excited-state photocatalyst and (2) generate an alkyl radical. To accomplish this, 
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we sought a mediator that could serve as an electron donor as well as facilitate radical generation 
via H-atom transfer from C(sp3)–H bonds. Although our group focused on diaryl ketones to 
facilitate direct arylation of C(sp3)–H bonds, the MacMillan group identified quinuclidine 
derivatives as highly efficient additives for a related transformation.46 
Based on the well-established reactivity of excited state diaryl ketone diradicals, which 
form ketyl radicals upon hydrogen atom abstraction (HAT) from both activated and unactivated 
C(sp3)–H bonds,47 we envisioned a tricatalytic mechanism for net C-H arylation (Figure 1.21). 
Early studies employing THF as H-atom donor and solvent with one equivalent of benzophenone 
under standard coupling conditions afforded the desired product, albeit in moderate conversion. 
Addition of Brønsted bases significantly improved conversion, presumably by quenching the HBr 
byproduct. Additional optimization provided adequate conditions and represented an 
unprecedented example of directing group-free, Ni-catalyzed C(sp3)–H arylation at room 
temperature. Control studies confirmed the necessity for nickel catalyst, photocatalyst, and light, 
but we were surprised to discover significant conversion to the desired product without the diaryl 
ketone HAT mediator. The ability of iridium and nickel to co-catalyze C(sp3)–H arylation was 
concurrently discovered by Doyle, who developed conditions to couple aryl chlorides using higher 
loadings of a Ni(0) source and a stronger phosphate base.48 
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Figure 1.21. Initial mechanistic proposal. 
Although control studies demonstrated our initial mechanistic hypothesis was not 
responsible for the observed reactivity, we opted to examine the reaction scope, hoping that the 
limitations therein would provide insight into the nature of the bond-activating species. 
Unfortunately, the alkylation scope with respect to C(sp3)–H substrates was narrow, requiring 
activated partners to be used as solvent. Ethereal solvents, such as THF, 1,4-dioxane, DME, and 
Et2O, were effective (Figure 1.22). Arylation of C(sp3)–H bonds adjacent to nitrogen- and sulfur-
based heterocycles was also observed, with N-methylpyrrolidinone and tetrahydrothiophene 
undergoing α-arylation. Furthermore, toluene was effectively coupled at the benzylic position. 
Although the scope of the reaction with respect to the C(sp3)–H is unquestionably specific, it is also 
surprisingly effective given the stringent requirements for the substrate-solvent to: (1) donate an 
activated C(sp3)–H, (2) effectively solvate the reaction mixture, and (3) be sufficiently volatile for 
removal upon completion. Similar limitations were observed by Doyle, though they reported three 
examples of direct C(sp3)–H coupling with 10 equiv of H-atom donor in benzene, including an 
appreciable reactivity of the unactivated C(sp3)–H bonds of cyclohexane. 
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Figure 1.22. C–H functionalization via photoredox/Ni coupling. 
Approaching reaction development with an incomplete or inaccurate mechanistic 
understanding greatly limits the steps that can be taken to improve upon underlying limitations. 
Thus, mechanistic studies were necessary to develop a better understanding of the unexpected 
reactivity in the absence of a diaryl ketone. A representative transformation was thus carried out in 
a 1:1 mixture of THF:d8-THF, and this reaction displayed a kinetic isotope effect of 6:1, which is 
indicative of a thermodynamically-neutral H-atom transfer49 rather than formal C–H activation by 
a metal center. As a result of the observed KIE and the need for activated C(sp3)–H bonds, we 
suspected a bromide radical, which is capable of activating weak C(sp3)–H bonds, was generated 
under the photocatalytic conditions (Figure 1.23). 
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Figure 1.23. Kinetic isotope effect studies (top) and energy transfer experiments (bottom). 
We first speculated that the Ni(II) oxidative addition intermediate could be oxidized to a 
Ni(III) state by the iridium photocatalyst. The C(sp3)–H activation steps would occur via (1) 
homolysis of the Ni(III)–Br bond to generate a bromine radical, (2) H-atom transfer by the resulting 
bromine radical, and (3) alkyl radical addition to Ni(II). To provide support for this hypothesis, a 
series of photocatalysts were compared with higher oxidation potentials than the iridium 
photocatalyst. We first confirmed that 1 led to product and that no product formed under visible 
light excitation in the absence of photocatalyst. Next, to our surprise, no product was observed 
using the highly oxidizing ruthenium and acridinium photocatalyst 3 and 5, respectively. This 
suggests that simple oxidation of the Ni(II) complex by a photocatalyst may not be sufficient to 
explain the observed C(sp3)–H arylation.  
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An alternative explanation is a triplet-triplet energy transfer facilitated by photocatalyst 1, 
which has a higher triplet energy than 3 and 5 based on a comparison of their emission wavelengths 
(Figure 1.24). To test this new hypothesis, the Ni(II) complex was subjected to UV-B irradiation 
with emission wavelengths between 290–315 nm. Indeed, as shown in entry 5, product was 
observed. These results suggest that a Ni(II) excited state, which forms in the absence of an oxidant, 
is sufficient to facilitate the observed C(sp3)–H arylation. As a result, a mechanism based upon 
energy transfer was favored.  
We proposed that irradiation with UV light could promote Ni to a high-energy state that 
relaxes and undergoes intersystem crossing to a Ni(II) triplet that eliminates a halide radical.50  
Alternatively, the same Ni(II) excited state could be reached through a photocatalytic process: (1) 
photocatalyst excitation by visible light, (2) efficient intersystem crossing by the photocatalyst, and 
(3) triplet-triplet energy sensitization of the Ni(II) oxidative addition intermediate by a sufficiently 
high energy photocatalyst triplet state (Figure 1.24). Importantly, in the energy transfer scenario, 
the operative Ni excited state would be inaccessible in the presence of photocatalysts with 
insufficiently energetic triplet states (such as those exhibited by photocatalysts 3 and 5) or by 
irradiation with inadequately energetic wavelengths of light (i.e., visible light). Preliminary 
computational work shows that the formation of a formal Ni(II) triplet state would elongate the Ni-
Br bond and also result in transfer of electron density from the Ni center to the ligand, resulting in 
an excited-state species that may exhibit some similarities to the formal Ni(III) intermediates that 
are commonly invoked in photoredox/Ni cross-coupling. 
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Figure 1.24. Jablonski diagram with proposed energy transfer. 
Although we favor a mechanism based on energy transfer, we are admittedly unable to rule 
out the electron transfer-based mechanism favored in concurrently published work by Doyle et al.51 
It should be noted that the Doyle group has shown that Ni(II) oxidative addition complexes have 
redox potentials within the oxidation window and also display Stern-Volmer quenching of the 
iridium photocatalyst. However, Stern-Volmer quenching is insufficient to distinguish between 
energy and electron transfer processes. Transient absorption spectroscopic studies may be able to 
address this question51 and provide a stronger basis for further development. Importantly, the 
mechanistic difference may strongly bias efforts in catalyst development to improve the efficiency 
of these reactions. The prevailing focus of photocatalyst development on redox potentials (SET) 
reflects the more typical mode of activation in organic synthesis, but optimizing for less commonly 
invoked energy transfer processes is largely underdeveloped.43 Recently, Weaver et al. studied the 
important relationship between catalyst structure and cis/trans isomerization of alkenes via energy 
transfer,  but energy transfer52 between metals is particularly challenging given the lack of systems 
thought to operate by this mechanism and the difficulty in studying catalytic intermediates that may 
be transient in nature.53 
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The proposed mechanism is thus depicted in Figure 1.25. Ni(0) 9 undergoes oxidative 
addition with the aryl bromide followed by energy transfer (EnT) to form an excited Ni(II) complex 
10. We surmise that complex 10 can facilitate C–H abstraction from THF to form intermediate 11, 
which can then undergo reductive elimination to form the corresponding product. It should be noted 
that the transformation from 10 to 11 is currently under investigation using computational methods. 
Currently, the KIE studies suggest the formation of bromine radical followed by a HAT process to 
form the alkyl radical. Alternatively, there is the possibility of a concerted step involving a four-
membered transition state structure that is also consistent with experimental data. 
 
Figure 1.25. Proposed energy transfer mechanism. 
Although functionalizing C(sp3)–H bonds has historically been a challenging 
transformation, these preliminary results may provide a platform for further studies involving less 
reactive C–H bonds. Toward this end, the ability to channel visible light energy selectively into 
synthetically useful C(sp3)–H activation reactions through elementary radical H-atom transfer steps 
has already enabled a recent, rapid growth in methods for functionalization of unactivated C–H 
bonds at room temperature.54 Seeing the value of catalytic radical generation in various cross-
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within these previous paradigms typically resulted in the use of huge excesses of radical precursors 
and radical-generating reagents, which we were able to avoid using photoredox-generated radicals. 
The expansion of the chemical toolbox to include mild, bench-stable radical precursors as 
alkylating reagents under photoredox conditions was considered an attractive alternative to 
organometallics utilized in other C–C bond-forming reactions. The reaction of Grignard and 
organolithium reagents with C=O and C=N electrophiles has extensive value, but the instability 
and functional group intolerance of these highly reactive organometallics has always framed their 
use.55  To address this issue, we imagined that nucleophilic alkyl radicals generated via photoredox 
catalysis could serve as mild alkylating agents to facilitate Grignard-type additions to electrophilic 
imines.56 Previously reported radical-based approaches in which the radicals were generated 
stoichiometrically relied on conditions that were far from ideal [e.g., large excesses of flammable 
Et3B/O2 initiators, radical precursors (typically alkyl iodides), and reductants such as tin reagents 
or Zn], owing to the byproducts formed upon generation of the radicals. 
Further, although the addition of α-heteroatom-stabilized radicals to imines has been 
reported, we recognized that silicate radical precursors would provide access to a broader range of 
alkyl radicals. A variety of nitrogen-substituted imines were transformed into the corresponding α-
aryl-α-alkyl secondary amines utilizing alkyl radicals generated from bis-(catecholato)silicates. 
The transformation occurred readily under mild, redox neutral conditions without additives. The 
relatively low oxidation potentials of the silicate radical precursors facilitated the use of the organic 
photocatalyst 4CzIPN instead of Ru or Ir species, rendering the entire process metal-free. A variety 
of primary and secondary alkyl radicals bearing synthetically useful functional groups were readily 
intercepted by electronically varied α-(hetero)aryl imines under the optimized reaction conditions 
(Figure 1.26). 
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Figure 1.26. Alkylation of imines with alkylsilicates. 
We also explored the incorporation of readily available organophotocatalysts in allylation 
and alkenylation reactions.57  Alkenyl sulfones were employed as electrophilic reagents to effect 
the transition metal-free alkenylation and allylation of Boc-protected potassium α-
aminomethyltrifluoroborates. The inexpensive sodium salt of the organic photocatalyst Eosin Y 
(Ered = +0.83 V vs SCE) was found to be a suitable oxidant for potassium α-
pyrrolidinyltrifluoroborate (Ered = +0.78 V vs SCE) under the reaction conditions developed. 
Conversely, the related cesium carboxylate (Ered = +0.95 V vs SCE) required the use of an iridium 
photocatalyst. Exploring the scope of the alkenyl sulfones revealed that stabilization of the radical 
intermediates following radical addition was required. Various electron-neutral, electron-
withdrawing, and electron-donating substituents on the aryl ring were well tolerated under the 
reaction conditions (Figure 1.27). Protected homoallylic amines bearing styrene and acrylate 
groups were also generated from the corresponding allylic sulfones, although lower yields were 
observed. 
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Figure 1.27. Alkylation of allylic sulfones with α-aminomethyltrifluoroborates. 
A wide range of primary and secondary alkyltrifluoroborates was also incorporated into an 
organic photocatalyst-mediated deboronative cyanation reaction using the highly oxidizing 
MesAcr+ photocatalyst and tosyl cyanide (TsCN) as a radical trap (Figure 1.28). Classically, alkyl 
nitriles are synthesized via SN2 displacement of halides with nucleophilic cyanide sources.58  As a 
result, the formation of primary nitriles is favored over secondary and tertiary analogs. Based on 
the coupling of alkyltrifluoroborates with alkenyl and allylic sulfones, we sought to capture alkyl 
radicals (generated from photoinduced oxidation of alkyltrifluoroborates) with TsCN. By 
proceeding through radical intermediates, we anticipated that regiospecific cyanation should occur 
with mechanistic preference for less electrophilic carbon centers. The optimized reaction conditions 
provided access to primary and secondary as well as α-alkoxy-, γ-, β-, and α-amino alkyl nitriles 
under extremely mild reaction conditions. Notably, cyanation of an α-alkoxy alkyltrifluoroborate 
afforded a protected cyanohydrin, which can be difficult to synthesize by other methods given the 
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reversibility of cyanohydrin formation.59  A plausible mechanism is presented in Scheme 28. A 
visible light-excited organic catalyst oxidizes the potassium alkyltrifluoroborate via a single-
electron oxidation to provide an alkyl radical. The resulting radical then forms a new C–C bond in 
the presence of a suitable sulfonyl coupling partner while expelling a sulfonyl radical. The resultant 
sulfonyl radical is then reduced by one electron to close the catalytic cycle.60 
 
Figure 1.28. Direct cyanation of alkyltrifluoroborates. 
1.3 Conclusion and Future Outlook 
Since establishing photoredox/Ni dual catalysis in 2014, our group has successfully 
modified both radical precursors and electrophiles in further efforts to expand access to 
underexplored chemical space. Beyond aryl bromides, our group has demonstrated triflates, tosyl 
cyanide, imines, acid chlorides, and sulfones as feasible “electrophilic” partners in both dual 
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catalytic and metal-free manifolds. Additionally, since the initial demonstration of silicates as 
complementary radical precursors, a wider range of functionally rich alkyl radicals have been 
successfully cross-coupled. Although alkyltrifluoroborates and -silicates are fantastic reagents, step 
and atom economy is poor. Furthermore, the photoredox/Ni dual catalytic mechanism has led to a 
redefinition of alkyl coupling partners from traditional organometallic nucleophiles to redox-active 
radical precursors. Therefore, our group has searched for routes to access radical precursors from 
readily available functional groups. As demonstrated with DHPs (derived from aldehydes), 
feedstock functional groups hold great potential as latent radicals with wide commercial 
availability. Although DHPs are often more easily accessed than alkyltrifluoroborates and -
silicates, there is room for improvement in atom economy. In related work, we uncovered an 
energy-transfer pathway targeting activated C(sp3)–H bonds, which may inspire further related 
reaction design. 
Finally, these studies bear witness to the value of generating highly reactive radical 
intermediates catalytically, in a tightly orchestrated, controlled manner to avoid deleterious side-
reactions and lead to processes that are more efficacious and sustainable than those in which the 
radicals are created en mass by stoichiometric protocols. Herein, personal efforts in the field of 
photoredox catalysis are described. In addition to work accomplished in the area of dual catalysis, 
methods development in the area of C–H alkylation are described in addition to the development 
of late-stage functionalization protocols. 
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Chapter 2. C–H Alkylation of Heteroarenes via Photoredox Catalysis 
 
2.1 Introduction 
 During the process of drug development, medicinal chemists frequently employ nitrogen-
containing heteroarene scaffolds.1† Based on a survey of the “Top 200 Drugs” in 2014, a noteworthy 
59% of pharmaceuticals contained a nitrogen heterocycle.2 Although these small molecules are 
considered “privileged structures” in drug discovery, pharmacokinetic studies oftentimes determine 
modifications are necessary to improve ADME properties. Therefore, medicinal chemists have 
historically sought effective ways to alkylate heteroarenes in a step- and cost-economical way.3 
 
Figure 2.1. Functionally dense heterocycles and the innate positions of radical reactivity. 
 
 To overcome this challenge, two predominant (two-electron) strategies have emerged for 
diversifying common heteroaryl motifs: fluorination to enable facile SNAr-based chemistry4 and 
halogenation (bromination,5 chlorination6) followed by cross-coupling.7 These methods are highly 
effective for many systems, but in numerous cases installation of the halide at the desired site is 
 
 
† Reproduced in part from Matsui, J. K.; Primer, D. N.; Molander, G. A. Chem. Sci. 2017, 8, 3512. 
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unselective or impossible, requiring re-evaluation of the synthetic strategy. Furthermore, when 
successful incorporation of halides has occurred, heteroarenes are often obstinate partners in cross-
coupling chemistry,8 requiring careful screening to achieve fruitful union. Most importantly, from 
an efficiency standpoint, these strategies are sub-optimal as they first require a functional handle to 
be installed, only to be immediately replaced in a subsequent displacement reaction. 
Radical alkylations of heteroarenes (Minisci reactions)9 represent a more direct 
functionalization of specific C–H bonds. For this reason, radical alkylation strategies have recently 
risen to prominence for the late-stage functionalization of heteroaryl systems. In this single-electron 
transformation, a wide range of N-heteroarene and radical precursors have been utilized since the 
1970s (Figure 2.2).10 
 
Figure 2.2. Representative heteroarenes (left) and radical precursors (right) used for Minisci 
chemistry. Highlighted hydrogens represent sites of native reactivity. 
 
Although Minisci and coworkers initially used silver oxidants at elevated temperatures to 
generate alkyl radicals from the corresponding carboxylic acids,9 advances in alkyl radical 
generation have enabled much milder methods to be developed. These have included methods using 
boronic acids,11 peresters,12 and other precursors13 under much less forcing conditions. Most 
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notably, the Baran laboratory has pioneered the use of sulfinate salts14 that have enabled the 
extremely facile introduction of functionalized alkyl radicals into an impressive array of 
heteroarenes. These methods allow the formal C-H alkylation of heterocycles in a mild, metal-free 
manner – drawing rapid adoption by medicinal chemists for the late stage diversification of 
pharmaceutically relevant compounds. 
 Advances in the field of Minisci-based reactions have enabled synthetic chemists to tackle 
markedly more complicated heterocyclic scaffolds. Notably, camptothecin (an anti-cancer agent) 
demonstrated inhibition of cancer cell growth in vitro, but structure activity relationship studies 
demonstrated that alkylation at the C7 position not only increased solubility, but also increased 
efficacy in cells.15 
 Unfortunately, even with these advances, current methods are not without their limitations, 
particularly with regard to the continued requirement for high loadings of both the radical partner 
and oxidant. Even the milder methods employing sulfinate salts often require a significant excess 
of an expensive and synthetically demanding precursor (3–6 equiv) and oxidant (5–10 equiv) to 
achieve good yields. To date, methods grounded in stoichiometric radical generation have been 
continually limited by parasitic reactivity (e.g., homocoupling, H-atom abstraction, and chain 
processes) that appear to outcompete the desired Minisci alkylation. As such, often the only 
solution has been to push reactions to completion with increased reagent loadings or successive 
dosing (Figure 2.3). 
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Figure 2.3. Previous Minisci methods for alkylation of heteroarenes. 
 
To combat the disproportionate stoichiometry and typically harsh conditions, other groups 
have turned to photoredox catalysis for the efficient generation of radicals.16 Contributions by the 
MacMillan,17 DiRocco,18 Chen,19 and Barriault20 groups have all highlighted the advantages 
afforded under this paradigm. Although a variety of alkyl radicals precursors were presented in 
these photoredox contributions, each method exhibits some inherent limitations. For example, the 
MacMillan group targeted weak C-H bonds and were largely limited to α-heteroatom bonds.17 
Barriault and coworkers demonstrated that alkyl bromides could be reduced to generate the 
corresponding alkyl radicals, but 3 equivalents of these precursors and a UVA LED light source 
were required.20 Additionally, MacMillan and Barriault used expensive iridium or gold 
photocatalysts, respectively. The recent report by Chen addressed many of these issues with the use 
of sustainable boronic acid partners and inexpensive Ru(bpy)3, but their method employs the use 
of a stoichiometric iodine oxidant that seems uniquely required for activation.19 
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In light of these advances, we recognized the potential to marry photoredox Minisci 
chemistry with our laboratory’s interest in alkyltrifluoroborate reagents, especially given reports 
by our laboratory and others21 on the favorable single electron oxidation potentials of these salts to 
form alkyl radicals (Ered = +1.10 V vs SCE for 1o benzylic20a and +1.50 V vs SCE for a secondary 
alkyltrifluoroborates). Here, with appropriate organic photocatalyst selection (for 1: *Ered = +2.06 
V vs SCE22), all representative radical classes could be activated under identical reaction conditions 
(Figure 2.4). In this scenario, one can envision photocatalyst excitation serving as a chaperone for 
steady, synchronized, catalytic radical generation. Such a protocol insures that an excess of radicals 
is not generated, minimizing at least some of the byproducts formed through stoichiometric 
processes. The photoredox catalyst-coordinated generation of radicals in this manner leads to 
improvement in reagent and oxidant loading, thus enhancing the efficiency and sustainability of 
these methods. Serendipitiously, these aforementioned concepts, in conjunction with the generation 
of Lewis acidic BF3 byproduct, also led to enhanced reactivity and selectivity in these 
transformations. 
  
Figure 2.4. Envisioned transformation. 
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2.2 Reaction Design and Results 
Mechanistically, we anticipated that visible light irradiation of organic photocatalyst 1 
would generate the excited complex 1*, which is capable of oxidizing an alkyltrifluoroborate to 
release the desired alkyl radical 3 and BF3 (Figure 2.5). The generated radical 3 can then intercept 
the protonated heteroarene to form the radical cation 5. Reduction of persulfate (Ered =  > +0.35 V 
vs SCE) by the reduced form of the photocatalyst 4 (Ered = +0.49 V vs SCE) generates the sulfate 
dianion and sulfate radical anion, regenerating photocatalyst 1.21 Finally, H-atom abstraction of 5 
by the sulfate radical anion leads to rearomatization, affording the desired alkylated heteroarene 
6.16. Quantum yield studies indicate this is not a radical chain process as evidenced by a quantum 
yield of 0.31 (See Experimental Section for more details). Furthermore, addition of excess allyl 
acetate (a known sulfate radical anion trap23) did not interfere with reaction efficiency or 
conversion. 
 
  48 
  
Figure 2.5. Proposed mechanism. 
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The mesityl acridinium photocatalyst was then compared to other photocatalysts (entries 
7–10). Noting the need for a relatively high oxidizing potential of the photocatalyst, it was expected 
that ruthenium photocatalysts (with significantly lower oxidation potentials than the acridinium 
dyes) would experience diminished yields, which proved to be the case (entries 7, 8). During the 
period that photoredox catalysis has gained traction in the organic chemistry community, one major 
criticism has been the high cost of the key metal-based photocatalysts (i.e., those based on iridium 
and ruthenium). Nicewicz24 and Zhang25 have explored alternative organophotocatalysts that have 
been shown to exhibit similar reactivity to their metal-based counterparts. Surprisingly, 4CzIPN 
(entry 10) significantly outperformed MesAcr over a 12 h period. Neither excess 
alkyltrifluoroborate (entry 11) nor excess oxidant (entry 12) provided any perceived advantages.  
Table 2.1. Control experiments and optimization. 
 
In view of their low cost and ease of access, going forward we focused on the two 
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for our purposes, we scaled up the reactions described in entries 1 and 10, and discovered that 
running the reaction for 16 h afforded similar yields, consistent with the small scale reactions. It 
was important for this protocol to be general for primary, secondary, and tertiary 
alkyltrifluoroborates. Because primary alkyltrifluoroborates have a markedly higher oxidation 
potential (Ered = +1.80 V vs SCE) than secondary or tertiary alkyltrifluoroborates, MesAcr and 
4CzIPN were compared with a primary alkyltrifluoroborate (Figure 2.6). In this assay, MesAcr 
outperformed CzIPN, providing 76% versus <10% isolated yields, respectively. 
  
Figure 2.6. Comparing photocatalysts with a primary alkyltrifluoroborate. 
 
Tricoordinate organoboron compounds are isoelectronic with carbocations, and thus would 
not be expected to be easily oxidized by single electron transfer (SET) processes. To confirm that 
this chemistry was unique to alkyltrifluoroborates, a variety of organoboron reagents were 
synthesized and analyzed by cyclic voltammetry to determine their relative oxidation potentials 
(Table 2.2). As expected, the trivalent organoboron variants exhibit very high oxidation potentials 
as compared to their tetravalent, “ate” complex analogues. Consequently, under the reaction 
conditions, no radical formation from the boronic acids and/or esters was observed. For the 
tetravalent species, triolborates exhibit exceptionally low reduction potentials. Unfortunately, the 
swift hydrolysis of triolborates under the acidic, aqueous reaction conditions forms the redox 
inactive boronic acid.26 By contrast, alkyltrifluoroborates are both stable to the reaction conditions 
and redox amenable, resulting in an excellent 72% yield with methyl isoquinoline carboxylate after 
16 h. 
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Table 2.2. Exploring various boronate compounds. 
 
As mentioned previously, the use of tertiary radicals in Minisci chemistry has been very 
limited to date. Thus, before exploring the scope of the radical precursor, tert-butyltrifluoroborate 
was selected to examine the amenability of various heteroarene partners (Figure 2.7). 
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iodide radical precursors.8b Although efficient, drawbacks of this approach included using peroxide 
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the t-Bu group to the C2 position of the heteroarene in 72% yield (2.7.1). With substitution at the 
C4 position of quinoline, the reaction reached full conversion to product within 16 h as determined 
by GC-MS analysis (2.7.2). When isolated, a 95% yield of the desired product was achieved. 
Beyond alkyl substituents, halides and trifluoromethyl groups incorporated within the 
heteroaromatics allowed excellent conversion to product (2.7.3, 2.7.4).  
In addition to quinoline cores (2.7.1–2.7.4), indazole (2.7.5), isoquinoline (2.7.7), and 
quinoxaline (2.7.8, 2.7.9) moieties were successful partners under standard conditions. Indazole 
2.7.5 is particularly notable because of its prevalence in medicinal chemistry1 and, to the best of 
our knowledge, the absence of corresponding Minisci examples in the literature. As expected, the 
use of the benzimidazole core resulted in no conversion (2.7.6) because of the electron-rich nature 
of the C2 site. Additionally, N-methyl benzimidazole was similarly unreactive. Pyridines also 
exhibited selective mono-addition (2.7.10–2.7.12, 2.7.14). There has appeared only one report of 
nicotinamide alkylation via Minisci chemistry, wherein a statistical mixture of mono- and di-
alkylated product was formed.28 Therefore, it is remarkable that under the conditions developed 
herein, substitution occurred at the C6-position exclusively (2.7.14). A medicinally relevant core, 
quinazolinone 2.7.9, afforded product in 90% yield. Purine 2.7.18 contains two sites of potential 
radical addition, but substitution was only observed on the pyrimidine subunit. Impressively, the 
method was tolerant of a wide range of functional groups as demonstrated with quinine 2.7.19 
(possessing alkene, alcohol, tertiary amine groups). 
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Figure 2.7. Coupling tert-butyltrifluoroborate with various heteroarenes. 
 
Currently, there are a limited number of tertiary alkylboranes commercially available and 
no alkyltrifluoroborates. Presumably, this is a result of narrow synthetic utility compared to their 
primary and secondary counterparts. Although we demonstrated that tert-butyltrifluoroborate was 
viable, more highly elaborated systems could also be incorporated. Cook and coworkers recently 
reported a manganese-catalyzed borylation of alkyl bromides. Using Cook’s procedure,29 >1 g of 
pinacolborane intermediate 2.8.2 was synthesized from the corresponding alkyl bromide 2.8.1. This 
borylation was followed by treatment with saturated KHF2 to afford the corresponding 
alkyltrifluoroborate 2.8.3 (Figure 2.8). 
N
CO2Me
t-Bu
N
N
t-Bu
N
F3C t-Bu
N
Me
t-Bu
N
t-Bu
N
N Cl
t-Bu
2.7.2, 95% (16 h)
2.7.7, 77% (16 h)
2.7.4, 68% (16 h)
2.7.8, 70% (16 h)
2.7.10, 89% (16 h) 2.7.11, 74% (16 h)b 2.7.12, 73% (48 h)
Ac
Ac
N
H
N
t-Bu
N
NC
t-Bu
2.7.5, 80% (5 h)
2.7.9, 43% (16 h)
O N
Me
N
Me
N
N
Me
O
t-Bu
2.7.13, 70% (16 h)
N
Cl
t-Bu
CF3
N
NH
O
t-BuS
N
t-Bu
2.7.16, 90% (48 h)2.7.15, 66% (48 h)
N
O
NH2
2.7.14, 67% (4 h)
t-Bu BF3K + N
X
(1.0 equiv)
(1.0 equiv)
MesAcr (5 mol %)
K2S2O8 (2.0 equiv)
TFA (1.0 equiv)
MeCN/H2O (1:1, 0.1 M)
26 W CFL, rt, 16–48 h
N
X
t-Bu
N
H
N
t-Bu
2.7.6, <5% (16 h)
MeO
N
NHO
tBu
2.7.19, 54% (16 h)
3
2
1
(1) terminal alkene
(2) secondary alcohol
(3) tertiary amine
2.7.3, 86% (16 h)
NH
N
N
N
H
Nt-Bu
2.7.18, 79% (16 h)
N
Br
t-Bu
N t-Bu
2.7.1, 72% (16 h)
t-Bu
  54 
With tertiary alkyltrifluoroborate 2.8.3 in hand, radical addition to caffeine 2.8.4 and 
benzothiophene 2.8.5 was carried out. The development of the Cook approach to 3° 
alkyltrifluoroborates thus allows access to an even greater array of coupling partners. 
  
Figure 2.8. Synthesizing and utilizing a tertiary alkyltrifluoroborate. 
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pyrrolidine 2.9.8 was not successful. For azetidine 2.9.9, standard solvent conditions provided only 
trace amounts of product, but switching to DCE/H2O (1:1) proved to be beneficial. 
Cyclopropyltrifluoroborate, although unproductive in previously reported photoredox/Ni dual 
cross-coupling methods,20b afforded 2.9.10, albeit in 20% yield. 1-Adamantyltrifluoroborate has 
never been used in Minisci-type alkylations. Using the standard conditions, 2.9.11 was isolated in 
45% yield. Lastly, exquisite chemoselectivity was observed for 2.9.12; no radical addition to the 
pyridine moiety was observed, and the tertiary amine did not interfere with the photocatalytic cycle.  
  
Figure 2.9. Coupling secondary and tertiary alkyltrifluoroborates. 
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Moving forward, this Minisci process was anticipated to be broadly applicable even to 
primary alkyltrifluoroborates, which possess relatively high oxidation potentials (Figure 2.10). As 
an initial foray, we first investigated whether stabilized primary α-alkoxymethyltrifluoroborates 
could be competent partners in this process (2.10.1–2.10.4). Unstabilized alkyl radicals were also 
demonstrated in examples 2.10.5–2.9.12. Notably, 2.10.10 contains an ortho bromide functional 
handle for further elaboration. More remarkably, electron deficient 3,3,3-
trifluoropropyltrifluoroborate afforded 2.10.12, albeit in lower yield. 
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Figure 2.10. Demonstrating structural diversity for primary alkyltrifluoroborates. 
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The diversity of the process was expanded to underline the potential for widespread utility 
(Figure 2.11). Quinoline moieties were coupled with a variety of stabilized α-alkoxy (2.11.1–
2.11.3) and unstabilized (2.11.4–2.11.6) radicals. With quinoline, C2 regiospecificity was again 
observed (2.11.4, 2.11.5), albeit in diminished yields. This is particularly noteworthy given the 
challenges associated with avoiding complex mixtures of isomers in prior Minisci-type reaction 
reports.32 With heteroarene cores such as pyridine (2.11.6), benzothiazole (2.11.7), indazole 
(2.11.8), and quinazolinone (2.11.9, 2.11.10), exceptional yields were observed. When exploring 
reactivity with caffeine, methylcyclopentyltrifluoroborate afforded 2.11.11 in 37% yield. 
Additionally, a secondary alkyl radical was successfully appended to a functionally rich quinine as 
demonstrated in 2.11.12. 
  
Figure 2.11. Mixed table using various alkyltrifluoroborates and heteroarenes. 
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Given the success of this method, the use of this technology for selective ligand 
modifications was envisioned (Figure 2.12). As a case study, difunctionalization of a bipyridine-
based ligand was selected for further investigation. Commonly, these ligands are synthesized 
through the SNAr reaction of strong nucleophiles (e.g., tert-butyllithium) to a fluorinated bipyridine 
precursor, which is unfortunate given the popularity of these ligands in Cu and Ni catalysis.33 In 
contrast to the use of such pyrophoric alkylating agents, bench-stable alkyltrifluoroborates 
represent an attractive alternative. Gratifyingly, unfunctionalized substructures 2.12.1 and 2.12.3 
were converted to the desired products in 84% and 68% yields, respectively. Pyridine ligands are 
also valuable for the synthesis of iridium photocatalysts. Under the same reaction conditions, 
heteroarene 2.12.5 afforded mono-alkylated product 2.12.6 in 82% yield. When tridentate ligand 
terpyridine 2.12.7 was subjected to the standard conditions with two equivalents of tert-
butyltrifluoroborate, mono-alkylated 2.12.8 was formed exclusively.34 
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Figure 2.12. Applications within ligand design. 
 
Although medicinal chemists have principally capitalized on late-stage Minisci 
heteroarene alkylation,9 it can be advantageous to introduce alkyl substitution earlier in a synthetic 
sequence.35 Using the present protocol, the installation of alkyl subunits on brominated 
heteroarenes provides an excellent opportunity to highlight divergency in molecular synthesis. 
Furthermore, the halides installed within a variety of heteroarenes can serve a dual purpose: they 
may serve as an electronic bias for regioselective alkylations ortho to the halide,13d and they provide 
a functional handle for cross-coupling reactions, etc.5c To initiate studies to explore these concepts, 
a number of brominated heteroarenes were selected (Figure 2.13). First, pyrimidine 2.13.1 was 
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paired with an α-alkoxyalkyltrifluoroborate to yield exclusively the C4-substituted product. When 
moving to pyridines, a mixture of C2 and C6 alkylation occurred with tosyl-protected 
piperidinyltrifluoroborate 2.13.2. Conversely, with primary alkyltrifluoroborates, only the C2-
substituted products were observed in examples 2.13.3 and 2.13.4. Chloride substitution was also 
well tolerated as demonstrated in 2.13.4. When 4-bromoisoquinoline was utilized as a substrate, a 
mixture of regioisomers 2.13.5 and 2.13.6 was generated. 
  
Figure 2.13. Halogenated heteroarenes primed for further derivatization. 
 
2.3 Mechanistic Investigations 
From our previous reports on Minisci chemistry12 and the results provided herein, it became 
clear that the use of alkyltrifluoroborates provided clear advantages in terms of both reactivity 
(permitting a single equivalent of radical precursor to be employed) and regioselectivity in 
heteroarene alkylation. Given these observations, it seemed that there was some inherent advantage 
to the generation of BF3 byproduct during the course of the reaction. Two distinct possibilities were 
considered: (1) the BF3 produced was intimately involved with the generated radical, providing a 
shepherding effect in delivering the radical with enhanced selectivity, or (2) the BF3 was 
coordinating to the heteroarene prior to the radical addition, activating the heteroaryl substrate and 
enhancing preference for one site beyond the activation provided by the added protic acid.  
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To assess the first hypothesis, DFT calculations were performed to determine the effective 
“bond order” for radical association with BF3 in solution. This potential interaction was of 
particular interest as this escorting effect has little precedent in the chemical literature; currently, 
there are only examples of nitrogen- and oxygen-centered radicals interacting with BF3 in 
solution.36 Indeed, preliminary calculations suggest that a strong preference exists for the free 
radical over a BF3-bound complex in solution. Noting this lack of association, we were quick to 
investigate an alternative hypothesis.  
To probe each of the possible heteroarene complexes, we prepared stoichiometric solutions 
of one of our successful, selective substrates, quinoline, with no additive, trifluoroacetic acid (TFA) 
alone, BF3 alone, and finally TFA with added BF3, hoping to probe the effect of coordination on 
the proton and carbon shifts of heteroarene and provide some rationale for the differences between 
our chemistry and previously established protocols. 
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Figure 2.14. Observed proton shifts with additives. 
 
For trifluoroacetic acid, a clear downfield shift was observed in the C2 and C4 protons of 
quinoline (Figure 2.14). Likewise, for the addition of BF3, a slightly less pronounced, but clear, 
downfield shift was also observed for the same protons. However, the combination of both 
additives together produced a wholly different shift in resonances to a unique heteroarene species. 
Perhaps more importantly, the carbon shifts of C2 relative to C4 possess enhanced differentiation 
in relative downfield shift (~3 ppm) in comparison to the BF3 and trifluoroacetic acid complexes 
alone (~1 ppm) (Figure 2.15). Based on these chemical shifts, it is reasonable to suggest the C2 
position is preferentially activated over the C4 position37 under the reaction conditions, resulting 
in the enhanced regioselective mono-alkylation observed for the quinoline system and, by 
analogy, many of the other systems in which alkyltrifluoroborates appear uniquely reactive and 
selective (vida infra). 
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Figure 2.15. Observed carbon shifts with additives. 
 
To probe these findings further, we hoped that the use of alternative radical precursors 
(e.g., sulfinate salts or carboxylic acids) could be used in the presence and/or absence of BF3 to 
achieve the same desired regioselectivity. Unfortunately, under our standard conditions, sulfinate 
salts were universally ineffective, and carboxylic acids gave the same regio-mixture, even with 
added BF3. Given this current ambiguity, this enhanced reactivity and regioselectivity appears to 
remain unique to the trifluoroborate precursors. 
At this time, it is impossible to propose a structure for this distinct, activated species, but 
whatever complex is formed is likely a result of BF3 activation of either the heteroarene π-cloud38 
or polarization of the trifluoroacetic acid39 to increase its effective pKa. This type of dual activation 
could perhaps be more broadly operative in the selective alkylation of other heteroaryl cores. 
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2.4 Conclusion 
In summary, a mild, room temperature method for the introduction of a diverse palette of 
alkyl groups has been developed. Under a set of unified reaction conditions, primary, secondary, 
and tertiary alkyltrifluoroborates can be employed in photoredox Minisci chemistry for the first 
time. This chemistry makes use of an inexpensive, mild oxidant, organic photocatalyst, and requires 
only one equivalent of alkyl radical partner, providing one of the most cost efficient and sustainable 
approaches to date. Additionally, enhanced regioselectivity was observed compared to current 
“state of the art” Minisci-type alkylations. Both of these phenomena may be related to the 
synchronized, catalytic generation of radicals in conjunction with the in situ generation of BF3 
during the course of the reaction. The resultant method has been demonstrated broadly with respect 
to the heteroarene and alkyltrifluoroborate partners. Furthermore, access to bipyridine-type ligands 
as well as the late stage diversification of medicinally relevant substructures has been showcased. 
Finally, NMR studies provided support for a unique, highly activated species caused by the 
formation of BF3 upon the single-electron oxidation of alkyltrifluoroborates.  
Given the wide array of commercially available alkyltrifluoroborates, those synthesized by 
our laboratory and emerging from other groups, this approach provides a valuable contribution to 
the Minisci-type alkylation literature and is both highly competitive and complementary to existing 
protocols. As alkyltrifluoroborates are well behaved, bench stable salts, these reagents will continue 
to serve as useful “radicals in a bottle” for synthetic chemists. 
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GENERAL CONSIDERATIONS: 
 
NMR Spectra (1H, 13C, 19F) were performed at 298 K. 1H NMR spectra were referenced to residual 
non-deuterated chloroform (δ 7.26) in CDCl3, residual DMSO-d5 (δ 2.50) in DMSO-d6, acetone-d5 
(δ 2.09) in acetone-d6, and residual MeCN-d2 (δ 1.94) in MeCN-d3. 13C NMR spectra were 
referenced to CDCl3 (δ 77.2) and DMSO-d6 (δ 39.5). Reactions were monitored by HPLC, GC/MS, 
1H NMR, and/or by TLC on silica gel plates (60 Å porosity, 250 µm thickness). TLC analysis was 
performed using hexanes/EtOAc as the eluant and visualized using UV light. Silica plugs utilized 
flash silica gel (60 Å porosity, 32–63 µm). Flash chromatography was accomplished using an 
automated system (visualizing at 254 nm, monitoring at 280 nm) with silica cartridges (60 Å 
porosity, 20–40 µm). Solvents were purified by use of drying cartridges through a solvent delivery 
system. Melting points (°C) are uncorrected.  
Deuterated NMR solvents were either used as purchased (DMSO-d6) or were stored over 4Å 
molecular sieves and/or K2CO3 (CDCl3). Na2SO4, MgSO4, MeOH, CH2Cl2, MeCN, pentane, Et2O, 
trifluoroacetic acid, and K2S2O8 were used as purchased. Heteroarenes were purchased from 
commercial suppliers and used without further purification. MeCN/H2O was degassed thoroughly 
with N2 and stored under N2. The photocatalyst N-Me-9-mesityl acridinium tetrafluoroborate was 
donated by Pfizer and used without further purification. 
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General Procedure 
To a 4.0 mL vial, alkyltrifluoroborate (0.30 mmol, 1.0 equiv), heteroarene (0.30 mmol, 1.0 equiv), 
photocatalyst (6.2 mg, 0.015 mmol, 0.05 equiv), and K2S2O8 (162.2 mg, 0.60 mmol, 2.0 equiv) 
were added. Open to air, a mixture of 3.0 mL MeCN/H2O (1:1) was added, followed by 
trifluoroacetic acid (34.2 mg, 0.30 mmol, 1.0 equiv). The mixture was stirred under 26 W CFLs 
(GE FLE26HT3/2/D) for 5–48 h under a fan. The reaction mixture was quenched with saturated 
NaHCO3 and extracted with CH2Cl2 (3 x 20 mL). The organic extracts were combined and 
concentrated on Celite. The crude mixture was purified by silica gel column chromatography.  
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Compound Characterization 
 
 
2-(tert-Butyl)quinoline (2.7.1) 
Physical state: 40 mg, 72% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 8.6 Hz, 2H), 7.77 – 7.75 (m, 1H), 7.68 – 7.64 (m, 1H), 
7.54 – 7.52 (m, 1H), 7.49 – 7.46 (m, 1H), 1.48 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 169.4, 147.6, 136.0, 129.6, 129.1, 127.4, 126.6, 125.7, 118.3, 38.3, 
30.3. 
HRMS (ES+) m/z calc. for C13H16N [M+H] 186.1283, found 186.1280. 
FT-IR (cm-1, neat, ATR) 2961, 1619, 1601, 1565, 1504, 1364, 1138, 1103, 829, 756, 478. 
 
 
2-(tert-Butyl)-4-methylquinoline (2.7.2) 
Reference: Gabriele, B.; Mancuso, R; Salerno, G.; Ruffolo, G.; Plastina, P. J. Org. Chem. 2007, 
72, 6873. 
Physical state: 57 mg, 95% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 7.93-7.90 (m, 1H), 7.66-7.64 (m, 1H), 
7.49-7.27 (m, 1H), 7.34 (s, 1H), 2.67 (s, 3H), 1.47 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 169.1, 147.5, 143.7, 130.1, 128.8, 126.7, 125.5 123.5, 119.0, 38.1, 
30.3, 19.1. 
 
N t-Bu
N
Me
t-Bu
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4-Bromo-2-(tert-butyl)quinoline (2.7.3) 
Physical state: 68 mg, 86% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.10 (d, J = 8.4 Hz, 1H), 8.06-8.02 (m, 1H), 7.79 (s, 1H), 7.69 (dd 
J = 7.7, 7.6 Hz, 1H), 7.54 (dd, J = 7.7, 7.6 Hz, 1H), 1.45 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 169.5, 148.3, 134.0, 130.1, 130.0, 127.0, 126.5, 126.2, 122.5, 
38.3, 30.2. 
HRMS (ES+) m/z calc. for C13H15BrN [M+H] 264.0388, found 264.0397. 
FT-IR (cm-1, neat, ATR) 2957, 1585, 1488, 820, 756. 
 
 
2-(tert-Butyl)-4-chloro-8-(trifluoromethyl)quinoline (2.7.4) 
Physical state: 78 mg, 70% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.38 (d, J = 8.4 Hz, 1H), 8.08 (d, J = 7.2 Hz, 1H), 7.68 (s, 1H), 7.61-
7.59 (m, 1H), 1.47 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 170.5, 144.9, 142.6, 128.5 (q, J = 5.5 Hz), 128.3 (q, J = 29.1 Hz), 
128.2, 125.3, 125.2, 123.1, 119.3, 38.9, 29.9. 
HRMS (ES+) m/z calc. for C14H14ClF3N [M+H] 288.0767, found 288.0762. 
N
Br
t-Bu
N
Cl
t-Bu
CF3
	  73 
FT-IR (cm-1, neat, ATR) 2965, 1592, 1489, 1463, 1293, 1145, 1118, 766. 
 
 
3-(tert-Butyl)-1H-indazole (2.7.5) 
Reference: Li, P.; Wu, C.; Zhao, J.; Rogness, D. C.; Shi, F. J. Org. Chem. 2012, 77, 3149 
Physical state: 41 mg, 80% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 10.07 (bs, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.44 (d, J = 8.2 Hz, 1H), 
7.36-7.33 (m, 1H), 7.14-7.11 (m, 1H), 1.55 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 154.8, 142.1, 126.3, 122.3, 120.7, 120.0, 110.1, 34.0, 30.2. 
HRMS (ES+) m/z calc. for C11H15N2 [M+H] 175.1235, found 175.1229. 
FT-IR (cm-1, neat, ATR) 3146, 3112, 3073, 2963, 2928, 2900, 1342, 739. 
 
 
Methyl 1-(tert-Butyl)isoquinoline-3-carboxylate (2.7.7) 
Physical state: 55 mg isolated, 77% yield, white solid (mp = 55 °C). 
1H NMR (500 MHz, CDCl3) δ 11.64 (s, 1H), 8.50 – 8.45 (m, 2H), 7.72 – 7.70 (m, 2H), 4.06 (s, 
3H), 1.64 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 171.8, 158.0, 155.4, 129.6, 129.3, 129.0, 128.8, 127.3, 124.3, 118.4, 
52.9, 39.7, 31.2. 
HRMS: submitted. 
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FT-IR (cm-1, neat, ATR) 2953, 1661, 1450, 1337, 1242, 1164. 
 
 
2-(tert-Butyl)quinoxaline (2.7.8) 
Physical state: 39 mg, 70% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.99 (s, 1H), 8.06 (dd, J = 8.0, 3.8 Hz, 2H), 7.71 (m, 2H), 1.52 (s, 
9H). 
13C NMR (126 MHz, CDCl3) δ 163.8, 143.6, 141.8, 141.0, 129.8, 129.5, 129.1, 129.0, 37.4, 29.9. 
HRMS (ES+) m/z calc. for C12H15N2 [M+H] 186.1157, found 186.1158. 
FT-IR (cm-1, neat, ATR) 2963, 1558, 1492, 1464, 1365, 1237, 1155, 1128, 1097, 1014, 968, 761, 
607. 
 
 
2-(tert-Butyl)-3-chloroquinoxaline (2.7.9) 
Physical state: 28 mg isolated, 43% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.99 (s, 1H), 8.07 – 8.05 (m, 2H), 7.74 – 7.68 (m, 2H), 1.52 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 163.8, 143.6, 141.8, 141.0, 129.8, 129.5, 129.1, 129.0, 37.4, 29.9. 
HRMS (ES+) m/z calc. for C12H15ClN2 [M+H] 221.0846, found 221.0844. 
FT-IR (cm-1, neat, ATR) 2977, 1167, 1104, 1008, 761. 
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6-(tert-Butyl)nicotinonitrile (2.7.10) 
Physical state: 42 mg, 89% yield, yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.82 (s, 1H), 7.87 (d, J = 8.2 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 1.38 
(s, 9H). 
13C NMR (126 MHz, CDCl3) δ 174.1, 151.7, 139.5, 119.3, 117.3, 106.9, 38.4, 30.0. 
HRMS (ES+) m/z calc. for C10H13N2 [M+H] 161.1079, found 161.1078. 
FT-IR (cm-1, neat, ATR) 2960, 2050, 1721, 1596. 
 
 
2-(tert-Butyl)-4-(trifluoromethyl)pyridine (2.7.11) 
Reference: Stowers, K. J.; Fortner, K. C.; Sanford, M. S. J. Am. Chem. Soc. 2011, 133, 6541. 
Physical state: 58 mg, 95% yield, light yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.74 (d, J = 4.9 Hz, 1H), 7.53 (s, 1H), 7.31 (d, J = 5.0 Hz, 1H), 1.40 (d, J = 
1.9 Hz, 9H). 
13C NMR (126 MHz, CDCl3) δ 171.2, 149.7, 138.7 (q, J = 34.0 Hz), 123.4 (q, J = 271.0), 116.4 (q, J = 4.0 
Hz), 114.8, 114.81, 38.0, 30.2. 
19F NMR (477 MHz) δ -64.70. 
 
 
1,1'-(4-(tert-Butyl)pyridine-2,6-diyl)bis(ethan-1-one) (2.7.12) 
Physical state: 48 mg, 73% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.22 (s, 2H), 2.78 (s, 6H), 1.36 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 200.1, 162.9, 153.0, 122.0, 35.6, 30.6, 25.9. 
N
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HRMS (ES+) m/z calc. for C13H18NO2 [M+H] 220.1338, found 220.1334. 
FT-IR (cm-1, neat, ATR) 2968, 2975, 1700, 1362, 1244, 1131, 610. 
 
 
8-(tert-Butyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione (2.7.13) 
Physical state: 52 mg, 70% yield, white solid (173 °C). 
1H NMR (500 MHz, CDCl3) δ 4.11 (s, 3H), 3.56 (s, 3H), 3.39 (s, 3H), 1.47 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 160.1, 155.8, 151.9, 147.1, 108.4, 34.3, 34.2, 29.7, 29.1, 28.0. 
HRMS (ES+) m/z calc. for C12H19N4O2 [M+H] 251.1508, found 251.1505. 
FT-IR (cm-1, neat, ATR) 2974, 1699, 1656, 1543, 1492, 1428, 1364, 1240, 740. 
 
 
2-(tert-Butyl)nicotinamide (2.7.14) 
Reference: Tada, M.; Yokoi, Y. J. Heterocyclic Chem. 1989, 26, 45. 
Physical state: 36 mg, 67% yield, light yellow solid (mp = 94 °C). 
1H NMR (500 MHz, DMSO-d6) δ 8.95 (d, J = 2.3 Hz, 1H), 8.17 – 7.99 (m, 2H), 7.51 (d, J = 8.2 
Hz, 2H), 1.31 (s, 9H). 
13C NMR (126 MHz, DMSO) δ 171.2, 166.5, 147.6, 135.6, 127.0, 118.5, 20.8, 14.1. 
HRMS (ES+) m/z calc. for C10H15N2O [M+H] 179.1184, found 179.1190. 
FT-IR (cm-1, neat, ATR) 3433, 2253, 2127, 1667, 1394, 1051, 1023, 820, 760. 
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2-(tert-Butyl)benzo[d]thiazole (2.7.15) 
Physical state: 38 mg, 66% yield, yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.46 – 7.43 (m, 
1H), 7.35 – 7.32 (m, 1H), 1.53 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 182.0, 153.4, 135.1, 125.9, 124.6, 122.8, 121.6, 38.5, 30.9. 
HRMS (ES+) m/z calc. for C11H14NS [M+H] 192.0847, found 192.0847. 
FT-IR (cm-1, neat, ATR) 2965, 1513, 1438, 1044, 1008, 758. 
 
 
2-(tert-Butyl)quinazolin-4(3H)-one (2.7.16) 
Reference: Li, Z.; Dong, J.; Chen, X.; Li, Q.; Zhou, Y.; Yin, S. -F. J. Org, Chem. 2015, 80, 9392. 
Physical state: 54 mg, 90% yield, white solid (mp = 110–113 °C). 
1H NMR (500 MHz, CDCl3) δ 11.40 (s, 1H), 8.29 (d, J = 7.6 Hz, 1H), 7.74 (d, J = 9.8 Hz, 2H), 
7.45 (t, J = 7.6 Hz, 1H), 1.50 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 164.1, 162.3, 149.4, 134.6, 127.8, 126.4, 126.3, 120.7, 100.1, 37.6, 
28.4. 
HRMS (ES+) m/z calc. for C12H15N2O [M+H] 203.1184, found 203.1183. 
FT-IR (cm-1, neat, ATR) 3189, 3079, 2968, 1667, 1611, 772. 
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N-Benzyl-2-(tert-butyl)-7H-purin-6-amine (2.7.18) 
Physical state: 67 mg, 79% yield, yellow solid (mp = 125–127 °C). 
1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 7.44 – 7.41 (m, 2H), (dd, J = 7.5, 7.5 Hz, 2H), 7.29 (d, 
J = 7.5 Hz, 1H), 6.12 (bs, 1H), 4.89 (s, 2H), 1.53 (s, 9H) (highlighted proton not observed). 
13C NMR (126 MHz, CDCl3) δ 160.7, 154.2, 151.6, 138.7, 128.8, 128.7, 128.2, 127.6, 100.1, 33.9, 
29.6, 27.8. 
HRMS (ES+) m/z calc. for C16H20N5 [M+H] 282.1719, found 282.1718. 
FT-IR (cm-1, neat, ATR) 2972, 1619, 1598, 1351, 1299. 
 
 
(1R)-(2-(tert-Butyl)-6-methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (2.7.19) 
Reference: Yardley, J. P.; Bright, R. E.; Rane, L.; Rees, R. W.; Russell, P. B.; Smith, H. J. Med. 
Chem. 1971, 14, 62. 
Physical state: 62 mg, 54% yield, light yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 9.2 Hz, 1H), 7.67 (s, 1H), 7.30 (d, J = 9.2 Hz, 1H), 7.20 
(s, 1H), 5.73 (dt, J = 17.6, 9.0 Hz, 1H), 5.58 (s, 1H), 4.97 – 4.90  (m, 2H), 3.89 (s, 3H), 3.50 – 3.45 
(m, 1H), 3.20 – 3.08 (m, 2H), 2.71 – 2.65 (m, 2H), 2.29 – 2.25 (m, 1H), 1.81 (s, 1H), 1.79 – 1.65 
(m, 2H), 1.52 – 1.43 (m, 11H). 
13C NMR (126 MHz, CDCl3) δ 166.6, 157.4, 146.9, 143.8, 142.0, 131.9, 124.7, 120.9, 115.5, 114.6, 
101.3, 72.6, 60.1, 57.3, 55.8, 43.5, 40.1, 38.1, 30.3, 28.1, 27.8, 21.6. 
HRMS (ES+) m/z calc. for C24H32N2O2 [M+H] 381.2536, found 381.2543. 
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FT-IR (cm-1, neat, ATR)2954, 1621, 1601, 1561, 1505, 1471, 1363, 1343, 1263, 1231, 1106, 1034, 
911, 832, 734, 645. 
 
 
Methyl 1-(1-(Benzyloxy)-3-phenylpropyl)isoquinoline-3-carboxylate (2.9.1) 
Physical state: 71 mg, 58% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.88 (d, J = 8.5 Hz, 1H), 8.52 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.78 
– 7.76 (m, 1H), 7.70 – 7.66 (m, 1H), 7.41 – 7.35 (m, 1H), 7.31 – 7.22 (m, 7H), 7.19 – 7.12 (m, 2H), 
5.26 – 5.22 (m, 1H), 4.52 – 4.43 (m, 2H), 4.08 (s, 3H), 3.12 – 2.96 (m, 1H), 2.78 – 2.72 (m, 1H), 
2.61 – 2.53 (m, 1H), 2.33 – 2.25 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 166.4, 161.5, 141.7, 140.2, 138.1, 136.5, 130.6, 129.1, 128.8, 128.4, 
128.2, 128.1(9), 127.8, 127.7, 127.5, 126.2, 125.7, 124.2, 85.1, 71.5, 52.8, 37.8, 32.5. 
HRMS (ES+) m/z calc. for C27H25NO3Na [M+Na] 434.1732, found 434.1734. 
FT-IR (cm-1, neat, ATR) 3052, 2950, 1736, 1717, 1373, 1147, 1027, 908, 782, 490. 
 
 
Methyl 1-(4,4-Difluorocyclohexyl)isoquinoline-3-carboxylate (2.9.2) 
Physical state: 32 mg, 35% yield, yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H), 8.22 (d, J = 7.8 Hz, 1H), 7.98 – 7.95 (m, 1H), 7.77 – 
7.72 (m, 2H), 4.02 (s, 3H), 3.72 – 3.58 (m, 1H), 2.40 – 2.27 (m, 4H), 2.16 – 1.90 (m, 4H). 
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13C NMR (126 MHz, CDCl3) δ 166.7, 163.5, 163.5, 140.6, 136.1, 130.4, 129.4, 129.4, 129.3, 127.6, 
125.2, 124.5, 123.3, 122.9, 121.4, 52.7, 39.7, 33.9, 33.7, 33.7, 33.5, 28.3, 28.2. 
19F NMR (471 MHz, C6D6) δ 2.26 (d, J = 235.5 Hz), 6.03 (d, J = 235.5 Hz). 
HRMS (ES+) m/z calc. for C17H17F2NO3 [M+Na] 328.1125, found 328.1124. 
FT-IR (cm-1, neat, ATR) 2951, 1736, 1450, 1374, 1236, 1205, 1101, 956, 784. 
 
 
Methyl 1-(Tetrahydro-2H-pyran-4-yl)isoquinoline-3-carboxylate (2.9.3) 
Physical state: 60 mg, 74% yield, white semi-solid. 
1H NMR (300 MHz, CDCl3) δ 8.45 (s, 1H), 8.35 – 8.22 (m, 1H), 8.07 – 7.90 (m, 1H), 7.76 (dt, J 
= 5.4, 3.2 Hz, 2H), 4.20 (dd, J = 11.4, 2.6 Hz, 2H), 4.05 (s, 3H), 3.93 – 3.56 (m, 3H), 2.51 – 2.23 
(m, 2H), 1.91 (dd, J = 13.4, 1.5 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 163.9, 141.0, 140.9, 136.3, 130.4, 129.4, 127.7, 124.6, 122.9, 
68.3, 52.8, 39.4, 32.0. 
HRMS (ES+) m/z calc. for C16H17NO3Na [M+Na] 294.1106, found 294.1111. 
FT-IR (cm-1, neat, ATR) 2962, 1589, 1489, 1387, 850. 
 
 
Methyl 1-(1-Tosylpiperidin-4-yl)isoquinoline-3-carboxylate (2.9.4) 
Physical state: 84 mg, 66% yield, pale yellow solid (mp = dec ~195 ⁰C). 
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1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.11 (d, J = 8.5 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.74-
7.66 (m, 4H), 7.37 (d, J = 8.0 Hz, 2H), 4.03 (s, 3H), 3.98 (d, J = 11.5 Hz, 2H), 3.53-3.48 (m, 1H), 
2.62-2.52 (m, 2H), 2.48 (s, 3H), 2.45-2.32 (m, 2H), 2.05-2.03 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.5, 162.9, 143.3, 140.6, 133.3, 130.2, 129.5, 129.2, 129.1(9), 
128.8, 127.8, 127.4, 124.1, 122.8, 52.6, 46.3, 39.1, 30.4, 21.5. 
HRMS (ES+) m/z calc. for C23H25N2O4S [M+H] 425.1535, found 425.1531. 
FT-IR (cm-1, neat, ATR) 2962, 1589, 1489, 1387, 850. 
 
 
Methyl 1-(1-(tert-Butoxycarbonyl)piperidin-4-yl)isoquinoline-3-carboxylate (2.9.5) 
Physical state: 41 mg, 51% yield, white semi-solid. 
1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.25 (d, J = 7.3 Hz, 1H), 8.06 – 7.89 (m, 1H), 7.84 – 
7.64 (m, 2H), 4.32 (m, 2H), 4.02 (s, 3H), 3.72 (t, J = 11.4 Hz, 1H), 2.99 (m, 2H), 2.03 (m, 4H), 
1.49 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 164.1, 154.9, 140.8, 136.3, 130.5, 129.4, 127.8, 124.6, 122.9, 79.6, 
58.5, 52.8, 40.2, 31.2, 28.7. 
HRMS (ES+) m/z calc. for C21H27N2O4 [M+H] 371.1971, found 371.1984. 
FT-IR (cm-1, neat, ATR) 2962, 1589, 1489, 1387, 850. 
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Methyl 1-(1-Hydroxy-3-phenylpropan-2-yl)isoquinoline-3-carboxylate (2.9.6) 
Physical state: 20 mg, 20% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.48 (s, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.78 
– 7.75 (m, 1H), 7.72 – 7.68 (m, 1H), 7.34 – 7.18 (m, 5H), 5.65 (d, J = 10.1 Hz, 1H), 4.19 (d, J = 
11.3 Hz, 1H), 4.05 (s, 3H), 3.98 – 3.93 (m, 1H), 3.88 – 3.84 (m, 1H), 3.39 – 3.34 (m, 1H), 3.12 – 
3.07 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 166.2, 165.4, 140.1, 139.6, 136.3, 131.1, 129.9, 129.5, 129.4, 128.7, 
128.0, 126.5, 125.0, 123.2, 63.1, 53.0, 44.4, 38.1. 
HRMS (ES+) m/z calc. for C20H20NO2 [M+H] 322.1443, found 322.1452. 
FT-IR (cm-1, neat, ATR) 1734, 1451, 1244, 1207, 749, 702. 
 
 
Methyl 1-(Tetrahydrofuran-3-yl)isoquinoline-3-carboxylate (2.9.7) 
Physical state: 43.7 mg, 34% yield, colorless oil. 
1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.27 (d, J = 7.2 Hz, 1H), 8.00 – 7.93 (m, 1H), 7.80 – 
7.70 (m, 2H), 4.42 – 4.32 (m, 2H), 4.25 – 4.15 (m, 2H), 4.08 – 3.96 (m, 4H), 2.79 – 2.57 (m, 1H), 
2.53 – 2.31 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 166.5, 161.2, 136.0, 134.0, 130.4, 129.4, 129.0, 128.4, 124.8, 123.0, 
112.7, 77.2, 68.8, 52.6, 43.4, 32.1. 
HRMS (ES+) m/z calc. for C15H16NO3 [M+H] 258.1130, found 258.1140. 
FT-IR (cm-1, neat, ATR) 2987, 2870, 1208, 1063, 861, 837. 
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Methyl 1-(1-(tert-Butoxycarbonyl)azetidin-3-yl)isoquinoline-3-carboxylate (2.9.9) 
1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 8.01 (d, J = 8.1 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.82 
– 7.71 (m, 2H), 4.64 – 4.45 (m, 5H), 4.05 (s, 3H), 1.47 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 166.3, 159.7, 156.3, 140.3, 135.9, 130.7, 129.7, 129.2, 127.7, 124.3, 
123.4, 79.4, 52.6, 33.0, 28.3. 
HRMS (ES+) m/z calc. for C19H23N2O4 [M+H] 343.1658, found 343.1666. 
FT-IR (cm-1, neat, ATR) 2987, 2870, 1208, 1063, 861, 837. 
 
 
Methyl 1-Cyclopropylisoquinoline-3-carboxylate (2.9.10) 
Physical state: 21 mg, 31% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.54 – 8.44 (m, 1H), 8.36 (s, 1H), 8.01 – 7.89 (m, 1H), 7.76 – 7.73 
(m, 2H), 4.01 (s, 3H), 2.75 (tt, J = 8.5, 4.9 Hz, 1H), 1.37 – 1.34 (m, 2H), 1.17 – 1.13 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 162.5, 140.7, 135.8, 130.6, 129.5, 129.4, 129.0, 125.6, 122.3, 
52.9, 14.4, 9.3. 
HRMS (ES+) m/z calc. for C14H13NO2 [M+H] 228.1025, found 228.1019. 
FT-IR (cm-1, neat, ATR) 2951, 1737, 1321, 1269, 1244, 988. 
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Methyl 1-((3r,5r,7r)-Adamantan-1-yl)isoquinoline-3-carboxylate (2.9.11) 
Physical state: 43.4 mg, 45% yield, off-white solid (mp = 210–212 oC) 
1H NMR (500 MHz, CDCl3) δ 11.63 (s, 1H), 8.73 – 8.71 (m, 1H), 8.58 – 8.38 (m, 1H), 7.71 – 7.70 
(m, 2H), 4.08 (s, 3H), 2.38 (s, 6H), 2.21 (s, 3H), 1.89 (m, 6H). 
13C NMR (126 MHz, CDCl3) δ 171.6, 157.4, 155.1, 129.5, 129.1, 128.6, 128.4, 126.8, 124.2, 118.5, 
52.7, 42.2, 41.9, 37.0, 29.1. 
HRMS (ES+) m/z calc. for C21H24NO2 [M+H] 322.1807, found 322.1797. 
FT-IR (cm-1, neat, ATR) 2951, 1737, 1321, 1269, 1244, 988. 
 
 
Methyl 1-(1-(Pyridin-2-yl)piperidin-4-yl)isoquinoline-3-carboxylate (2.9.12) 
Physical state: 75 mg, 72% yield, yellow solid (mp = 154–157 oC). 
1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.31 (s, 1H), 8.20 (s, 1H) 7.98 (d, J = 3.5 Hz, 1H), 
7.76 – 7.74 (m, 2H), 7.49 – 7.45 (m, 1H), 6.74 (d, J = 8.5 Hz, 1H), 6.60-6.59 (m, 1H), 4.52 (d, J = 
12.5 Hz, 2H), 4.00 (s, 3H), 3.82-3.80 (m, 1H), 3.12 (t, J = 12.5 Hz, 2H), 2.34-2.26 (m, 2H), 2.10-
2.04 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 164.3, 159.6, 148.1, 140.9, 137.5, 136.3, 130.4, 129.4, 129.4, 
127.8, 124.8, 122.9, 112.8, 107.4, 52.8, 45.8, 40.7, 31.2. 
N
CO2Me
N
CO2Me
N
N
H
	  85 
HRMS (ES+) m/z calc. for C21H22N3O2 [M+H] 348.1712, found 348.1714. 
FT-IR (cm-1, neat, ATR) 2962, 1589, 1489, 1387, 850. 
 
 
1,3,9-Trimethyl-8-(2-methyl-1-phenylpropan-2-yl)-3,9-dihydro-1H-purine-2,6-dione (2.8.4) 
Physical state: 52 mg, 53% yield, pale yellow solid (mp = 101–103 oC). 
1H NMR (500 MHz, CDCl3) δ 7.23-7.21 (m, 3H), 6.88-6.85 (m, 2H), 3.80 (s, 3H), 3.56 (s, 3H), 
3.41 (s, 3H), 3.03 (s, 2H), 1.51 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 158.7, 155.5, 146.9(4), 146.9(1), 137.4, 129.8, 128.1, 126.7, 107.7, 
48.2, 39.4, 33.8, 29.5, 27.8, 27.2. 
HRMS (ES+) m/z calc. for C17H23N4O2 [M+H] 327.1821, found 327.1820. 
FT-IR (cm-1, neat, ATR) 3055, 2987, 1758, 1699, 1656, 1422, 1040, 896, 733, 703. 
 
 
2-(2-Methyl-1-phenylpropan-2-yl)benzo[d]thiazole (2.8.5) 
Physical state: 52 mg, 53% yield, pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 8.2 Hz, 1H), 7.86 (dd, J = 8.0, 0.5 Hz, 1H), 7.53 – 7.44 
(m, 1H), 7.41 – 7.32 (m, 1H), 7.27 – 7.12 (m, 3H), 7.09 – 6.98 (m, 2H), 3.18 (s, 2H), 1.52 (s, 6H). 
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13C NMR (126 MHz, CDCl3) δ 180.7, 153.2, 137.6, 134.8, 130.4, 127.8, 126.3, 125.7, 124.5, 122.7, 
121.4, 49.5, 42.2, 28.0. 
HRMS (ES+) m/z calc. for C17H18NS [M+H] 268.1160, found 268.1168. 
FT-IR (cm-1, neat, ATR) 3028, 2927, 1505, 1495, 1385, 1280, 1005, 743, 687. 
 
 
Methyl 1-((Cyclopentyloxy)methyl)isoquinoline-3-carboxylate (2.10.1) 
Physical state: 72 mg, 84% yield, clear viscous oil. 
1H NMR (500 MHz, CDCl3) δ 8.52 (s, 1H), 8.45 (d, J = 7.7 Hz, 1H), 7.94 (d, J = 7.4 Hz, 1H), 7.74 
(s, 2H), 5.10 (s, 2H), 4.13 (s, 1H), 4.04 (s, 3H), 1.52 (m, 8H). 
13C NMR (126 MHz, CDCl3) δ 166.5, 158.6, 140.3, 136.3, 130.9, 129.6, 129.1, 128.6, 126.7, 
124.7, 82.3, 77.4, 77.2, 76.9, 72.5, 53.0, 32.4, 23.6. 
HRMS (ES+) m/z calc. for C17H20NO3 [M+H] 286.1443, found 286.1454. 
FT-IR (cm-1, neat, ATR) 2952, 1737, 1334, 1246, 1110, 1096, 791. 
 
 
Methyl 1-((2-(Trimethylsilyl)ethoxy)methyl)isoquinoline-3-carboxylate (2.10.2) 
Physical state: 61 mg, 86% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.53 (s, 1H), 8.47 (d, J = 7.9 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.78 
– 7.71 (m, 2H), 5.13 (s, 2H), 4.04 (s, 3H), 3.76 – 3.55 (m, 2H), 1.11 – 0.90 (m, 2H), -0.03 (s, 9H). 
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13C NMR (126 MHz, CDCl3) δ 166.5, 158.4, 140.4, 136.3, 130.9, 129.6, 129.0, 128.6, 126.6, 124.7, 
73.5, 68.5, 52.9, 18.5, -1.3. 
HRMS (ES+) m/z calc. for C17H23NO3Si [M+Na] 340.1345, found 340.1347. 
FT-IR (cm-1, neat, ATR) 2951, 1740, 1719, 1247, 1208, 860. 
 
  
Methyl 1-(((3-Methylbut-3-en-1-yl)oxy)methyl)isoquinoline-3-carboxylate (2.10.3) 
Physical state: 55 mg, 64% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.54 (s, 1H), 8.49 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.78 
– 7.70 (m, 2H), 5.16 (s, 2H), 4.74 (s, 1H), 4.70 (s, 1H), 4.04 (s, 3H), 3.68 (t, J = 6.9 Hz, 2H), 2.32 
(t, J = 6.9 Hz, 2H), 1.68 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 166.4, 158.2, 142.8, 140.3, 136.3, 131.0, 129.6, 129.0, 128.6, 126.6, 
124.8, 111.7, 74.2, 69.4, 53.0, 37.9, 22.7. 
HRMS (ES+) m/z calc. for C17H19NO3Na [M+Na] 308.1263, found 308.1263. 
FT-IR (cm-1, neat, ATR) 2950, 1738, 1450, 1295, 1209, 1109. 
 
 
Methyl 1-((((1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl)oxy)methyl)isoquinoline-3-carboxylate 
(2.10.4) 
N
CO2Me
O
Me
N
CO2Me
OMe
Me
Me
	  88 
Physical state: 65 mg, 61% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.53 (s, 1H), 8.46 (d, J = 7.7 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.79 
– 7.70 (m, 2H), 5.30 (d, J = 11.3 Hz, 1H), 5.04 (d, J = 11.3 Hz, 1H), 4.04 (s, 3H), 3.28 (td, J = 10.5, 
4.1 Hz, 1H), 2.07 – 2.03 (m, 1H), 1.67 – 1.54 (m, 2H), 1.43 – 1.17 (m, 3H), 0.97 – 0.75 (m, 9H), 
0.43 (d, J = 6.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 166.6, 158.9, 140.3, 136.3, 130.9, 129.4, 129.2, 128.6, 127.0, 124.8, 
79.3, 71.3, 52.9, 48.5, 40.4, 34.6, 31.6, 25.3, 23.1, 22.5, 21.1, 15.7. 
HRMS (ES+) m/z calc. for C22H29NO3Na [M+Na] 378.2047, found 378.2045. 
FT-IR (cm-1, neat, ATR) 2954, 2869, 1722, 1244, 1108, 984, 907, 688, 646. 
 
 
Methyl 1-(3-(Benzyloxy)propyl)isoquinoline-3-carboxylate (2.10.5) 
Physical state: 52 mg, 56% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.03 (d, J = 7.4 Hz, 2H), 7.96 
(d, J = 8.1 Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.54 (t, J = 7.0 Hz, 1H), 7.42 
(t, J = 7.6 Hz, 2H), 4.41 (t, J = 6.4 Hz, 2H), 4.04 (s, 3H), 3.46 (t, J = 7.9 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 166.8, 162.5, 140.8, 136.1, 133.0, 133.0, 130.7, 130.6, 129.7, 
129.7, 129.52, 129.1, 128.5, 125.6, 123.1, 100.1, 77.4, 77.2, 76.9, 64.9, 64.8, 62.6, 53.0, 35.3, 29.4, 
29.0, 26.4, 25.4. 
HRMS (ES+) m/z calc. for C19H17NO3 [M+Na] 308.1287, found 308.1283. 
FT-IR (cm-1, neat, ATR) 2951, 1716, 1315, 1275, 1246, 712. 
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Methyl 1-Isobutylisoquinoline-3-carboxylate (2.10.6) 
Physical state: 45 mg, 62% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H), 8.21 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.71 
(m, 2H), 4.03 (s, 3H), 3.25 (d, J = 7.3 Hz, 2H), 2.32 (m, 1H), 0.98 (d, J = 6.7 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 166.9, 162.5, 140.8, 136.1, 130.5, 129.2, 129.0, 129.0, 125.9, 122.8, 
52.9, 44.1, 29.8, 22.9. 
HRMS (ES+) m/z calc. for C15H17NO2Na [M+Na] 266.1157, found 266.1161. 
FT-IR (cm-1, neat, ATR) 2955, 1737, 1718, 1294, 1242, 1205. 
 
 
Methyl 1-Benzylisoquinoline-3-carboxylate (2.10.7) 
Physical state: 56 mg, 67% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.51 (s, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.73 
– 7.68 (m, 1H), 7.64 – 7.60 (m, 1H), 7.27 – 7.20 (m, 4H), 7.19 – 7.13 (t, J = 7.0 Hz, 1H), 4.78 (s, 
2H), 4.07 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 166.7, 160.9, 140.8, 139.2, 136.4, 130.7, 129.6, 129.0, 128.8, 128.7 
128.7, 126.5, 126.4, 123.7, 53.0, 42.6. 
HRMS (ES+) m/z calc. for C18H16NO2 [M+H] 278.1181, found 278.1171. 
FT-IR (cm-1, neat, ATR) 2949, 1736, 1568, 1438, 1242, 1208, 1150, 1106, 742, 692. 
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Methyl 1-Phenethylisoquinoline-3-carboxylate (2.10.8) 
Physical state: 28 mg, 32% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.47 (s, 1H), 8.19 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.78 
– 7.66 (m, 2H), 7.32 – 7.15 (m, 5H), 4.06 (s, 3H), 3.76 – 3.62 (m, 2H), 3.28 – 3.15 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 166.8, 162.0, 141.8, 140.8, 136.1, 130.7, 129.5, 129.1, 128.6, 
128.6, 126.2, 125.5, 123.2, 53.0, 37.4, 35.6 (one aryl carbon peak overlaps). 
HRMS (ES+) m/z calc. for C19H18NO2 [M+H] 314.1157, found 314.1157. 
FT-IR (cm-1, neat, ATR) 2949, 1737, 1716, 1240, 1208, 749. 
 
 
Methyl 1-(3-Phenylpropyl)isoquinoline-3-carboxylate (2.10.9) 
Physical state: 76% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.06 (d, J = 8.3 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.76 – 7.68 
(m, 2H), 7.35 – 7.26 (m, 2H), 7.25 – 7.16 (m, 3H), 4.05 (s, 3H), 3.48 – 3.27 (m, 2H), 2.81 (t, J = 7.7 Hz, 2H), 
2.26 – 2.19 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 162.8, 142.1, 140.8, 136.1, 130.6 129.4, 129.0, 128.7, 128.5, 128.5, 
126.0, 125.6, 123.1, 53.0, 36.1, 35.2, 31.6. 
HRMS (ES+) m/z calc. for C20H20NO2 [M+H] 306.1494, found 306.1492. 
FT-IR (cm-1, neat, ATR) 2949, 1736, 1716, 1242, 1209, 747. 
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Methyl 1-(4-(2-Bromophenyl)butyl)isoquinoline-3-carboxylate (2.10.10) 
Physical state: 67 mg, 56% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.20 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.75 – 7.70 
(m, 2H), 7.51 (d, J = 8.0 Hz, 1H), 7.24 – 7.19 (m, 2H), 7.03 (s, 1H), 4.04 (s, 3H), 3.42 (t, J = 8.1 Hz, 2H), 
2.85 – 2.76 (m, 2H), 2.01 – 1.90 (m, 2H), 1.85 – 1.76 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 162.9, 141.7, 140.8, 136.1, 132.9, 130.6, 130.5, 129.4, 129.0, 128.5, 
127.6, 125.7, 124.6, 123.0, 53.0, 36.2, 35.7, 30.2, 29.8. 
HRMS (ES+) m/z calc. for C21H20BrNO2 [M+Na] 420.0575, found 420.0576. 
FT-IR (cm-1, neat, ATR) 2946, 1735, 1438, 1239, 1207, 1020, 748. 
 
 
Methyl 1-(3-(Phenylthio)propyl)isoquinoline-3-carboxylate (2.10.11) 
Physical state: 50 mg, 49% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.15 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.76 
– 7.70 (m, 1H), 7.70 – 7.64 (m, 1H), 7.36 (d, J = 7.7 Hz, 2H), 7.31 – 7.21 (m, 2H), 7.19 – 7.14 (m, 
1H), 4.04 (s, 3H), 3.58 – 3.46 (m, 2H), 3.11 (t, J = 7.0 Hz, 2H), 2.30 – 2.21 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.7, 161.9, 140.7, 136.5, 136.1, 130.7, 129.6, 129.4, 129.0, 128.5, 
126.1 125.6, 123.2, 53.0, 34.4, 33.6, 29.0 (one aryl peak overlaps). 
HRMS (ES+) m/z calc. for C20H20NO2S [M+H] 338.1215, found 338.1198. 
FT-IR (cm-1, neat, ATR) 2950, 1737, 1716, 1449, 1325, 1294, 1243, 1210. 
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Methyl 1-(3,3,3-Trifluoropropyl)isoquinoline-3-carboxylate (2.10.12) 
Physical state: 15 mg, 18% yield, viscous oil. 
1H NMR (500 MHz, CDCl3) δ 8.48 (s, 1H), 8.20 (d, J = 8.6 Hz, 1H), 8.06 – 7.93 (m, 1H), 7.86 – 
7.74 (m, 2H), 4.05 (s, 3H), 3.68 – 3.57 (m, 2H), 2.96 – 2.77 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.5, 158.7, 140.6, 136.0, 131.1, 130.1, 129.3, 128.4, 124.8, 
123.7, 53.1, 32.5 (q, J = 29.0 Hz), 29.0, 27.4. 
19F NMR (471 MHz, CDCl3) δ -66.42. 
HRMS (ES+) m/z calc. for C14H12F3NO2Na [M+Na] 306.0718, found 306.0721. 
FT-IR (cm-1, neat, ATR) 3071, 1715, 1240, 1126. 
 
 
Methyl 1-(But-3-en-1-yl)isoquinoline-3-carboxylate (2.10.16) 
Physical state: 40 mg, 55% yield, crystalline powder (mp = 54–57 °C). 
1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.21 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.76 
– 7.68 (m, 2H), 6.05 – 5.90 (m, 1H), 5.12 (d, J = 17.0 Hz, 1H), 5.01 (d, J = 10.2 Hz, 1H), 4.04 (s, 
3H), 3.47 (t, J = 8.2 Hz, 2H), 2.70 – 2.60 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.7, 162.3, 140.8, 137.8, 136.1, 130.6, 129.5, 129.1, 128.5, 125.6, 
123.1, 115.3, 53.0, 35.0, 33.8. 
HRMS (ES+) m/z calc. for C15H15NO2 [M+Na] 264.1000, found 264.0998. 
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FT-IR (cm-1, neat, ATR) 1748, 1656, 1596, 1157. 
 
 
4-Methyl-2-((2-(Trimethylsilyl)ethoxy)methyl)quinoline (2.11.1) 
Reference: Molander, G. A.; Colombel, V.; Braz, V. Org. Lett. 2011, 13, 1852. 
Physical state: 62 mg, 77% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.3 Hz, 1H), 7.71 – 7.66 (m, 
1H), 7.55 – 7.51 (m, 1H), 7.46 (s, 1H), 4.74 (s, 2H), 3.72 – 3.63 (m, 2H), 2.71 (s, 3H), 1.11 – 1.03 
(m, 2H), -0.03 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 159.3, 147.5, 145.0, 129.7, 129.3, 127.7, 126.1, 123.8, 120.2, 74.1, 
68.6, 19.0, 18.5, -1.2. 
FT-IR (cm-1, neat, ATR) 2953, 1603, 1249, 1101, 850, 836, 757. 
 
 
1-(4-Methylquinolin-2-yl)-3-phenylpropyl benzoate (2.11.2) 
Physical state: 48 mg, 42% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.15 (d, J = 7.7 Hz, 2H), 8.10 (d, J = 8.4 Hz, 1H), 7.97 (d, J = 8.3 
Hz, 1H), 7.72 – 7.69 (m, 1H), 7.62 – 7.59 (m, 1H), 7.56 – 7.52 (m, 1H), 7.51 – 7.47 (m, 2H), 7.34 
(s, 1H), 7.30 – 7.12 (m, 5H), 6.20 (dd, J = 8.3, 5.1 Hz, 1H), 2.90 – 2.78 (m, 2H), 2.69 (s, 3H), 2.60 
– 2.45 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 166.1, 159.7, 147.6, 145.3, 141.5 133.3, 130.3, 130.0, 129.4, 128.8, 
128.6, 128.4, 127.8, 126.5, 126.4, 126.1, 123.8, 119.1, 36.9, 32.1, 19.1. 
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HRMS (ES+) m/z calc. for C26H23NO2 [M+Na] 404.1626, found 404.1630. 
FT-IR (cm-1, neat, ATR) 1719, 1602, 1451, 1270, 1111, 1070, 1027, 713. 
 
 
2-((But-3-en-1-yloxy)methyl)quinoline (2.11.3) 
Physical state: 24 mg, 38% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.18 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.82 (d, J = 8.4 
Hz, 1H), 7.72 – 7.68 (m, 1H), 7.64 – 7.61 (m, 1H), 7.54 – 7.51 (m, 1H), 5.92 – 5.84 (m, 1H), 5.15 
– 5.06 (m, 2H), 4.82 (s, 2H), 3.65 (t, J = 6.6 Hz, 2H), 2.45 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 159.6, 147.7, 136.9, 135.3, 129.7, 129.1, 127.8, 127.7, 126.4, 119.5, 
116.7, 74.6, 70.5, 34.4. 
HRMS (ES+) m/z calc. for C14H16NO [M+H] 214.1232, found 214.1234. 
FT-IR (cm-1, neat, ATR) 2858, 1601, 1506, 1428, 1359, 1106, 996, 916, 829, 784, 755, 618. 
 
 
2-Octylquinoline (2.11.4) 
Physical state: 32 mg, 44% yield, yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.80 (d, J = 4.4 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 8.4 
Hz, 1H), 7.71 – 7.68 (m, 1H), 7.57 – 7.54 (m, 1H), 7.23 (d, J = 4.3 Hz, 1H), 3.09 – 3.04 (m, 2H), 
1.80 – 1.73 (m, 2H), 1.47 – 1.41 (m, 2H), 1.40 – 1.17 (m, 8H), 0.88 (t, J = 6.6 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 150.4, 148.9, 148.5, 130.4, 129.1, 127.8, 126.3, 123.8, 120.9, 32.3, 
32.0, 30.3, 29.9, 29.6, 29.4, 22.8, 14.2. 
HRMS (ES+) m/z calc. for C17H24N [M+H] 242.1909, found 242.1904. 
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FT-IR (cm-1, neat, ATR) 2924, 2855, 1592, 1508, 1463, 760. 
 
 
2-((2R)-2-Methylcyclopentyl)quinoline (2.11.5) 
Physical state: 38 mg, 60% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.08 – 8.04 (m, 2H), 7.77 (d, J = 8.1 Hz, 1H), 7.69 – 7.65 (m, 1H), 
7.49 – 7.45 (m, 1H), 7.31 (d, J = 8.6 Hz, 1H), 2.90 – 2.84 (m, 1H), 2.33 – 2.17 (m, 2H), 2.09 – 1.93 
(m, 2H), 1.92 – 1.77 (m, 2H), 1.45 – 1.37 (m, 1H), 1.01 (d, J = 6.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 165.6, 148.1, 136.2, 129.3, 129.2, 127.6, 127.1, 125.7, 120.4, 57.3, 
42.5, 35.2, 34.3, 24.5, 19.0. 
HRMS (ES+) m/z calc. for C15H18N [M+H] 212.1439, found 212.1444. 
FT-IR (cm-1, neat, ATR) 3050, 2946, 1601, 1255. 
 
1,1'-(3-Phenethylpyridine-2,6-diyl)bis(ethan-1-one) (2.11.6) 
Physical state: 52 mg, 65% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.04 (d, J = 8.0 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.30 – 7.25 (m, 
2H), 7.22 – 7.18 (m, 3H), 3.33 – 3.30 (m, 2H), 2.93 – 2.90 (m, 2H), 2.75 (s, 3H), 2.73 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 201.8, 199.4, 151.1, 150.6, 142.0, 141.0, 140.9, 128.8, 128.6, 126.4, 
123.7, 37.4, 35.4, 28.4, 25.7. 
HRMS (ES+) m/z calc. for C17H18NO2 [M+H] 268.1338, found 268.1339. 
FT-IR (cm-1, neat, ATR) 1699, 1358, 1296, 700. 
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2-(1-(Benzyloxy)-2-phenylethyl)benzo[d]thiazole (2.11.7) 
Physical state: 52 mg, 53% yield, colorless oil. 
1H NMR (500 MHz, CDCl3) δ 8.07 – 8.00 (m, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.52 – 7.47 (m, 1H), 
7.43 – 7.36 (m, 5H), 7.35 – 7.31 (m, 1H), 7.28 – 7.24 (m, 2H), 7.17 (d, J = 7.8 Hz, 3H), 4.85 (dd, 
J = 8.3, 4.8 Hz, 1H), 4.70 (d, J = 11.4 Hz, 1H), 4.52 (d, J = 11.4 Hz, 1H), 2.93 – 2.82 (m, 1H), 2.82 
– 2.71 (m, 1H), 2.41 – 2.29 (m, 1H), 2.29 – 2.19 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 175.4, 153.3, 141.3, 137.6, 135.1, 128.7, 128.6(5), 128.5(7), 128.3, 
128.1, 126.1(5), 126.1(3), 125.3, 123.2, 122.1, 79.0, 72.3, 38.9, 31.7. 
HRMS (ES+) m/z calc. for C23H23NOS [M+H] 360.1422, found 360.1420. 
FT-IR (cm-1, neat, ATR) 3027, 2922, 2861, 1516, 1495, 1093, 1027, 1014, 758, 697. 
 
 
3-Isopropyl-1H-indazole (2.11.8) 
Physical state: 33 mg, 69% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 9.84 (bs, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.45 – 7.42 (m, 1H), 7.38 – 
7.35 (m, 1H), 7.15 – 7.12 (m, 1H), 3.44 (sept, J = 7.0 Hz, 1H), 1.48 (d, J = 7.0 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 152.8, 141.6, 126.7, 121.4, 120.8, 120.2, 109.9, 27.9, 22.3. 
HRMS (ES+) m/z calc. for C10H12N2 [M+] 160.1000, found 160.1001. 
FT-IR (cm-1, neat, ATR) 3189, 2968, 1623, 1501, 1349, 742. 
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2-Isopropylquinazolin-4(3H)-one (2.11.9) 
Reference: Shen, G.; Zhou, H.; Sui, Y.; Liu, Q.; Zou, K. Tetrahedron Lett. 2016, 57, 587 
Physical state: 45 mg, 79% yield, white solid (mp = 123 °C). 
1H NMR (500 MHz, CDCl3) δ 11.64 (s, 1H), 8.30 (d, J = 7.9 Hz, 1H), 7.79 – 7.72 (m, 2H), 7.47 – 
7.45 (m, 1H), 3.06 (sept, J = 7.0 Hz, 1H), 1.45 (d, J = 7.0 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 164.4, 161.0, 149.6, 134.8, 127.5, 126.4, 126.4, 120.9, 35.1, 20.6. 
HRMS (ES+) m/z calc. for C11H12N2ONa [M+Na] 211.0847, found 211.0851. 
FT-IR (cm-1, neat, ATR) 2970, 2932, 1622, 1609, 1472, 1384, 1252, 772. 
 
 
2-((1R,2R)-2-Methylcyclohexyl)quinazolin-4(3H)-one (2.11.10) 
Physical state: 30 mg, 41% yield, white powder (mp = 89–93 °C). 
1H NMR (500 MHz, CDCl3) δ 11.48 (s, 1H), 8.29 (d, J = 7.9 Hz, 1H), 7.80 – 7.71 (m, 2H), 7.48 – 
7.46 (m, 1H), 2.39 – 2.33 (m, 1H), 2.05 – 1.96 (m, 2H), 1.92 – 1.73 (m, 4H), 1.57 – 1.49 (m, 1H), 
1.43 – 1.35 (m, 1H), 1.26 – 1.12 (m, 1H), 0.88 (d, J = 6.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 164.1, 159.9, 149.6, 134.8, 127.5, 126.4, 120.9, 100.1, 52.9, 35.2, 
35.2, 31.5, 26.2, 26.1, 20.6. 
HRMS (ES+) m/z calc. for C15H19N2O [M+H] 243.1497, found 243.1500. 
FT-IR (cm-1, neat, ATR) 2926, 1668, 1471, 773. 
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1,3,7-Trimethyl-8-((2S)-2-methylcyclopentyl)-3,7-dihydro-1H-purine-2,6-dione (2.11.11) 
Physical state: 31 mg, 37%, light yellow oil. 
1H NMR (500 MHz, CDCl3) δ 3.93 (s, 3H), 3.56 (s, 3H), 3.40 (s, 3H), 2.67 – 2.63 (m, 1H), 2.50 -
2.40 (m, 1H), 2.14 – 2.01 (m, 2H), 1.96 – 1.76 (m, 4H), 1.02 (d, J = 6.5 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.6, 155.5, 152.0, 148.4, 107.4, 44.8, 41.3, 34.6, 32.4, 31.7, 29.9, 
28.0, 24.2, 19.2. 
HRMS (ES+) m/z calc. for C14H21N4O2 [M+H] 277.1658, found 277.1661. 
FT-IR (cm-1, neat, ATR) 2954, 1703, 1661, 1543, 1436, 1221, 1041, 981, 747. 
 
 
(1R)-(2-Isopropyl-6-methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (2.11.12) 
Physical state: 82 mg, 75% yield, light yellow solid (mp = 145 °C). 
1H NMR (500 MHz, CDCl3) δ 7.89 (d, J = 9.1 Hz, 1H), 7.52 (s, 1H), 7.22 (d, J = 9.1 Hz, 1H), 7.07 
(s, 1H), 5.80 (s, 1H), 5.73 – 5.60 (m, 1H), 5.00 – 4.92 (m, 2H), 3.81 – 3.73 (m, 4H), 3.26 – 3.08 
(m, 3H), 2.85 – 2.75 (m, 3H), 2.42 – 2.35 (m, 1H), 1.90 – 1.80 (m, 2H), 1.65 – 1.60 (m, 1H), 1.49 
– 1.39 (m, 1H), 1.34 (d, J = 6.9 Hz, 6H) 
13C NMR (126 MHz, CDCl3) δ 164.7, 157.6, 146.3, 143.8, 140.1, 131.3, 124.7, 121.5, 116.5, 115.8, 
100.6, 60.2, 60.1, 56.2, 55.9, 43.7, 39.0, 37.2, 27.7, 26.4, 22.7, 20.2. 
O N
N
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HRMS (ES+) m/z calc. for C23H30N2O2 [M+H] 367.2361, found 367.2394. 
FT-IR (cm-1, neat, ATR) 2962, 1674, 1620, 1236. 
 
 
2,9-Di-tert-butyl-1,10-phenanthroline (2.12.2) 
Reference: Xu, C.; Zhang, L.; Dong, C.; Xu, J.; Pan, Y.; Li, Y.; Zhang, H.; Li, H.; Yu, Z.; Xu, L. 
Adv. Synth. Catal. 2016, 358, 567. 
Physical state: 38 mg, 42% yield, white semi-solid. 
1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 8.4 Hz, 2H), 7.84 – 7.48 (m, 4H), 1.60 (s, 18H). 
13C NMR (126 MHz, CDCl3) δ 169.4, 145.0, 136.0, 127.0, 125.5, 119.7, 38.8, 30.4. 
HRMS (ES+) m/z calc. for C20H25N [M+H] 293.2018, found 293.2020. 
FT-IR (cm-1, neat, ATR) 2962, 1589, 1489, 1387, 850. 
 
 
2,9-Di-tert-butyl-4,7-diphenyl-1,10-phenanthroline (2.12.4) 
Reference: Sugihara, S.; Okada, T.; Hiratani, K. Anal. Sci. 1993, 9, 593. 
Physical state: 152 mg, 68% yield, yellow oil. 
1H NMR (500 MHz, CDCl3) δ 7.72 (s, 2H), 7.63 (s, 2H), 7.56 – 7.43 (m, 10H), 1.64 (s, 18H). 
13C NMR (126 MHz, CDCl3) δ 168.8, 148.4, 145.7, 139.2, 129.9, 128.6, 128.2, 124.9, 123.1, 
120.1, 38.9, 30.5. 
N N
t-Bu t-Bu
N N
t-Bu t-Bu
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2-(tert-Butyl)-6-(2,4-difluorophenyl)pyridine (2.12.6) 
Physical state: 61 mg, 82% yield, light yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.61 (d, J = 5.1 Hz, 1H), 7.96 (m, 1H), 7.72 (s, 1H), 7.28 – 7.22 (m, 
1H), 6.99 (t, J = 8.4 Hz, 1H), 6.91 (m, 1H), 1.36 (s, 9H). 
13C NMR (126 MHz, CDCl3) δ 163.2 (dd, J = 250.5, 12.1 Hz), 160.6 (dd, J = 252.0, 11.9 
Hz), 160.6, 149.8, 132.4 (dd, J = 9.7, 4.6 Hz), 124.5 (dd, J = 12.0, 3.9 Hz), 122.6, 121.5 (d, J = 
8.9 Hz), 119.7, 111.9 (dd, J = 21.0, 3.8 Hz), 104.4 (m), 35.0, 30.7. 
HRMS (ES+) m/z calc. for C15H16F2N [M+H] 248.1251, found 248.1241. 
FT-IR (cm-1, neat, ATR) 2949, 1736, 1716, 1242, 1209, 747, 700. 
 
 
6-(tert-Butyl)-2,2':6',2''-terpyridine (2.12.8) 
Physical state: 64 mg, 74% yield, yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.75 (s, 1H), 8.71 – 8.60 (m, 3H), 8.45 (m, 2H), 7.94 (m, 1H), 
7.86 (m, 1H), 7.33 (dt, J = 6.7, 3.5 Hz, 2H), 1.43 (s, 9H). 
N
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N N
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13C NMR (126 MHz, CDCl3) δ 160.9, 156.3, 155.6, 149.3, 149.3, 138.1, 137.0, 137.0, 123.9, 
121.3, 121.1, 121.1, 121.0, 120.9, 118.2, 35.1, 30.7. 
HRMS (ES+) m/z calc. for: submitted. 
FT-IR (cm-1, neat, ATR) 2963, 1602, 1579, 1548, 1456, 1391, 820, 770. 
 
 
4-((Benzyloxy)methyl)-5-bromopyrimidine (2.13.1) 
Physical state: 42 mg, 50% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 9.13 (s, 1H), 8.77 (s, 1H), 7.43 – 7.30 (m, 5H), 4.73 (s, 2H), 4.71 
(s, 2H). 
13C NMR (126 MHz, CDCl3) δ 164.1, 158.9, 157.1, 137.4, 128.7, 128.2, 128.2, 120.3, 73.7, 71.1. 
HRMS (ES+) m/z calc. for C12H12BrN3O [M+H] 279.0133, found 279.0135. 
FT-IR (cm-1, neat, ATR) 2860, 1560, 1454, 1388, 1360, 1216, 1097, 1036, 738, 698. 
 
 
3-Bromo-4-methyl-2-(1-tosylpiperidin-4-yl)pyridine and 5-bromo-4-methyl-2-(1-tosylpiperidin-
4-yl)pyridine (2.13.2) 
Physical state: 69 mg, 57% yield, white amorphous solid (mp = 120–122 °C). 
1H NMR (500 MHz, CDCl3) δ 8.52 (s, 1H – minor isomer), 8.31 (d, J = 4.8 Hz, 1H – major isomer), 
7.72 – 7.67 (m, 3H – both isomers), 7.38 – 7.33 (m, 2H -  both isomers), 7.01 (d, J = 4.8 Hz, 1H – 
N N
Br
OBn
N
Me
Br
TsN
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major isomer), 6.99 (s, 2H – minor isomer), 3.94 (m, 2H – both isomers), 3.16 (m, 1H – both 
isomers), 2.61 – 2.34 (m, 8H – both isomers), 2.12 – 1.79 (m, 4H – both isomers). 
13C NMR (126 MHz, CDCl3) δ 161.0, 147.6, 147.1, 129.5, 127.7, 127.6, 123.94, 122.91, 121.68, 
46.37, 41.60, 29.77, 23.46, 21.44. (major peaks) 
HRMS (ES+) m/z calc. for C18H22BrN2O2S [M+H] 408.0585, found 409.0586. 
FT-IR (cm-1, neat, ATR) 3052, 2915, 2801, 1351, 1331, 1160, 927, 726, 648, 548. 
 
 
3-Bromo-4-methyl-2-phenethylpyridine (2.13.3) 
Physical state: 50 mg, 60% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.33 (d, J = 4.8 Hz, 1H), 7.30 (d, J = 4.4 Hz, 4H), 7.21 (p, J = 4.1 
Hz, 1H), 7.03 (d, J = 4.8 Hz, 1H), 3.37 – 3.22 (m, 2H), 3.05 (dd, J = 10.2, 6.7 Hz, 2H), 2.43 (s, 
3H). 
13C NMR (126 MHz, CDCl3) δ 159.9, 147.9, 147.2, 141.9, 128.6, 128.5, 126.1, 124.3, 123.9, 40.4, 
34.8, 23.6. 
HRMS (ES+) m/z calc. for C14H14BrN [M+H] 276.0388, found 276.0388. 
FT-IR (cm-1, neat, ATR) 1727, 1591, 1435, 1281, 1258, 1084, 738, 698. 
 
  
4-Chloro-2-phenethylquinoline (2.13.4) 
Physical state: 38 mg, 47% yield, clear oil. 
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1H NMR (500 MHz, CDCl3) δ 8.20 (d, J = 8.3 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.76 (t, J = 7.7 
Hz, 1H), 7.60 (t, J = 7.6 Hz, 1H), 7.35 (s, 1H), 7.30 (t, J = 7.5 Hz, 2H), 7.22 (dd, J = 15.9, 8.7 Hz, 
2H), 3.29 – 3.23 (m, 2H), 3.16 (dd, J = 9.7, 6.3 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 161.9, 149.0, 142.7, 141.3, 130.5, 129.4, 128.6, 126.9, 126.3, 
125.2, 124.1, 121.7, 40.9, 35.8. 
HRMS (ES+) m/z calc. for C17H15ClN [M+H] 268.0893, found 268.0896. 
FT-IR (cm-1, neat, ATR) 3062, 3027, 1589, 1493, 1149, 866, 759, 698. 
 
 
4-Bromo-3-isopropylisoquinoline (2.13.5) 
Physical state: 30 mg, 40% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.67 (s, 1H), 8.24 – 8.18 (m, 2H), 7.79 – 7.76 (m, 1H), 7.67 – 7.64 
(m, 1H), 3.91 (sept, J = 6.8 Hz, 1H), 1.43 (d, J = 6.8 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 166.1, 143.8, 135.0, 130.9, 127.9, 127.7, 127.0, 125.2, 117.7, 31.2, 
22.3. 
HRMS (ES+) m/z calc. for C12H13BrN [M+H] 250.0231, found 250.0224. 
FT-IR (cm-1, neat, ATR) 2965, 2929, 1565, 1387, 1240, 1009, 928. 
 
 
4-Bromo-1-isopropylisoquinoline (2.13.6) 
N
Br
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Physical state: 22 mg, 29% yield, clear oil. 
1H NMR (500 MHz, CDCl3) δ 8.51 (s, 1H), 8.35 (d, J = 8.5 Hz, 1H), 7.62 – 7.59 (m, 1H), 7.52 – 
7.49 (m, 1H), 7.43 (d, J = 8.5 Hz, 1H), 4.08 (sept, J = 6.8 Hz, 1H), 1.55 (d, J = 6.8 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 166.8, 143.2, 136.3, 129.9, 127.1, 126.9, 126.3, 125.9, 125.1, 31.3, 
22.4. 
HRMS (ES+) m/z calc. for C12H14BrN [M+H] 250.0231, found 250.0224. 
FT-IR (cm-1, neat, ATR) 2965, 1556, 1502, 1388, 1246, 765. 
 
 
Potassium Trifluoro(2-methyl-1-phenylpropan-2-yl)borate (1u) 
Synthesized using Silas’ procedure from (2-bromo-2-methylpropyl)benzene (J. Am. Chem. Soc. 
2016, 138, 6139) in 70% yield (~85% purity by mass), 840 mg white crystalline solid (mp = 170 – 
172 °C). 
1H NMR (500 MHz, acetone-d6) δ 7.16 – 7.13 (m, 2H), 7.08 – 7.05 (m, 3H), 2.52 (s, 2H), 0.63 (s, 
6H). Peaks at 0.75 and 0.13 correspond to EtBF3K generated during borylation procedure. 
13C NMR (126 MHz, acetone-d6) δ 142.1, 130.5, 126.6, 124.2, 44.5, 22.5 (carbon α to boron not 
observed due to quadrupolar relaxation). 
19F NMR (470.7 MHz, acetone-d6) δ -153.1 (product), -142.7 (EtBF3K). 
11B NMR (128.4 MHz, acetone-d6) δ -6.43. 
HRMS (ES+) m/z calc. for C10H13BF3- [M-] calc. 201.0198, found: submitted. 
FT-IR (cm-1, neat, ATR) 2970, 2928, 2861, 1467, 1225, 1019, 945, 749, 702. 
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CYCLIC VOLTAMMETRY OF TERT-BUTYL TRIFLUOROBORATE 
Electrochemical measurements were recorded on a CH Instruments: Model 600E Series 
Electrochemical Analyzer (observed in 0.002 M MeCN; [N(Bu)4](PF6) = 0.1 M; Ag/AgCl = 
electrode; reported in SCE based on a ferrocene internal standard). 
 
 
 
 
 
 
 
 
 
 
 
Of the organoboron reagents examined, only the potassium cyclohexyltriolborate XX (~1.1 V vs 
SCE) and potassium cyclohexyltrifluoroborate (~1.5 V vs SCE) exhibited oxidations within the 
solvent window of MeCN. These potentials have been reported previously by Akita and coworkers 
(Adv. Synth. Cat. 2012, 354 (18), 3414). No features were observed for oxidation of the cyclohexyl 
boronic acid, MIDA, and pincaol boronates. 
 
 
 
 
-­‐8.00E-­‐05
-­‐7.00E-­‐05
-­‐6.00E-­‐05
-­‐5.00E-­‐05
-­‐4.00E-­‐05
-­‐3.00E-­‐05
-­‐2.00E-­‐05
-­‐1.00E-­‐05
0.00E+00
1.00E-­‐05
2.00E-­‐05
-­‐0.500.511.522.5
t-BuBF3K Oxidation Potential
	  106 
1H (CDCl3, 500 MHz) spectra of  2-(tert-butyl)quinoline (2.7.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  107 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)quinoline (2.7.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  108 
1H (CDCl3, 500 MHz) spectra of  2-(tert-butyl)-4-methylquinoline (2.7.2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  109 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)-4-methylquinoline (2.7.2)  
 
 
 
 
 
 
 
 
 
 
	  110 
1H (CDCl3, 500 MHz) spectra of 4-bromo-2-(tert-butyl)quinoline (2.7.3)  
 
 
 
 
 
 
 
 
 
	  111 
13C NMR (CDCl3, 125.8 MHz) spectrum of 4-bromo-2-(tert-butyl)quinoline (2.7.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  112 
1H (CDCl3, 500 MHz) spectra of  2-(tert-butyl)-4-chloro-8-(trifluoromethyl)quinoline (2.7.4)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  113 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)-4-chloro-8-(trifluoromethyl)quinoline 
(2.7.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  114 
1H (CDCl3, 500 MHz) spectra of  3-(tert-butyl)-1H-indazole (2.7.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  115 
13C NMR (CDCl3, 125.8 MHz) spectrum of 3-(tert-butyl)-1H-indazole (2.7.5)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  116 
1H (CDCl3, 500 MHz) spectra of methyl 1-(tert-butyl)isoquinoline-3-carboxylate (2.7.6)  
 
 
 
 
 
 
 
 
 
 
	  117 
13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(tert-butyl)isoquinoline-3-carboxylate 
(2.7.6) 
 
 
 
 
 
 
 
 
 
 
 
 
	  118 
1H (CDCl3, 500 MHz) spectra of 2-(tert-butyl)quinoxaline (2.7.8)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  119 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)quinoxaline (2.7.8)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  120 
1H (CDCl3, 500 MHz) spectra of 2-(tert-butyl)-3-chloroquinoxaline (2.7.9)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  121 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)-3-chloroquinoxaline (2.7.9)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  122 
1H (CDCl3, 500 MHz) spectra of 6-(tert-butyl)nicotinonitrile (2.7.10)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  123 
13C NMR (CDCl3, 125.8 MHz) spectrum of 6-(tert-butyl)nicotinonitrile (2.7.10)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  124 
19F (CDCl3, 477 MHz) spectra of 2-(tert-Butyl)-4-(trifluoromethyl)pyridine (2.7.11) with 
fluorobenzene 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product peak 
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1H (CDCl3, 500 MHz) spectra of 1,1'-(4-(tert-butyl)pyridine-2,6-diyl)bis(ethan-1-one) (2.7.12)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  126 
13C NMR (CDCl3, 125.8 MHz) spectrum of 1,1'-(4-(tert-butyl)pyridine-2,6-diyl)bis(ethan-1-one) 
(2.7.12)  
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1H (CDCl3, 500 MHz) spectra of 8-(tert-butyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione 
(2.7.13)  
 
 
 
 
 
 
 
 
 
 
 
 
	  128 
13C NMR (CDCl3, 125.8 MHz) spectrum of 8-(tert-butyl)-1,3,7-trimethyl-3,7-dihydro-1H-
purine-2,6-dione (2.7.13)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  129 
1H (CDCl3, 500 MHz) spectra of 2-(tert-butyl)nicotinamide (2.7.14)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  130 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)nicotinamide (2.7.14)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  131 
1H (CDCl3, 500 MHz) spectra of 2-(tert-butyl)benzo[d]thiazole (2.7.15)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  132 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)benzo[d]thiazole (2.7.15)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  133 
1H (CDCl3, 500 MHz) spectra of 2-(tert-butyl)quinazolin-4(3H)-one (2.7.16)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  134 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(tert-butyl)quinazolin-4(3H)-one (2.7.16)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  135 
1H (CDCl3, 500 MHz) spectra of N-benzyl-2-(tert-butyl)-7H-purin-6-amine (2.7.18)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  136 
13C NMR (CDCl3, 125.8 MHz) spectrum of N-benzyl-2-(tert-butyl)-7H-purin-6-amine (2.7.18)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  137 
1H (CDCl3, 500 MHz) spectra of (1R)-(2-(tert-butyl)-6-methoxyquinolin-4-yl)(5-vinylquinuclidin-
2-yl)methanol (2.7.19)  
 
 
 
 
 
 
 
 
 
 
 
 
	  138 
13C NMR (CDCl3, 125.8 MHz) spectrum of (1R)-(2-(tert-butyl)-6-methoxyquinolin-4-yl)(5-
vinylquinuclidin-2-yl)methanol (2.7.19)  
 
 
 
 
 
 
 
 
 
 
 
 
	  139 
1H (CDCl3, 500 MHz) spectra of 1,3,9-trimethyl-8-(2-methyl-1-phenylpropan-2-yl)-3,9-dihydro-
1H-purine-2,6-dione (2.8.4)  
 
 
 
 
 
 
 
 
 
 
 
 
	  140 
13C NMR (CDCl3, 125.8 MHz) spectrum of 1,3,9-trimethyl-8-(2-methyl-1-phenylpropan-2-yl)-
3,9-dihydro-1H-purine-2,6-dione (2.8.4)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  141 
1H (CDCl3, 500 MHz) spectra of 2-(2-methyl-1-phenylpropan-2-yl)benzo[d]thiazole (2.8.5)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  142 
13C NMR (CDCl3, 125.8 MHz) spectrum of 2-(2-methyl-1-phenylpropan-2-yl)benzo[d]thiazole 
(2.8.5)  
 
 
 
 
 
 
 
 
 
 
 
 
	  143 
1H (CDCl3, 500 MHz) spectra of methyl 1-(1-(benzyloxy)-3-phenylpropyl)isoquinoline-3-
carboxylate (2.9.1)  
 
 
 
 
 
 
 
 
	  144 
13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-(benzyloxy)-3-
phenylpropyl)isoquinoline-3-carboxylate (2.9.1)  
 
 
 
 
 
 
 
 
 
 
 
	  145 
1H (CDCl3, 500 MHz) spectra of methyl 1-(4,4-difluorocyclohexyl)isoquinoline-3-carboxylate 
(2.9.2)  
 
 
 
 
 
 
 
 
 
 
 
 
	  146 
13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(4,4-difluorocyclohexyl)isoquinoline-3-
carboxylate (2.9.2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  147 
1H (CDCl3, 500 MHz) spectra of methyl 1-(tetrahydro-2H-pyran-4-yl)isoquinoline-3-carboxylate 
(2.9.3)  
 
 
 
 
 
 
 
 
	  148 
13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(tetrahydro-2H-pyran-4-yl)isoquinoline-3-
carboxylate (2.9.3)  
 
 
 
 
 
 
 
 
 
	  149 
1H (CDCl3, 500 MHz) spectra of methyl 1-(1-tosylpiperidin-4-yl)isoquinoline-3-carboxylate 
(2.9.4)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  150 
13C (CDCl3, 125.8 MHz) spectra of methyl 1-(1-tosylpiperidin-4-yl)isoquinoline-3-carboxylate 
(2.9.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  151 
1H (CDCl3, 500 MHz) spectra of methyl 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)isoquinoline-3-
carboxylate (2.9.5)  
 
 
 
 
 
 
 
 
 
 
 
 
	  152 
13C (CDCl3, 125.8 MHz) spectra of methyl 1-(1-(tert-butoxycarbonyl)piperidin-4-yl)isoquinoline-
3-carboxylate (2.9.5)  
 
 
 
 
 
 
 
 
 
 
 
	  153 
1H (CDCl3, 500 MHz) spectra of methyl 1-(1-hydroxy-3-phenylpropan-2-yl)isoquinoline-3-
carboxylate (2.9.6)  
 
 
 
 
 
 
 
 
 
 
 
	  154 
13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-hydroxy-3-phenylpropan-2-
yl)isoquinoline-3-carboxylate (2.9.6)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  155 
1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(tetrahydrofuran-3-yl)isoquinoline-3-
carboxylate (2.9.7)  
 
 
 
 
 
 
 
 
 
 
 
 
	  156 
1C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(tetrahydrofuran-3-yl)isoquinoline-3-
carboxylate (2.9.7)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  157 
1H NMR (CDCl3, 500 MHz) spectrum of methyl 1-(1-(tert-butoxycarbonyl)azetidin-3-
yl)isoquinoline-3-carboxylate (2.9.9)  
 
 
 
 
 
 
 
 
 
 
 
 
 
	  158 
13C NMR (CDCl3, 125.8 MHz) spectrum of methyl 1-(1-(tert-butoxycarbonyl)azetidin-3-
yl)isoquinoline-3-carboxylate (2.9.9)  
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Chapter 3. Accesssing Novel Heteroaryl Chromanones via Photoredox-Mediated Alkylation 
 
3.1 Introduction 
 For decades, chromanones have captured the attention of the synthetic community because 
of their prevalence in natural products and in unnatural, biologically relevant compounds.1† Given 
the immense interest in the chromanone cores as potential pharmacological cores, numerous 
biochemists have studied the biological pathway used to construct the flavone moieties. Based on 
these aforementioned studies, the proposed biological pathway starts with acetyl CoA and a 
chalcone scaffold.2 After the initial coupling, the requisite chalcone can cyclize via an oxo-Michael 
addition to the enone to afford various flavanones. Subesquent in vivo modifications provide 
unsaturated bioactive intermediates. 
  
Figure 3.1. Flavone biosynthesis. 
 
 
 
† Reproduced in part from Matsui, J. K.; Molander, G. A. Org. Lett. 2017, 19, 950. 
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Although there are a large number of 2-aryl-substituted chromanones reported in the 
literature, there remain significant gaps among certain subclasses of these molecules.  For example, 
there are less than 30 reported 2-quinolinyl-substituted 4-chromanones and no examples of 2-
isoquinolinyl-substituted 4-chromanones. 
To date, 2-aryl-4-chromanones are primarily accessed through a chalcone precursor that is 
subsequently cyclized to form the pyranone ring under acidic (Figure 3.2), basic, or photochemical 
conditions.3 Although these routes are effective for providing targeted substructures, accessing a 
diverse array of aryl- or heteroaryl-substituted chromanones is challenging using a late-stage 
cyclization pathway. 
  
Figure 3.2. Oxa-Michael cyclization to access flavanones. 
 
3.2 Reaction Design and Results 
 Inspired by these shortcomings, a photocatalyzed Minisci reaction was envisioned. Thus, 
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sustainable approach to molecule construction that is being employed with increasing frequency.4 
Until recently, Minisci reactions typically required superstoichiometric amounts of oxidant for 
radical generation under forcing conditions.5 Notably, our laboratory demonstrated trifluoroborates 
to be viable radical sources under “classical” Minisci reaction conditions, requiring either 
manganese or silver oxidant.5f,g Radical intermediates have been accessed via photocatalysis in a 
significantly milder manner, but limitations remain, including the need for excess radical 
precursor,4d expensive photocatalysts,4e or complex radical precursors that limit substrate scope.4e 
Keeping these limitations in mind, alkyltrifluoroborates appeared to be an attractive alternative 
given the precedent for single-electron oxidation of trifluoroborates via photoredox catalysis 
reported by Akita and coworkers.6 Therefore, a robust method was sought to harness the reactivity 
of 2-trifluoroborato-4-chromanones as radical precursors to construct a wide range of 2-heteroaryl-
4-chromanones in a photo-catalytic fashion that would address the shortcomings of previously 
reported methods. 
In this vein, we recently developed a protocol for alkylation of heteroarenes in which 
primary, secondary, and tertiary alkyltrifluoroborates could be used in photoredox Minisci 
chemistry,7 allowing alkylation of numerous heteroarenes. The chemistry made use of an organic 
photocatalyst (a mesityl acridinium dye) and an inexpensive, mild oxidant, and required only one 
equivalent of alkyltrifluoroborate as an alkyl radical precursor (Figure 3.3).  
  
Figure 3.3. Previous demonstration of photoredox alkyltrifluoroborate C–H alkylation. 
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suitable photocatalyst possessed a redox potential sufficiently high to induce a single-electron 
oxidation of the trifluoroboratochromanone (I) to afford the a-alkoxy radical (II). The stabilized 
radical (II) would add to the heteroarene, activated by a Bronsted acid. An appropriate oxidant 
would be required to regenerate the ground state photocatalyst as well as to rearomatize 
intermediate III via hydrogen atom transfer (HAT). 
 
Figure 3.4. Proposed mechanism. 
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Figure 3.5. Borylation procedure for enone scaffolds. 
 
As alluded to above, access to the requisite 2-trifluoroborato-4-chromanones was achieved 
through a conjugate borylation reaction previously reported by our group (Figure 3.5).8 Although 
a variety of cyclic and acyclic enones were reported to engage in the b-borylation, to the best of 
our knowledge there were no reports of pyranone borylation (Figure 3.6). Nonetheless, with 
minimal optimization a variety of chromanones were acquired with excellent tolerance of 
functional groups and diverse substitution patterns (Figure 3.7). 
 
Figure 3.6. Literature search for pyranone core. 
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Figure 3.7. Borylation of chromanone scaffolds. 
 
With several 2-trifluoroborato-4-chromanones in hand, the development of the Minisci 
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Figure 3.8. Optimization and control studies. 
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Figure 3.9. Stern-Volmer results. 
 
 
Figure 3.10. Dynamic versus static quenching pathways. 
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light to demonstrate that the catalyst is active only in its photoexcited state.15 With the completion 
of control experiments and Stern-Volmer quenching studies, we proposed the mechanism outlined 
in Figure 3.4. 
With suitable conditions in hand, the substrate scope for the heteroarene partners was 
explored (Figure 3.11). Lepidine, a prototypical substrate in Minisci chemistry,3 was first used as 
a reacting partner. As expected, 3.11.1 was obtained regioselectively in relatively high yield (61%). 
Product 3.11.2 was obtained along with trace amounts of regioisomers, but was primarily selective 
ortho to the nitrogen.  
  
Figure 3.11. Trifluoroboratochromanone coupling with heteroarenes. 
 
Steric sensitivity was probed with 3-bromoquinoline, affording a lower yield of 3.11.3 
(33%). When 4-bromoquinoline was used, the yield of 3.11.4 improved to 50%. Notably, when the 
reaction was performed on gram scale, the yield was a comparable 46% yield. Conversion was 
significantly higher with 4-chloroquinoline, which provided an excellent yield of 3.11.5. 2-
Chloroquinoline was next explored, and selective addition to the 4-position was observed (3.11.6). 
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With a more decorated chloroquinoline, 4-chloro-8-(trifluoromethyl)quinoline, a modest 32% yield 
was achieved. Halogenated isoquinolines were next explored to access products possessing 
functional handles for further diversification (Figure 3.12). 1-Chloroisoquinoline afforded a lower 
30% yield (3.12.1), but when the halide was appended on the adjacent ring, the yield improved to 
50% (3.12.2). Alkyl substitution at the C4 position resulted in <5% conversion, suggesting 
electron-withdrawing groups enhance the electrophilicity of the isoquinoline moieties. The scope 
was further explored with substrates containing more heteroatoms. Quinoxaline yielded mono-
substituted product 3.12.4 in 66% yield. A slightly lower yield of 3.12.5 was observed with 2-
chloroquinoxaline. Caffeine, another nitrogen-rich heteroarene, also provided a modest yield of the 
alkylated product (3.12.6). Pyridine moieties, a common pharmacophore in medicinal chemistry,16 
were next probed. After screening various para-substituted pyridines, 4-trifluoromethylpyridine 
yielded 3.12.7 in a modest yield. Other, more electron rich, systems (e.g., substituted pyrazine 
3.12.8 and benzothiazole 3.12.9) could not be accessed. Typically, more electrophilic radicals such 
as CF3 provide higher yields in reactions with such electron-rich heteroarenes.4a  
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Figure 3.12. Expanding heteroarene scope. 
 
Because 6-bromo-2-trifluoroboratochromanone (Figure 3.13) has potential for elaboration 
on the aryl ring, an array of substrates was explored to confirm that the reactivity was similar to 
that of the unfunctionalized trifluoroboratochromanone. 
  
Figure 3.13. Borylation of bromo-chromanone. 
 
Coupling the bromo-substituted trifluoroboratochromanone with 4-chloroquinoline 
resulted in a markedly higher yield (3.14.1). Other functionalized quinolines resulted in more 
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modest yields (3.14.2–3.14.4). Isoquinoline 3.14.5 could not be accessed utilizing this protocol, but 
quinoxaline 3.14.6 was generated in 63% yield.  
  
Figure 3.14. Mixed table using bromotrifluoroboratochromanone. 
 
Finally, functionalized trifluoroboratochromanones were coupled with a variety of 
heteroarenes. Alkyl substitution (Figure 3.15) yielded similar results to the unfunctionalized 
trifluoroborate. Suprisingly, heteroaryl substitution on the aryl ring led to markedly higher yields 
(3.15.1, 3.14.3). 
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Figure 3.15. Introducing functionality on aryl ring. 
 
3.3 Conclusion 
In conclusion, a new class of 2-heteroaryl-substituted 4-chromanones has been accessed 
via sustainable photoredox-catalyzed coupling with a variety of heteroarene partners. An 
inexpensive organophotocatalyst was utilized to provide markedly higher yields relative to precious 
metal photocatalysts. This reaction proceeds chemo- and regioselectively, providing a viable 
method for radical-induced C–H functionalization of activated heteroarenes. The net result is an 
efficient, robust, and reasonably general route to a class of compounds that, as a class, is 
underrepresented in the current literature. 
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GENERAL PROCEDURE FOR PHOTOREDOX CATALYZED MINISCI COUPLING 
An 8 mL vial equipped with a stir bar was added trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 
heterocycle (0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 
0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The vial was then evacuated 
and purged three times. Under nitrogen, degassed MeCN/H2O (1:1, 4.0 mL) and trifluoroacetic acid 
(38 µL, 0.50 mmol, 1.0 equiv) were added in quick succession. The resulting solution was stirred 
next to two 26 W CFLs under a fan for 16–24 h. After completion, the mixture was quenched with 
saturated sodium bicarbonate (10 mL) and transferred to a separatory funnel with CH2Cl2 (15 mL) 
and extracted with CH2Cl2 (2 x 15 mL). The organic layers were combined and dried over Na2SO4 
and dry loaded with Celite. The crude mixture was purified by column chromatography. 
 
 
 
2-(4-Methylquinolin-2-yl)chroman-4-one (3.11.1) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), lepidine 
(66 µL, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 
mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound was purified 
by column chromatography (silica gel, 4:1 hexanes/EtOAc), affording the coupled product (88 mg, 
61% yield) as a yellow oil. 
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1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 8.4 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.84 – 7.76 (m, 
2H), 7.73 (s, 1H), 7.70 – 7.64 (m, 1H), 7.64 – 7.58 (m, 1H), 7.17 (d, J = 8.3 Hz, 1H), 7.11 (t, J = 
7.5 Hz, 1H), 5.93 (dd, J = 11.0, 3.6 Hz, 1H), 3.45 (dd, J = 16.9, 11.0 Hz, 1H), 3.16 – 3.05 (m, 1H), 
2.75 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 191.8, 161.2, 157.5, 147.5, 145.9, 136.2, 130.2, 129.7, 128.0, 127.3, 
126.8, 123.9, 121.9, 121.5, 119.3, 118.3, 80.7, 42.8, 19.2. 
FT-IR (cm-1, neat, ATR) 3066, 1657, 1607, 1355, 1224, 763. 
HRMS (ES+) m/z calc. for C19H16NO2 [M+H] 290.1181, found 290.1180. 
 
 
 
2-(Quinolin-2-yl)chroman-4-one (3.11.2) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), quinoline 
(64.6 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 
mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound was purified 
by column chromatography (silica gel, 4:1 hexanes/EtOAc), affording the coupled product (96 mg, 
70% yield) as a light yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 8.26 (d, J = 8.5 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 8.2 
Hz, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.76 (dd, J = 18.0, 8.1 Hz, 2H), 7.55 (dt, J = 23.1, 7.6 Hz, 2H), 
7.12 (d, J = 8.3 Hz, 1H), 7.07 (t, J = 7.5 Hz, 1H), 5.80 (dd, J = 11.8, 3.8 Hz, 1H), 3.33 (dd, J = 
17.0, 11.8 Hz, 1H), 3.24 (dd, J = 17.0, 3.7 Hz, 1H). 
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13C NMR (126 MHz, CDCl3) δ 191.7, 161.1, 157.9, 147.6, 137.5, 136.3, 130.1, 129.6, 127.9, 127.8, 
127.3, 127.1, 121.9, 121.5, 118.6, 118.3, 80.5, 42.8. 
FT-IR (cm-1, neat, ATR)  3075, 1691, 1607, 1464, 1305, 1223, 763. 
HRMS (ES+) m/z calc. for C18H14NO2 [M+H] 276.1025, found 276.1025. 
 
 
 
2-(3-Bromoquinolin-2-yl)chroman-4-one (3.11.3) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 3-
bromoquinoline (103.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), 
affording the coupled product (58 mg, 33% yield) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 9.00 (s, 1H), 8.61 (dd, J = 8.4, 2.9 Hz, 1H), 8.21 – 8.15 (m, 1H), 
8.04 (dt, J = 8.0, 2.0 Hz, 1H), 7.82 – 7.74 (m, 1H), 7.65 – 7.53 (m, 2H), 7.16 (td, J = 7.6, 2.4 Hz, 
1H), 7.08 (dd, J = 8.3, 2.5 Hz, 1H), 6.45 (dd, J = 14.5, 3.2 Hz, 1H), 3.50 (ddd, J = 17.1, 14.9, 2.4 
Hz, 1H), 2.90 (dd, J = 17.3, 3.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 190.4, 160.9, 152.2, 147.9, 140.7, 136.6, 130.8, 130.0, 127.8, 127.7, 
126.9, 125.2, 122.6, 121.2, 118.4, 82.0, 80.0, 41.4. 
FT-IR (cm-1, neat, ATR) 3050, 2900, 1681, 1601, 1472, 1464, 1306, 1224, 731. 
HRMS (ES+) m/z calc. for C18H13BrNO2 (M+H) 354.0130, found 354.0162. 
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2-(4-Bromoquinolin-2-yl)chroman-4-one (3.11.4) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4-
bromoquinoline (103.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), 
affording the coupled product (88 mg, 50% yield) as a semi-solid. 
 
1H NMR (500 MHz, CDCl3) δ 8.70 (s, 1H), 8.40 (d, J = 8.5 Hz, 1H), 8.25 (d, J = 8.5 Hz, 1H), 7.97 
(dd, J = 7.9, 1.8 Hz, 1H), 7.85 (ddd, J = 8.3, 6.8, 1.2 Hz, 1H), 7.75 (ddd, J = 8.4, 6.9, 1.3 Hz, 1H), 
7.44 (ddd, J = 8.7, 7.2, 1.8 Hz, 1H), 7.08 – 7.01 (m, 1H), 6.95 (d, J = 8.4 Hz, 1H), 6.36 (dd, J = 
10.1, 3.7 Hz, 1H), 3.68 (dd, J = 17.1, 10.1 Hz, 1H), 3.14 (dd, J = 17.1, 3.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.8, 160.2, 154.2, 143.1, 135.8, 135.3, 131.4, 128.7, 127.8, 126.9, 
126.9, 125.1, 121.8, 121.4, 120.9, 117.8, 40.6, 24.5. 
FT-IR (cm-1, neat, ATR) 
HRMS (ES+) m/z calc. for C18H11BrNO2Na (M+Na) 375.9949, found 375.9942. 
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2-(4-Chloroquinolin-2-yl)chroman-4-one (3.11.5) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4-
chloroquinoline (81.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate 
(1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound 
was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), affording the coupled 
product (69 mg, 85% yield) as a pale yellow solid (mp = 80–82 °C). 
 
1H NMR (500 MHz, CDCl3) δ 8.25 (d, J = 8.4 Hz, 1H), 8.12 (d, J = 8.5 Hz, 1H), 7.99 – 7.89 (m, 
2H), 7.81 (t, J = 7.7 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.58 – 7.51 (m, 1H), 7.14 (d, J = 8.4 Hz, 1H), 
7.09 (t, J = 7.5 Hz, 1H), 5.78 (dd, J = 8.7, 6.8 Hz, 1H), 3.27 (d, J = 7.2 Hz, 2H). 
13C NMR (126 MHz, CDCl3) δ 191.2, 165.7, 160.8, 158.0, 148.4, 143.9, 136.3, 130.9, 129.9, 128.0, 
127.3, 126.0, 124.2, 122.1, 121.5, 118.8, 118.2, 42.5. 
FT-IR (cm-1, neat, ATR) 3055, 2900, 1694, 1606, 1496, 1473, 1412, 1362, 1303, 886, 836, 761. 
HRMS (ES+) m/z calc. for C18H12ClNO2Na [M+Na] 332.0454, found 332.0473. 
 
 
 
 
2-(2-Chloroquinolin-4-yl)chroman-4-one (3.11.6) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 2-
chloroquinoline (81.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate 
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(1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound 
was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), affording the coupled 
product (53.8 mg, 66% yield) as a pale yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 9.19 (s, 1H), 8.84 (s, 3H), 7.51 (m, 1H), 7.48 – 7.34 (m, 1H), 7.11 
(s, 1H), 7.09 – 6.89 (m, 2H), 5.86 (dd, J = 11.5, 3.7 Hz, 1H), 3.37 (dd, J = 17.0, 11.4 Hz, 1H), 3.24 
(dd, J = 17.0, 3.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 190.8, 160.5, 152.2, 144.9, 143.3, 143.3, 142.9, 142.3, 141.5, 136.3, 
130.5, 130.2, 129.4, 127.1, 122.2, 118.2, 78.5, 41.7. 
FT-IR (cm-1, neat, ATR) 3053, 2900, 1689, 1604, 1588, 1577, 1562, 1472, 1328, 1223, 760. 
HRMS (ES+) m/z calc. for C18H13ClNO2 (M+H) 310.0635, found 310.0623. 
 
 
 
2-(4-Chloro-8-(trifluoromethyl)quinolin-2-yl)chroman-4-one (3.11.7) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4-chloro-
8-(trifluoromethyl)quinoline (115.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), 
affording the coupled product (60.3 mg, 32% yield) as a pale yellow oil. 
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1H NMR (500 MHz, CDCl3) δ 8.44 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 7.3 Hz, 1H), 8.02 (s, 1H), 7.95 
(d, J = 7.8 Hz, 1H), 7.69 (t, J = 7.9 Hz, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.14 (d, J = 8.3 Hz, 1H), 7.08 
(t, J = 7.5 Hz, 1H), 5.78 (dd, J = 11.6, 3.7 Hz, 1H), 3.40 (dd, J = 17.1, 3.7 Hz, 1H), 3.26 (dd, J = 
17.1, 11.5 Hz, 1H), 1.26 (s, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.2, 160.6, 158.9, 144.7, 144.1, 139.6 (q, 2J = 34.3 Hz), 129.3, 
128.5, 127.3, 126.6, 126.5, 124.8, 123.7 (q, 1J = 218.5 Hz), 122.2, 121.7, 119.8 (q, 3J = 3.2 Hz), 
116.7 (q, 3J = 3.5 Hz), 79.3, 41.9.  
19F NMR (471 MHz, CDCl3) δ -60.15. 
FT-IR (cm-1, neat, ATR)3052, 1677, 1605, 1469, 1316, 1187. 
HRMS (ES+) m/z calc. for C19H12ClF3NO2 (M+H) 378.0508, found 378.0492. 
 
 
 
2-(1-Chloroisoquinolin-3-yl)chroman-4-one (3.12.1) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 1-
chloroisoquinoline (81.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), 
affording the coupled product (46.4 mg, 30% yield) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 8.21 (dd, J = 8.0, 1.7 Hz, 1H), 7.90 (dd, J = 7.8, 1.8 Hz, 1H), 7.86 
(d, J = 5.9 Hz, 1H), 7.68 (ddd, J = 8.7, 7.1, 1.7 Hz, 1H), 7.54 – 7.44 (m, 2H), 7.41 (ddd, J = 8.1, 
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7.2, 1.1 Hz, 1H), 7.09 – 7.02 (m, 1H), 6.99 (d, J = 8.2 Hz, 1H), 6.35 (d, J = 5.9 Hz, 1H), 3.03 (dd, 
J = 16.7, 3.5 Hz, 1H), 2.90 (dd, J = 16.7, 4.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 192.0, 160.4, 154.4, 143.4, 136.1, 135.5, 131.6, 128.9, 128.0, 127.1, 
127.1, 125.3, 122.0, 121.6, 121.2, 118.1, 76.8, 40.9. 
FT-IR (cm-1, neat, ATR) 3363, 2924, 1689, 1637, 1607, 1579, 1464, 1406, 1303, 1258, 877. 
HRMS 
 (ES+) m/z calc. for C18H13ClNO2 (M+H) 310.0635, found 310.0633. 
 
 
 
2-(5-Bromoisoquinolin-1-yl)chroman-4-one (3.12.2) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 6-
bromoquinoline (103.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), 
affording the coupled product (88 mg, 50% yield) as a white solid (mp = 179–181 °C). 
 
1H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 8.7 Hz, 1H), 7.24 (d, J = 8.5 Hz, 1H), 7.13 (dd, J = 7.9, 
1.7 Hz, 1H), 7.08 – 7.00 (m, 2H), 6.81 – 6.74 (m, 1H), 6.72 (ddd, J = 8.6, 7.2, 1.7 Hz, 1H), 6.31 (d, 
J = 8.3 Hz, 1H), 6.26 (s, 1H), 6.26 (dd, J = 15.1, 1.1 Hz, 1H), 5.00 (dd, J = 11.1, 4.1 Hz, 2H), 2.51 
(dd, J = 17.0, 11.1 Hz, 2H), 2.44 (dd, J = 17.0, 4.1 Hz, 2H). 
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13C NMR (126 MHz, CDCl3) δ 191.4, 160.9, 158.8, 148.3, 137.0, 136.3, 130.8, 130.3, 129.5, 127.4, 
127.3, 122.1, 122.0, 121.5, 119.8, 118.3, 80.0, 42.5. 
FT-IR (cm-1, neat, ATR) 3072, 1693, 1608, 1463, 1304, 1222, 115, 814, 764. 
HRMS (ES+) m/z calc. for C18H13BrNO2 [M+H] 354.0130, found 354.0125. 
 
 
 
2-(Quinoxalin-2-yl)chroman-4-one (3.12.4) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 
quinoxaline (65.1 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 
mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound 
was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), affording the coupled 
product (91 mg, 66% yield) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 9.22 (s, 1H), 8.18 – 8.13 (m, 1H), 8.13 – 8.07 (m, 1H), 7.96 (dd, J 
= 7.9, 1.8 Hz, 1H), 7.84 – 7.77 (m, 2H), 7.55 (ddd, J = 8.7, 7.2, 1.8 Hz, 1H), 7.14 (dd, J = 8.3, 1.0 
Hz, 1H), 7.09 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 5.89 (dd, J = 11.5, 3.7 Hz, 1H), 3.40 (dd, J = 17.0, 
11.5 Hz, 1H), 3.27 (dd, J = 17.0, 3.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.0, 160.6, 152.3, 143.6, 142.5, 141.6, 136.5, 130.7, 130.6, 129.6, 
129.5, 127.3, 122.3, 121.5, 118.3, 78.7, 41.9. 
FT-IR (cm-1, neat, ATR) 3072, 2898, 1691, 1607, 1578, 1493, 1472, 1462, 1367, 1304, 1226, 1206, 
762. 
HRMS (ES+) m/z calc. for C17H13N2O2 [M+H] 277.0977, found 277.0971. 
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2-(3-Chloroquinoxalin-2-yl)chroman-4-one (3.12.5) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 2-
chloroquinoxaline (82 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), 
affording the coupled product (77.5 mg, 50% yield) as a semi-solid. 
 
1H NMR (500 MHz, CDCl3) δ 8.19 – 8.12 (m, 1H), 8.09 – 8.03 (m, 1H), 7.98 (dd, J = 7.9, 1.8 Hz, 
1H), 7.89 – 7.78 (m, 2H), 7.51 (ddd, J = 8.7, 7.2, 1.8 Hz, 1H), 7.12 – 7.03 (m, 2H), 6.22 (dd, J = 
10.7, 3.7 Hz, 1H), 3.64 (dd, J = 17.1, 10.7 Hz, 1H), 3.14 (dd, J = 17.1, 3.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.0, 160.3, 148.6, 146.4, 141.9, 140.1, 136.1, 131.8, 130.6, 129.4, 
128.1, 126.8, 122.0, 121.2, 118.0, 75.9, 40.2. 
FT-IR (cm-1, neat, ATR) 3054, 2914, 1690, 1606, 1462, 1303, 1222, 1115, 1047, 934, 760. 
HRMS (ES+) m/z calc. for C17H12ClN2O2 [M+H] 311.0587, found 311.0591. 
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1,3,7-Trimethyl-8-(4-oxochroman-2-yl)-3,7-dihydro-1H-purine-2,6-dione (3.12.6) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), caffeine 
(97.1 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 
mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound was purified 
by column chromatography (silica gel, 3:1 hexanes/EtOAc), affording the coupled product (77.8 
mg, 44% yield) as a white solid (mp = 240–242 °C). 
 
1H NMR (500 MHz, CDCl3) δ 7.93 (dd, J = 7.9, 1.7 Hz, 1H), 7.50 (ddd, J = 8.6, 7.3, 1.8 Hz, 1H), 
7.08 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 5.71 (dd, J = 9.9, 3.9 Hz, 1H), 4.12 (s, 3H), 3.56 
(dd, J = 17.3, 9.9 Hz, 1H), 3.52 (s, 3H), 3.38 (s, 3H), 3.11 (dd, J = 17.2, 3.9 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 190.1, 159.5, 155.7, 151.7, 148.0, 147.3, 136.5, 127.3, 122.7, 121.4, 
117.8, 109.1, 71.0, 40.0, 32.6, 30.0, 28.2. 
FT-IR (cm-1, neat, ATR) 1715, 1682, 1664, 1605, 1549, 1472, 1335, 1222, 771, 764. 
HRMS (ES+) m/z calc. for C17H16N4O4Na [M+Na] 363.1069, found 363.1082. 
 
 
 
2-(4-(Trifluoromethyl)pyridin-2-yl)chroman-4-one (3.12.7) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4-
(trifluoromethyl)pyridine (58 µL, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
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The title compound was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), 
affording the coupled product (49.8 mg, 34% yield) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 8.81 (d, J = 5.1 Hz, 1H), 7.96 (dd, J = 7.8, 1.7 Hz, 1H), 7.91 (s, 
1H), 7.63 – 7.45 (m, 2H), 7.19 – 7.05 (m, 2H), 5.68 (dd, J = 12.4, 3.5 Hz, 1H), 3.22 (dd, J = 17.0, 
3.5 Hz, 1H), 3.11 (dd, J = 17.0, 12.4 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.1, 160.7, 159.7, 150.5, 140.6 (q, 2J = 34.0 Hz), 136.5, 127.3, 
127.2, 122.8 (q, 1J = 218.4 Hz), 121.4, 119.1 (m), 118.2, 116.7 (m), 79.3, 42.8. 
19F NMR (471 MHz, CDCl3) δ -64.75.  
FT-IR (cm-1, neat, ATR) 1692, 1607, 1473, 1362, 1328, 1137, 1118, 846, 703. 
HRMS (ES+) m/z calc. for C15H11F3NO2 [M+H] 294.0742, found 294.0739. 
 
 
 
6-Bromo-2-(4-chloroquinolin-2-yl)chroman-4-one (3.14.1) 
The general procedure was followed with trifluoroborate (249 mg, 0.75 mmol, 1.5 equiv), 4-
chloroquinoline (81.5, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate 
(1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound 
was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), affording the coupled 
product (191 mg, 99% yield) as a yellow oil. 
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1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 8.4 Hz, 1H), 8.11 – 8.03 (m, 2H), 7.85 (s, 1H), 7.80 (t, 
J = 7.7 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.60 (d, J = 9.0 Hz, 1H), 7.03 (d, J = 8.7 Hz, 1H), 5.74 
(dd, J = 9.5, 5.7 Hz, 1H), 3.33 – 3.24 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 177.6, 155.4, 155.3, 152.9, 150.7, 129.0, 128.0, 125.2, 119.6, 118.7, 
113.0, 108.1, 107.3, 77.4, 77.4, 77.2, 76.9, 13.8. 
FT-IR (cm-1, neat, ATR) 3060, 2975, 1685, 1596, 1459, 1414, 1272, 1212, 760. 
HRMS (ES+) m/z calc. for C18H12BrClNO2 [M+H] 387.9740, found 387.9744. 
 
 
 
6-Bromo-2-(4-chloro-8-(trifluoromethyl)quinolin-2-yl)chroman-4-one (3.14.2) 
The general procedure was followed with trifluoroborate (249 mg, 0.75 mmol, 1.5 equiv), 4-chloro-
8-(trifluoromethyl)quinoline (115.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), 
affording the coupled product (107 mg, 47% yield) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 8.46 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 7.3 Hz, 1H), 8.05 (d, J = 2.4 
Hz, 1H), 7.99 (s, 1H), 7.72 (t, J = 7.9 Hz, 1H), 7.61 (dd, J = 8.8, 2.5 Hz, 1H), 7.04 (d, J = 8.8 Hz, 
1H), 5.79 (dd, J = 11.0, 3.9 Hz, 1H), 3.40 (dd, J = 17.3, 3.9 Hz, 1H), 3.29 (dd, J = 17.3, 11.0 Hz, 
1H). 
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13C NMR (126 MHz, CDCl3) δ 190.0, 159.4, 158.3, 144.7, 144.3, 139.0, 129.9, 129.5 (m), 128.8, 
128.6 (q, 2J = 30.0 Hz), 128.5, 127.5 (q, 1J = 257.2 Hz), 126.6, 123.0, 120.3, 119.9, 115.1, 79.4, 
41.4. 
19F NMR (471 MHz, CDCl3) δ -60.20.  
FT-IR (cm-1, neat, ATR) 1690, 1606, 1578, 1564, 1462, 1318, 1279, 1222, 760. 
HRMS (ES+) m/z calc. for C19H11BrClF3NO2 [M+H] 455.9614, found 455.9613. 
 
 
 
6-Bromo-2-(4-methylquinolin-2-yl)chroman-4-one (3.14.3) 
The general procedure was followed with trifluoroborate (249 mg, 0.75 mmol, 1.5 equiv), lepidine 
(71.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 
mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound was purified 
by column chromatography (silica gel, 3:1 hexanes/EtOAc), affording the coupled product (89.9 
mg, 49% yield) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 8.12 – 8.04 (m, 2H), 8.01 (d, J = 8.4 Hz, 1H), 7.73 (t, J = 7.6 Hz, 
1H), 7.63 – 7.51 (m, 3H), 7.01 (d, J = 8.7 Hz, 1H), 5.73 (dd, J = 11.8, 3.6 Hz, 1H), 3.33 (dd, J = 
17.1, 11.7 Hz, 1H), 3.20 (dd, J = 17.2, 3.6 Hz, 1H), 2.77 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 190.5, 160.0, 156.9, 147.4, 146.1, 138.8, 130.2, 129.8, 129.7, 
128.0, 127.0, 123.9, 122.8, 120.3, 119.3, 114.6, 80.7, 42.2, 19.2. 
FT-IR (cm-1, neat, ATR) 1682, 1595, 1470, 1419, 1276, 1215, 1159, 755. 
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HRMS (ES+) m/z calc. for C19H15BrNO2 [M+H] 368.0286, found 368.0285. 
 
 
 
6-Bromo-2-(8-chloro-2-methylquinolin-4-yl)chroman-4-one (3.14.4) 
The general procedure was followed with trifluoroborate (249 mg, 0.75 mmol, 1.5 equiv), 2-
methyl-8-chloroquinoline (89 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 5:1 hexanes/EtOAc), 
affording the coupled product (124.3 mg, 62% yield) as a semi-solid. 
 
1H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 2.5 Hz, 1H), 7.92 (d, J = 7.5 Hz, 1H), 7.86 (d, J = 8.5 
Hz, 1H), 7.80 (s, 1H), 7.67 (dd, J = 8.8, 2.5 Hz, 1H), 7.55 (t, J = 8.0 Hz, 1H), 7.06 (d, J = 8.8 Hz, 
1H), 6.20 (dd, J = 13.0, 3.2 Hz, 1H), 3.17 – 3.00 (m, 2H), 2.96 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 189.3, 160.6, 159.9, 146.5, 142.6, 139.4, 132.75, 131.2, 129.9, 
127.3, 124.6, 122.3, 121.4, 120.3, 120.3, 115.5, 75.9, 43.9, 25.0. 
FT-IR (cm-1, neat, ATR) 3076, 1694, 1639, 1599, 1505, 1466, 1417, 1381, 1330, 1272, 1219, 1181, 
1133, 1091, 1056, 907, 888, 707. 
HRMS (ES+) m/z calc. for C19H14BrClNO2 [M+H] 401.9896, found 401.9890. 
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6-Bromo-2-(quinoxalin-2-yl)chroman-4-one (3.14.6) 
The general procedure was followed with trifluoroborate (249 mg, 0.75 mmol, 1.5 equiv), 
quinoxaline (65.1 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 
mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound 
was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), affording the coupled 
product (111.5 mg, 63% yield) as a clear oil. 
 
1H NMR (500 MHz, CDCl3) δ 9.19 (s, 1H), 8.18 – 8.13 (m, 1H), 8.12 – 8.09 (m, 1H), 8.06 (d, J = 
2.5 Hz, 1H), 7.83 (dt, J = 6.6, 3.4 Hz, 2H), 7.61 (dd, J = 8.8, 2.6 Hz, 1H), 7.04 (d, J = 8.9 Hz, 1H), 
5.88 (dd, J = 11.1, 3.8 Hz, 1H), 3.41 (dd, J = 17.3, 11.4 Hz, 1H), 3.28 (dd, J = 17.1, 3.8 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 189.7, 159.4, 151.7, 143.5, 142.6, 141.6, 139.1, 130.8, 130.8, 129.8, 
129.6, 129.5, 122.8, 120.4, 115.1, 78.7, 41.4. 
FT-IR (cm-1, neat, ATR) 3065, 2903, 1694, 1651, 1599, 1569, 1493, 1465, 1416, 1368, 1269, 1222, 
1129, 1068, 1014, 1000, 933, 910, 732. 
HRMS (ES+) m/z calc. for C17H12BrN2O2 [M+H] 355.0082, found 355.0088.  
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6-Methyl-2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-one (3a) 
Trifluoroborate was prepared according to literature procedure and used crude (reference: 
Molander, G. A.; McKee, S. A. Org. Lett. 2011, 13, 4684). 
The general procedure was followed with trifluoroborate (201 mg, 0.75 mmol, 1.5 equiv), 4-
(trifluoromethyl)pyridine (73.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), 
hexanes/EtOAc), affording the coupled product (59.9 mg, 39% yield) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3 δ 8.81 (d, J = 5.0 Hz, 1H), 7.91 (s, 1H), 7.74 (d, J = 2.1 Hz, 1H), 7.53 
(d, J = 5.0 Hz, 1H), 7.36 (dd, J = 8.4, 2.2 Hz, 1H), 7.04 (d, J = 8.4 Hz, 1H), 5.64 (dd, J = 12.4, 3.4 
Hz, 1H), 3.26 – 3.14 (m, 1H), 3.08 (dd, J = 17.0, 12.4 Hz, 1H), 2.34 (s, 3H). 
13C NMR (126 MHz, CDCl3) 191.2, 160.7, 160.0, 150.5, 140.8 (q, 2J = 34.7 Hz), 136.5, 127.3, 
127.2, 124.0, 122.5 (q, 1J = 273.7 Hz), 119.1 (m), 118.2, 116.7 (m), 79.3, 42.9, 39.0. 
19F NMR (471 MHz, CDCl3) δ -64.82. 
FT-IR (cm-1, neat, ATR) 2931, 1693, 1618, 1579, 1489, 1420, 1361, 1328, 1290, 1228, 1171, 1137, 
1086, 1011, 906, 848, 824. 
HRMS (ES+) m/z calc. for C16H12F3NO2 [M] 307.0820, found 307.0827. 
  
 
6-(Thiophen-2-yl)-2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-one (3b) 
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Trifluoroborate was prepared according to literature procedure and used crude (reference: 
Molander, G. A.; McKee, S. A. Org. Lett. 2011, 13, 4684). 
 
The general procedure was followed with trifluoroborate (168 mg, 0.75 mmol, 1.5 equiv), 4-
(trifluoromethyl)pyridine (73.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), 
affording the coupled product (60 mg, 32% yield) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 8.81 (d, J = 5.1 Hz, 1H), 8.17 (d, J = 2.4 Hz, 1H), 7.91 (s, 1H), 7.79 
(dd, J = 8.6, 2.4 Hz, 1H), 7.53 (d, J = 5.0 Hz, 1H), 7.30 (d, J = 3.7 Hz, 1H), 7.28 (d, J = 5.1 Hz, 
1H), 7.16 (d, J = 8.6 Hz, 1H), 7.10 – 7.06 (m, 1H), 5.69 (dd, J = 12.2, 3.5 Hz, 1H), 3.25 (dd, J = 
17.0, 3.6 Hz, 1H), 3.14 (dd, J = 17.0, 12.2 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.0, 160.0, 159.6, 150.6, 142.9, 139.8, 139.6 (q, 2J = 34.2 Hz), 
134.0, 129.1, 128.3, 125.1, 124.1, 123.0 (q, 1J = 273.3 Hz), 121.5, 119.2 (q, 3J = 4.2 Hz), 119.0, 
116.8 (q, 3J = 4.3 Hz), 79.5, 42.8. 
19F NMR (471 MHz, CDCl3) δ -64.73. 
FT-IR (cm-1, neat, ATR) 3076, 1694, 1613, 1574, 1533, 1486, 1421, 1362, 1328, 1286, 846. 
HRMS (ESI) m/z calc. for C19H13F3NO2S [M+H] 376.0619, found 376.0620. 
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6-(5-Methylfuran-2-yl)-2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-one (3c) 
Note: Trifluoroborate was prepared according to literature procedure and used crude (reference: 
Molander, G. A.; McKee, S. A. Org. Lett. 2011, 13, 4684). 
The general procedure was followed with trifluoroborate (250.5 mg, 0.75 mmol, 1.5 equiv), 4-
(trifluoromethyl)pyridine (73.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium 
tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K2S2O8 (135 mg, 0.05 mmol, 1.0 equiv). 
The title compound was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), 
affording the coupled product (130.6 mg, 70% yield) as a yellow oil. 
 
1H NMR (500 MHz, CDCl3) δ 8.81 (d, J = 5.0 Hz, 1H), 8.17 (d, J = 2.2 Hz, 1H), 7.91 (s, 1H), 7.81 
(dd, J = 8.7, 2.3 Hz, 1H), 7.53 (d, J = 5.1 Hz, 1H), 7.14 (d, J = 8.7 Hz, 1H), 6.52 (d, J = 3.2 Hz, 
1H), 6.05 (d, J = 3.2 Hz, 1H), 5.68 (dd, J = 12.3, 3.6 Hz, 1H), 3.24 (dd, J = 17.0, 3.6 Hz, 1H), 3.13 
(dd, J = 17.0, 12.2 Hz, 1H), 2.36 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 191.1, 159.7, 159.4, 152.4, 151.1, 150.5, 139.9, 139.4 (q, 2J = 34.1), 
131.5, 126.1, 122.6 (q, 1J = 273.4 Hz), 121.4, 119.1 (m), 118.6, 116.8 (m), 108.0, 106.1, 79.4, 42.9, 
13.9. 
19F NMR (471 MHz, CDCl3) δ -65.48. 
FT-IR (cm-1, neat, ATR) 1696, 1609, 1481, 1425, 1363, 1261, 1228, 1173, 1138. 
HRMS (ESI) m/z calc. for C20H15F3NO3 [M+H] 374.1004, found 374.0996. 
 
GENERAL PROCEDURE FOR BETA BORYLATION 
 
2-(Trifluoro-λ4-boranyl)chroman-4-one, potassium salt (IV) 
A 50 mL round bottom flask was charged with chroman-4-one (896 mg, 4.0 mmol, 1.0 equiv) and 
brought into the glove box. (HO)2BB(OH)2 (538.2 mg, 6.0 mmol, 1.5 equiv), CuCl (7 mg, 0.08 
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mmol, 0.02 equiv), CyJohnPhos (28 mg, 0.08 mmol, 0.02 equiv), and NaOt-Bu (115.3 mg, 1.2 
mmol, 0.3 equiv) were added to the flask, which was capped in the glovebox. Under nitrogen, 
freshly distilled EtOH (20 mL) was added, and the mixture was stirred for 3 h at rt. Upon 
completion of the reaction, the EtOH was removed in vacuo, and the residue was dissolved in 
MeOH (20 mL) and cooled to 0 °C. Saturated KHF2 (8 mL, 4.5 M) was added dropwise to the 
reaction, and the resulting mixture was allowed to warm to rt. After 30 min, the solution was 
concentrated in vacuo and placed on the lyophilizer overnight. A Soxhlet extraction of the solid 
was performed using i-PrOAc for 16 h, and the extract was concentrated. The resulting red solid 
was dissolved in acetone (~5 mL), and Et2O was added dropwise until precipitation was induced. 
Additional Et2O (20 mL) was added, and the solid was filtered to afford a light orange powder 
(1.115 g, 84% yield). 
 
 
 
6-Bromo-2-(trifluoro-l4-boranyl)chroman-4-one, potassium salt 
Physical properties: light orange solid (mp = 180–184 °C). 
1H NMR (500 MHz, DMSO-d6) δ 7.70 (s, 1H), 7.56 (d, J = 8.9 Hz, 1H), 6.93 (d, J = 8.9 Hz, 1H), 
3.60 (d, J = 15.0 Hz, 1H), 2.68 – 2.56 (m, 1H), 2.35 (d, J = 17.1 Hz, 1H). 
13C NMR (126 MHz, DMSO-d6) δ 194.1, 163.5, 137.3, 128.1, 122.4, 120.7, 110.6, 30.7, 15.2. 
11B NMR (128 MHz, DMSO-d6) δ 2.6. 
19F NMR (471 MHz, DMSO-d6) δ 143.39. 
FT-IR (cm-1, neat, ATR) 3415, 1676, 1598, 1465, 1275, 1223, 1185, 873, 820. 
HRMS (ESI) m/z calc. for C11H9O2NBF1 [M-F+CH3N] 314.9878, found 314.9879. 
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EMISSION QUENCHING EXPERIMENTS 
 
A stock solution of MesAcr photocatalyst (1.5 x 10-5 M, 10 mL) in MeCN/H2O (1:1) was made and 
degassed vigorously with N2 for 20 min. In separate 1 dram vials, 2-(trifluoroboranyl)chroman-4-
one (blue) and persulfate (green) were added. Each vial was evacuated and purged three times 
followed by addition of the stock solution under inert atmosphere. Data was collected using a 
Fluorolog-3 spectrophotometer. Samples were excited at 500 nm and the emission intensity was 
collected at 550 nm. Each data point is the average of five runs. 
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1H (CDCl3, 500 MHz) spectra of 2-(4-methylquinolin-2-yl)chroman-4-one (3.11.1)  
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13C (CDCl3, 125.8 MHz) spectra of 2-(4-methylquinolin-2-yl)chroman-4-one (3.11.1) 
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1H (CDCl3, 500 MHz) spectra of 2-(quinolin-2-yl)chroman-4-one (3.11.2)  
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13C (CDCl3, 125.8 MHz) spectra of 2-(quinolin-2-yl)chroman-4-one (3.11.2) 
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1H (CDCl3, 500 MHz) spectra of 2-(3-bromoquinolin-2-yl)chroman-4-one (3.11.3) 
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13C (CDCl3, 125.8 MHz) spectra of 2-(3-bromoquinolin-2-yl)chroman-4-one (3.11.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 289 
1H (CDCl3, 500 MHz) spectra of 2-(4-bromoquinolin-2-yl)chroman-4-one (3.11.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 290 
13C (CDCl3, 125.8 MHz) spectra of 2-(4-bromoquinolin-2-yl)chroman-4-one (3.11.4) 
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1H (CDCl3, 500 MHz) spectra of 2-(4-chloroquinolin-2-yl)chroman-4-one (3.11.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 292 
13C (CDCl3, 125.8 MHz) spectra of 2-(4-chloroquinolin-2-yl)chroman-4-one (3.11.5) 
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1H (CDCl3, 500 MHz) spectra of 2-(2-chloroquinolin-4-yl)chroman-4-one (3.11.6) 
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13C (CDCl3, 125.8 MHz) spectra of 2-(2-chloroquinolin-4-yl)chroman-4-one (3.11.6) 
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1H (CDCl3, 500 MHz) spectra of 2-(4-chloro-8-(trifluoromethyl)quinolin-2-yl)chroman-4-one 
(3.11.7) 
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13C (CDCl3, 125.8 MHz) spectra of 2-(4-chloro-8-(trifluoromethyl)quinolin-2-yl)chroman-4-one 
(3.11.7) 
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19F NMR (471 MHz, CDCl3) spectra of 2-(4-chloro-8-(trifluoromethyl)quinolin-2-yl)chroman-4-
one (3.11.7) 
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1H (CDCl3, 500 MHz) spectra of 2-(1-chloroisoquinolin-3-yl)chroman-4-one (3.12.1) 
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13C (CDCl3, 125.8 MHz) spectra of 2-(1-chloroisoquinolin-3-yl)chroman-4-one (3.12.1) 
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1H (CDCl3, 500 MHz) spectra of 2-(4-bromoisoquinolin-1-yl)chroman-4-one (3.12.2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 301 
13C (CDCl3, 125.8 MHz) spectra of 2-(4-bromoisoquinolin-1-yl)chroman-4-one (3.12.2) 
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1H (CDCl3, 500 MHz) spectra of 2-(quinoxalin-2-yl)chroman-4-one (3.12.4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 303 
13C (CDCl3, 125.8 MHz) spectra of 2-(quinoxalin-2-yl)chroman-4-one (3.12.4) 
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1H (CDCl3, 500 MHz) spectra of 2-(3-chloroquinoxalin-2-yl)chroman-4-one (3.12.5) 
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13C (CDCl3, 125.8 MHz) spectra of 2-(3-chloroquinoxalin-2-yl)chroman-4-one (3.12.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 306 
1H (CDCl3, 500 MHz) spectra of 1,3,7-trimethyl-8-(4-oxochroman-2-yl)-3,7-dihydro-1H-purine-
2,6-dione (3.12.6)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 307 
13C (CDCl3, 125.8 MHz) spectra of 1,3,7-trimethyl-8-(4-oxochroman-2-yl)-3,7-dihydro-1H-
purine-2,6-dione (3.12.6) 
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1H (CDCl3, 500 MHz) spectra of 2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-one (3.12.7)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 309 
13C (CDCl3, 125.8 MHz) spectra of 2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-one (3.12.7)  
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19F NMR (471 MHz, CDCl3) spectra of 2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-one (3.12.7)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 311 
1H (CDCl3, 500 MHz) spectra of 6-bromo-2-(4-chloroquinolin-2-yl)chroman-4-one (3.14.1) 
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13C (CDCl3, 125.8 MHz) spectra of 6-bromo-2-(4-chloroquinolin-2-yl)chroman-4-one (3.14.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 313 
1H (CDCl3, 500 MHz) spectra of 6-bromo-2-(4-chloro-8-(trifluoromethyl)quinolin-2-yl)chroman-
4-one (3.14.2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 314 
13C (CDCl3, 125.8 MHz) spectra of 6-bromo-2-(4-chloro-8-(trifluoromethyl)quinolin-2-
yl)chroman-4-one (3.14.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 315 
19F NMR (471 MHz, CDCl3) spectra of 6-bromo-2-(4-chloro-8-(trifluoromethyl)quinolin-2-
yl)chroman-4-one (3.14.2)  
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1H (CDCl3, 500 MHz) spectra of 6-bromo-2-(4-methylquinolin-2-yl)chroman-4-one (3.14.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 317 
13C (CDCl3, 125.8 MHz) spectra of 6-bromo-2-(4-methylquinolin-2-yl)chroman-4-one (3.14.3) 
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1H (CDCl3, 500 MHz) spectra of 2-(8-chloro-2-methylquinolin-4-yl)chroman-4-one (3.14.4)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C (CDCl3, 125.8 MHz) spectra of 2-(8-chloro-2-methylquinolin-4-yl)chroman-4-one (3.14.4) 
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1H (CDCl3, 500 MHz) spectra of 6-bromo-2-(quinoxalin-2-yl)chroman-4-one (3.14.6) 
 320 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13C (CDCl3, 125.8 MHz) spectra of 6-bromo-2-(quinoxalin-2-yl)chroman-4-one (3.14.6) 
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 322 
1H (CDCl3, 500 MHz) spectra of 6-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-one 
(3.15.1)  
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13C (CDCl3, 125.8 MHz) spectra of 6-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-one 
(3.15.1) 
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19F NMR (471 MHz, CDCl3) spectra of 6-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-
one (3.15.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 325 
1H (CDCl3, 500 MHz) spectra of 6-(thiophen-2-yl)-2-(4-(trifluoromethyl)pyridin-2-yl)chroman-4-
one (3.15.2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 326 
13C (CDCl3, 125.8 MHz) spectra of 6-(thiophen-2-yl)-2-(4-(trifluoromethyl)pyridin-2-
yl)chroman-4-one (3.15.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 327 
19F NMR (471 MHz, CDCl3) spectra of 6-(thiophen-2-yl)-2-(4-(trifluoromethyl)pyridin-2-
yl)chroman-4-one (3.15.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 328 
1H (CDCl3, 500 MHz) spectra of 6-(5-methylfuran-2-yl)-2-(4-(trifluoromethyl)pyridin-2-
yl)chroman-4-one (3.15.3)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 329 
13C (CDCl3, 125.8 MHz) spectra of 6-(5-methylfuran-2-yl)-2-(4-(trifluoromethyl)pyridin-2-
yl)chroman-4-one (3.15.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 330 
19F NMR (471 MHz, CDCl3) spectra of 6-(5-methylfuran-2-yl)-2-(4-(trifluoromethyl)pyridin-2-
yl)chroman-4-one (3.15.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 331 
1H (DMSO-d6, 500 MHz) spectra of 6-bromo-2-(trifluoroboranyl)chroman-4-one, potassium salt 
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13C (DMSO-d6, 125.8 MHz) spectra of 6-bromo-2-(trifluoroboranyl)chroman-4-one, potassium 
salt 
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11B NMR (DMSO-d6, 128.4 MHz) spectra of 6-bromo-2-(trifluoroboranyl)chroman-4-one, 
potassium salt 
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Chapter 4. Engaging 1,4-Dihydropyridines in Alkylation of Heteroarenes 
 
4.1 Introduction 
 Nitrogen-containing heterocycles and quinones are ubiquitous chemical motifs present in 
pharmaceuticals, natural products, and ligand scaffolds among other examples, thus highlighting 
the importance of such structures.1† Late-stage modification of these entities within the context of 
complex molecules is not trivial, and, often, a simple modification of such compounds requires a 
lengthy synthetic strategy where the new substituent must be installed in early stages. In an ideal 
scenario, numerous derivatives should be accessible from a common and complex molecule at any 
stage in a synthesis. Consequently, rapid, late-stage, selective alkylation processes for complex 
molecules under mild reaction conditions are of great value and significance.2 A powerful example 
in medicinal chemistry efforts is the derivatization of camptothecin (Figure 4.1). To date, a wide 
range of radical precursors have been demonstrated (e.g., aldehydes, carboxylic acids).2 
 
Figure 4.1. Literature examples of aldehydes and carboxylic acids as radical precursors. 
 
 
 
† Reproduced in part from Gutierrez-Bonet, A.; Remeur, C. R., Matsui, J. K.; Molander, G. A. J. Am. 
Chem. Soc. 2017, 139, 12251. 
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Polar approaches to such transformations are limited because of their typically lower 
functional group tolerance. By contrast, radical processes have the advantage of tolerating a wider 
array of functional handles. Yet, the reaction conditions required to generate radical intermediates 
are themselves often harsh, thus limiting their applicability.3 Indeed, radical alkylation of complex 
heterocycles has been well developed in the Minisci reaction,4 where a radical is coupled with a 
heterocycle under acidic, oxidizing conditions, delivering the functionalized product. Interestingly, 
the regioselectivity is orthogonal to that observed for the Friedel-Crafts reaction, thus increasing 
the appeal of such transformations. Traditionally, carboxylic acids5 and halides6 have been 
employed as radical precursors, but more recently the toolbox has been expanded to include 
alcohols,7 boronic acids,8 sulfinate salts,9 alkenes,10 and alkyltrifluoroborates.11 However, in most 
of the previous contributions, high temperatures, (sub)stoichiometric amounts of expensive metal 
salts, excess of the radical precursor, and strong oxidants or expensive photocatalysts7,11a,12 are 
required to achieve good yields. 
Aldehydes, which are readily available, have been employed as acyl radical precursors to 
access acylated products13 and, to a lesser extent and with limited applicability, as a source of alkyl 
radicals as well14 generated through decarbonylation of an acyl radical (Figure 4.2).15 
Unfortunately, this acyl radical can react with the heterocycle or undergo further oxidation, 
resulting in non-productive pathways. It is known that the acyl/alkyl radical equilibrium can be 
shifted by increasing the reaction temperature, resulting in a more efficient CO extrusion event.16 
Consequently, such transformations usually employ temperatures above 100 ˚C to improve the 
selectivity toward the alkylation, while an excess of the aldehyde motif is required to achieve 
competitive yields, thus highlighting the narrow applicability of such a strategy.13,14 
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Figure 4.2. Previous strategies for fragmentation of aldehydes. 
4.2 Reaction Design and Results 
Recently, 1,4-dihydropyridines (DHPs), which are readily prepared from aldehydes in one 
step,17 have been demonstrated to undergo homolysis under photoredox conditions to form Csp3-
centered alkyl radicals that can be engaged in different processes with prefunctionalized 
substrates.18 Notably, DHPs can be regarded as masked aldehydes that exclusively deliver alkyl 
radicals by circumnavigating acyl radical intermediates, thus avoiding the formation of acylated 
byproducts or the required for high temperatures, strong oxidants, and excess of the aldehydic 
partner given the efficiency of oxidative fragmentation from DHPs. Based on this result, we 
envisioned exploration of the reactivity of DHPs in a transformation beyond prefunctionalized 
substrates, tar-geting, therefore, a much more appealing, yet challenging, C-H bond. In this regard, 
we considered the C-H alkylation of nitrogen-containing heterocycles and 1,4-quinones, so that the 
traditional drawbacks of Minisci chemistry with aldehydes could be overcome, thus allowing a re-
introduction of this attractive feedstock into radical C-H alkylation processes.  
For the optimization of the reaction conditions, we chose 4.3.3 as a model substrate in 
combination with i-Pr-DHP and found that the reaction proceeded in almost quantitative yields 
using a small excess of sodium persulfate as oxidant, and TFA to activate the heterocycle (Figure 
4.3). Cation exchange of the persulfate oxidant had little effect on the reaction outcome (entries 4–
5) whereas stronger oxidants (entry 6) typically employed for aldehydes had a deleterious effect on 
R1 R2
O
R1 R2
HO
A. H-atom transfer - CO
B. [M]–OOH - HCO2H
R1 R2
OHO
O
[M]
alkylated 
productsR1 R2
DHP
one-step procedure 
from aldehyde SET
 337 
the reactivity. Interestingly, the addition of TFA was not an absolute requirement for the reaction 
to proceed (entry 3), albeit a diminished yield was obtained without this additive. TCA showed no 
effect (entry 3 vs entry 7), whereas BF3•OEt2 (entry 9) showed activity similar to that of TFA. Not 
surprisingly, the solvent system played a crucial role, as in this type of process diffusion between 
the aqueous phase hosting the oxidant and the organic phase accommodating the organic partners 
is critical.19  
  
Figure 4.3. Optimization conditions. 
 
Next, we tested this new set of reaction conditions with DHPs featuring different alkyl 
units at the C4-position (Figure 4.4). Both acyclic (4.4.1–4.4.5) and cyclic radicals (4.4.6–4.4.8) 
could be coupled with the heterocyclic backbone in moderate to good yields. Notably, alkene 
functional groups were well tolerated as demonstrated by the melonal-derived and cyclohexenyl 
DHPs (4.4.5 and 4.4.7, respectively). Oxygen-containing heterocyclic motifs did not hamper the 
reaction (4.4.9–4.4.10). Importantly, primary radicals could be engaged in the presence of a 
stabilizing α-oxygen atom (4.4.11). Unfortunately, non-stabilized, primary alkyl radicals did not 
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deliver the expected product as the corresponding DHP does not undergo homolytic C-C cleavage 
but rather C-H homolysis, resulting in the formation of a 4-alkylated-pyridine byproduct.20 
 
Figure 4.4. Quinazolinone scope. 
 
Combinations of different heteroarenes with distinct DHPs were then explored in an effort 
to access unprecedented structural motifs (Figure 4.5). For example, C2-alkylated lepidine 
derivatives have shown antituberculosis activity,21 and thus several different lepidine derivatives 
(4.5.1–4.5.7) were prepared. Whereas simple alkyl motifs gave high yields of the corresponding 
product (4.5.1), more complex motifs led to lower yields (4.5.2–4.5.3). Interestingly, primary α-
amidomethyl radicals could be employed, although with poor yields (4.5.3). Substituted quinolines 
were explored and generated the expected products in moderate to good yields. Likewise, 
isoquinolines were well accommodated (4.5.8) as well as pyridine (4.5.10) pyrimidine (4.5.11), and 
benzothiazole cores (4.5.12). To test the regioselectivity of the protocol, heterocycles with 
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differentially reactive C-H bonds were tested. Unfortunately, mixtures of mono- and dialkylation 
were observed (4.5.5). However, in the presence of other leaving groups under radical conditions 
(e.g., MeSO2-, and Cl-, 4.5.11), exclusive addition at the C-H bond was observed.22 
  
Figure 4.5. Expanding heteroarene scope. 
 
To highlight the applicability of the protocol, we attempted the late-stage C-H alkylation 
of different natural products and pharmaceuticals (Figure 4.6). Notably, we observed a wide 
functional group tolerance (e.g., amines, alkenes, hydroxyls, sulfonamides) in alkylating natural 
products such as nicotine (4.6.1) and caffeine (4.6.2). Cinchonine, a common ligand scaffold for 
numerous organocatalytic processes,23 could be rapidly modified (4.6.3), allowing the formation of 
a new generation of cinchonine-based ligands under mild reaction conditions. Likewise, 
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structurally related quinine, an antimalarial drug, could be rapidly diversified to 4.6.4. 
Antivasospatic fasudil hydrochloride24 and apoptosis inducer camptothecin were effectively 
elaborated under the reaction conditions, delivering the C-H alkylated product in good to high 
yields and excellent regioselectivity (4.6.5). Notably, alkylated camptothecin-derivatives have 
shown even higher activities than the base molecule itself.25 
 
Figure 4.6. Late-stage functionalization efforts. 
 
Spurred on by the possibility of introducing the decarbonylated aldehyde feedstock while 
overcoming its inherent drawbacks in radical processes, we envisioned the introduction of quinones 
as radical acceptors. Quinones are of extreme importance because of their ability to partake in 
electron transport processes in primary metabolic routes. Furthermore, they display important 
pharmacological activities and are very versatile intermediates for organic synthesis.26 Because 
functionalization of quinones usually relies on the use of transition-metal catalysis,27 we sought to 
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carry out the metal-free C-H alkylation of quinones from DHPs under mild conditions. Previously, 
these interesting scaffolds have been functionalized using radicals generated with metal-based 
catalysts to afford mostly arylated quinones from organoboron compounds28 and carboxylic acids,29 
among others.30 However, aldehydes have never been employed before as alkyl radical precursors 
with this class of substrates,31 thus ignoring an important feedstock that could help increase the 
chemical space. 
To demonstrate the versatility of our protocol, different 1,4-quinones were tested (Figure 
4.7).32 Interestingly, in the presence of two identical reactive sites, monoalkylation was observed 
in good levels (4.7.1). Apoptosis inducer Coenzyme Q0, with only one reactive site and two 
methoxy groups, was effectively coupled with different DHPs in moderate to good yields (4.7.2–
4.7.3). Notably, π-extended naphthoquinones such as vitamin K3 (4.7.4) smoothly reacted, as well 
as 2-hydroxynaphthoquinone (Lawsone reagent) (4.7.5–4.7.6), which, when combined with Cy-
DHP, yielded Parvaquone (marketed as Clexon®, 4.7.6) in 54% yield. The latter is employed for 
the treatment of theileriosis, a cattle disease that represents an important threat to livestock 
production in Africa, generating losses above $200 million annually.33 Alternatively, Atovaquone 
(an anti-malarial drug that acts by inhibiting the mitochondrial electron transport system and 
marketed as Malarone® when combined with proguanil hydrochloride),34 could be synthesized in 
a 54% yield as a kinetic mixture of diastereomers that could be easily converted to the more active 
trans-Atovaquone under acidic conditions.30a Importantly, previous syntheses of Atovaquone based 
on a radical alkylation approach relied on the use of silver salts, significantly  increasing the total 
cost of such a synthetic route. 
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Figure 4.7. C–H alkylation of quinones. 
 
Once the versatility of DHPs as alkylating agents was demonstrated in radical C-H 
alkylating processes, we moved on to study the influence of the 1,4-dihydropyridine backbone in 
the reaction outcome (Figure 4.8). Because of their dual role as H-atom donors and Csp3-alkyl 
radical precursors, DHPs are becoming more prominent in organic synthesis.18 Consequently, it 
was of interest to gain a deeper understanding of the factors controlling their reactivity. To this end, 
six different 1,4-dihydropyridine cores were tested under the developed reaction conditions. 
Interestingly, cyano-substitution at C3 and C5 on the dihydropyridine backbone led to only traces 
of product, whereas acridine derivative led to no conversion with 6-isopropylacridine being 
observed exculsively.35 Importantly, no relationship between the oxidation potential and the 
reactivity was observed. However, a trend between the steric bulk of the functional groups at C3 
and C536 and the reactivity was detected. We believe that the higher the steric hindrance at the C4-
position of the pyridine byproduct formed upon oxidation is, the less prone the isopropyl radical is 
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to undergo competitive rebound with it, thus favoring the alkylation of lepidine and higher yields 
of the desired product. Notably, modification of the ester residue led to comparable yields for 
isopropyl substitution whereas the tert-butyl analog behaved poorly because of its low solubility in 
the solvent system.  
 
Figure 4.8. DHP backbone modifications. 
 
Once the influence of the DHP backbone was studied, we then explored the subtleties of 
this transformation. Upon monitoring the reaction progress, an intermediate (4.9.1) was observed 
via HPLC that was later consumed to form product. 
To confirm its role as an intermediate, a reaction with 4.9.1 under the developed reaction 
conditions was conducted, showing quantitative conversion to 4.9.2, thus demonstrating its 
competency as intermediate (Figure 4.9). Based on the oxidation potential of 4.9.1 (Eox = +1.19 V 
vs SCE), we believe that radical cation intermediate formed upon addition of the radical to the 
heterocyclic base, is reduced by the DHP [Eox = +1.05 V vs SCE] via SET, thus resulting in 
formation of 4.9.1 and alkyl radical. Such a succession of events would be indicative of a chain-
radical mechanism. To confirm this hypothesis, a test reaction with 20 mol % of Na2S2O8 was 
performed, resulting in the isolation of product in 47% yield and intermediate 4.9.1 in 25% yield, 
indicating that at least 3.6 equivalents of DHP are generated per equivalent of oxidant and 
supporting the initial hypothesis of a radical chain propagation mechanism.37 
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Figure 4.9. Observed intermediate oxidation. 
 
To gain further insight into the reaction mechanism we performed two different deuterium-
labelling experiments. First, an equimolar mixture of C2-deuterated and non-deuterated heterocycle 
1a was treated under reaction conditions for 70 min (Figure 4.10). NMR analysis of the isolated 
compounds showed proton-enrichment of 4.10.1, indicating a secondary inverse KIE of 0.79, which 
can be rationalized on the basis of a Csp2–Csp3 rehybridization upon addition of isopropyl radical 
to the C2-position of the heterocycle.38 Next, two similar reactions were performed, with the only 
modification being the use of a deuterated solvent-system and TFA-d for one of them (Figure 4.10). 
Notably, a solvent KIE of 8.5 was measured39 based on pyridine 7 formation, which probably arises 
from a fast scrambling of the DHP N-H proton with the deuterated protic solvent. Afterward, such 
a scrambling was confirmed to occur in less than 3 min by NMR analysis in 1:1 mixtures of 
CD3CN/D2O.40 
 
Figure 4.10. KIE studies with deuterated quinazolinone. 
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To study further the role of the N-H bond during the oxidative cleavage, a test reaction 
with the N-methylated DHP was conducted (Figure 4.11). No product was formed and the 
methylated DHP partially decomposed to several by-products as judged by GC-MS. Based on 
literature precedent,41 we believe that this result might be indicative of a deprotonation of the DHP+• 
prior to the homolytic cleavage. 
  
Figure 4.11. Probing role of N–H DHP bond in reaction. 
 
On the basis of the previous observations, we envision a mechanistic scenario40 that is 
initiated by SET oxidation of the DHP 4.12.1 by Na2S2O8, resulting in the formation of pyridine 
4.12.5 and alkyl radical R (Figure 4.12). The nature of such a homolysis has been discussed above. 
Subsequently, the Csp3-radical adds to the protonated heterocycle, resulting in the rehybridization 
of the C2-carbon, which is made evident by the observed inverse KIE. Next, the resulting radical 
cation 4.12.2 oxidizes the DHP 4.12.1, resulting in propagation of the radical chain while forming 
the observed intermediate 4.12.3. Eventually, 4.12.3 will be oxidized by persulfate to deliver the 
final product 4.12.4. Notably, the nature of this step remains unknown, with several available 
options such as SET oxidation to form 4.12.2 which will then undergo H-atom abstraction by SO4•–
42 or further oxidation and deprotonation.  
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Figure 4.12. Proposed mechanism. 
 
4.3 Conclusion 
In summary, we demonstrated the ability of DHPs to deliver Csp3-centered alkyl radicals, 
which can then be engaged in C-H alkylation of non-prefunctionalized heterocycles and quinones. 
Importantly, DHPs, which are easily accessible from aldehydes, eliminate the drawbacks associated 
with the latter for this kind of transformation, i.e., formation of acylated byproducts, harsh reaction 
conditions (strong oxidants at temperatures >100 ˚C), and use of an excess of the aldehyde motif. 
The mild reaction conditions developed allow late-stage C-H alkylation of natural products and 
drugs. More importantly, relevant marketed pharmaceuticals were prepared from readily available 
compounds. Finally, mechanistic studies revealed that the reaction proceeds under a radical-chain 
mechanism via a dearomatized intermediate. Key insights into the underlying nature of the DHP 
oxidation have been examined and elucidated. First, deuterium-labelling studies showed an inverse 
isotope effect arising from a rehybridization upon radical addition, whereas a solvent isotope effect 
pointed toward a slower homolytic cleavage of the DHP scaffold upon deuteration of the N-H bond. 
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Reactivity studies showed a relationship between the steric bulk of the DHP substituents and the 
reaction outcome. These studies help inform the design and synthesis of improved DHP scaffolds 
and provide greater understanding of fragmentation and structural reorganization in DHP-like 
systems. 
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GENERAL CONSIDERATIONS 
Reagents 
All reactions were carried out under an inert atmosphere of nitrogen or argon unless otherwise 
noted. Standard Schlenk techniques were used for the manipulation of solvents and reagents. 
Reactions were monitored by GC/MS, HPLC, 1H NMR, and/or by TLC on silica gel plates (60 Å 
porosity, 250 µm thickness). TLC analysis was performed using hexanes/EtOAc as the eluent and 
visualized using permanganate stain and/or UV light. Silica plugs utilized flash silica gel (60 Å 
porosity, 32-63 µm). Flash chromatography was accomplished using an automated system 
(visualizing at 254 nm and 280 nm) with silica cartridges (60 Å porosity, 20-40 µm). All chemicals 
were used as received unless otherwise noted. Solvents were purified by use of drying cartridges 
through a solvent delivery system. 
 
Analytical Methods 
Melting points (°C) are uncorrected. NMR Spectra (1H, 13C{1H}) were recorded on a 500 MHz 
spectrometer at 298 K. All 1H NMR spectra are reported in parts per million (ppm) downfield of 
TMS and were measured relative to the signals for CHCl3 (7.26 ppm). All 13C NMR spectra were 
reported in ppm relative to residual CHCl3 (77.2 ppm) and were obtained with 1H decoupling. 
Coupling constants, J, are reported in Hertz (Hz). In the case of diastereomeric mixtures, crude 
NMR was recorded to determine the ratio. HRMS was obtained by either ESI or CI with a TOF 
spectrometer in MeCN or CH2Cl2. IR spectra were obtained on neat samples. 
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C-H Alkylation of N-Containing Heterocycles 
General Procedure II: A vial was charged with the heterocyclic substrate (0.5 mmol, 1.0 equiv), 
4-alkyl-1,4-dihydropyridine (0.55 mmol, 1.1 equiv) and Na2S2O8 (142.9 mg, 0.6 mmol, 1.2 equiv). 
Then, the vial was capped and purged with three cycles of vacuum/argon and then, under argon 
atmosphere, degassed CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M) and TFA (114.9 mg, 0.75 mmol, 1.5 
equiv) were added. The reaction was vigorously stirred for 18 h at rt. After completion, the reaction 
was quenched by addition of aq NaHCO3 (sat, 10.0 mL) and extracted three times with EtOAc 
(10.0 mL). The combined organic layers were washed with brine (20.0 mL), dried (MgSO4), 
filtered, and concentrated. The crude product was then adsorbed on Celite® and purified on an 
automated system. 
Characterization Data: C-H Alkylation of N-Containing Heterocycles. 
 
2-Isopropylquinazolin-4(3H)-one (4.4.1): Following General Procedure II using 4-
hydroxyquinazoline (43.8 mg, 0.3 mmol, 1.0 equiv), diethyl 4-isopropyl-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (97.5 mg, 0.33 mmol, 1.1 equiv), Na2S2O8 (85.7 mg, 0.36 mmol, 
1.2 equiv) and TFA (51.3 mg, 0.45 mmol, 1.5 equiv) in CH3CN/H2O (3.0 mL, 1:1 v/v, 0.1 M). The 
product was isolated as a white fluffy solid (54.2 mg, 97% yield). mp= 218-221 ºC. 1H NMR (500 
MHz, CDCl3) δ 10.35 (s, 1H), 8.28 (d, J = 7.9 Hz, 1H), 7.76 (t, J = 7.5 Hz, 1H), 7.71 (d, J = 8.2 
Hz, 1H), 7.46 (t, J = 7.5 Hz, 1H), 2.99 (hept, J = 6.8 Hz, 1H), 1.43 (d, J = 7.0 Hz, 6H) ppm. 13C 
NMR (126 MHz, CDCl3) δ 163.9, 160.7, 149.6, 134.8, 127.6, 126.5, 126.4, 121.0, 35.1, 20.6 ppm. 
Spectral data is consistent with previously reported values. 10 
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2-(sec-Butyl)quinazolin-4(3H)-one (4.4.1): Following General Procedure II using 4-
hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(sec-butyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (170.1 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.6 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 
M).  The product was isolated as a white solid (87.0 mg, 86% yield). mp = 173-175 ºC. 1H NMR 
(500 MHz, CDCl3) δ 11.74 (s, 1H), 8.30-8.29 (m, 1H), 7.77-7.71 (m, 2H), 7.47-7.44 (m, 1H), 2.85-
2.78 (m, 1H), 2.00-1.91 (m, 1H), 1.79-1.71 (m, 1H), 1.43 (d, J = 6.9 Hz, 3H), 0.98 (t, J = 7.4 Hz, 
3H) ppm. 13C NMR (126 MHz, CDCl3) δ 164.3, 160.4, 149.6, 134.7, 127.5, 126.3 (2C), 120.9, 
42.3, 28.2, 18.3, 12.0 ppm. Spectral data is consistent with previously reported values.11 
 
2-(Pentan-3-yl)quinazolin-4(3H)-one (4.4.2): Following General Procedure II using 4-
hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 2,6-dimethyl-4-(pentan-3-yl)-1,4-
dihydropyridine-3,5-dicarboxylate (177.8 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.6 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (3.0 mL, 1:1 v/v, 0.1 
M). The product was isolated as a white solid (81.0 mg, 75% yield). mp = 140-143 ºC. 1H NMR 
(500 MHz, CDCl3) δ 11.69 (s, 1H), 8.31-8.29 (m, 1H), 7.78-7.71 (m, 2H), 7.48-7.45 (m, 1H), 2.63-
2.57 (m, 1H), 1.96-1.77 (m, 4H), 0.94 (t, J = 7.3 Hz, 6H) ppm. 13C NMR (126 MHz, CDCl3) δ 
164.3, 159.6, 149.6, 134.7, 127.5, 126.4, 126.3, 120.8, 50.1, 26.5, 12.1 ppm. IR (neat, cm-1): 2964, 
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2875, 1676, 1608, 1466, 889, 768. HRMS (EI+) calcd for C13H16N2O [M+] 216.1263, found 
216.1264. 
 
2-(Heptan-3-yl)quinazolin-4(3H)-one (4.4.3): Following General Procedure II using 4-
hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(heptan-3-yl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (193.3 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.6 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 
M). The product was isolated as a white solid (90.0 mg, 74% yield). mp = 117-120 ºC. 1H NMR 
(500 MHz, CDCl3) δ 11.43 (s, 1H), 8.30-8.29 (m, 1H), 7.78-7.71 (m, 2H), 7.47-7.44 (m, 1H), 2.68-
2.62 (m, 1H), 1.93-1.71 (m, 4H), 1.40-1.22 (m, 4H), 0.94 (t, J = 7.40 Hz, 3H), 0.83 (t, J = 7.03 Hz, 
3H) ppm. 13C NMR (126 MHz, CDCl3) δ 164.1, 159.7, 149.6, 134.7, 127.5, 126.3, 126.3, 120.9, 
48.5, 33.2, 29.8, 26.9, 22.7, 14.0, 12.1 ppm. Spectral data is consistent with previously reported 
values.12 
 
2-(1-(4-Isopropylphenyl)propan-2-yl)quinazolin-4(3H)-one (4.4.4): Following General 
Procedure II using quinazolin-4(3H)-one (29.2 mg, 0.20 mmol, 1.0 equiv), diethyl 4-(1-(4-
isopropylphenyl)propan-2-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (90.9 mg, 0.22 
mmol, 1.1 equiv), Na2S2O8 (57.1 mg, 0.24 mmol, 1.2 equiv) and TFA (23.0 µL, 0.75 mmol, 1.5 
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equiv) in CH3CN/H2O (2.0 mL, 1:1 v/v, 0.1 M). The product was isolated as a pale oil (36.0 mg, 
59% yield). 1H NMR (500 MHz, CDCl3) δ 11.38 (d, J = 8.4 Hz, 1H), 8.31 (d, J = 7.9 Hz, 1H), 7.77 
(dt, J = 15.7, 8.0 Hz, 2H), 7.49 (t, J = 7.4 Hz, 1H), 7.19 (d, J = 7.8 Hz, 2H), 7.11 (d, J = 7.9 Hz, 
2H), 3.24 (dd, J = 13.4, 6.4 Hz, 1H), 3.13 (q, J = 7.1 Hz, 1H), 2.87 (ddd, J = 26.4, 12.9, 7.6 Hz, 
2H), 1.40 (d, J = 6.9 Hz, 3H), 1.20 (d, J = 7.0 Hz, 6H) ppm. 13C NMR (126 MHz, CDCl3) δ 164.0, 
159.9, 149.6, 147.1, 136.6, 134.8, 129.2, 129.1, 127.6, 126.6, 126.5, 126.4, 121.0, 42.5, 41.0, 33.8, 
24.1, 24.1, 18.0 ppm. IR (neat, cm-1): 2961, 1678, 1610, 1469, 772, 629. HRMS (EI+) calcd for 
C20H22N2O [M+] 306.1732, found 306.1742. 
 
2-(6-Methylhept-5-en-2-yl)quinazolin-4(3H)-one (4.4.5): Following General Procedure II using 
4-hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 2,6-dimethyl-4-(7-methyloct-6-en-
3-yl)-1,4-dihydropyridine-3,5-dicarboxylate (199.9 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 
mg, 0.6 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 
v/v, 0.1 M).  The product was isolated as a white solid (47.4 mg, 37% yield). mp = 134-136 ºC. 1H 
NMR (500 MHz, CDCl3) δ 11.59 (s, 1H), 8.29 (d, J = 7.85 Hz, 1H), 7.76 (t, J = 7.78 Hz, 1H), 7.71 
(d, J = 8.10 Hz, 1H), 7.45 (t, J = 7.48 Hz, 1H), 5.12-5.10 (m, 1H), 2.92-2.87 (m, 1H), 2.13-1.96 
(m, 3H), 1.76-1.70 (m, 1H), 1.61 (s, 3H), 1.53 (s, 3H), 1.43 (d, J = 7.00 Hz, 3H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 164.2, 160.4, 149.6, 134.7, 132.4, 127.5, 126.3, 126.3, 123.7, 120.9, 40.3, 
35.1, 26.0, 25.7, 18.7, 17.7 ppm. IR (neat, cm-1): 2970, 1675, 1618, 1468, 896, 771. HRMS (EI+) 
calcd for C17H20N2O [M+H]+ 257.1654, found 257.1652. 
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2-Cyclohexylquinazolin-4(3H)-one (4.4.6): Following General Procedure II using 4-
hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 4-cyclohexyl-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (184.5 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.6 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 
M). The product was isolated as a white solid (97.1 mg, 85% yield). mp = 213-215 ºC. 1H NMR 
(500 MHz, CDCl3) δ 11.78 (s, 1H), 8.29-8.27 (m, 1H), 7.77-7.70 (m, 2H), 7.47-7.44 (m, 1H), 2.77-
2.70 (m, 1H), 2.06-2.04 (m, 2H), 1.93-1.91 (m, 2H), 1.81-1.73 (m, 3H), 1.49-1.38 (m, 3H) ppm. 
13C NMR (126 MHz, CDCl3) δ 164.4, 160.3, 149.7, 134.8, 127.5, 126.4, 126.3, 120.9, 45.0, 30.6, 
26.1, 25.8 ppm. IR (neat, cm-1): 2929, 2852, 1679, 1605, 1467, 976, 776. Spectral data is consistent 
with previously reported values.13 
 
2-(Cyclohex-3-en-1-yl)quinazolin-4(3H)-one (4.4.7): Following General Procedure II using 4-
hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(cyclohex-3-en-1-yl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarboxylate (183.3 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.6 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 
M). The product was isolated as a white solid (47.5 mg, 42% yield). mp = 236-238 ºC. 1H NMR 
(500 MHz, CDCl3) δ 11.42 (s, 1H), 8.27 (d, J = 7.90 Hz, 1H), 7.76 (t, J = 7.60 Hz, 1H), 7.70 (d, J 
= 8.05 Hz, 1H), 7.46 (t, J = 7.43 Hz, 1H), 5.84-5.79 (m, 2H), 3.02-2.96 (m, 1H), 2.59-2.53 (m, 1H), 
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2.47-2.42 (m, 1H), 2.33-2.25 (m, 2H), 2.17-2.14 (m, 1H), 2.01-1.93 (m, 1H) ppm. 13C NMR (126 
MHz, CDCl3) δ 164.1, 159.6, 149.6, 134.8, 127.5, 127.0, 126.5, 126.4, 125.5, 120.9, 40.4, 29.0, 
27.0, 25.1 ppm. IR (neat, cm-1): 2830, 1675, 1607, 1468, 987, 897, 769. HRMS (ES-) calcd for 
C14H13N2O [M-H]+ 225.1028, found 225.1029. 
 
2-(Bicyclo[2.2.1]heptan-2-yl)quinazolin-4(3H)-one (4.4.8): Following General Procedure II 
using 4-hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(bicyclo[2.2.1]heptan-2-yl)-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (191.1 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 
(142.8 mg, 0.6 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 
mL, 1:1 v/v, 0.1 M). The product was isolated as a white solid (49.0 mg, 41% yield). mp = 210-
213 ºC. 1H NMR of the crude reaction mixture showed a >20:1 dr. 1H NMR (500 MHz, CDCl3) δ 
11.08 (s, 1H), 8.26 (d, J = 7.8 Hz, 1H), 7.83 – 7.62 (m, 2H), 7.45 (t, J = 7.2 Hz, 1H), 2.76 (dd, J = 
8.6, 5.0 Hz, 1H), 2.63 (d, J = 4.0 Hz, 1H), 2.43 (s, 1H), 2.37 – 2.29 (m, 1H), 1.83 – 1.58 (m, 4H), 
1.55 – 1.27 (m, 1H), 1.40 – 1.30 (m, 1H), 1.21 (d, J = 9.8 Hz, 1H) ppm. 13C NMR (126 MHz, 
CDCl3) δ 164.0, 158.9, 149.4, 134.7, 127.8, 126.4, 126.3, 120.8, 47.2, 42.6, 36.5, 36.2, 34.2, 30.1, 
29.0 ppm. IR (neat, cm-1): 2953, 2867, 1666, 1608, 1465, 1248, 902, 771. HRMS (EI+) calcd for 
C15H16N2O [M+] 240.1263, found 240.1258. 
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2-(Tetrahydro-2H-pyran-4-yl)quinazolin-4(3H)-one (4.4.9): Following General Procedure II 
using 4-hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 2,6-dimethyl-4-(tetrahydro-
2H-pyran-4-yl)-1,4-dihydropyridine-3,5-dicarboxylate (185.5 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 
(142.8 mg, 0.6 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 
mL, 1:1 v/v, 0.1 M). The product was isolated as a white solid (52.9 mg, 46% yield). mp = 215-
217 ºC. 1H NMR (500 MHz, CDCl3) δ 11.61 (s, 1H), 8.28 (d, J = 7.85 Hz, 1H), 7.78 (t, J = 7.48 
Hz, 1H), 7.72 (d, J = 8.00 Hz, 1H), 7.49 (t, J =7.28 Hz, 1H), 4.14 (d, J = 10.45 Hz, 2H), 3.60 (t, J 
= 11.58 Hz, 2H), 2.98 (m, 1H), 2.14-2.07 (m, 2H), 2.00-1.98 (m, 2H) ppm. 13C NMR (126 MHz, 
CDCl3) δ 164.2, 158.0, 149.5, 134.9, 127.7, 126.7, 126.3, 120.9, 67.6, 41.5, 30.2 ppm. IR (neat, 
cm-1): 3023, 2838, 1681, 1468, 908, 777, 625. HRMS (ES-) calcd for C13H13N2O2[M-H]+ 229.0977, 
found 229.0973. 
 
2-(Tetrahydro-2H-pyran-2-yl)quinazolin-4(3H)-one (4.4.10): Following General Procedure II 
using 4-hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 2,6-dimethyl-4-(tetrahydro-
2H-pyran-2-yl)-1,4-dihydropyridine-3,5-dicarboxylate (185.5 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 
(142.8 mg, 0.6 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 
mL, 1:1 v/v, 0.1 M). The product was isolated as a white solid (69.2 mg, 60% yield). mp = 122-
125 ºC. 1H NMR (500 MHz, CDCl3) δ 9.68 (s, 1H), 8.26 (dd, J = 7.95, 1.35 Hz, 1H), 7.74-7.71 (m, 
1H), 7.64 (d, J = 7.95 Hz, 1H), 7.46-7.42 (m, 1H), 4.36 (dd, J = 11.20, 2.60 Hz, 1H), 4.18-4.15 (m, 
1H), 3.65-3.60 (m, 1H), 2.26-2.23 (m, 1H), 1.99-1.96 (m, 1H), 1.70-1.52 (m, 4H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 161.6, 155.9, 149.0, 134.6, 127.2, 126.7 (2C), 121.6, 76.2, 68.7, 30.9, 25.5, 
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23.0 ppm. IR (neat, cm-1): 2930, 1683, 1624, 1467, 1175, 888, 775. HRMS (ES-) calcd for 
C13H13N2O2 [M-H]+ 229.0977, found 229.0968.  
 
2-((Benzyloxy)methyl)quinazolin-4(3H)-one (4.4.11): Following General Procedure II using 4-
hydroxyquinazoline (73.1 mg, 0.5 mmol, 1.0 equiv), diethyl 4-((benzyloxy)methyl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarboxylate (205.4 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.6 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 
M). The product was isolated as a white solid (73.3 mg, 55% yield). mp = 159-161 ºC. 1H NMR 
(500 MHz, CDCl3) δ 9.84 (s, 1H), 8.26 (d, J = 7.90 Hz, 1H), 7.74 (t, J = 7.63 Hz, 1H), 7.63 (d, J = 
8.15 Hz, 1H), 7.46 (t, J = 7.53 Hz, 1H), 7.38-7.33 (m, 5H), 4.69 (s, 2H), 4.55 (s, 2H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 161.7, 152.8, 148.8, 136.4, 134.9, 128.9, 128.6, 128.3, 127.2, 126.9, 126.8, 
121.8, 73.9, 68.7 ppm. IR (neat, cm-1): 1675, 1609, 1466, 1116, 869, 771. HRMS (ES+) calcd for 
C16H15N2O2 [M+H]+ 267.1134, found 267.1135. 
 
2-Isopropyl-4-methylquinoline (4.5.1): Following General Procedure II using lepidine (71.6 mg, 
0.5 mmol, 1.0 equiv), diethyl 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
(162.4 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.6 mmol, 1.2 equiv) and TFA (85.5 mg, 
0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M). The product was isolated as a 
yellow oil (71.2 mg, 78% yield). 1H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 8.45 Hz, 1H), 7.94 (d, 
J = 8.30 Hz, 1H), 7.66 (t, J = 7.60 Hz, 1H), 7.05 (t, J = 8.45 Hz, 1H), 7.17 (s, 1H), 3.21 (sept, J = 
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6.93 Hz, 1H), 2.68 (s, 3H), 1.39 (d, J = 6.95 Hz, 6H) ppm. 13C NMR (126 MHz, CDCl3) δ 167.4, 
147.7, 144.3, 129.7, 129.0, 127.1, 125.5, 123.6, 119.9, 37.3, 22.6, 18.9 ppm. IR (neat, cm-1): 2929, 
2852, 1679, 1605, 1467, 976, 776. Spectral data is consistent with previously reported values.14 
 
4-Methyl-2-(4-(5-methylhex-2-en-1-yl)cyclohex-3-en-1-yl)quinoline (mixture of isomers) 
(4.5.2): Following General Procedure II using 4-methylquinoline (66.3 mg, 0.5 mmol, 1.0 equiv), 
diethyl (E)-2,6-dimethyl-4-(4-(5-methylhex-2-en-1-yl)cyclohex-3-en-1-yl)-1,4-dihydropyridine-
3,5-dicarboxylate (236.1 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.60 mmol, 1.2 equiv) 
and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M). The product 
was isolated as a clear oil (53.0 mg, 35% yield). The compound was isolated as a mixture of 
different diastereomers coming from the commercially available aldehyde. 1H NMR (500 MHz, 
CDCl3) δ 8.06 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.50 (t, J = 
7.6 Hz, 1H), 7.18 (s, 1H), 5.53 (d, J = 11.7 Hz, 1H), 5.43 – 5.05 (m, 2H), 3.16 – 3.01 (m, 1H), 2.69 
(d, J = 4.3 Hz, 3H), 2.40 (d, J = 8.4 Hz, 2H), 2.32 – 2.16 (m, 2H), 2.07 (m, 6H), 1.95 (ddt, J = 17.5, 
11.7, 5.8 Hz, 2H), 1.71 – 1.68 (m, 3H), 1.64 – 1.59 (m, 4H) ppm. 13C NMR (126 MHz, CDCl3) δ 
166.2, 166.2, 147.8, 144.5, 144.5, 137.8, 137.7, 137.3, 131.6, 131.5, 129.6, 129.1, 127.2, 125.6, 
124.5, 124.5, 124.3, 123.7, 120.6, 120.5, 120.5, 120.3, 117.4, 43.8, 43.4, 38.0, 37.9, 37.7, 37.5, 
34.9, 31.8, 29.5, 29.2, 29.0, 28.7, 26.7, 26.7, 26.6, 25.9, 25.9, 19.0, 17.9, 17.8 ppm. IR (neat, cm-
1): 2964, 2914, 2838, 1603, 1438, 862, 757. HRMS (EI+) calcd for C22H27N [M+] 305.2144, found 
305.2155. 
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1-((4-Methylquinolin-2-yl)methyl)pyrrolidin-2-one (4.5.3): Following General Procedure II 
using lepidine (71.6 mg, 0.5 mmol, 1.0 equiv), diethyl 2,6-dimethyl-4-((2-oxopyrrolidin-1-
yl)methyl)-1,4-dihydropyridine-3,5-dicarboxylate (192.7 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 
(261.9 mg, 1.1 mmol, 2.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 
mL, 1:1 v/v, 0.1 M). The product was isolated as a yellow semi-solid that melts when handled (26.7 
mg, 22% yield). 1H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 7.98 (d, J = 8.3 Hz, 1H), 
7.70 (t, J = 7.6 Hz, 1H), 7.56 (t, J = 7.6 Hz, 1H), 7.22 (s, 1H), 4.73 (s, 2H), 3.41 (t, J = 7.1 Hz, 2H), 
2.69 (s, 3H), 2.50 (t, J = 8.1 Hz, 2H), 2.12 – 1.95 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 
175.4, 157.0, 147.6, 145.6, 129.8, 129.5, 127.6, 126.4, 123.9, 120.7, 49.4, 47.4, 31.0, 18.9, 18.1 
ppm. IR (neat, cm-1): 3256, 2948, 1599, 1438, 1422, 1286, 1261, 753. HRMS (EI+) calcd for 
C15H16NO2 [M+] 240.1263, found 240.1287. 
 
4-Bromo-1-(sec-butyl)isoquinoline (4.5.4): Following General Procedure II using 4-
bromoisoquinoline (104.0 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(sec-butyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (170.1 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.60 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 
M). The product was isolated as a clear oil (76.0 mg, 58% yield). 1H NMR (500 MHz, CDCl3) δ 
8.69 (s, 1H), 8.21 (dd, J = 12.1, 8.5 Hz, 2H), 7.77 (t, J = 7.6 Hz, 1H), 7.64 (t, J = 7.7 Hz, 1H), 3.67 
(m, 1H), 2.01 (m, 1H), 1.74 (dq, J = 14.0, 7.0 Hz, 1H), 1.39 (d, J = 6.8 Hz, 3H), 0.89 (t, J = 7.4 Hz, 
3H) ppm. 13C NMR (126 MHz, CDCl3) δ 165.6, 143.8, 135.0, 130.9, 128.4, 127.9, 127.0, 125.2, 
117.6, 37.9, 29.7, 20.3, 12.5 ppm. IR (neat, cm-1): 2964, 2931, 1460, 1297, 919, 758. HRMS (EI+) 
calcd for C13H14NBr [M+] 263.0310, found 263.0323. 
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6-Bromo-2,4-di-sec-butylquinoline (4.5.5): Following General Procedure II using 6-
bromoquinoline (104.0 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(sec-butyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (170.1 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.60 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 
M). The product was isolated as a yellow oil (40.0 mg, 46% yield with DHP as the limiting reagent). 
1H NMR (500 MHz, CDCl3) δ 8.17 (s, 1H), 7.92 (d, J = 8.7 Hz, 1H), 7.71 (d, J = 9.0 Hz, 1H), 7.15 
(s, 1H), 3.38 (m, 1H), 2.95 (m, 1H), 1.83 (dt, J = 14.5, 7.2 Hz, 2H), 1.71 (dt, J = 12.2, 6.5 Hz, 2H), 
1.35 (d, J = 7.0 Hz, 6H), 0.90 (dt, J = 20.7, 7.4 Hz, 7H) ppm. 13C NMR (126 MHz, CDCl3) δ 167.3, 
152.7, 147.0, 132.1, 131.9, 127.6, 125.5, 119.5, 117.2, 117.0, 44.8, 35.3, 30.1, 30.0, 20.9, 20.4, 
20.3, 12.3, 12.1 ppm. IR (neat, cm-1): 2963, 2930, 2874, 1599, 1556, 1489, 1460, 1379, 829. HRMS 
(EI+) calcd for C17H22NBr 319.0936 [M+], found 319.0936. 
 
2-(sec-Butyl)-4-chloroquinoline (4.5.6): Following General Procedure II using 4-chloroquinoline 
(81.8 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(sec-butyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (170.1 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.60 mmol, 1.2 equiv) and 
TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M). The product was 
isolated as a clear oil (89.0 mg, 81% yield). 1H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 8.3 Hz, 1H), 
8.07 (d, J = 8.4 Hz, 1H), 7.71 (t, J = 7.7 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.38 (s, 1H), 2.97 (m, 
1H), 1.85 (m, 1H), 1.70 (dq, J = 14.2, 7.1 Hz, 1H), 1.36 (d, J = 7.1 Hz, 3H), 0.90 (t, J = 7.4 Hz, 
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3H) ppm. 13C NMR (126 MHz, CDCl3) δ 167.1, 148.8, 142.7, 130.2, 129.5, 126.7, 125.2, 124.0, 
119.9, 44.6, 29.9, 20.3, 12.3 ppm. IR (neat, cm-1): 2962, 2930, 2874, 1589, 1493, 869. HRMS (EI+) 
calcd for C13H14NCl [M+] 219.0815, found 219.0827. 
 
2-(sec-Butyl)-4-chloro-7-(trifluoromethyl)quinoline (4.5.7): Following General Procedure II 
using 4-chloro-7-(trifluoromethyl)quinoline (47.6 mg, 0.2 mmol, 1.0 equiv), diethyl 4-(sec-butyl)-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (95.9 mg, 0.31 mmol, 1.5 equiv), Na2S2O8 
(73.8 mg, 0.31 mmol, 1.5 equiv) and TFA (35.3 mg, 0.31 mmol, 1.5 equiv) in CH3CN/H2O (2.0 
mL, 1:1 v/v, 0.1 M). The product was isolated as a yellow oil (38.7 mg, 67% yield). 1H NMR (500 
MHz, CDCl3) δ 8.39 (s, 1H), 8.30 (d, J = 8.7 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.49 (s, 1H), 3.14 
– 2.90 (m, 1H), 1.85 (dq, J = 14.3, 7.1 Hz, 1H), 1.73 (dq, J = 13.7, 6.9 Hz, 1H), 1.37 (d, J = 6.9 Hz, 
3H), 0.90 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 168.8, 148.0, 142.7, 132.1 (q, J 
= 32.6 Hz), 127.5 (q, J = 4.0 Hz), 126.9, 125.4, 124.0 (q, J = 272.5 Hz), 122.4 (q, J = 3.2 Hz), 
122.0, 44.6, 29.9, 20.2, 12.2 ppm. 19F NMR (471 MHz, CDCl3) δ -62.8 ppm. IR (neat, cm-1): 2956, 
1594, 1230, 1165, 1126, 1061, 826. HRMS (EI+) calcd for C14H13NClF3 [M+] 287.0689, found 
287.0700. 
 
Methyl 1-(heptan-3-yl)isoquinoline-3-carboxylate (4.5.8): Following General Procedure II using 
methyl isoquinoline-3-carboxylate (93.6 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(heptan-3-yl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (193.2 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 
mg, 0.60 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 
v/v, 0.1 M). The product was isolated as a clear oil (120.0 mg, 84% yield). 1H NMR (500 MHz, 
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CDCl3) δ 8.38 (s, 1H), 8.29 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.70 (m, 2H), 4.02 (s, 
3H), 3.59 (m, 1H), 2.05 (dt, J = 15.7, 7.6 Hz, 2H), 1.89 – 1.78 (m, 2H), 1.27 (dd, J = 13.4, 6.8 Hz, 
3H), 1.09 (td, J = 11.3, 5.5 Hz, 1H), 0.80 (dt, J = 11.3, 5.1 Hz, 6H) ppm. 13C NMR (126 MHz, 
CDCl3) δ 167.1, 166.0, 141.1, 136.1, 130.2, 129.4, 129.1, 129.1, 125.1, 122.1, 52.7, 44.1, 35.0, 
30.3, 28.4, 23.0, 14.1, 12.6 ppm. IR (neat, cm-1): 2956, 1740, 1717, 1238, 1202, 782, 750. HRMS 
(EI+) calcd for C18H23NO2 [M+] 285.1729, found 285.1743. 
 
Methyl 1-(6-Methylhept-5-en-2-yl)isoquinoline-3-carboxylate (4.5.9): Following General 
Procedure II using methyl isoquinoline-3-carboxylate (93.6 mg, 0.5 mmol, 1.0 equiv), diethyl 4-
(sec-butyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (170.1 mg, 0.55 mmol, 1.1 equiv), 
Na2S2O8 (142.8 mg, 0.60 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in 
CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M). The product was isolated as a clear oil (68.0 mg, 46% yield). 
1H NMR (500 MHz, CDCl3) δ 8.39 (s, 1H), 8.26 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 7.6 Hz, 1H), 7.71 
(m, 2H), 5.14 (t, J = 7.4 Hz, 1H), 4.02 (s, 3H), 3.81 (m, 1H), 2.15 (dq, J = 14.1, 7.3 Hz, 1H), 2.00 
(q, J = 7.5 Hz, 2H), 1.80 (dq, J = 14.0, 7.1 Hz, 1H), 1.64 (s, 3H) 1.50 – 1.41 (m, 6H) ppm. 13C 
NMR (126 MHz, CDCl3) δ 167.0, 166.4, 140.9, 136.2, 131.9, 130.2, 129.1, 129.1, 128.3, 125.1, 
124.6, 122.4, 52.7, 36.4, 36.3, 26.4, 25.8, 20.4, 17.7 ppm. IR (neat, cm-1): 2927, 1740, 1716, 1322, 
1239, 780, 750. HRMS (EI+) calcd for C19H23NO2 [M+] 297.1729, found 297.1733. 
 
2-Isopropyl-6-phenylpyridine and 2,4-Diisopropyl-6-phenylpyridine (4.5.10): Following 
General Procedure II using 2-phenyl pyridine (77.5 mg, 0.5 mmol, 1.0 equiv), diethyl 4-isopropyl-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (324.7 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 
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(85.7 mg, 0.36 mmol, 1.2 equiv) and TFA (51.3 mg, 0.45 mmol, 1.5 equiv) in CH3CN/H2O (3.0 
mL, 1:1 v/v, 0.1 M). A 1:1 mixture of mono- and di-substituted compound was obtained as a clear 
oil, 72% overall yield). 1H NMR (500 MHz, CDCl3) δ 8.05 (t, J = 8.7 Hz, 4H), 7.66 (s, 1H), 7.54 
(d, J = 7.8 Hz, 1H), 7.46 (d, J = 8.4 Hz, 4H), 7.40 (s, 3H), 7.12 (d, J = 7.7 Hz, 1H), 6.97 (s, 1H), 
3.13 (dq, J = 14.2, 7.2 Hz, 2H), 2.93 (q, J = 7.3 Hz, 1H), 1.37 (d, J = 6.8 Hz, 12H), 1.32 (s, 6H) 
ppm. 13C NMR (126 MHz, CDCl3) δ 167.3, 158.5, 156.6, 156.5, 140.5, 140.1, 137.1, 128.8, 128.7, 
128.6, 127.2, 127.1, 119.0, 117.8, 117.4, 116.3, 36.7, 34.1, 29.9, 23.5, 22.9, 22.8. IR (neat, cm-1): 
2963, 1600, 1571, 1446, 1162, 762 ppm. HRMS (EI+) calcd for C14H15N [M+] 197.1204, found 
197.1205 (mono alkylated). HRMS (EI+) calcd for C17H21N [M+] 239.1674, found 239.1660 
(double alkylated product). 
 
4-(sec-Butyl)-2-chloro-6-(methylsulfonyl)pyrimidine (4.5.11): Following General Procedure II 
using 2-chloro-4-(methylsulfonyl)pyrimidine (96.0 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(sec-
butyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (170.1 mg, 0.55 mmol, 1.1 equiv), 
Na2S2O8 (142.8 mg, 0.60 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in 
CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M). The product was isolated as a clear oil (120.0 mg, 70% 
yield). 1H NMR (500 MHz, CDCl3) δ 7.74 (s, 1H), 3.27 (s, 3H), 2.91 (m, 1H), 1.80 (m, 1H), 1.66 
(m, 1H), 1.31 (d, J = 6.9 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 
183.3, 167.7, 166.1, 162.3, 161.6, 141.1, 123.2, 113.0, 66.0, 61.6, 44.1, 39.3, 29.3, 25.1, 19.3, 15.4, 
14.4, 12.0 ppm. IR (neat, cm-1): 2969, 1719, 1522, 1320, 1232, 748, 532. HRMS (EI+) calcd for 
C9H13N2ClSO2 [M+] 248.0386, found 248.0380. 
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2-Cyclohexylbenzo[d]thiazole (4.5.12): Following General Procedure II using benzothiazole 
(68.1 mg, 0.5 mmol, 1.0 equiv), diethyl 4-cyclohexyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (335.4 mg, 1.0 mmol, 2.0 equiv), Na2S2O8 (357.2 mg, 1.5 mmol, 3.0 equiv) and TFA 
(85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M). The product was isolated 
as a colorless oil (62.5 mg, 58% yield). 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 8.2 Hz, 1H), 
7.85 (d, J = 8.0 Hz, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 3.11 (tt, J = 11.6, 3.4 Hz, 
1H), 2.21 (d, J = 12.6 Hz, 2H), 1.98 – 1.85 (m, 2H), 1.82 – 1.73 (m, 1H), 1.65 (qd, J = 12.4, 3.2 
Hz, 2H), 1.53 – 1.39 (m, 2H), 1.39 – 1.21 (m, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 177.7, 
153.3, 134.7, 125.9, 124.6, 122.7, 121.7, 43.6, 33.6, 26.2, 25.9 ppm. Spectral data is consistent with 
previously reported values.15 
 
(S)-2-Cyclohexyl-5-(1-methylpyrrolidin-2-yl)pyridine (4.6.1): Following General Procedure II 
using (-)-nicotine (81.1 mg, 0.5 mmol, 1.0 equiv), diethyl 4-cyclohexyl-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (184.5 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.9 mg, 0.6 
mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 
M). The product was isolated as a colorless oil (59.7 mg, 49% yield). 1H NMR (500 MHz, CDCl3) 
δ 8.41 (s, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 3.23 (t, J = 8.5 Hz, 1H), 3.04 (t, 
J = 8.3 Hz, 1H), 2.69 (t, J = 11.7 Hz, 1H), 2.29 (q, J = 9.0 Hz, 1H), 2.16 (s, 3H), 1.95 (d, J = 11.4 
Hz, 2H), 1.85 (d, J = 12.5 Hz, 3H), 1.78 – 1.72 (m, 2H), 1.52 (q, J = 12.4 Hz, 2H), 1.41 (q, J = 
11.4, 10.2 Hz, 3H), 1.35 – 1.24 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 165.6, 148.9, 135.8, 
135.4, 121.0, 68.9, 57.2, 46.4, 40.6, 35.2, 33.2, 26.8, 26.3, 22.7 ppm. Spectral data is consistent 
with previously reported values.16 
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8-(sec-Butyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione (4.6.2): Following General 
Procedure II using 1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione (65.0 mg, 0.5 mmol, 1.0 
equiv), diethyl 4-(sec-butyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (170.1 mg, 0.55 
mmol, 1.1 equiv), Na2S2O8 (142.8 mg, 0.60 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 
equiv) in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M). The product was isolated as a clear oil (47.0 mg, 
38% yield). 1H NMR (500 MHz, CDCl3) δ 3.92 (s, 3H), 3.56 (s, 3H), 3.39 (s, 3H), 2.83 (q, J = 7.2 
Hz, 1H), 1.84 (dq, J = 14.5, 7.5 Hz, 1H), 1.68 (tt, J = 14.1, 7.2 Hz, 1H), 1.31 (d, J = 6.8 Hz, 3H), 
0.88 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 158.5, 155.6, 151.9, 148.4, 107.1, 
33.2, 31.6, 29.9, 28.8, 28.0, 19.0, 12.1 ppm. IR (neat, cm-1): 1698, 1662, 1648, 1427, 755, 738. 
HRMS (EI+) calcd for C12H18N4O2 [M+] 250.1430, found 250.1410. 
 
(1S)-(2-(sec-Butyl)quinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol (4.6.3): 
Following General Procedure II using cinchonine (147.2 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(sec-
butyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (170.2 mg, 0.55 mmol, 1.1 equiv), 
Na2S2O8 (142.9 mg, 0.6 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O 
(5.0 mL, 1:1 v/v, 0.1 M). The product was isolated as a white solid (100.2 mg, 57% yield). mp = 
154-156 ºC. 1H NMR showed a 1:1 dr. 1H NMR (500 MHz, CDCl3) δ 8.07 (d, J = 8.4 Hz, 1H), 
7.91 (d, J = 8.4 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 7.53 (d, J = 3.5 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 
6.02 – 5.87 (m, 1H), 5.79 – 5.70 (m, 1H), 5.07 – 4.94 (m, 2H), 3.31 – 3.19 (m, 1H), 3.14 – 3.07 (m, 
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1H), 3.03 – 2.97 (m, 1H), 2.96 – 2.86 (m, 2H), 2.82 – 2.73 (m, 1H), 2.26 – 2.16 (m, 1H), 2.02 – 
1.94 (m, 1H), 1.90 – 1.81 (m, 1H), 1.78 – 1.67 (m, 2H), 1.56 – 1.48 (m, 2H), 1.36 (d, J = 7.0 Hz, 
3H), 1.21 – 1.13 (m, 1H), 0.88 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 166.8, 
149.2, 148.0, 140.7, 130.0, 128.8, 125.8, 124.5, 122.7, 116.8, 116.6, 114.7, 71.9, 60.1, 50.3, 49.8, 
49.8, 44.9, 44.9, 40.2, 30.1, 30.0, 28.5, 26.4, 20.7, 20.7, 20.5, 20.5, 12.4, 12.3 ppm. IR (neat, cm-
1): 3068, 2932, 1596, 1454, 1110, 993, 905, 752. HRMS (EI+) calcd for C23H30N2O [M+] 350.2358, 
found 350.2368. 
 
5-((1,4-Diazepan-1-yl)sulfonyl)-1-cyclohexylisoquinoline (4.6.5.1): Following General 
Procedure II using Fasudil hydrochloride (164.4 mg, 0.5 mmol, 1.0 equiv), diethyl 4-cyclohexyl-
2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (251.6 mg, 0.75 mmol, 1.5 equiv), Na2S2O8 
(178.6 mg, 0.75 mmol, 1.5 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 
mL, 1:1 v/v, 0.1 M). The product was isolated as a brown solid (156.9 mg, 84% yield). mp= 108-
112 ºC. 1H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 6.1 Hz, 1H), 8.47 (d, J = 8.6 Hz, 1H), 8.31 (d, J 
= 7.3 Hz, 1H), 8.27 (d, J = 6.1 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 3.62 – 3.51 (m, 1H), 3.53 – 3.43 
(m, 4H), 3.04 – 2.95 (m, 4H), 2.77 – 2.57 (m, 1H), 2.00 – 1.91 (m, 4H), 1.91 – 1.78 (m, 5H), 1.59 
– 1.46 (m, 2H), 1.46 – 1.32 (m, 1H) ppm. 13C NMR (126 MHz, CDCl3) δ 166.7, 144.0, 135.3, 
132.4, 132.4, 130.4, 127.1, 125.2, 115.6, 50.9, 50.3, 47.7, 47.5, 42.2, 32.9, 31.0, 26.9, 26.3 ppm. 
IR (neat, cm-1): 2922, 1318, 1138, 818, 596. HRMS (EI+) calcd for C20H27N3O2S [M+] 373.1824, 
found 373.1830. 
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5-((1,4-Diazepan-1-yl)sulfonyl)-1-((benzyloxy)methyl)isoquinoline (4.6.5.2): Following 
General Procedure II using Fasudil hydrochloride (164.4 mg, 0.5 mmol, 1.0 equiv), diethyl 4-
((benzyloxy)methyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (280.1 mg, 0.75 mmol, 
1.5 equiv), Na2S2O8 (178.6 mg, 0.75 mmol, 1.5 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) 
in CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M). The product was isolated as a yellow thick oil (105.3 mg, 
51% yield). 1H NMR (500 MHz, CDCl3) δ 8.62 (t, J = 7.9 Hz, 2H), 8.44 (d, J = 6.1 Hz, 1H), 8.34 
(d, J = 7.4 Hz, 1H), 7.67 (t, J = 7.9 Hz, 1H), 7.37 – 7.33 (m, 4H), 7.32 – 7.28 (m, 1H), 5.17 (s, 2H), 
4.64 (s, 2H), 3.49 (t, J = 6.1 Hz, 2H), 3.48 – 3.41 (m, 2H), 3.09 – 2.90 (m, 4H), 2.22 – 1.98 (m, 
1H), 1.90 – 1.81 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3 δ 158.2, 143.7, 137.7, 135.2, 132.8, 
132.5, 131.7, 128.6, 128.2 (2C), 128.1, 125.9, 118.1, 73.4, 73.1, 51.1, 50.4, 47.8, 47.5, 31.1 ppm. 
IR (neat, cm-1):  2918, 2850, 1453, 1321, 1146, 1070, 697, 587. HRMS (EI+) calcd for C22H25N3O3S 
[M+] 411.1617, found 411.1624. 
 
 
(S)-11-((Benzyloxy)methyl)-4-ethyl-4-hydroxy-1,12-dihydro-14H-
pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (4.6.6): Following General 
N
S
NO
O
NH
OBn
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Procedure II using (S)-(+)-Camptothecin (50.0 mg, 0.14 mmol, 1.0 equiv), diethyl 4-
((benzyloxy)methyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (104.6 mg, 0.28 mmol, 
2.0 equiv), Na2S2O8 (66.7 mg, 0.28 mmol, 2.0 equiv) and TFA (31.9 mg, 0.28 mmol, 2.0 equiv) in 
CH3CN/H2O (1.4 mL, 1:1 v/v, 0.1 M). The product was isolated as a yellow solid (42.2 mg, 64% 
yield). mp = 213-215 ºC. 1H NMR (500 MHz, CDCl3) δ 8.23 (d, J = 8.5 Hz, 1H), 7.98 (d, J = 8.2 
Hz, 1H), 7.80 (t, J = 7.6 Hz, 1H), 7.64 (d, J = 10.3 Hz, 2H), 7.44 – 7.38 (m, 4H), 7.36 (d, J = 4.7 
Hz, 1H), 5.76 (d, J = 16.3 Hz, 1H), 5.43 (s, 2H), 5.31 (d, J = 16.2 Hz, 1H), 5.18 (s, 2H), 4.79 (s, 
2H), 3.73 (s, 1H), 1.99 – 1.81 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H) ppm. 13C NMR (126 MHz, CDCl3) 
δ 174.1, 157.7, 152.7, 150.1, 149.0, 146.5, 139.4, 137.2, 130.7, 130.3, 128.9, 128.5, 128.1, 128.0, 
127.1, 125.9, 123.5, 118.8, 97.9, 73.9, 72.9, 67.2, 66.6, 50.9, 31.8, 8.0 ppm. Spectral data is 
consistent with previously reported values.17 
 
C-H Alkylation of Quinones 
General Procedure III: A vial was charged with quinone starting material (0.5 mmol, 1.0 equiv), 
4-alkyl-1,4-dihydropyridine (1.0 mmol, 2.0 equiv) and Na2S2O8 (357.2 mg, 1.5 mmol, 3.0 equiv). 
Then, the vial was capped and purged with three cycles of vacuum/argon and then, under an argon 
atmosphere, degassed CH3CN/H2O (5.0 mL, 1:1 v/v, 0.1 M) and TFA (114.9 mg, 0.75 mmol, 1.5 
equiv) were added. The reaction was vigorously stirred for 36-48 h at rt. After completion, the 
reaction was quenched by addition of aq NaHCO3 (sat, 0.0 mL), and extracted three times with 
EtOAc (10.0 mL). The combined organic layers were washed with brine (20.0 mL), dried (MgSO4), 
filtered and concentrated. The crude product was then adsorbed on Celite® and purified on an 
automated system. 
 373 
Characterization Data: C-H Alkylation of Quinones. 
 
2,5-Dimethyl-3-(tetrahydro-2H-pyran-4-yl)cyclohexa-2,5-diene-1,4-dione (4.7.1): Following 
General Procedure III using 2,5-dimethyl-p-benzoquinone (68.1 mg, 0.5 mmol, 1.0 equiv) and 
diethyl 2,6-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1,4-dihydropyridine-3,5-dicarboxylate (337.4 
mg, 1.0 mmol, 2.0 equiv). The product was isolated as an orange solid (61.3 mg, 56% yield). mp = 
93-96 ºC. 1H NMR (500 MHz, CDCl3) δ 6.56 (d, J = 1.6 Hz, 1H), 4.06 (dd, J = 11.4, 4.4 Hz, 2H), 
3.45 (td, J = 11.9, 2.1 Hz, 2H), 3.05 (tt, J = 12.4, 3.6 Hz, 1H), 2.31 (qd, J = 12.6, 4.4 Hz, 2H), 2.10 
(s, 3H), 2.02 (d, J = 1.6 Hz, 3H), 1.47 – 1.36 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 187.9, 
187.8, 146.1, 145.9, 141.2, 132.8, 68.6, 37.1, 29.7, 16.1, 12.0 ppm. IR (neat, cm-1): 29583, 1647, 
1439, 1267, 1119, 833. HRMS (EI+) calcd for C13H16O3 [M+] 220.1099, found 220.1106. 
 
3,4-Dimethoxy-6-methyl-[1,1'-bi(cyclohexane)]-3,6-diene-2,5-dione (4.7.2): Following General 
Procedure III using 2,3-dimethoxy-5-methyl-p-benzoquinone (Coenzyme Q0) (91.1 mg, 0.5 mmol, 
1.0 equiv) and diethyl 4-cyclohexyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (335.4 
mg, 1.0 mmol, 2.0 equiv). The product was isolated as an orange solid (84.3 mg, 64% yield). mp = 
59-63 ºC. 1H NMR (500 MHz, CDCl3) δ 3.98 (s, 3H), 3.97 (s, 3H), 2.81 – 2.64 (m, 1H), 2.05 (s, 
3H), 1.99 – 1.86 (m, 2H), 1.86 – 1.78 (m, 2H), 1.77 – 1.68 (m, 1H), 1.58 – 1.46 (m, 2H), 1.40 – 
1.21 (m, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 185.1, 184.5, 146.1, 144.5, 143.7, 138.8, 61.2, 
O
O
Me
Me
O
O
O
MeO
MeO
Me
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61.2, 40.1, 30.1, 27.1, 26.0, 12.0 ppm. IR (neat, cm-1): 2934, 2913, 1659, 1647, 1635, 1599, 1193, 
1074, 976. HRMS (EI+) calcd for C15H20O4 [M+] 264.1362, found 264.1354. 
 
2,3-Dimethoxy-5-methyl-6-(6-methylhept-5-en-2-yl)cyclohexa-2,5-diene-1,4-dione (4.7.2): 
Following General Procedure III using 2,3-dimethoxy-5-methyl-p-benzoquinone (Coenzyme Q0) 
(91.1 mg, 0.5 mmol, 1.0 equiv) and diethyl 2,6-dimethyl-4-(6-methylhept-5-en-2-yl)-1,4-
dihydropyridine-3,5-dicarboxylate (363.5 mg, 1.0 mmol, 2.0 equiv). The product was isolated as a 
red oil (81.5 mg, 56% yield). 1H NMR (500 MHz, CDCl3) δ 5.03 (t, J = 7.0 Hz, 1H), 3.99 (s, 3H), 
3.97 (s, 3H), 2.99 – 2.87 (m, 1H), 2.01 (s, 3H), 1.95 – 1.81 (m, 3H), 1.72 – 1.66 (m, 1H), 1.65 (s, 
3H), 1.52 (s, 3H), 1.23 (d, J = 7.1 Hz, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 184.9, 184.3, 146.3, 
144.6, 143.7, 139.2, 132.1, 124.5, 61.2 (2C), 35.1, 34.2, 26.9, 25.8, 19.1, 17.8, 11.9 ppm. IR (neat, 
cm-1): 2930, 2857, 1646, 1604, 1115, 1066, 747. HRMS (EI+) calcd for C17H24O4 [M+] 292.1675, 
found 292.1693. 
 
2-(sec-Butyl)-3-methylnaphthalene-1,4-dione (4.7.4): Following General Procedure II using 2-
chloro-4-(methylsulfonyl)pyrimidine (96.0 mg, 0.5 mmol, 1.0 equiv), diethyl 4-(sec-butyl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (170.1 mg, 0.55 mmol, 1.1 equiv), Na2S2O8 (142.8 
mg, 0.60 mmol, 1.2 equiv) and TFA (85.5 mg, 0.75 mmol, 1.5 equiv) in CH3CN/H2O (5.0 mL, 1:1 
v/v, 0.1 M). The product was isolated as a clear oil (120.0 mg, 70% yield). 1H NMR (500 MHz, 
CDCl3) δ 8.12 – 7.96 (m, 2H), 7.71 – 7.60 (m, 2H), 3.02 (m, 1H), 2.21 (s, 3H), 1.89 (dq, J = 15.4, 
O
O
MeO
MeO
Me
Me
Me
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O
O
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7.6 Hz, 1H), 1.75 (dq, J = 14.6, 7.3 Hz, 1H), 1.33 (d, J = 7.1 Hz, 3H), 0.87 (t, J = 7.5 Hz, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 185.7, 185.1, 150.7, 143.8, 133.5, 133.2, 132.9, 132.0, 126.3, 126.2, 
37.0, 28.1, 18.8, 13.1, 12.8 ppm. IR (neat, cm-1): 2963, 2932, 1657, 1289, 717. HRMS (EI+) calcd 
for C15H16O2 [M+] 228.1150, found 228.1161. 
 
2-Cyclohexyl-3-hydroxynaphthalene-1,4-dione (Parvaquone, 4.7.5):  Following General 
Procedure III using 2-hydroxy-1,4-naphthoquinone (Lawsone) (87.1 mg, 0.5 mmol, 1.0 equiv) and 
diethyl 4-cyclohexyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (335.4 mg, 1.0 mmol, 
2.0 equiv). The product was isolated as a yellow solid (69.8 mg, 54% yield). mp = 128-130 ºC. 1H 
NMR (500 MHz, CDCl3) δ 8.11 (d, J = 7.7 Hz, 1H), 8.06 (d, J = 7.0 Hz, 1H), 7.78 – 7.71 (m, 1H), 
7.70 – 7.63 (m, 1H), 7.41 (s, 1H), 3.08 (tt, J = 12.1, 3.3 Hz, 1H), 2.04 – 1.91 (m, 2H), 1.86 – 1.77 
(m, 2H), 1.77 – 1.70 (m, 1H), 1.66 – 1.58 (m, 2H), 1.44 – 1.22 (m, 3H) ppm. 13C NMR (126 MHz, 
CDCl3) δ 184.7, 182.1, 153.0, 135.0, 133.3, 132.8, 129.4, 128.0, 127.1, 126.0, 35.3, 29.4, 26.9, 26.1 
ppm. Spectral data is consistent with previously reported values.18 
 
2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione (Atovaquone, 4.7.6): 
Following General Procedure III using 2-hydroxy-1,4-naphthoquinone (Lawsone) (64.4 mg, 0.37 
mmol, 1.0 equiv) and diethyl 4-(trans-4-(4-chlorophenyl)cyclohexyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (327.2 mg, 0.73 mmol, 2.0 equiv). The product was isolated as 
O
O
OH
O
O
OH
Cl
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a yellow solid (73.7 mg, 54% yield). HPLC analysis showed a 62:38 cis/trans ratio. Over the yellow 
solid (26.1 mg), conc H2SO4 (0.3 mL) was added and the reaction was stirred at rt until HPLC 
analysis showed complete isomerization to the trans isomer (30 min-1 h). At this point, H2O (5.0 
mL) was added over the reaction mixture, and the yellow solid was filtered off and washed several 
times with H2O (5.0 mL x 3). The following spectral data are of the pure trans product. mp = 204-
206 ºC. 1H NMR (500 MHz, CDCl3) δ 8.14 (d, J = 7.7 Hz, 1H), 8.08 (d, J = 7.6 Hz, 1H), 7.77 (t, J 
= 7.5 Hz, 1H), 7.69 (t, J = 7.6 Hz, 1H), 7.48 (s, 1H), 7.29 – 7.26 (m, 2H), 7.18 (d, J = 8.0 Hz, 2H), 
3.20 – 3.12 (m, 1H), 2.68 – 2.55 (m, 1H), 2.27 – 2.12 (m, 2H), 2.00 – 1.94 (m, 2H), 1.81 – 1.74 (m, 
2H), 1.66 – 1.52 (m, 2H) ppm. 13C NMR (126 MHz, CDCl3) δ 184.7, 181.9, 153.1, 146.2, 135.2, 
133.3, 133.0, 131.6, 129.3, 128.6, 128.3, 127.4, 127.1, 126.2, 43.4, 34.6, 34.5, 29.3 ppm. Spectral 
data is consistent with previously reported values.5 
 
 
 
 
 
Cyclic Voltammetry Measurements 
Voltammetric measurement were recorded on a CH Instrument: Model 600E Series 
Electrochemical Analyzer using a standard three electrodes setup in dry, degassed MeCN (10.0 
mL), with ferrocene as internal reference (E01/2 = + 0.41 V vs SCE) and Bu4NPF6 as electrolyte (0.1 
mmol). Cyclic voltammograms were recorded with a step potential of 0.002 V at a scan rate of 0.1 
V/s. Voltammetric measurements were repeated at different scan rates to ensure the accuracy of the 
measurement. 
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1H and 13C NMR Spectra 
1H NMR (CDCl3, 500 MHz) of 2-isopropylquinazolin-4(3H)-one (4.3.3) 
 
  
 382 
13C NMR (CDCl3, 126 MHz) of 2-isopropylquinazolin-4(3H)-one (4.3.3) 
 
  
 383 
1H NMR (CDCl3, 500 MHz) of 2-(sec-butyl)quinazolin-4(3H)-one (4.4.1) 
 
  
 384 
13C NMR (CDCl3, 126 MHz) of 2-(sec-butyl)quinazolin-4(3H)-one (4.4.1) 
 
  
 385 
1H NMR (CDCl3, 500 MHz) of 2-(pentan-3-yl)quinazolin-4(3H)-one (4.4.2) 
 
  
 386 
13C NMR (CDCl3, 126 MHz) of 2-(pentan-3-yl)quinazolin-4(3H)-one (4.4.2) 
 
  
 387 
1H NMR (CDCl3, 500 MHz) of 2-(heptan-3-yl)quinazolin-4(3H)-one (4.4.3) 
 
  
 388 
13C NMR (CDCl3, 126 MHz) of 2-(heptan-3-yl)quinazolin-4(3H)-one (4.4.3) 
 
  
 389 
1H NMR (CDCl3, 500 MHz) of 2-(1-(4-isopropylphenyl)propan-2-yl)quinazolin-4(3H)-
one (4.4.4) 
 
  
 390 
13C NMR (CDCl3, 126 MHz) of 2-(1-(4-isopropylphenyl)propan-2-yl)quinazolin-4(3H)-
one (4.4.4) 
 
  
 391 
1H NMR (CDCl3, 500 MHz) of 2-(6-methylhept-5-en-2-yl)quinazolin-4(3H)-one (4.4.5) 
 
  
 392 
13C NMR (CDCl3, 126 MHz) of 2-(6-methylhept-5-en-2-yl)quinazolin-4(3H)-one (4.4.5) 
 
  
 393 
1H NMR (CDCl3, 500 MHz) of 2-cyclohexylquinazolin-4(3H)-one (4.4.6) 
 
  
 394 
13C NMR (CDCl3, 126 MHz) of 2-cyclohexylquinazolin-4(3H)-one (4.4.6) 
 
  
 395 
1H NMR (CDCl3, 500 MHz) of 2-(cyclohex-3-en-1-yl)quinazolin-4(3H)-one (4.4.7) 
 
  
 396 
13C NMR (CDCl3, 126 MHz) of 2-(cyclohex-3-en-1-yl)quinazolin-4(3H)-one (4.4.7) 
 
  
 397 
1H NMR (CDCl3, 500 MHz) of 2-(bicyclo[2.2.1]heptan-2-yl)quinazolin-4(3H)-one (4.4.8) 
 
  
 398 
13C NMR (CDCl3, 126 MHz) of 2-(bicyclo[2.2.1]heptan-2-yl)quinazolin-4(3H)-one (4.4.8) 
 
  
 399 
1H NMR (CDCl3, 500 MHz) of 2-(tetrahydro-2H-pyran-4-yl)quinazolin-4(3H)-one (4.4.9) 
 
  
 400 
13C NMR (CDCl3, 126 MHz) of 2-(tetrahydro-2H-pyran-4-yl)quinazolin-4(3H)-one (4.4.9) 
 
  
 401 
1H NMR (CDCl3, 500 MHz) of 2-(tetahydro-2H-pyran-2-yl)quinazolin-4(3H)-one (4.4.10) 
 
  
 402 
13C NMR (CDCl3, 126 MHz) of 2-(tetahydro-2H-pyran-2-yl)quinazolin-4(3H)-one 
(4.4.10) 
 
  
 403 
1H NMR (CDCl3, 500 MHz) of 2-((benzyloxy)methyl)quinazolin-4(3H)-one (4.4.11) 
 
  
 404 
13C NMR (CDCl3, 126 MHz) of 2-((benzyloxy)methyl)quinazolin-4(3H)-one (4.4.11) 
 
  
 405 
1H NMR (CDCl3, 500 MHz) of 2-isopropyl-4-methylquinoline (4.5.1) 
 
  
 406 
13C NMR (CDCl3, 126 MHz) of 2-isopropyl-4-methylquinoline (4.5.1) 
 
  
 407 
1H NMR (CDCl3, 500 MHz) of 4-methyl-2-(4-(5-methylhex-2-en-1-yl)cyclohex-3-en-1-
yl)quinoline (mixture of isomers) (4.5.2) 
 
  
 408 
13C NMR (CDCl3, 126 MHz) of 4-methyl-2-(4-(5-methylhex-2-en-1-yl)cyclohex-3-en-1-
yl)quinoline (mixture of isomers) (4.5.2) 
 
  
 409 
1H NMR (CDCl3, 500 MHz) of 1-((4-methylquinolin-2-yl)methyl)pyrrolidin-2-one (4.5.3) 
 
  
 410 
13C NMR (CDCl3, 126 MHz) of 1-((4-methylquinolin-2-yl)methyl)pyrrolidin-2-one 
(4.5.3) 
 
  
 411 
1H NMR (CDCl3, 500 MHz) of 4-bromo-1-(sec-butyl)isoquinoline (4.5.4) 
 
  
 412 
13C NMR (CDCl3, 126 MHz) of 4-bromo-1-(sec-butyl)isoquinoline (4.5.4) 
 
  
 413 
1H NMR (CDCl3, 500 MHz) of 6-bromo-2,4-di-sec-butylquinoline (4.5.5) 
 
  
 414 
13C NMR (CDCl3, 126 MHz) of 6-bromo-2,4-di-sec-butylquinoline (4.5.5) 
 
  
 415 
1H NMR (CDCl3, 500 MHz) of 2-(sec-butyl)-4-chloroquinoline (4.5.6) 
 
  
 416 
13C NMR (CDCl3, 126 MHz) of 2-(sec-butyl)-4-chloroquinoline (4.5.6) 
 
  
 417 
1H NMR (CDCl3, 500 MHz) of 2-(sec-butyl)-4-chloro-7-(trifluoromethyl)quinoline (4.5.7) 
 
  
 418 
13C NMR (CDCl3, 126 MHz) of 2-(sec-butyl)-4-chloro-7-(trifluoromethyl)quinoline (4.5.7) 
 
  
 419 
19F NMR (471 MHz, CDCl3) of 2-(sec-butyl)-4-chloro-7-(trifluoromethyl)quinoline (4.5.7) 
 
 
 
  
 420 
1H NMR (CDCl3, 500 MHz) of methyl 1-(heptan-3-yl)isoquinoline-3-carboxylate (4.5.8) 
 
  
 421 
13C NMR (CDCl3, 126 MHz) of methyl 1-(heptan-3-yl)isoquinoline-3-carboxylate (4.5.8) 
 
  
 422 
1H NMR (CDCl3, 500 MHz) of methyl 1-(6-methylhept-5-en-2-yl)isoquinoline-3-
carboxylate (4.5.9) 
 
  
 423 
13C NMR (CDCl3, 126 MHz) of methyl 1-(6-methylhept-5-en-2-yl)isoquinoline-3-
carboxylate (4.5.9) 
 
  
 424 
1H NMR (CDCl3, 500 MHz) of 2-isopropyl-6-phenylpyridine and 2,4-Diisopropyl-6-
phenylpyridine (4.5.10) 
 
  
 425 
13C NMR (CDCl3, 126 MHz) of 2-isopropyl-6-phenylpyridine and 2,4-Diisopropyl-6-
phenylpyridine (4.5.10) 
 
  
 426 
1H NMR (CDCl3, 500 MHz) of 4-(sec-butyl)-2-chloro-6-(methylsulfonyl)pyrimidine 
(4.5.11) 
 
  
 427 
13C NMR (CDCl3, 126 MHz) of 4-(sec-butyl)-2-chloro-6-(methylsulfonyl)pyrimidine 
(4.5.11) 
 
  
 428 
1H NMR (CDCl3, 500 MHz) of 2-cyclohexylbenzo[d]thiazole (4.5.12) 
 
  
 429 
13C NMR (CDCl3, 126 MHz) of 2-cyclohexylbenzo[d]thiazole (4.5.12) 
 
  
 430 
1H NMR (CDCl3, 500 MHz) of (S)-2-cyclohexyl-5-(1-methylpyrrolidin-2-yl)pyridine 
(4.6.1) 
 
  
 431 
13C NMR (CDCl3, 126 MHz) of (S)-2-cyclohexyl-5-(1-methylpyrrolidin-2-yl)pyridine 
(4.6.1) 
 
  
 432 
1H NMR (CDCl3, 500 MHz) of 8-(sec-butyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-
dione (4.6.2) 
 
  
 433 
13C NMR (CDCl3, 126 MHz) of 8-(sec-butyl)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-
dione (4.6.2) 
 
  
 434 
1H NMR (CDCl3, 500 MHz) of (1S)-(2-(sec-butyl)quinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methanol (4.6.3)  
 
  
 435 
13C NMR (CDCl3, 126 MHz) of (1S)-(2-(sec-butyl)quinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methanol (4.6.3) 
 
  
 436 
1H NMR (CDCl3, 500 MHz) of (1R)-(2-(1-(4-isopropylphenyl)propan-2-yl)-6-
methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (4.6.4.1) 
 
 
  
 437 
13C NMR (CDCl3, 126 MHz) of (1R)-(2-(1-(4-isopropylphenyl)propan-2-yl)-6-
methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol (4.6.4.1) 
 
  
 438 
1H NMR (CDCl3, 500 MHz) of 5-((1,4-diazepan-1-yl)sulfonyl)-1-cyclohexylisoquinoline 
(4.6.5) 
 
  
 439 
13C NMR (CDCl3, 126 MHz) of 5-((1,4-diazepan-1-yl)sulfonyl)-1-cyclohexylisoquinoline 
(4.6.5) 
 
  
 440 
1H NMR (CDCl3, 500 MHz) of 5-((1,4-diazepan-1-yl)sulfonyl)-1-
((benzyloxy)methyl)isoquinoline (4.6.6) 
 
  
 441 
13C NMR (CDCl3, 126 MHz) of 5-((1,4-diazepan-1-yl)sulfonyl)-1-
((benzyloxy)methyl)isoquinoline (4.6.6) 
 
  
 442 
1H NMR (CDCl3, 500 MHz) of (S)-11-((benzyloxy)methyl)-4-ethyl-4-hydroxy-1,12-
dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (4.7.1) 
 
  
 443 
13C NMR (CDCl3, 126 MHz) of (S)-11-((benzyloxy)methyl)-4-ethyl-4-hydroxy-1,12-
dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione (4.7.1) 
 
  
 444 
1H NMR (CDCl3, 500 MHz) of 2,5-dimethyl-3-(tetrahydro-2H-pyran-4-yl)cyclohexa-2,5-
diene-1,4-dione (4.7.2) 
 
  
 445 
13C NMR (CDCl3, 126 MHz) of 2,5-dimethyl-3-(tetrahydro-2H-pyran-4-yl)cyclohexa-2,5-
diene-1,4-dione (4.7.2) 
 
  
 446 
1H NMR (CDCl3, 500 MHz) of 3,4-dimethoxy-6-methyl-[1,1'-bi(cyclohexane)]-3,6-diene-
2,5-dione (4.7.3) 
 
  
 447 
13C NMR (CDCl3, 126 MHz) of 3,4-dimethoxy-6-methyl-[1,1'-bi(cyclohexane)]-3,6-
diene-2,5-dione (4.7.3) 
 
  
 448 
1H NMR (CDCl3, 500 MHz) of 2,3-dimethoxy-5-methyl-6-(6-methylhept-5-en-2-
yl)cyclohexa-2,5-diene-1,4-dione (4.7.3) 
 
  
 449 
13C NMR (CDCl3, 126 MHz) of 2,3-dimethoxy-5-methyl-6-(6-methylhept-5-en-2-
yl)cyclohexa-2,5-diene-1,4-dione (4.7.3) 
 
  
 450 
1H NMR (CDCl3, 500 MHz) of 2-(sec-butyl)-3-methylnaphthalene-1,4-dione (4.7.4) 
 
  
 451 
13C NMR (CDCl3, 126 MHz) of 2-(sec-butyl)-3-methylnaphthalene-1,4-dione (4.7.4) 
 
  
 452 
1H NMR (CDCl3, 500 MHz) of 2-cyclohexyl-3-hydroxynaphthalene-1,4-dione 
(Parvaquone, 4.7.5) 
 
  
 453 
13C NMR (CDCl3, 126 MHz) of 2-cyclohexyl-3-hydroxynaphthalene-1,4-dione 
(Parvaquone, 4.7.5) 
 
  
 454 
1H NMR (CDCl3, 500 MHz) of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-
naphthalenedione (Atovaquone, 4.7.6) 
 
  
 455 
13C NMR (CDCl3, 126 MHz) of 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-
naphthalenedione (Atovaquone, 4.7.6) 
 
  
 456 
1H NMR (CDCl3, 500 MHz) of 4-hydroxyquinazoline-2-d (1a-d) 
 
  
 457 
13C NMR (CDCl3, 126 MHz) of 4-hydroxyquinazoline-2-d (1a-d) 
 
  
 458 
1H NMR (DMSO-d6, 500 MHz) of 2-isopropyl-2,3-dihydroquinazolin-4(1H)-one (6a) 
 
  
 459 
13C NMR (CDCl3, 126 MHz) of 2-isopropyl-2,3-dihydroquinazolin-4(1H)-one (6a) 
 
  
 460 
1H NMR (CDCl3, 500 MHz) of 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate-1-d (2a-d) 
 
  
 461 
13C NMR (CDCl3, 126 MHz) of 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate-1-d (2a-d) 
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Chapter 5. C–H Alkylation of Heteroarenes via Photoredox Catalysis 
 
5.1 Introduction 
 Over the past 15 years, the number of known flavanones has increased significantly, to the 
point of where they can be considered a class of their own, alongside the related flavones.1† 
Flavanones are readily found in nature (e.g., citrus fruits), and their role in flavonoid biosynthetic 
pathways has been extensively studied.2 Chalcone cores are typically the biosynthetic precursors 
to flavanones (Figure 5.1), accessed through a cyclization of the reactive chalcone moiety. In turn, 
flavanone cores are intermediates in the synthesis of a wide range of flavonoids (Figure 5.1).3 
Because of the natural abundance of the flavonoids, many practical uses for these materials have 
been explored. For decades, flavanones and flavonoids have been used as dietary supplements and 
also as potent therapeutic agents (e.g., as antianxiety agents2c and inhibitors of HIV-1 reverse 
transcriptase4). Additionally, substituted flavones have recently been used as fluorescent scaffolds.5 
 
Figure 5.1. Biosynthetic pathways for flavonoid synthesis. 
 
 
 
† Reproduced in part from Matsui, J. K.; Molander, G. A. Org. Lett. 2017, 19, 950. 
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 Currently, the primary synthetic route to access functionalized flavanones has traversed 
through chalcones, in analogy to the biosynthetic pathway.6 Although there have been robust 
methods developed, synthesis of the chalcone precursor is not necessarily straightforward. 
Limitations become even more apparent when attempting to move to more complex cores. As a 
result, there have been significant efforts devoted toward alternative synthetic routes. For example, 
the Porco group disclosed a vinylogous addition to specifically functionalized chromones, 
synthesizing a variety of chromanone butenolides (Figure 5.2, eq 1).7 The Stoltz group also 
published a palladium-catalyzed conjugate addition of arylboronic acids to chromone cores, 
accessing 2-aryl flavanones (Figure 5.2, eq 2).8 In a complementary approach, Glorius and 
coworkers reported a ruthenium-catalyzed asymmetric hydrogenation of flavones to the 
corresponding enantioenriched flavanols, which were subsequently oxidized by PCC to the 
optically active flavanones (Figure 5.2, eq 3).9 
 
Figure 5.2. Synthetic routes toward flavanones. 
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We were interested in establishing a complementary route, allowing access to both 2-aryl- 
and 2-heteroaryl-substituted flavanones. Inspired by recent work in our group,10 novel 
trifluoroboratochromanones were envisioned to serve as radical precursors in the photoredox/Ni 
dual catalytic cross-coupling with a variety of aryl- and heteroaryl bromides. By synthesizing such 
unprecedented 2-trifluoroboratochromanone building blocks, a large library of natural and 
unnatural flavanones could quickly be accessed. 
In the past decade, photoredox catalysis has experienced renewed popularity in the organic 
synthesis community, largely because of the mild and robust conditions typically used.11 Our group 
disclosed a dual catalytic photoredox/nickel paradigm, making previously challenging cross-
couplings possible at room temperature.10a More recently, there have been reports of  a-alkoxy 
couplings, creating precedent for the transformation proposed herein.10c–d Previous examples were 
composed exclusively of 1º alkoxymethyltrifluoroborates and acyclic 2º 
alkoxyalkyltrifluoroborates,12 the latter of which would be anticipated to exhibit a similar or even 
more favorable redox profile as the 1º counterpart (Ered = +1.11 V vs SCE). Before exploring the 
feasibility of the proposed transformation, a robust route to the desired, but previously unknown, 
2-trifluoroboratochromanones 5.3.1 was needed. 
5.1 Reaction Design and Scope 
In a first effort toward the synthesis of 5.3.1, a copper-catalyzed method reported by our 
group was used.13 Although there were numerous methods for b-borylation of b-unsaturated 
carbonyl substrates,14 these conditions were ultimately chosen because they incorporated an 
inexpensive, readily available copper catalyst and the atom economical bisboronic acid. 
Gratifyingly, little optimization was required, for a 75% yield of 5.3.1 was achieved using 
published conditions. Slightly higher yields were achieved by increasing the CuCl and ligand 
loadings to 2 mol % from 1 mol % (Figure 5.3). Alkyl substituents were tolerated as demonstrated 
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in 5.3.2. Chloride moieties were also preserved during the borylation (5.5.3), thus providing a 
handle for further decoration. 
 
Figure 5.3. Chromone borylation scope. 
 
With the trifluoroborate building blocks in hand, the viability of the coupling was explored. 
Using conditions that were appropriate for 2º alkyltrifluoroborate cross-couplings using Ir catalyst 
3 (2.5 mol %), NiCl2•dme (5 mol %), dtbbpy (5 mol %), Cs2CO3 (1.5 equiv), and dioxane,10b a 
modest 24% yield was achieved. To assess more suitable conditions quickly, high throughput 
experimentation15 was utilized to screen various nickel sources, bases, and solvents. Although 
Ni(COD)2 was found to yield slightly higher conversions, NiCl2•dme was ultimately chosen 
because of its stability and consequent ease of handling. K2HPO4 was found to be the preferred 
additive to sequester the BF3 generated in the oxidation of the trifluoroborate, and dioxane was a 
suitable solvent.  
Our attention was next directed to the photocatalyst (Figure 5.4). It was noted that the 
ultimate practicality of the reaction was hampered by the high cost of the iridium photocatalyst 
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5.4.2 (~$1/mg). Other, less expensive photocatalysts were compared, including 
organophotocatalysts Eosin Y15 and MesAcr (Figure 5.4, bottom). Although the oxidation potential 
for MesAcr is more than sufficient (Ered = +2.06 V vs SCE) to oxidize the trifluoroborate,11c the 
reduction potential (Ered = +0.49 V vs SCE)11c was not adequate to turn over the nickel cycle (Ered 
= +1.10 V vs SCE).16 Conversely, Eosin Y has insufficient oxidation potential to induce a single 
electron oxidation (Ered = +0.83 V vs SCE)22 of 5.3.1. During the optimization process, the Zhang 
group disclosed the synthesis of a rationally designed organophotocatalyst amenable to 
photoredox/nickel dual catalytic manifolds.17 At merely $6/g, 4CzIPN (5.4.4) was a highly 
attractive alternative. Just as Zhang and coworkers observed in their systems, 4CzIPN 
outperformed the iridium photocatalyst (entry 4) and was therefore used in the remainder of the 
study. 
  
Figure 5.4. Optimization with various photocatalysts. 
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After establishing suitable conditions, the scope of the reaction in terms of aryl/heteroaryl 
bromide partners was explored (Figure 5.5). Initially, aryl bromides with various functional groups 
were investigated (5.5.2–5.5.4). The activated 4-bromocyanobenzene used for optimization 
afforded a 70% yield, but when steric pressure was applied at the ortho position (5.5.4), the yield 
was significantly reduced. An aldehyde functional group was tolerated, providing a respectable 
67% yield (5.5.2). Chloride groups would allow further functionalization; thus, 5.5.3 is 
appropriately functionalized for additional cross-coupling, and 5.5.9 is primed for subsequent SN2 
reactions. Trifluoromethyl substituents, commonly used in medicinal chemistry, were well 
tolerated (5.5.6, 5.5.8, 5.5.15). Additionally, protic functional groups as in the halide partner 
leading to 5.5.10 also proved viable.  
Next, the heteroaryl halide scope was probed. Suprisingly, heteroarenes such as thiophene 
(5.5.13), benzofuran (5.5.11), and pyridine (5.5.15) had markedly higher yields than their aryl 
counterparts. Although electron deficient pyridines were well tolerated, electron-donating groups 
led to diminished reactivity (5.5.14). Additionally, bromo-substituted indoles and pyrroles were not 
suitable partners, presumably because of their electron rich nature. Lastly, it is worth noting that 
although they are relatively simple derivatives, only 7 arylchromanones have been previously 
reported in the literature, highlighting the utility of this protocol for accessing a wide range of novel, 
functionalized flavanones. 
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Figure 5.5. Engaging trifluoroboratochromanone in cross-coupling with aryl bromides. 
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further diversification within the heteroaryl core. Although unexplored at this time, we predict 
halide substituents at different positions of the aryl ring would yield similar results. Finally, nitro 
substituents were not tolerated (5.6.2), as observed by other groups in photoredox-catalyzed 
processes.18 
 
Figure 5.6. Varying aryl backbone of chromanone. 
5.3 Conclusion 
In conclusion, a simple and robust method has been established for accessing the 
increasingly important flavanone core. This study details the first synthesis of 2-boryl-substituted 
chromanones. With this procedure in place, practitioners are well equipped to access 2-
aryl/heteroaryl flavanones quickly and efficiently, and these substructures can be decorated with a 
wide range of functional groups owing to the availability of literally thousands of diverse, 
commercially available (hetero)aryl bromide partners. The photoredox/Ni dual catalytic cross-
coupling reactions proceed with a sustainable organic photocatalyst and a base-metal cross-
coupling catalyst under extraordinarily mild conditions (weak base, ambient temperature, visible 
light). Lastly, the method highlights the applicability of photoredox/nickel dual catalysis for 
challenging coupling reactions that are typically prone to undesirable side reactions (e.g., b-hydride 
elimination), allowing access to unique structures by transformations that are complementary to 
more traditional approaches. 
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GENERAL PROCEDURE FOR BETA BORYLATION 
 
2-(Trifluoro-λ4-boranyl)chroman-4-one, potassium salt (5.3.1) 
 
A 50 mL round bottom flask was charged with chroman-4-one (585 mg, 4.0 mmol, 1.0 equiv) and 
brought into the glove box. (HO)2BB(OH)2 (538.2 mg, 6.0 mmol, 1.5 equiv), Cu(I)Cl (7 mg, 0.08 
mmol, 0.02 equiv), CyJohnPhos (28 mg, 0.08 mmol, 0.02 equiv), and NaOt-Bu (115.3 mg, 1.2 
mmol, 0.3 equiv) were added to the flask, which was capped in the glovebox. Under nitrogen, 
freshly distilled EtOH (20 mL) was added, and the mixture was stirred for 3 h at rt. Upon 
completion of the reaction, the EtOH was removed in vacuo, and the residue was dissolved in 
MeOH (20 mL) and cooled to 0 °C. Saturated KHF2 (8 mL, 4.5 M) was added dropwise to the 
reaction, and the resulting mixture was allowed to warm to rt. After 30 min, the solution was 
concentrated in vacuo and placed on the lyophilizer overnight. A Soxhlet extraction of the solid 
was performed using i-PrOAc for 16 h, and the extract was concentrated. The resulting red solid 
was dissolved in acetone (~5 mL), and Et2O was added dropwise until precipitation was induced. 
Additional Et2O (20 mL) was added, and the solid was filtered to afford a light orange powder (650 
mg, 64% yield). mp = 135–140 °C. 
 
1H NMR (500 MHz, CDCl3) δ 7.64 (dd, J = 7.8, 1.8 Hz, 1H), 7.41 (ddd, J = 8.6, 6.9, 1.8 Hz, 1H), 
7.00 – 6.75 (m, 2H), 3.79 – 3.47 (m, 1H), 2.72 – 2.55 (m, 1H), 2.30 (dd, J = 16.9, 2.4 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ 206.5, 195.4, 164.5, 134.9, 126.1, 120.9, 118.9, 117.9, 30.7. 
19F NMR (471 MHz, C6D6) δ -143.3. 
11B NMR (128 MHz, DMSO) δ 3.9. 
O
O
BF3K
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FT-IR (cm-1, neat, ATR) 2848, 1674, 1604, 1463, 1308, 1149, 907, 755. 
HRMS (ESI) m/z calc. for C9H7O2BF3 (M-) 215.0491, found 215.0483. 
 
 
6-Methyl-2-(trifluoro-l4-boranyl)chroman-4-one, potassium salt (5.3.2) 
The general procedure was followed with chromone (320.2 mg, 2.0 mmol, 1.0 equiv). After 2 h at 
rt, the title compound was isolated (294 mg, 1.10 mmol, 55% yield). 
 
Physical properties: light yellow solid (mp = 122–125 °C). 
1H NMR (500 MHz, DMSO-d6) δ 7.44 (s, 1H), 7.23 (d, J = 8.6 Hz, 1H), 6.81 (d, J = 8.6 Hz, 1H), 
3.52 (d, J = 15.6 Hz, 1H), 2.58 (t, J = 15.9 Hz, 1H), 2.28 (d, J = 16.9 Hz, 1H), 2.22 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 195.4, 162.5, 135.9, 127.7, 125.7, 120.5, 117.8, 30.7, 20.0 (did not 
observe highlighted carbon). 
19F NMR (471 MHz, C6D6) δ -143.40. 
11B NMR (128 MHz, DMSO) δ 2.8. 
FT-IR (cm-1, neat, ATR) 2877, 1676, 1489, 1293, 996, 868. 
HRMS (ESI) m/z calc. for C12H12O3NBF2 [M-F+CH3N] 251.0929, found 251.0929. 
 
 
6-Chloro-7-methyl-2-(trifluoro-l4-boranyl)chroman-4-one, potassium salt  (5.3.3) 
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The general procedure was followed with chromone (388 mg, 2.0 mmol, 1.0 equiv). After 2 h at rt, 
the title compound was isolated (374 mg, 1.24 mmol, 62% yield). 
 
Physical properties: white powdery solid (mp = 165 °C). 
1H NMR (500 MHz, DMSO-d6) δ 7.54 (s, 1H), 6.92 (s, 1H), 3.57 (t, J = 16.7 Hz, 1H), 3.04 – 2.97 
(m, 1H), 2.56 (d, J = 15.7 Hz, 1H), 2.29 (s, 3H). 
13C NMR (126 MHz, DMSO) δ 193.9, 163.0, 142.8, 125.3, 123.9, 120.3, 47.3, 20.1 (did not 
observe highlighted carbon.) 
19F NMR (471 MHz, C6D6) δ -155.36. 
11B NMR (128 MHz, DMSO) δ 2.6. 
FT-IR (cm-1, neat, ATR) 2952, 3592, 1665, 1611, 1452, 1091, 863. 
HRMS (ESI) m/z calc. for C10H8BClF3O2 [M] 263.0258, found 263.0237. 
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GENERAL PROCEDURE FOR PHOTOREDOX/NICKEL ARYLATION 
 
To an 8 mL vial equipped with a stir bar was added trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 
4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 
equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 mmol, 0.05 equiv), K2HPO4 (174.2 mg, 1.0 
mmol, 2.0 equiv), and aryl halide (0.50 mmol, 1.0 equiv). The vial was then evacuated and purged 
three times. Under nitrogen, degassed dioxane (4.0 mL) was added under nitrogen. The resulting 
solution was stirred next to a 26 W CFL for varying amounts of time. After completion, the mixture 
was quenched with saturated NaHCO3 (10 mL) and transferred to a separatory funnel with CH2Cl2 
(15 mL) and extracted with CH2Cl2 (2 x 15 mL). The organic layers were combined and dry loaded 
with Celite. The crude mixture was purified by column chromatography. 
 
 
4-(4-Oxochroman-2-yl)benzonitrile (5.5.1) 
Reference: Wang, L. Angew. Chem. Int. Ed. 2008, 47, 8670. 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4-
bromobenzonitrile (91 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 
0.02 equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 
0.025 mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the 
reaction was allowed to run for 36 h. The title compound was purified by column chromatography 
(silica gel, 4:1 hexanes/EtOAc) to afford a crystalline solid (81 mg, 65% yield). mp = 75–77 °C (lit 
mp = 84–86 °C). 
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1H NMR (500 MHz, CDCl3) δ 8.14 (dd, J = 7.9, 1.8 Hz, 1H), 8.05 (dd, J = 8.1, 1.8 Hz, 1H), 7.97 
(dd, J = 7.9, 1.8 Hz, 1H), 7.87 – 7.78 (m, 2H), 7.53 – 7.47 (m, 1H), 7.11 – 7.00 (m, 2H), 6.21 (dd, 
J = 10.6, 3.6 Hz, 1H), 3.63 (dd, J = 17.0, 10.7 Hz, 1H), 3.12 (dd, J = 17.1, 3.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.3, 160.6, 148.9, 146.7, 142.2, 140.4, 136.3, 132.0, 127.1, 122.2, 
121.5, 118.2, 76.2, 40.4. 
 
 
4-(4-Oxochroman-2-yl)benzaldehyde (5.5.2) 
Reference: Ahmed, N.; Konduru, N. K.; Ahmad, S.; Owais, M. Eur. J. Med. Chem. 2014, 75, 233. 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4-bromo 
benzaldehyde (93 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 16 h. The title compound was purified by column chromatography (silica 
gel, 5:1 hexanes/EtOAc) to afford a light yellow oil (85 mg, 67% yield). 
 
1H NMR (500 MHz, CDCl3) δ 10.09 (s, 1H), 8.02 – 7.96 (m, 3H), 7.71 (d, J = 7.9 Hz, 2H), 7.58 
(t, J = 7.8 Hz, 1H), 7.13 (dd, J = 8.0, 5.3 Hz, 2H), 5.62 (dd, J = 13.0, 3.2 Hz, 1H), 3.08 (dd, J = 
16.8, 13.1 Hz, 1H), 3.03 – 2.95 (m, 1H). 
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13C NMR (126 MHz, CDCl3) δ 191.8, 191.2, 161.3, 145.4, 136.7, 136.6, 130.4, 127.3, 126.7, 122.2, 
121.1, 118.3, 79.0, 44.8. 
 
 
2-(2-Chlorophenyl)chroman-4-one (5.5.3) 
Reference: Jiang, H.; Zheng, X.; Yin, Z.; Xie, J. J. Chem. Res. 2011, 35, 220. 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 1-bromo-
2-chlorobenzene (96 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 16 h. The title compound was purified by column chromatography (silica 
gel, 5:1 hexanes/EtOAc) to afford a yellow oil (120 mg, 93% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 7.7 Hz, 1H), 7.53 (t, J = 7.8 
Hz, 1H), 7.40 (q, J = 7.7 Hz, 2H), 7.32 (t, J = 7.7 Hz, 1H), 7.08 (t, J = 7.7 Hz, 2H), 5.88 (dd, J = 
13.5, 2.6 Hz, 1H), 3.04 (dd, J = 16.7, 2.8 Hz, 1H), 2.89 (dd, J = 16.8, 13.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.6, 161.7, 136.9, 136.3, 131.8, 129.9, 129.74, 127.6, 127.4, 
127.3, 122.0, 121.1, 118.2, 76.7, 43.7. 
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2-(4-Oxochroman-2-yl)benzonitrile (5.5.4) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 2-
bromobenzonitrile (91 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 
0.02 equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 
0.025 mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the 
reaction was allowed to run for 36 h. The title compound was purified by column chromatography 
(silica gel, 4:1 hexanes/EtOAc) to afford a clear oil (32 mg, 35% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 7.7 Hz, 1H), 7.79 (d, J = 7.9 Hz, 1H), 7.77 – 7.69 (m, 
2H), 7.53 (dt, J = 15.4, 7.7 Hz, 2H), 7.15 – 7.05 (m, 2H), 5.85 (dd, J = 13.1, 3.4 Hz, 1H), 3.16 – 
2.93 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 190.6, 161.2, 142.3, 136.6, 133.6, 133.5, 129.3, 127.4, 127.1, 122.4, 
121.1, 118.2, 116.9, 110.9, 77.3, 44.1. 
FT-IR (cm-1, neat, ATR) 3072, 2223, 1688, 1605, 1463, 1225, 730. 
HRMS (ES+) m/z calc. for C16H11NO2 [M+H] 250.0868, found 250.0874. 
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2-(3-Tolyl)chroman-4-one (5.5.5) 
Reference: Zhao, D.; Beiring, B.; Glorius, F. Angew. Chem. Int. Ed. 2013, 52, 8454. 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 1-bromo-
3-methylbenzene (85 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 16 h. The title compound was purified by column chromatography (silica 
gel, 5:1 hexanes/EtOAc) to afford a clear oil (93 mg, 78% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 7.8 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.37 (d, J = 5.0 
Hz, 1H), 7.14 (d, J = 3.5 Hz, 1H), 7.08 – 7.02 (m, 3H), 5.75 (dd, J = 11.7, 3.3 Hz, 1H), 3.26 – 3.15 
(m, 1H), 3.07 (dd, J = 16.8, 3.3 Hz, 1H), 2.88 (d, J = 16.7 Hz, 1H), 2.40 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 192.2, 161.8, 138.8, 138.8, 136.3, 129.7, 128.9, 127.2, 127.0, 123.4, 
121.7, 121.1, 118.3, 79.9, 44.9, 21.6. 
FT-IR (cm-1, neat, ATR) 3070, 2924, 2925, 1691, 1608, 1577, 1472, 1463, 1378, 1304, 1224, 1149, 
1114, 1066, 1035, 982, 891, 851, 764, 708, 530, 490. 
 
 
2-(4-(Trifluoromethyl)phenyl)chroman-4-one (5.5.6) 
Reference: Zhao, D.; Beiring, B.; Glorius, F. Angew. Chem. Int. Ed. 2013, 52, 8454. 
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The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 1-bromo-
4-(trifluoromethyl)benzene (112 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 
mmol, 0.02 equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 
mg, 0.025 mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, 
the reaction was allowed to run for 16 h. The title compound was purified by column 
chromatography (silica gel, 5:1 hexanes/EtOAc) to afford a clear oil (107 mg, 73% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 7.8 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.42 (d, J = 2.1 
Hz, 4H), 7.11 – 7.02 (m, 2H), 5.47 (dd, J = 13.2, 3.0 Hz, 1H), 3.04 (dd, J = 16.9, 13.2 Hz, 1H), 
2.89 (dd, J = 16.8, 3.0 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.2, 161.3, 142.9, 136.5, 130.9 (q, J = 32.5 Hz), 127.3, 126.5, 
126.0 (q, J = 3.7 Hz), 124.0 (q, J = 272.0 Hz), 121.1, 118.2, 78.9, 44.8. 
 
 
2-Phenylchroman-4-one (5.5.7) 
Reference: Zhao, D.; Beiring, B.; Glorius, F. Angew. Chem. Int. Ed. 2013, 52, 8454. 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 
bromobenzene (78.5 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 16 h. The title compound was purified by column chromatography (silica 
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gel, 5:1 hexanes/EtOAc) to afford a white solid (62 mg, 55% yield). mp = 68–70 °C (lit mp = 64–
66 °C). 
 
1H NMR (500 MHz, CDCl3) δ 7.94 (d, J = 7.4 Hz, 1H), 7.55 – 7.35 (m, 6H), 7.06 (dt, J = 7.5, 3.2 
Hz, 2H), 5.49 (dd, J = 13.4, 2.9 Hz, 1H), 3.10 (dd, J = 16.9, 13.3 Hz, 1H), 2.90 (dd, J = 16.9, 2.9 
Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 192.1, 161.7, 138.9, 136.4, 129.0, 128.9, 127.2, 126.3, 121.8, 121.1, 
118.3, 79.8, 44.9.  
 
 
2-(3,5-Bis(trifluoromethyl)phenyl)chroman-4-one (5.5.8) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 3,5-
bistrifluoromethyl bromobenzene (84 µL, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 
0.004 mmol, 0.02 equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl 
bipyridine (6.7 mg, 0.025 mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under 
a 26 W CFL, the reaction was allowed to run for 16 h. The title compound was purified by column 
chromatography (silica gel, 4:1 hexanes/EtOAc) to afford a clear oil (120 mg, 67% yield). 
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1H NMR (500 MHz, CDCl3) δ 7.96 (d, J = 7.4 Hz, 3H), 7.92 (s, 1H), 7.57 (t, J = 7.8 Hz, 1H), 7.12 
(t, J = 7.6 Hz, 2H), 5.61 (dd, J = 13.1, 3.3 Hz, 1H), 3.11 – 2.91 (m, 2H). 
13C NMR (126 MHz, CDCl3) δ 190.5, 161.0, 141.7, 136.7, 132.7, 132.4, 132.1, 127.4, 126.3, 124.3, 
122.8, 122.5, 122.2, 121.0, 118.2, 78.3, 44.9. 
FT-IR (cm-1, neat, ATR) 2934, 1698, 1605, 1354, 1339, 1308, 1287, 1227, 1204, 1164, 1151, 1126, 
1077, 897, 882, 856, 843, 768, 705, 685. 
HRMS (ES+) m/z calc. for C17H11FO2 [M+H] 361.0623, found 361.0651. 
 
 
2-(4-(Chloromethyl)phenyl)chroman-4-one (5.5.9) 
Reference: Wang, L. Angew. Chem. Int. Ed. 2008, 47, 8670. 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4-bromo 
benzyl chloride (103 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 16 h. The title compound was purified by column chromatography (silica 
gel, 5:1 hexanes/EtOAc) to afford a clear oil (74 mg, 27% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 7.8, 1.8 Hz, 1H), 7.52 – 7.40 (m, 3H), 7.18 – 7.11 (m, 
2H), 7.01 (t, J = 7.3 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 4.65 (dq, J = 9.0, 6.3 Hz, 1H), 3.14 (dd, J = 
14.1, 6.8 Hz, 1H), 3.00 (dd, J = 14.1, 5.7 Hz, 1H), 2.70 – 2.65 (m, 2H). 
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13C NMR (126 MHz, CDCl3) δ 192.1, 161.4, 136.2, 135.4, 131.8, 131.5, 127.1, 121.6, 121.1, 121.1, 
118.1, 78.0, 42.4, 40.7. 
FT-IR (cm-1, neat, ATR) 2076, 2930, 1692, 1606, 1464, 1305, 1227, 1119, 764. 
 
 
2-(3-Hydroxyphenyl)chroman-4-one (5.5.10) 
Reference: Jung, H.; Shin, S. Y.; Jung, Y.; Tran, T. A.; Lee, H. O.; Jung, K. -Y. Koh, D.; Cho, S. 
K.; Lim, Y. Chem. Biol. Drug, Des. 2015, 86, 496. 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 3-
bromophenol (86 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 16 h. The title compound was purified by column chromatography (silica 
gel, 5:1 hexanes/EtOAc) to afford a white semi-solid (76 mg, 63% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 7.8 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.42 (d, J = 2.1 
Hz, 4H), 7.11 – 7.02 (m, 2H), 5.75 (br s, 1H), 5.47 (dd, J = 13.2, 3.0 Hz, 1H), 3.04 (dd, J = 16.9, 
13.2 Hz, 1H), 2.89 (dd, J = 16.8, 3.0 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 192.6, 161.7, 156.3, 140.6, 136.6, 130.3, 127.2, 125.9, 121.9, 121.0, 
118.4, 118.31, 115.9, 113.3, 44.7. 
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2-(Benzofuran-5-yl)chroman-4-one (5.5.11) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 5-bromo 
benzofuran (98 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 16 h. The title compound was purified by column chromatography (silica 
gel, 4:1 hexanes/EtOAc) to afford a clear oil (102 mg, 77% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.95 (d, J = 8.0 Hz, 1H), 7.74 (s, 1H), 7.68 (s, 1H), 7.57 (d, J = 8.5 
Hz, 1H), 7.52 (t, J = 7.8 Hz, 1H), 7.43 (s, 1H), 7.07 (t, J = 6.9 Hz, 2H), 6.81 (s, 1H), 5.58 (dd, J = 
13.5, 2.7 Hz, 1H), 3.17 (dd, J = 16.7, 13.6 Hz, 1H), 2.93 (dd, J = 16.9, 2.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 192.2, 161.8, 155.1, 146.1, 136.4, 133.6, 127.95, 127.2, 122.8, 
121.8, 121.1, 119.4, 118.3, 111.9, 106.9, 80.1, 45.2. 
FT-IR (cm-1, neat, ATR) 3076, 2896, 1688, 1606, 1578, 1572, 1472, 1464, 1449, 1377, 1305, 1265, 
1224, 1149, 1128, 1114, 765. 
HRMS (ES+) m/z calc. for C17H13O3 [M+H] 265.0865, found 265.0864. 
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2-(Benzo[b]thiophen-5-yl)chroman-4-one (5.5.12) 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 2-bromo 
benzothiophene (103 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 36 h. The title compound was purified by column chromatography (silica 
gel, 4:1 hexanes/EtOAc) to afford a clear oil (80 mg, 57% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 7.6 Hz, 1H), 7.84 – 7.80 (m, 1H), 7.77 – 7.74 (m, 1H), 
7.51 (t, J = 7.7 Hz, 1H), 7.38 – 7.31 (m, 3H), 7.06 (dd, J = 14.0, 7.7 Hz, 2H), 5.84 (dd, J = 10.8, 
3.7 Hz, 1H), 3.25 (dd, J = 16.9, 10.8 Hz, 1H), 3.15 (dd, J = 16.8, 3.7 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 190.9, 160.8, 142.2, 139.9, 139.1, 136.5, 136.4, 127.2, 125.1, 124.7, 
124.1, 122.6, 122.1, 121.2, 118.4, 75.7, 44.1. 
FT-IR (cm-1, neat, ATR) 3368, 3059, 2900, 1687, 1604, 1577, 1471, 1461, 1438, 1362, 1299, 1221, 
1148, 1112, 1066, 906, 891, 862, 828, 761, 747, 726, 558. 
HRMS (ES+) m/z calc. for C17H13O2S [M+H] 281.0636, found 281.0658. 
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2-(Thiophen-2-yl)chroman-4-one (5.5.13) 
Reference: Kavala, V.; Lin, C.; Kuo, C. -W.; Fang, H.; Yao, C. -F. Tetrahedron 2012, 68, 1321. 
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 2-
bromothiophene (81 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 0.02 
equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 0.025 
mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the reaction 
was allowed to run for 16 h. The title compound was purified by column chromatography (silica 
gel, 5:1 hexanes/EtOAc) to afford a clear oil (105 mg, 91% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.93 (d, J = 7.8 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.37 (d, J = 5.0 
Hz, 1H), 7.14 (d, J = 3.5 Hz, 1H), 7.08 – 7.02 (m, 3H), 5.75 (dd, J = 11.7, 3.3 Hz, 1H), 3.26 – 3.15 
(m, 1H), 3.07 (dd, J = 16.8, 3.3 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.3, 161.1, 141.6, 136.4, 127.2, 127.0, 126.5, 126.0, 122.0, 121.2, 
118.4, 75.3, 44.5. 
FT-IR (cm-1, neat, ATR) 3070, 2924, 2925, 1691, 1608, 1577, 1472, 1463, 1378, 1304, 1224, 1149, 
1114, 1066, 1035, 982, 891, 851, 764, 708, 530, 490. 
 
 
2-(5-(Trifluoromethyl)pyridin-2-yl)chroman-4-one (5.5.15) 
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The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 2-bromo-
5-trifluoromethyl pyridine (113 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 
mmol, 0.02 equiv), NiCl2 dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 
mg, 0.025 mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, 
the reaction was allowed to run for 16 h. The title compound was purified by column 
chromatography (silica gel, 5:1 hexanes/EtOAc) to afford a yellow oil (120 mg, 82% yield). 
 
1H NMR (500 MHz, CDCl3) δ 8.88 (s, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.81 
(d, J = 8.3 Hz, 1H), 7.54 (t, J = 7.8 Hz, 1H), 7.10 (dd, J = 12.7, 7.7 Hz, 2H), 5.68 (dd, J = 11.9, 3.7 
Hz, 1H), 3.22 (dd, J = 16.9, 3.7 Hz, 1H), 3.12 (dd, J = 17.0, 11.9 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 191.0, 161.8, 160.7, 147.8, 146.5 (q, J = 4.2 Hz), 134.5 (q, J = 3.4 
Hz), 127.8, 126.6, 126.3, 122.3, 121.4, 120.6, 118.2, 79.4, 42.7.  
FT-IR (cm-1, neat, ATR) 3063, 1681, 1609, 1578, 1474, 1328, 1217, 1161, 1135, 1116, 1084, 1017, 
852, 769, 759. 
HRMS (ES+) m/z calc. for C15H11F3NO2 [M+H] 294.0742, found 294.0754. 
 
 
 
4-(6-Methyl-4-oxochroman-2-yl)benzonitrile (3b) 
The general procedure was followed with trifluoroborate (201.0 mg, 0.75 mmol, 1.5 equiv), 4-
bromobenzonitrile (91.0 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 
0.02 equiv), NiCl2dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 
0.025 mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the 
O
O
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reaction was allowed to run for 16 h. The title compound was purified by column chromatography 
(silica gel, 5:1 hexanes/EtOAc) to afford a clear oil (89.5 mg, 68% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 8.1 Hz, 3H), 7.61 (d, J = 7.9 Hz, 2H), 7.35 (d, J = 8.5 
Hz,1H), 6.98 (d, J = 8.5 Hz, 1H), 5.52 (d, J = 12.4 Hz, 1H), 3.07 – 2.83 (m, 2H), 2.34 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 191.1, 159.2, 144.2, 137.7, 132.8, 131.8, 126.9, 126.8, 120.7, 118.5, 
118.0, 112.7, 78.6, 44.7, 20.6. 
FT-IR (cm-1, neat, ATR) 2918, 1687, 1617, 1489, 1134, 829, 596. 
HRMS (ES+) m/z calc. for C17H14NO2 [M+H] 263.0946, found 264.1016. 
 
 
 
4-(6-chloro-7-methyl-4-oxochroman-2-yl)benzonitrile (2d) 
The general procedure was followed with trifluoroborate (226.5 mg, 0.75 mmol, 1.5 equiv), 4-
bromobenzonitrile (91.0 mg, 0.50 mmol, 1.0 equiv), 4CzIPN photocatalyst (7.9 mg, 0.004 mmol, 
0.02 equiv), NiCl2dme (5.5 mg, 0.025 mmol, 0.05 equiv), 4,4’-di-tert-butyl bipyridine (6.7 mg, 
0.025 mmol, 0.05 equiv), and K2HPO4 (174.2 mg, 1.0 mmol, 2.0 equiv). Under a 26 W CFL, the 
reaction was allowed to run for 16 h. The title compound was purified by column chromatography 
(silica gel, 5:1 hexanes/EtOAc) to afford a clear oil (105.4 mg, 71% yield). 
 
1H NMR (500 MHz, CDCl3) δ 7.86 (s, 1H), 7.73 (d, J = 8.0 Hz, 2H), 7.59 (d, J = 7.9 Hz, 2H), 6.97 
(s, 1H), 5.52 (d, J = 12.3 Hz, 1H), 3.02 – 2.84 (m, 2H), 2.40 (s, 3H). 
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13C NMR (126 MHz, CDCl3) δ 189.6, 159.3, 145.8, 143.7, 132.9, 128.5, 127.0, 126.7, 120.3, 120.0, 
118.4, 112.82, 78.8, 44.3, 21.0. 
FT-IR (cm-1, neat, ATR) 3066, 1690, 1613, 1407, 1236, 1154, 893, 837, 655. 
HRMS: compound unstable. 
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Chapter 6. Introduction 1,4-Dihydropyridines to Photoredox/Ni Dual Catalysis 
 
6.1 Introduction 
 In the last decades, cross-coupling reactions have become among the most employed means 
to construct new C-C bonds.1† However, despite their numerous advantages, cross-coupling 
reactions, especially in the context of Csp2–Csp3 bond formation, suffer from some limitations that 
hinder their more widespread utilization. In particular, the high activation energy barrier associated 
with the transmetalation step in the coupling of many Csp3 nucleophiles results in a need to use 
unstable and functional group-intolerant organometallic reagents, negatively impacting the 
generality and operational simplicity of these methods.2 In this regard, the recently developed nick-
el/photoredox dual catalytic process has proved to be an excellent alternative and complementary 
approach to overcome such limitations3 by triggering a facile transmetalation-like event that is 
initiated by single-electron oxidation of an organometallic reagent.  The odd-electron nature of this 
reactivity paradigm proceeds most rapidly with Csp3 coupling partners, effectively inverting the 
reactivity hierarchy observed in more conventional cross-coupling processes. As a result, reactive 
organometallic nucleophiles can be exchanged for a variety of functional group-tolerant radical 
precursors. 
Among alkyl radical precursors, different partners have been previously reported such as 
trifluoroborates,4 silicates,5 carboxylic acids,6 halides,7 and activated C-H bonds.8 However, it 
remains of utmost importance to introduce new feedstock functional groups amenable to oxidative 
fragmentation, forming suitable alkyl radicals.9 Within this context, aldehydes represent an 
attractive option because aliphatic aldehydes are abundant in nature and readily available from 
 
 
† Reproduced in part from Gutierrez-Bonet, A.; Tellis, J. C.; Matsui, J. K.; Vara, B. A.; Molander, G. A. 
ACS Catal. 2016, 6, 8004. 
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commercial sources. Although nature has long ago developed very effective means to promote 
oxidative deformylation reactions,10 such transformations still pose significant challenges for the 
scientific community, which rely on two distinct approaches (Figure 6.1). First, an acyl radical can 
be formed through a hydrogen-atom transfer (HAT) process, usually involving thiyl radicals, then, 
decarbonylation delivers the targeted alkyl radical (route A).11 This latter step is usually slow, and 
acylated byproducts are often observed. Alternatively, superoxometal complexes have been 
employed (route B);12 however, strong, stoichiometric oxidants are required, thus hampering the 
applicability and breadth of substrates employed. 
 
 
Figure 6.1. Generating carbon-centered radicals from aldehydes. 
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6.2 Reaction Design and Results 
Aware of the inherent difficulties associated with the formation of alkyl radicals directly 
from aldehydes,13 we explored different aldehyde derivatives able to undergo photochemical 
homolysis. 1,4-Dihydropyridines (DHPs) can be easily prepared from aldehydes in one step, even 
with high functionalization levels,14 and their photochemical oxidation delivers hydrogen (H2) with 
concomitant pyridine formation. However, in the presence of alkyl substituents in the 4-position, 
the oxidation has been shown to generate carbon-centered alkyl radicals.15 Importantly, the 
Nishibayashi group16 has successfully applied such an approach in aromatic substitution reactions. 
More recently, Ma and Cheng coupled a variety of DHPs with activated tertiary alkyl bromides 
under photocatalytic conditions.17 
To ensure effective oxidative cleavage of the 1,4-DHP (Eox = +1.05 V vs SCE),18 the 
organic dye 4CzIPN (excited state Ered = +1.35 V vs SCE) was employed as a photocatalyst,19 and 
different nickel(II) sources were tested (Figure 6.2, entries 1–5).20 As shown, dtbbpy outperformed 
other ligands tested, with dMeObpy and bpy showing lower yields (entries 2–4). Interestingly, the 
preformed [Ni(dtbbpy)(H2O)4]Cl2 afforded the higher yields with no deleterious effects observed 
from the water. Other photocatalysts were also explored (entries 6–7). Not surprisingly, 
[Ru(bpy)3](PF6)2 only delivered traces of product, likely because of its low oxidation potential (Ered 
= +0.77 V vs SCE) whereas an Ir-photocatalyst (entry 6) delivered the product in moderate yields 
(Ered = +1.32 V vs. SCE). The highly oxidizing organic photocatalyst mesityl acridinium (Eox = 
2.06 V vs SCE)23 was next explored but afforded no product likely because of its inability to reduce 
the putative Ni(I) intermediate.4j Consequently, 4CzIPN was chosen because of its lower cost 
($6.01/g), more straightforward preparation, and higher activity. Finally, although other common 
solvents for photoredox cross-coupling reactions were examined (entries 8–9), acetone out-
performed both CH3CN and DMF. As anticipated, control experiments showed that all parameters 
were essential for the reaction to proceed. Importantly, we observed complete consumption of 1a 
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in the presence of the photocatalyst, delivering the pyridine byproduct. Therefore, in some cases 
we decided to boost the reactivity by increasing the amount of Ni-catalyst and DHP, thus obtaining 
higher yields. It should be noted that the disclosed reaction conditions are particularly user-friendly, 
allowing the construction of complex structural motifs in a “dump and stir” fashion. 
 
Figure 6.2. Control studies and optimization. 
Encouraged by these results, we turned our attention to study the influence of several 
(hetero)aryl bromides in the reaction. As illustrated in Figure 6.3, different (hetero)aryl bromides 
were well accommodated with aromatic substrates (6.3.1–6.3.2) and heteroaromatic entities such 
as pyridines (6.3.3), thiazole (6.3.4), and thiophene (6.3.6–6.3.7). Notably, we observed that 2-
bromoheteroarenes were more reactive than other heteroaryl bromides.21 Likewise, bifunctional 
heteroaryl bromides bearing carbonyl moieties (6.3.6–6.3.7) proved to be useful coupling partners, 
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and the products of these reactions thus contain reactive groups that can be used for further 
elaboration. 
 
Figure 6.3. Scope of (hetero)aryl bromides. 
Once the versatility of the protocol was demonstrated against different (hetero)aryl 
bromides, we decided to focus our attention on both the DHP radical precursors and the aryl 
bromide partners simultaneously in an effort to showcase the “real-world” utility of this method in 
cases where both the nucleophilic and electrophilic partner present structural and/or electronic 
challenges (Figure 6.4). The developed reaction conditions were highly general, and various 
substitution patterns were well accommodated. The diverse range of alkylated arenes and 
heteroarenes were isolated in modest to high yields. Unactivated secondary alkyl DHPs could be 
coupled independently of the cyclic or acyclic nature of the radical. More interestingly, alkyl radi-
cals bearing distal alkenes (6.4.5–6.4.7) were well tolerated. No evidence of radical cyclization was 
observed for the melonal-derived DHP (6.4.10). A pyran-derived DHP was likewise tolerated, and 
the resulting product was isolated in good yield (6.4.11). Importantly, even at almost 10-fold higher 
scale the reaction went to 60% yield without further optimization. Similar results were achieved 
for a benzylic DHP when coupled with a challenging pyridine (6.4.12). In addition to unactivated 
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alkyl radicals, α-heteroalkyl substrates could be employed. Pyrrolidine (6.4.13) as well as protected 
amino alcohol (6.4.14) and amino acid-derived (6.4.15) DHPs all succeeded in delivering the cross-
coupled product, although in modest yields. 
 
Figure 6.4. Exploring radical breadth. 
To demonstrate further the applicability of the developed method, the protocol was tested 
for the synthesis of two saccharide derivatives. Previous literature reports for the synthesis of C -
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synthesis of the requisite alkyl glycosidic stannanes and alkyl  boronates would suffer β-elimination 
of the adjacent alkoxy group. Thus, current approaches require a cumbersome synthesis of the 
dihydropyranylmetallics, followed by coupling and hydrogenation. By contrast, for the present 
transformation, 1,4-dihydropyridines from saccharides are readily available,14a and the particularly 
mild reaction conditions allow the formation of saccharide-containing product (6.5.1) in good yield 
and excellent diastereoselectivity. Access to 6.5.2 demonstrates that a fully deprotected 
carbohydrate core can be coupled, albeit in modest yield (Figure 6.5). 
 
 
Figure 6.5. Incorporating monosaccharide moieties. 
The developed method does present a few limitations24 owing to the intrinsic stability of 
the radical intermediate formed. Consequently, primary alkyl or cyclopropyl DHPs did not succeed 
in delivering the cross-coupling product, because oxidation of the DHP delivers only the 4-
alkylated pyridine byproduct.15 Nonetheless, this is arguably a minor limitation considering 
complementary cross-coupling protocols available for primary or cyclopropyl motifs.2a 
Based on our previous studies with alkyltrifluoroborates25 as well as previous studies 
detailing the photochemical oxidative cleavage of DHPs,15,16 we propose the mechanistic scenario 
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quenched by the DHP derivative (6.6.1), thus forming a radical cation (not pictured), which 
undergoes homolysis, delivering the carbon-centered alkyl radical 6.6.2. This radical reacts with 
active Ni(0) catalyst, forming the alkylnickel(I) intermediate 6.6.3, which undergoes further 
oxidative addition with the aryl bromide, forming the Ni(III) complex 6.6.4.26,27 Subsequently, 
reductive elimination delivers the cross-coupled product along with Ni(I) complex 6.6.3, which can 
be reduced to Ni(0) by the reduced photo-catalyst, thus regenerating both active catalysts. We 
believe that the homolysis of the DHP unit occurs via formation of a radical cation followed by a 
deprotonation step, forming an aminyl radical that will then undergo homolysis.15,16 Notably, we 
observed that N-Me DHP failed to deliver the cross-coupling product under reaction conditions, 
thus supporting the deprotonation prior to the C-C cleavage event hypothesis. 
 
Figure 6.6. Proposed dual catalytic mechanism. 
6.3 Conclusion 
In summary, the use of DHPs as radical precursors has allowed the successful and general 
introduction of an interesting feedstock into the dual Ni/photoredox cross-coupling toolbox. 
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unrepresented radicals can be accessed, thereby expanding the chemical space of Csp2-Csp3 cross-
couplings. Importantly, the reaction is characterized by its sustainability, as the only metal 
introduced in the entire process is the base metal cross-coupling catalyst. The transformation 
furthermore proceeds under extremely mild reaction conditions using visible light, allowing the 
inclusion of diverse and unexplored coupling partners such as carbohydrate cores. 
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GENERAL CONSIDERATIONS 
Reagents 
All reactions were carried out under an inert atmosphere of nitrogen or argon unless 
otherwise noted. Standard Schlenk techniques were used for the manipulation of solvents 
and reagents. Reactions were monitored by GC/MS, HPLC, 1H NMR, and/or by TLC on 
silica gel plates (60 Å porosity, 250 µm thickness). TLC analysis was performed using 
hexanes/EtOAc as the eluant and visualized using permanganate stain and/or UV light. Silica 
plugs utilized flash silica gel (60 Å porosity, 32-63 µm). Flash chromatography was 
accomplished using an automated system (visualizing at 254 nm, monitoring at 280 nm) 
with silica cartridges (60 Å porosity, 20-40 µm). Solvents were purified either by distillation 
over sodium or CaH2 or by use of drying cartridges through a solvent delivery system. 
Irradiation of reaction vessels was accomplished using blue LEDs (Light-emitting diode) at 
a distance of ~3 cm. A fan was employed to ensure reactions remained at or near rt when 
using LEDs. 
Analytical Methods 
Melting points (°C) are uncorrected. NMR Spectra (1H, 13C {1H}) were recorded on a 500 
or 400 MHz spectrometer at 298 K. All 1H NMR spectra are reported in parts per million 
(ppm) downfield of TMS and were measured relative to the signals for CHCl3 (7.26 ppm). 
All 13C NMR spectra were reported in ppm relative to residual CHCl3 (77.2 ppm) and were 
obtained with 1H decoupling. Coupling constants, J, are reported in Hertz (Hz). In the case 
of diastereisomeric mixtures, a crude NMR was recorded to determine the ratio. HRMS was 
obtained by either ESI or CI with a TOF spectrometer in MeCN or CH2Cl2. IR spectra were 
obtained on neat samples. The yields reported in Table 2 and Table 3 refer to isolated yields 
and represent an average of at least two independent runs. The procedures described in this 
section are representative. Thus, the yields may differ slightly from those given in Tables 2 
and 3.  
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Synthesis of 1,4-Dihydropyridines 
General Procedure I: Synthesis of 1,4-dihydropyridnes: 1,4-Dihydropyridnes were prepared 
following a modified literature protocol.1 Into a round-bottom flask charged with ethyl 3-
aminocrotonate (1.0 equiv) was added ethylene glycol (2.5 M). Next, ethyl acetoacetate (1.0 
equiv) was added followed by the aldehyde (1.0 equiv).2 Finally, Bu4NHSO4 (12 mol %) 
was added in one portion. The flask was closed with a septum and heated at 80 ºC for 3-4 h. 
At this time, the reaction was cooled to rt and diluted with EtOAc. The solution was poured 
into a separatory funnel containing brine and extracted three times with EtOAc. After drying 
over MgSO4, it was filtered and taken to dryness. The crude reaction mixture was purified 
using an automated system (visualizing at 254 nm, monitoring at 280 nm) with silica 
cartridges (60 Å porosity, 20-40 µm) using hexanes/EtOAc (0 to 40%) as eluent. 
Characterization Data: 1,4-Dihydropyridines 
 
 
Diethyl 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.1) 
Following General Procedure I using isobutyraldehyde (793.2 mg, 11.0 mmol, 1.0 equiv). 
The product was isolated as a white solid (2.01 g, 62% yield). Mp = 95-97 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 5.51 (s, 1H), 4.27 – 4.08 (m, 4H), 3.92 (d, J = 5.4 Hz, 1H), 
2.30 (s, 6H), 1.63 – 1.57 (m, 1H), 1.29 (t, J = 7.1 Hz, 6H), 0.75 (d, J = 6.9 Hz, 6H) ppm.  
13C NMR (126 MHz, CDCl3) δ 168.9, 144.7, 101.9, 59.7, 38.9, 35.7, 19.5, 18.6, 14.5 ppm. 
The spectral data were in agreement with those previously reported.3 
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Diethyl 4-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (6.1.2) 
Following General Procedure I using (R)-2,2-dimethyl-1,3-dioxolane-4-carboxaldehyde 
(1.0 g,  7.7 mmol, 1.0 equiv). The product was isolated as a white solid (1.85 g, 68% yield). 
Mp = 106-109 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 5.61 (br s, 1H), 4.32 (d, J = 4.9 Hz, 1H), 4.26 – 4.13 (m, 4H), 
4.04 – 3.96 (m, 1H), 3.83 (td, J = 8.1, 1.9 Hz, 1H), 3.79 – 3.69 (m, 1H), 2.31 (dd, J = 5.0, 
2.0 Hz, 6H), 1.36 – 1.24 (m, 12H) ppm.  
13C NMR (126 MHz, CDCl3) δ 168.2, 168.1, 146.1, 145.5, 108.7, 99.8, 99.4, 79.6, 66.3, 
59.9, 36.2, 26.3, 25.8, 19.6, 19.5, 14.5 ppm. IR (neat, cm-1): 3327, 2984, 1693, 1664, 1206, 
1095, 1046, 775. HRMS calcd for (C18H27NO6+H) 354.1917, found 354.1903. 
 
 
Diethyl 4-cyclohexyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.3) 
Following General Procedure I using cyclohexanecarboxaldehyde (1.1 g, 10.0 mmol, 1.0 
equiv). The product was isolated as a white solid (1.88 g, 56% yield). Mp = 111-114 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 5.51 (s, 1H), 4.27 – 4.09 (m, 4H), 3.92 (d, J = 5.6 Hz, 1H), 
2.30 (s, 6H), 1.70 – 1.62 (m, 2H), 1.58 – 1.51 (m, 3H), 1.30 (t, J = 7.1 Hz, 6H), 1.25 – 1.17 
(m, 1H), 1.13 – 1.03 (m, 3H), 0.99 – 0.86 (m, 2H) ppm.  
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13C NMR (126 MHz, CDCl3) δ 168.9, 145.0, 101.5, 59.6, 45.8, 38.4, 28.8, 26.7, 26.6, 19.2, 
14.4 ppm. The spectroscopical data were in agreement with those previously reported.4 
 
 
Diethyl 4-(cyclohex-3-en-1-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
(6.1.4) 
Following General Procedure I using 3-cyclohexene-1-carboxaldehyde (1.4 g, 12.8 mmol, 
1.0 equiv) The product was isolated as a white solid (2.26 g, 53% yield). Mp = 127-130 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 5.64 – 5.56 (m, 2H), 5.55 (s, 1H), 4.30 – 4.08 (m, 4H), 4.02 
(d, J = 5.9 Hz, 1H), 2.31 (s, 6H), 2.11 – 1.84 (m, 3H), 1.82 – 1.72 (m, 1H), 1.68 – 1.59 (m, 
1H), 1.58 – 1.50 (m, 1H), 1.30 (t, J = 7.1 Hz, 6H), 1.26 – 1.13 (m, 1H) ppm.  
13C NMR (126 MHz, CDCl3) δ 168.7, 168.6, 144.9, 144.8, 127.2, 126.8, 101.8, 59.8, 41.7, 
37.9, 27.6, 26.2, 25.1, 19.7, 19.6, 14.5 ppm.  
IR (neat, cm-1): 3350, 1644, 1485, 1215, 1098, 1049, 661.  
HRMS calcd for (C19H27NO4+Na) 356.1838, found 358.1827. 
 
 
Diethyl 4-(heptan-3-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.5) 
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Following General Procedure I using 2-ethylhexanal (1.3 g, 10.3 mmol, 1.0 equiv). The 
product was isolated as a yellow solid (2.20 g, 61% yield). Mp = 63-65 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 5.89 – 5.45 (m, 1H), 4.22 – 4.10 (m, 5H), 2.28 (d, J = 2.6 Hz, 
6H), 1.30 (t, J = 7.1 Hz, 6H), 1.27 – 1.17 (m, 5H), 1.15 – 1.07 (m, 4H), 0.86 (t, J = 7.0 Hz, 
6H) ppm.  
13C NMR (126 MHz, CDCl3) δ 169.0, 169.0, 144.9, 144.8, 102.1, 102.0, 59.7, 48.2, 35.0, 
29.6, 28.4, 23.3, 21.8, 19.3, 19.3, 14.4, 14.2, 11.9 ppm.  
IR (neat, cm-1): 3361, 1618, 1486, 1268, 1200, 1110, 1096, 1017, 741.  
HRMS calcd for (C20H33NO4+Na) 374.2307, found 374.2320. 
 
 
Diethyl 2,6-dimethyl-4-(7-methyloct-6-en-3-yl)-1,4-dihydropyridine-3,5-dicarboxylate 
(6.1.6) 
Following General Procedure I using 2,6-dimethyl-5-heptenal (1.7 g, 12.1 mmol, 1.0 equiv). 
The product was isolated as a yellow oil (2.47 g, 54% yield).  
 
1H NMR (500 MHz, CDCl3) δ 5.46 (s, 1H), 5.03 (t, J = 7.0 Hz, 1H), 4.25 – 4.09 (m, 4H), 
4.01 (d, J = 4.4 Hz, 1H), 2.29 (d, J = 3.6 Hz, 6H), 2.03 – 1.93 (m, 1H), 1.92 – 1.82 (m, 1H), 
1.66 (s, 3H), 1.58 (s, 3H), 1.48 – 1.40 (m, 1H), 1.38 – 1.32 (m, 1H), 1.29 (td, J = 7.1, 2.7 
Hz, 6H), 1.05 – 0.94 (m, 1H), 0.73 (d, J = 6.8 Hz, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 169.0, 168.6, 144.8, 144.6, 130.9, 125.3, 102.2, 101.4, 59.7, 
59.7, 41.0, 38.1, 32.8, 26.2, 25.8, 19.5, 19.4, 17.8, 15.1, 14.5, 14.5 ppm.  
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The spectral data were in agreement with those previously reported.5 
 
 
Diethyl 2,6-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1,4-dihydropyridine-3,5-
dicarboxylate (6.1.7) 
Following General Procedure I using 4-formyltetrahydropyran (2.0 g, 17.8 mmol, 1.0 equiv). 
The product was isolated as a yellowish solid (4.09 g, 68% yield). Mp = 113-117 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 5.60 (s, 1H), 4.25 – 4.12 (m, 4H), 3.99 (d, J = 5.9 Hz, 1H), 
3.95 – 3.87 (m, 2H), 3.30 – 3.14 (m, 2H), 2.32 (s, 6H), 1.50 – 1.32 (m, 5H), 1.30 (t, J = 7.1 
Hz, 6H) ppm.  
13C NMR (126 MHz, CDCl3) δ 168.4, 145.2, 101.3, 68.5, 59.8, 42.7, 37.8, 29.0, 19.6, 14.5 
ppm.  
IR (neat, cm-1): 3342, 1698, 1646, 1223, 1205, 1139, 1087, 772. HRMS calcd for 
(C18H27NO5+H) 338.1967, found 338.1970. 
 
 
Diethyl 4-benzyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.8) 
Following General Procedure I using phenylacetaldehyde (1.4 g, 11.5 mmol, 1.0 equiv). The 
product was isolated as a white solid (2.06 g, 52% yield). Mp = 102-106 ºC.  
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1H NMR (500 MHz, CDCl3) δ 7.20 – 7.11 (m, 3H), 7.02 (d, J = 7.8 Hz, 2H), 5.17 (s, 1H), 
4.20 (t, J = 5.4 Hz, 1H), 4.13 – 3.98 (m, 4H), 2.58 (d, J = 5.5 Hz, 2H), 2.18 (s, 6H), 1.23 (t, 
J = 7.2 Hz, 6H) ppm.  
13C NMR (126 MHz, CDCl3) δ 167.9, 145.5, 139.4, 130.2, 127.4, 125.7, 102.0, 59.7, 42.4, 
35.6, 19.4, 14.5 ppm.  
The spectral data were in agreement with those previously reported.4 
 
 
Diethyl 4-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-2,6-dimethyl-1,4-dihydropyridine-
3,5-dicarboxylate (6.1.9) 
Following General Procedure I using Boc-L-prolinal (1.0 g, 5.0 mmol, 1.0 equiv). The 
product was isolated as a yellow semisolid (1.31 g, 62% yield). Mixture of rotamers, major 
is reported:  
 
1H NMR (400 MHz, CDCl3): δ 7.85 (br s, 1H), 4.23–4.06 (m, 4H), 3.93 (d, J = 9.6 Hz, 1H), 
3.63 (dd, J = 10.4, 6.4 Hz, 1H), 3.26–3.22 (m, 2H), 2.32 (s, 3H), 2.20 (s, 3H), 2.01–1.78 (m, 
4H), 1.38 (s, 9H), 1.30 (t, J = 7.0 Hz, 6H) ppm. 
13C NMR (101 MHz, CDCl3): δ 168.2, 154.9, 147.9, 100.2, 78.6, 59.3, 45.6, 34.9, 28.4, 27.7, 
24.9, 22.6, 19.0, 14.3 ppm. 
IR (neat, cm-1): 2977, 2934, 1690, 1671, 1481, 1446, 1390, 1366, 1341, 1302, 1286, 1250, 
1210, 1165, 1121, 1098, 1050, 1019.  
HRMS calcd for (C22H34N2O6+H) 423.2495, found 423.2485. 
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Diethyl 4-(3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidin-4-yl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (6.1.10) 
Following General Procedure I using (S)-(-)-3-Boc-2,2-dimethyloxazolidine-4-
carboxaldehyde (424.1 mg, 1.85 mmol, 1.0 equiv). The product was isolated as a white 
semisolid (524.0 mg, 63% yield). Mixture of rotamers, major is reported: 
 
1H NMR (500 MHz, CDCl3): δ 6.97 (s, 1H), 4.29 (d, J = 9.0 Hz, 1H), 4.23–4.16 (m, 4H), 
3.90 (m, 1H), 3.76–3.73 (m, 1H), 3.67–3.65 (m, 1H), 2.32 (s, 3H), 2.24 (s, 3H), 1.48 (s, 3H), 
1.43 (s, 9H), 1.39 (s, 3H), 1.27 (t, J = 7.0 Hz, 6H) ppm.  
13C NMR (126 MHz, CDCl3): δ 167.8, 153.6, 146.8, 100.0, 64.0, 79.6, 65.6, 60.3, 59.6, 36.1, 
28.4, 26.6 (gem dimethyl), 24.5 (gem dimethyl), 19.3, 14.4 ppm. 
IR (neat, cm-1): 3333, 2979, 2937, 1692, 1551, 1480, 1366, 1285, 1252, 1213, 1170, 1096, 
1049, 951.  
HRMS calcd for (C23H36N2O7+Na) 475.2420, found 475.2417. 
 
 
Diethyl 4-(1-((tert-butoxycarbonyl)amino)-2-phenylethyl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (6.1.11) 
NH
Me
Me
CO2Et
EtO2C
NBoc
O
Me
Me
NH
Me
Me
CO2Et
EtO2C
BocHN
Ph
	  
	  
545 
Following General Procedure I using N-Boc-L-phenylalaninal (1.0 g, 4.0 mmol, 1.0 equiv). 
The product was isolated as a white solid (701.2 mg, 37% yield). Mp = 146–147 °C; Mixture 
of rotamers, major is reported (Coalescence was observed at 330 K):  
 
1H NMR (400 MHz, DMSO-d6): δ 8.92 (s, 1H), 7.15–7.12 (m, 2H), 7.11–7.06 (m, 3H), 5.95 
(d, J = 6.0 Hz, 1H), 4.11–3.96 (m, 4H), 3.90 (d, J = 7.2 Hz, 1H), 3.37–3.35 (m, 1H), 3.59–
2.54 (m, 2H), 2.23 (s, 3H), 2.18 (s, 3H), 1.04 (br s, 15H) ppm.  
13C NMR (101 MHz, DMSO-d6): δ 167.4, 155.0, 146.6, 140.2, 128.7, 127.7, 125.4, 98.6, 
76.7, 58.9, 55.5, 37.7, 30.6, 28.1, 18.4, 14.4 ppm.  
IR (neat, cm-1): 1693, 1659, 1632, 1528, 1474, 1368, 1303, 1252, 1236, 1206, 1166, 1122, 
1097, 1053, 1038, 1010, 776.  
 
Diethyl 2,6-dimethyl-4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-5H-
bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-1,4-dihydropyridine-3,5-dicarboxylate 
(6.1.12) 
Following General Procedure  using (3aR,5S,5aR,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-
5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-carbaldehyde6 (1.24 g, 4.94 mmol, 1.0 equiv). 
The product was isolated as a white solid (1.27 g, 53% yield). Mp = 154-159 ºC.  
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1H NMR (500 MHz, CDCl3) δ 5.40 (d, J = 4.9 Hz, 1H), 4.49 (d, J = 7.3 Hz, 1H), 4.46 (d, J 
= 7.9 Hz, 1H), 4.26 – 4.08 (m, 6H), 3.46 (d, J = 7.5 Hz, 1H), 2.31 (s, 3H), 2.29 (s, 3H), 1.42 
(s, 3H), 1.37 (s, 3H), 1.33 – 1.23 (m, 12H) ppm.  
13C NMR (126 MHz, CDCl3) δ 168.5, 168.3, 145.7, 144.0, 109.2, 108.2, 101.1, 99.4, 96.8, 
71.7, 71.3, 70.1, 59.9, 59.5, 35.0, 26.1, 26.0, 25.2, 24.9, 19.2, 14.4, 14.4 ppm.  
The spectroscopical data were in agreement with those previously reported.1 
 
2.1 Synthesis and Characterization of compound 4-isopropyl-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarbonitrile (1a-CN) 
 
 
A round bottom flask was charged with 3-aminocrotononitrile (1.6 g, 20 mmol), 
butyraldehyde (721.2 mg, 10 mmol) and glacial AcOH (10 mL). The reaction was heated at 
110 ºC with stirring for 3 h. Then it was allowed to cool to rt, diluted with H2O and extracted 
with EtOAc three times. The combined organic layers were neutralized with a saturated 
solution of NaHCO3 until a netural pH was reached, washed with brine, dried (MgSO4), and 
filtered. The crude reaction mixture was purified using an automated system using 
hexanes/EtOAc (0 to 40%) as eluent, obtaining the product as a white solid (1.56 g, 78% 
yield). Mp = 118-120 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 5.87 (s, 1H), 3.16 (d, J = 3.3 Hz, 1H), 2.13 (s, 6H), 1.95 – 
1.86 (m, 1H), 1.00 (d, J = 7.0 Hz, 6H) ppm.  
13C NMR (126 MHz, CDCl3) δ 148.2, 120.0, 81.9, 42.2, 35.9, 18.3, 18.3 ppm.  
IR (neat, cm-1): 3277, 3234, 3118, 2197, 1655, 1507, 1435, 1287, 1012, 622.  
HRMS calcd for (C12H15N3+H) 202.1344, found 202.1350. 
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General Procedures for Cross-Coupling 
General Procedure A (GP-A): A 20.0 mL sealable screw cap vial was charged with DHP 
(0.6 mmol, 1.2 equiv) and aryl bromide (0.5 mmol, 1.0 equiv) if solids followed by addition 
of [Ni(dtbbpy)(H2O)4]Cl2 (11.8 mg, 0.025 mmol, 5 mol %) and 4CzlPN (11.8 mg, 0.015 
mmol, 3 mol %). The vial was sealed and three vacuum/argon cycles were made. Next, dry, 
degassed acetone6 was added (10.0 mL, 0.05 M). If the (hetero)aryl bromide 2 or 1 were 
oils, they were added at this point as a solution in acetone or directly via microsyringe. The 
reaction was placed under blue LED irradiation and stirred for 24 h at rt. Next, the reaction 
was taken to dryness and purified on an automated liquid chromatographic system, obtaining 
the pure product. 
General Procedure B (GP-B): A 20.0 mL sealable screw cap vial was charged with DHP 
(0.75 mmol, 1.5 equiv) and aryl bromide (0.5 mmol, 1.0 equiv) if solids followed by addition 
of [Ni(dtbbpy)(H2O)4]Cl2 (23.6 mg, 0.025 mmol, 10 mol %) and 4CzlPN (11.8 mg, 0.015 
mmol, 3 mol %). The vial was sealed and three vacuum/argon cycles were made. Next, dry, 
degassed acetone6 was added (10.0 mL, 0.05 M). If the (hetero)aryl bromide 2 or 1 were 
oils, they were added at this point as a solution in acetone or directly via microsyringe. The 
reaction was placed under blue LED irradiation and stirred for 24 h at rt. Next, the reaction 
was taken to dryness and purified on an automated liquid chromatographic system, obtaining 
the pure product. 
Characterization Data: (Hetero)aryl bromide scope  
 
 
4-Isopropylbenzonitrile (6.2.1) 
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Prepared following GP-A. The product was purified using hexanes/EtOAc (0 to 5%) on an 
automated system and was obtained as a colorless oil (43.8 mg, 60% yield).   
 
1H NMR (500 MHz, CDCl3) δ 7.58 (d, J = 7.1 Hz, 2H), 7.32 (d, J = 7.7 Hz, 2H), 3.00 – 2.90 
(m, 1H), 1.26 (d, J = 6.9 Hz, 6H) ppm.  
13C NMR (126 MHz, CDCl3) δ 154.5, 132.4, 127.4, 119.3, 109.7, 34.5, 23.7 ppm.  
The spectral data were in agreement with those previously reported.7 
 
 
2,2-Dimethyl-4-(4-(trifluoromethyl)phenyl)-1,3-dioxolane (6.3.1) 
Prepared following GP-B. The product was purified using pentane/Et2O (0 to 15%) on an 
automated system and was obtained as a colorless oil (42.5 mg, 35% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.62 (d, J = 7.9 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 5.13 (t, J 
= 7.1 Hz, 1H), 4.35 (t, J = 7.6 Hz, 1H), 3.69 (t, J = 8.2 Hz, 1H), 1.55 (s, 3H), 1.50 (s, 3H) 
ppm.  
13C NMR (126 MHz, CDCl3) δ 143.7, 130.3 (q, J = 32.8 Hz), 126.5, 125.6 (q, J = 3.6 Hz), 
124.2 (q, J = 272.0 Hz), 110.3, 77.3, 71.6, 26.6, 26.0 ppm.  
IR (neat, cm-1): 2989, 1621, 1323, 1160, 1122, 1112, 1063, 833. 
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2,2-Dimethyl-4-(naphthalen-2-yl)-1,3-dioxolane (6.3.2) 
Prepared following GP-B. The product was purified using hexanes/Et2O (3:1) and obtained 
as a colorless oil (47.0 mg, 46% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 6.6 Hz, 4H), 7.49 (d, J = 7.7 Hz, 3H), 5.26 (s, 
1H), 4.39 (s, 1H), 3.81 (t, J = 8.4 Hz, 1H), 1.63 (s, 3H), 1.55 (s, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 136.7, 133.4, 133.3, 128.6, 128.1, 127.9, 126.4, 126.1, 125.4, 
124.0, 110.0, 78.2, 71.7, 26.8, 26.1 ppm.  
IR (neat, cm-1): 2985, 1379, 1370, 1212, 1154, 1060, 855.  
HRMS calcd for (C15H16O2+H) 229.1229, found 229.1226. 
 
 
2-(2,2-Dimethyl-1,3-dioxolan-4-yl)-5-(trifluoromethyl)pyridine (6.3.3) 
Prepared following GP-A. The product was purified using pentane/Et2O (0 to 40%) on an 
automated system and obtained as a colorless oil (74.1 mg, 60% yield).  
 
1H NMR (500 MHz, CDCl3) δ 8.80 (s, 1H), 7.94 (dd, J = 8.3, 2.3 Hz, 1H), 7.69 (d, J = 8.2 
Hz, 1H), 5.25 (t, J = 6.7 Hz, 1H), 4.50 (dd, J = 8.5, 7.0 Hz, 1H), 3.98 (dd, J = 8.5, 6.3 Hz, 
1H), 1.53 (s, 3H), 1.51 (s, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 164.7, 146.1 (q, J = 3.4 Hz), 134.0 (q, J = 3.4 Hz), 126.9 – 
124.7 (m), 122.6, 119.9, 110.8, 77.9, 70.2, 26.6, 25.6 ppm.  
IR (neat, cm-1): 2990, 1607, 1373, 1325, 1213, 1159, 1124, 1077, 844.  
HRMS calcd for (C11H12F3NO2+H) 248.0898, found 248.0891. 
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2-(2,2-Dimethyl-1,3-dioxolan-4-yl)thiazole (6.3.4) 
Prepared following GP-B. The product was purified using pentane/Et2O (0 to 40%) on an 
automated system and obtained as a yellow oil (48.4 mg, 52% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 3.3 Hz, 1H), 7.30 (d, J = 3.3 Hz, 1H), 5.40 (t, J 
= 6.1 Hz, 1H), 4.44 (dd, J = 8.6, 6.6 Hz, 1H), 4.08 (dd, J = 8.6, 5.6 Hz, 1H), 1.57 (s, 3H), 
1.47 (s, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 172.0, 143.1, 119.3, 111.1, 75.7, 70.5, 26.6, 25.5 ppm. IR 
(neat, cm-1): 2987, 2936, 1721, 1210, 1142, 842, 724, 510.  
HRMS calcd for (C8H11NO2S+H) 186.0589, found 186.0589. 
 
 
4-(Benzo[b]thiophen-2-yl)-2,2-dimethyl-1,3-dioxolane (6.3.5) 
Prepared following GP-B. The product was purified using hexanes/Et2O (5:1) and obtained 
as a colorless oil (34.0 mg, 73% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.73 (d, J = 7.7 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.31 – 7.17 
(m, 2H), 7.16 (s, 1H), 5.32 (t, J = 6.7 Hz, 1H), 4.34 – 4.19 (m, 1H), 3.89 (t, J = 7.8 Hz, 1H), 
1.50 (s, 3H), 1.41 (s, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 144.1, 139.8, 139.6, 124.5, 124.5, 123.6, 122.6, 121.5, 110.5, 
74.6, 71.4, 26.7, 26.0 ppm.  
IR (neat, cm-1): 3056, 2986, 2935, 1208, 1061, 837, 583.  
HRMS calcd for (C13H14O2S) 234.0711, found 234.0715.  
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HRMS calcd for (C13H14O2S+H) 235.0793, found 235.0782. 
 
 
5-(2,2-Dimethyl-1,3-dioxolan-4-yl)thiophene-2-carbaldehyde (6.3.6) 
Prepared following GP-A. The product was purified using hexanes/EtOAc (0 to 20%) on an 
automated system and was obtained as a yellow oil (71.4 mg, 67% yield).  
 
1H NMR (500 MHz, CDCl3) δ 9.87 (s, 1H), 7.65 (d, J = 3.1 Hz, 1H), 7.09 (d, J = 3.3 Hz, 
1H), 5.32 (t, J = 6.5 Hz, 1H), 4.36 (t, J = 7.3 Hz, 1H), 3.86 (t, J = 7.6 Hz, 1H), 1.55 (s, 3H), 
1.46 (s, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 183.0, 154.8, 143.2, 136.4, 125.4, 110.9, 74.1, 71.6, 26.6, 
25.8 ppm.  
IR (neat, cm-1): 3073, 1418, 1231, 1212, 1044, 726, 663.  
HRMS calcd for (C11H14O3S+H) 227.0743, found 227.0742. 
 
 
1-(5-(2,2-Dimethyl-1,3-dioxolan-4-yl)thiophen-2-yl)ethan-1-one (6.3.7) 
Prepared following GP-B. The product was purified using hexanes/Et2O (5:1) and obtained 
as a yellow oil (39.0 mg, 86%).  
 
1H NMR (500 MHz, CDCl3) δ 7.56 (s, 1H), 7.01 (s, 1H), 5.28 (d, J = 6.7 Hz, 1H), 4.34 (t, J 
= 7.5 Hz, 1H), 3.85 (t, J = 7.8 Hz, 1H), 2.53 (s, 3H), 1.54 (s, 3H), 1.46 (s, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 197.2, 190.7, 152.8, 143.9, 132.4, 125.4, 110.8, 74.1, 71.6, 
26.8, 26.6, 25.9 ppm.  
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IR (neat, cm-1): 2987, 1662, 1276, 1061.  
HRMS calcd for (C11H14O3S+H) 227.0742, found 227.0743. 
 
Characterization Data: (Hetero)aryl bromide Scope 
 
 
2-Isopropylbenzo[b]thiophene (6.4.1) 
Prepared following GP-B. The product was purified using hexanes/Et2O (5:1) and obtained 
as a clear oil (61.2, 70% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.32 (t, J 
= 7.6 Hz, 1H), 7.27 (d, J = 7.7 Hz, 1H), 7.03 (s, 1H), 3.26 (hept, J = 7.0 Hz, 1H), 1.42 (d, J 
= 6.8 Hz, 6H) ppm.  
13C NMR (126 MHz, CDCl3) δ 154.2, 140.2, 139.0, 124.1, 123.5, 122.9, 122.3, 118.4, 30.7, 
24.5 ppm.  
IR (neat, cm-1): 2962, 2930, 1457, 1436, 1071, 1001, 855.  
HRMS calcd for (C11H12S+H) 177.0738, found 177.0745. 
 
 
Ethyl 5-cyclohexylfuran-2-carboxylate (6.4.2) 
Prepared following GP-A. The product was purified using hexanes/EtOAc (0 to 20%) on an 
automated system and was obtained as a colorless oil (73.5 mg, 66% yield).  
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1H NMR (500 MHz, CDCl3) δ 7.08 (d, J = 3.5 Hz, 1H), 6.08 (d, J = 3.4 Hz, 1H), 4.34 (q, J 
= 7.1 Hz, 2H), 2.73 – 2.66 (m, 1H), 2.05 (d, J = 10.8 Hz, 2H), 1.80 (d, J = 12.6 Hz, 2H), 
1.71 (d, J = 12.8 Hz, 1H), 1.46 – 1.30 (m, 7H), 1.30 – 1.19 (m, 1H) ppm.  
13C NMR (126 MHz, CDCl3) δ 165.8, 159.1, 142.9, 118.9, 105.5, 60.7, 37.6, 31.4, 26.0, 
25.9, 14.5 ppm. IR (neat, cm-1): 2929, 2855, 1517, 1294, 1213, 1174, 1138, 1120, 799.  
HRMS calcd for (C13H18O3+H) 223.1334, found 223.1344. 
 
 
1-(5-Cyclohexylthiophen-2-yl)ethan-1-one (6.4.3) 
Prepared following GP-A. The product was purified using hexanes/EtOAc (0 to 15%) on an 
automated system and was obtained as a white solid (47.2 mg, 45% yield). Mp = 48-52 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 3.6 Hz, 1H), 6.83 (d, J = 3.7 Hz, 1H), 2.87 – 2.77 
(m, 1H), 2.51 (s, 3H), 2.04 (d, J = 11.3 Hz, 2H), 1.83 (d, J = 11.7 Hz, 2H), 1.73 (d, J = 11.3 
Hz, 1H), 1.52 – 1.33 (m, 4H), 1.32 – 1.19 (m, 1H) ppm.  
13C NMR (126 MHz, CDCl3) δ 190.7, 162.4, 141.4, 132.8, 123.6, 40.2, 35.2, 26.6, 26.4, 25.9 
ppm.  
IR (neat, cm-1): 2927, 2854, 1645, 1447, 1354, 1030, 927, 807, 595.  
HRMS calcd for (C12H16OS+H) 209.1000, found 209.0991. 
 
 
5-Cyclohexylthiophene-2-sulfonamide (6.4.4) 
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Prepared according to GP-B. The product was purified using hexanes/EtOAc (9:1) and 
obtained as a yellow oil (12.0 mg, 24% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.50 (d, J = 3.8 Hz, 1H), 6.76 (d, J = 3.8 Hz, 1H), 4.87 (s, 
2H), 2.82 (s, 1H), 2.05 (d, J = 10.0 Hz, 2H), 1.84 (d, J = 10.6 Hz, 2H), 1.41 (h, J = 12.3 Hz, 
4H), 1.26 (s, 1H).  
13C NMR (126 MHz, CDCl3) δ 160.4, 139.0, 132.1, 122.4, 40,0, 35.3, 26.4, 25.8 ppm.  
IR (neat, cm-1): 2931, 1447, 1334, 1157.  
HRMS calcd for (C10H15NO2S2+H) 246.0622, found 246.0630. 
 
 
1',2',3',6'-Tetrahydro-[1,1'-biphenyl]-4-carbonitrile (6.4.5) 
Prepared following GP-A. The product was purified using hexanes/EtOAc (0 to 5%) on an 
automated system and was obtained as a white solid (39.0 mg, 43% yield). Mp = 53-55 ºC.  
 
1H NMR (500 MHz, CDCl3) δ 7.59 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), 5.77 (s, 
2H), 2.93 – 2.80 (m, 1H), 2.33 – 2.25 (m, 1H), 2.24 – 2.08 (m, 3H), 1.97 – 1.89 (m, 1H), 
1.79 – 1.71 (m, 1H) ppm.  
13C NMR (126 MHz, CDCl3) δ 152.9, 132.4, 127.9, 127.2, 126.2, 119.2, 109.9, 40.4, 32.9, 
29.4, 25.5 ppm.  
IR (neat, cm-1): 3024, 2917, 2836, 226, 1607, 830, 690, 651, 561. HRMS calcd for 
(C13H13N+H) 184.1126, found 184.1123. 
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2-(Cyclohex-3-en-1-yl)benzo[b]thiophene (6.4.6) 
Prepared following GP-B. The product was purified using hexanes/Et2O (5:1) and obtained 
as a clear oil (40.3 mg, 38% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.79 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.32 (t, J 
= 7.5 Hz, 1H), 7.25 (d, J = 7.3 Hz, 1H), 7.06 (s, 1H), 5.78 (s, 2H), 3.20 (s, 1H), 2.57 – 2.40 
(m, 1H), 2.27 – 2.18 (m, 1H), 2.16 – 2.04 (m, 3H), 2.00 – 1.86 (m, 1H), 1.79 – 1.59 (m, 1H) 
ppm.  
13C NMR (126 MHz, CDCl3) δ 152.2, 140.2, 139.0, 127.2, 126.0, 124.2, 123.6, 123.0, 122.3, 
118.8, 36.2, 33.6, 30.7, 25.5 ppm.  
IR (neat, cm-1): 3023, 2916, 1436, 1068, 854, 734.  
HRMS calcd for (C14H14S+H) 215.0894, found 215.0891. 
 
 
1-(5-(Cyclohex-3-en-1-yl)thiophen-2-yl)ethan-1-one (6.4.7) 
Prepared following GP-B. The product was purified using hexanes/Et2O (5:1) and was 
obtained as a clear oil (67.3 mg, 65% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.55 (d, J = 3.8 Hz, 1H), 6.87 (d, J = 3.7 Hz, 1H), 5.75 (s, 
2H), 3.14 (tt, J = 9.5, 4.1 Hz, 1H), 2.52 (s, 3H), 2.49 – 2.37 (m, 1H), 2.28 – 2.13 (m, 3H), 
2.13 – 2.04 (m, 1H), 1.76 (m, 1H) ppm.  
13C NMR (126 MHz, CDCl3) δ 209.7, 190.7, 161.3, 141.8, 132.8, 127.2, 125.7, 124.0, 36.2, 
33.6, 30.7, 26.6, 25.3 ppm.  
IR (neat, cm-1): 3025, 2913, 2837, 1659, 1455, 1278, 670.  
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4-(Heptan-3-yl)benzonitrile (6.4.8): Prepared following GP-A. The product was purified 
using hexanes/EtOAc (0 to 5%) on an automated system and was obtained as a colorless oil 
(56.2 mg, 56% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 6.8 Hz, 2H), 7.23 (d, J = 6.9 Hz, 2H), 2.52 – 2.41 
(m, 1H), 1.75 – 1.61 (m, 2H), 1.59 – 1.46 (m, 2H), 1.34 – 1.16 (m, 2H), 1.20 – 1.08 (m, 1H), 
1.10 – 0.98 (m, 1H), 0.82 (t, J = 7.3 Hz, 3H), 0.74 (t, J = 7.2 Hz, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 152.1, 132.2, 128.7, 119.3, 109.7, 48.3, 36.0, 29.8, 29.5, 
22.8, 14.1, 12.2 ppm.  
IR (neat, cm-1): 2959, 2927, 2873, 2858, 2227, 1607, 1460, 834, 570.  
HRMS calcd for (C14H19N+H) 202.1596, found 202.1595. 
 
 
1-(5-(Heptan-3-yl)thiophen-2-yl)ethan-1-one (6.4.9) 
Prepared following GP-B. The product was purified using hexanes/Et2O (5:1) and was 
obtained as a clear oil (51.3 mg, 46%).  
 
1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 3.8 Hz, 1H), 6.80 (d, J = 3.8 Hz, 1H), 2.74 (tt, J 
= 9.4, 5.2 Hz, 1H), 2.52 (s, 3H), 1.71 (m, 2H), 1.64 – 1.50 (m, 2H), 1.37 – 1.11 (m, 4H), 
0.84 (m, 6H).  
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13C NMR (126 MHz, CDCl3) δ 190.6, 160.9, 141.9, 132.7, 125.3, 44.1, 37.2, 30.8, 29.7, 
26.6, 22.7, 14.1, 12.0 ppm.  
IR (neat, cm-1): 2960, 2929, 1661, 1457, 1278, 809.  
HRMS calcd for (C14H22OS+H) 239.1470, found 239.1470. 
 
 
1-(5-(6-Methylhept-5-en-2-yl)thiophen-2-yl)ethan-1-one (6.4.10) 
Prepared following GP-B. The product was purified using hexanes/Et2O (5:1) and was 
obtained as a yellow oil (92.0 mg, 83% yield).  
 
1H NMR (500 MHz, CDCl3) δ 7.53 (s, 1H), 6.81 (s, 1H), 5.06 (s, 1H), 3.05 – 3.01 (m, 1H), 
2.50 (s, 3H), 1.95 (m, 2H), 1.65 (m, 5H), 1.53 (s, 3H), 1.31 (d, J = 7.0 Hz, 3H).  
13C NMR (126 MHz, CDCl3) δ 190.6, 162.2, 141.7, 132.7, 132.2, 124.3, 123.7, 39.2, 35.8, 
26.6, 25.9, 25.8, 23.0, 17.8 ppm.  
IR (neat, cm-1): 2965, 2918, 1600, 1447, 1276, 807.  
HRMS calcd for (C14H20OS+H) 237.1313, found 237.1296. 
 
 
1-(5-(Tetrahydro-2H-pyran-4-yl)thiophen-2-yl)ethan-1-one (6.4.11) 
Prepared following GP-A. The product was purified using hexanes/EtOAc (0 to 30%) on an 
automated system and was obtained as a white solid (80.1 mg, 77% yield). Mp = 58-61 ºC.   
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1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 3.8 Hz, 1H), 6.87 (d, J = 3.8 Hz, 1H), 4.26 – 3.91 
(m, 2H), 3.52 (td, J = 11.8, 2.1 Hz, 2H), 3.11 – 3.00 (m, 1H), 2.52 (s, 3H), 2.01 – 1.89 (m, 
2H), 1.82 (ddd, J = 24.7, 11.9, 4.0 Hz, 2H) ppm.  
13C NMR (126 MHz, CDCl3) δ 190.5, 159.6, 141.9, 132.8, 123.8, 67.8, 37.3, 34.5, 26.6 ppm.  
IR (neat, cm-1): 1650, 1448, 1271, 1087, 1015, 877, 818, 600 
HRMS calcd for (C11H14O2S+H) 211.0793, found 211.0780. 
 
 
3-Benzyl-5-chloropyridine (6.4.12) 
Prepared following GP-A and [Ni(dme)(dtbbpy)]Br2 (14.0 mg, 0.025 mmol, 5 mol %). The 
product was purified using pentane/Et2O (0 to 40%) on an automated system and was 
obtained as a colorless oil (42.9 mg, 42% yield).    
 
1H NMR (500 MHz, CDCl3) δ 8.43 (s, 1H), 8.38 (s, 1H), 7.45 (s, 1H), 7.33 (t, J = 7.4 Hz, 
2H), 7.29 – 7.21 (m, 1H), 7.17 (d, J = 7.4 Hz, 2H), 3.97 (s, 2H) ppm.  
13C NMR (126 MHz, CDCl3) δ 148.0, 146.7, 138.9, 138.0, 136.1, 132.1, 129.0 (2C), 126.9, 
38.7 ppm.  
IR (neat, cm-1): 3029, 1579, 1419, 1104, 1025, 708, 696, 682.  
HRMS calcd for (C12H10ClN+H) 204.0580, found 204.0587. 
 
 
tert-Butyl 2-(3-acetylphenyl)pyrrolidine-1-carboxylate (6.4.13) 
N
Cl
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Prepared following GP-B. The product was purified using hexanes/EtOAc (0 to 20%) on an 
automated system to afford a light yellow oil (55.0 mg, 38% yield); Mixture of rotamers, 
major is reported:  
 
1H NMR (500 MHz, CDCl3): δ 7.77 (m, 1H), 7.75 (s, 1H), 7.40–7.35 (m, 2H), 4.79 (br s, 
1H), 3.63 (br, 2H), 2.57 (s, 3H), 2.34 (br, 1H), 1.87–1.82 (m, 3H), 1.43 (s, 4H, Boc), 1.14 
(s, 5H, Boc) ppm. 
13C NMR (126 MHz, CDCl3): δ 198.0, 154.4, 145.7, 137.1, 130.1, 128.4, 126.7, 125.3, 79.3, 
61.1, 47.1, 35.9, 34.8, 28.4, 26.6, 23.2 ppm. 
IR (neat, cm-1): 2974, 2931, 2899, 1684, 1602, 1587, 1478, 1390, 1364, 1256, 1159, 1115, 
1080, 957, 905, 876.  
HRMS calcd for (C17H23NO3+Na) 312.1576, found 312.1561. 
 
 
tert-Butyl 4-(4-cyanophenyl)-2,2-dimethyloxazolidine-3-carboxylate (6.4.14) 
Prepared following GP-B. The product was purified using hexanes/EtOAc (0 to 10%) on an 
automated system to afford a light yellow oil (22.0 mg, 37% yield); Mixture of rotamers, 
major is reported:  
 
1H NMR (500 MHz, CDCl3): δ 7.64 (d, J = 8.0 Hz, 2H), 7.42 (m, 2H), 4.83 (br s, 1H), 4.30 
(dd, J = 9.0, 7.0 Hz, 1H), 3.83 (m, 1H), 1.60 (s, 3H), 1.58 (s, 3H), 1.45 (s, 9H) ppm. 
13C NMR (126 MHz, CDCl3): δ 151.6, 140.9, 132.4, 127.1, 118.7, 111.2, 95.0, 80.3, 70.2, 
60.8, 28.3, 26.0 (gem dimethyl), 24.9 (gem dimethyl) ppm. 
IR (neat, cm-1): 2980, 2929, 2229, 1695, 1609, 1505, 1478, 1457, 1376, 1365, 1255, 1206, 
1171, 1146, 1088, 1057.  
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HRMS calcd for (C17H22N2O3+H) 303.1709, found 303.1712. 
 
 
tert-Butyl (1-(4-cyanophenyl)-2-phenylethyl)carbamate (6.4.15) 
Prepared following GP-B. The product was purified using hexanes/EtOAc (0 to 20%) on an 
automated system to afford a light yellow oil (28.1 mg, 47%). 
 
1H NMR (500 MHz, CDCl3): δ 7.58 (d, J = 8.5 Hz, 2H), 7.36–7.21 (m, 5H), 7.01 (d, J = 6.5 
Hz, 2H), 4.97 (br s, 2H), 3.02 (br s, 2H), 1.40 (s, 9H) ppm. 
13C NMR (126 MHz, CDCl3): δ 155.1, 136.3, 132.4, 129.4 (2C), 128.7, 127.3, 127.1, 118.9, 
111.1, 80.2, 55.8, 43.1, 28.4 ppm. 
IR (neat, cm-1) 2978, 2229, 1695, 1608, 1495, 1455, 1391, 1366, 1289, 1247, 1163, 1108, 
1045, 1018, 911.  
HRMS calcd for (C20H22N2O2+H) 323.1760, found 323.1772. 
 
Characterization Data: Synthesis of Aryl-containing Saccharides 
 
(3aR,5S,5aR,8aS,8bR)-5-(Benzo[b]thiophen-2-yl)-2,2,7,7-tetramethyltetrahydro-5H-
bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran (6.5.1) 
Prepared following GP-B. The product was purified using hexanes/EtOAc (0 to 30%) on an 
automated system and was obtained as a white solid with a >20:1 dr (89.3 mg, 70% yield). 
Mp = 118-120 ºC.  
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1H NMR (500 MHz, DMSO-d6) δ 7.91 (d, J = 7.7 Hz, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.41 (s, 
1H), 7.38 – 7.28 (m, 2H), 5.63 (d, J = 5.0 Hz, 1H), 5.15 (s, 1H), 4.74 (dd, J = 7.8, 2.3 Hz, 
1H), 4.54 (dd, J = 7.8, 2.0 Hz, 1H), 4.47 (dd, J = 4.7, 1.9 Hz, 2H), 1.53 (s, 3H), 1.39 (s, 3H), 
1.34 (s, 3H), 1.28 (s, 3H) ppm.  
13C NMR (126 MHz, DMSO-d6) δ 141.8, 139.2, 138.7, 124.1, 124.0, 123.3, 122.1, 121.3, 
108.6, 108.2, 96.2, 72.8, 70.4, 69.9, 66.7, 25.9 (2C), 24.7, 24.2 ppm. The absolute 
configuration was determined by NOE NMR experiments in combination with HSQC and 
HMBC experiments.  
IR (neat, cm-1): 2927, 1377, 1163, 1142, 1065, 1040, 996, 895, 746.  
HRMS calcd for (C19H22O5S+H) 363.1266, found 363.1248.  
Crystals suitable for X-Ray difraction were achieved by slow evaporation of an acetonitrile 
solution of compound 3lf. 
 
 
(2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-((6-(6-methylhept-5-en-2-yl)naphthalen-2-
yl)oxy)tetrahydro-2H-pyran-3,4,5-triol (6.5.2) 
Prepared following GP-B. The product was purified using EtOAc/MeOH (9:1) and obtained 
as a light yellow oil (262.0 mg, 31% yield).  
 
1H NMR (500 MHz, DMSO-d6) δ 7.78 (d, J = 8.9 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 7.61 (s, 
1H), 7.42 (s, 1H), 7.35 (d, J = 8.5 Hz, 1H), 7.22 (d, J = 9.1 Hz, 1H), 5.33 (d, J = 4.5 Hz, 1H), 
5.12 – 5.05 (m, 2H), 5.00 (dd, J = 11.8, 6.1 Hz, 2H), 4.56 (t, J = 5.8 Hz, 1H), 3.73 (dd, J = 
12.1, 5.2 Hz, 1H), 3.50 (dt, J = 11.9, 6.1 Hz, 1H), 3.40 (t, J = 7.8 Hz, 1H), 3.32 – 3.27 (m, 
O
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2H), 3.21 (dt, J = 14.2, 6.8 Hz, 1H), 2.81 (h, J = 7.1 Hz, 1H), 1.83 (tt, J = 14.5, 7.3 Hz, 2H), 
1.73 – 1.54 (m, 5H), 1.44 (s, 3H), 1.26 (d, J = 6.9 Hz, 3H) ppm.  
13C NMR (126 MHz, DMSO-d6) δ 155.3, 143.2, 133.2, 131.4, 129.8, 129.3, 127.6, 126.7, 
126.7, 125.3, 125.3, 124.9, 119.3, 111.0, 111.0, 101.3, 101.3, 77.7, 77.3, 73.9, 70.4, 61.3, 
39.3, 38.4, 26.3, 26.1, 22.8, 18.1 ppm.  
IR (neat, cm-1): 3413, 2254, 2128, 1659, 1208, 1023, 823.  
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X-Ray Crystallographic data 
X-Ray Crystallograpic data for [Ni(dtbbpy)(H2O)4]Cl2: 
 
 
 
 Compound [Ni(dtbbpy)(H2O)4]Cl2, C22H40Cl2N2NiO5, crystallizes in the monoclinic 
space group C2/c (systematic absences hkl:  h+k=odd, h0l:  l=odd) with a=13.0843(9)Å, 
b=30.400(2)Å, c=6.6223(5)Å, β=92.470(2)°, V=2631.7(3)Å3, Z=4, and dcalc=1.368 g/cm3 . 
X-ray intensity data were collected on a Bruker D8QUEST [1] CMOS area detector 
employing graphite-monochromated Mo-Kα radiation (λ=0.71073Å) at a temperature of 
100K. Preliminary indexing was performed from a series of twenty-four 0.5° rotation frames 
with exposures of 10 seconds. A total of 1614 frames were collected with a crystal to detector 
distance of 34.1 mm, rotation widths of 0.5° and exposures of 15 seconds: 
scan type 2θ ω φ χ Frames 
  0.00 195.50 0.00 54.72 298 
  -1.00 345.19 0.00 54.72 720 
  0.00 195.50 90.00 54.72 298 
  0.00 195.50 180.00 54.72 298 
 
Rotation frames were integrated using SAINT [2], producing a listing of unaveraged F2 and 
σ(F2) values. A total of 36013 reflections were measured over the ranges 6.234 ≤ 2θ ≤ 
50.876°, -15 ≤ h ≤ 15, -36 ≤ k ≤ 36, -7 ≤ l ≤ 7 yielding 2417 unique reflections (Rint = 0.0650). 
N N
Ni
H2O OH2
H2O
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The intensity data were corrected for Lorentz and polarization effects and for absorption 
using SADABS [3] (minimum and maximum transmission 0.5113, 0.7456). The structure 
was solved by direct methods - SHELXT [4]. Refinement was by full-matrix least squares 
based on F2 using SHELXL-2014 [5]. All reflections were used during refinement. The 
weighting scheme used was w=1/[σ2(Fo2 )+ (0.1083P)2 + 11.2889P] where P = (Fo2 + 2Fc2)/3. 
Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined using a 
riding model, except for the water hydrogens, which were located on a difference map, but 
were not refined. Refinement converged to R1=0.0571 and wR2=0.1568 for 2217 observed 
reflections for which F > 4σ(F) and R1=0.0617 and wR2=0.1639 and GOF =1.083 for all 
2417 unique, non-zero reflections and 149 variables. The maximum Δ/σ in the final cycle of 
least squares was 0.001 and the two most prominent peaks in the final difference Fourier 
were +2.33 and -1.28 e/Å3. 
 Table S1. lists cell information, data collection parameters, and refinement data. 
Final positional and equivalent isotropic thermal parameters are given in Tables S2. and S3. 
Anisotropic thermal parameters are in Table S4. Tables S5. and S6. list bond distances and 
bond angles. Figure S2. is an ORTEP representation of the molecule with 50% probability 
thermal ellipsoids displayed. 
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ORTEP drawing of the title compound with 50% thermal ellipsoids. 
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Table S1.  Summary of Structure Determination of Compound [Ni(dtbbpy)(H2O)4]Cl2 
 
Empirical formula  C22H40Cl2N2NiO5  
Formula weight  542.17  
Temperature/K  100  
Crystal system  monoclinic  
Space group  C2/c  
a  13.0843(9)Å  
b  30.400(2)Å  
c  6.6223(5)Å  
β  92.470(2)°  
Volume  2631.7(3)Å3  
Z  4  
dcalc  1.368 g/cm3  
µ  0.974 mm-1  
F(000)  1152.0  
Crystal size, mm  0.28 × 0.18 × 0.03  
2θ range for data collection      6.234 - 50.876°  
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Index ranges  -15 ≤ h ≤ 15, -36 ≤ k ≤ 36, -7 ≤ l ≤ 7  
Reflections collected  36013  
Independent reflections  2417[R(int) = 0.0650]  
Data/restraints/parameters  2417/0/149  
Goodness-of-fit on F2  1.083  
Final R indexes [I>=2σ (I)]  R1 = 0.0571, wR2 = 0.1568  
Final R indexes [all data]  R1 = 0.0617, wR2 = 0.1639  
Largest diff. peak/hole  2.33/-1.28 eÅ-3  
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Table S2. Refined Positional Parameters for Compound [Ni(dtbbpy)(H2O)4]Cl2 
 
Atom x y z U(eq) 
Ni1 0.5 0.75601(2) 0.75 0.0138(2) 
O1 0.34718(18) 0.76087(8) 0.8088(4) 0.0195(5) 
O2 0.47754(17) 0.80527(8) 0.5361(4) 0.0200(5) 
N1 0.45760(19) 0.70343(9) 0.5649(4) 0.0152(6) 
C1 0.4691(2) 0.66373(11) 0.6532(5) 0.0157(7) 
C2 0.4241(2) 0.62601(11) 0.5727(5) 0.0171(7) 
C3 0.3651(2) 0.62789(11) 0.3920(5) 0.0172(7) 
C4 0.3560(2) 0.66888(12) 0.2989(5) 0.0180(7) 
C5 0.4021(2) 0.70527(12) 0.3898(5) 0.0181(7) 
C6 0.3068(2) 0.58811(11) 0.3054(5) 0.0194(7) 
C7 0.3345(3) 0.54563(12) 0.4189(6) 0.0269(8) 
C8 0.1919(2) 0.59735(14) 0.3260(6) 0.0256(8) 
C9 0.3289(3) 0.58191(12) 0.0807(6) 0.0242(8) 
Cl1 0.69206(6) 0.81637(3) 0.31042(12) 0.0181(3) 
O3 0 0.50320(12) 0.75 0.0273(8) 
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C10 0.0828(3) 0.53080(13) 0.8217(6) 0.0265(8) 
C11 0.0407(3) 0.57674(13) 0.8358(6) 0.0281(8) 
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Table S3. Positional Parameters for Hydrogens in Compound [Ni(dtbbpy)(H2O)4]Cl2 
  
Atom x y z U(eq) 
H1a 0.3391 0.7728 0.9211 0.05 
H1b 0.334 0.7305 0.8116 0.05 
H2a 0.4259 0.8094 0.4652 0.05 
H2b 0.5279 0.8162 0.4574 0.05 
H2 0.4331 0.5993 0.6394 0.023 
H4 0.3191 0.6718 0.1764 0.024 
H5 0.3943 0.7324 0.3262 0.024 
H7a 0.4067 0.5404 0.413 0.04 
H7b 0.2976 0.5215 0.3575 0.04 
H7c 0.3167 0.5484 0.5575 0.04 
H8a 0.153 0.5722 0.2809 0.038 
H8b 0.1723 0.6224 0.245 0.038 
H8c 0.1789 0.6032 0.465 0.038 
H9a 0.4002 0.5756 0.0679 0.036 
H9b 0.3114 0.6083 0.0078 0.036 
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H9c 0.2888 0.5579 0.0263 0.036 
H10a 0.138 0.53 0.7287 0.035 
H10b 0.1089 0.5209 0.9533 0.035 
H11a 0.093 0.5987 0.8144 0.037 
H11b 0.011 0.5819 0.9654 0.037 
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Table S4. Refined Thermal Parameters (U's) for Compound [Ni(dtbbpy)(H2O)4]Cl2 
 
Atom U11 U22 U33 U23 U13 U12 
Ni1 0.0037(3) 0.0250(4) 0.0126(4) 0 -0.0016(2) 0 
O1 0.0078(12) 0.0304(13) 0.0204(13) -0.005(1) 0.0008(9) -0.0016(9) 
O2 0.0088(11) 0.0308(13) 0.0202(12) 0.0051(10) -0.0029(9) 0.0005(9) 
N1 0.0056(12) 0.0267(14) 0.0133(13) -0.0002(11) -0.0011(10) 0.0008(10) 
C1 0.0049(14) 0.0271(17) 0.0152(16) -0.0004(13) 0.0014(12) -0.0006(12) 
C2 0.0083(15) 0.0259(17) 0.0172(16) -0.0006(13) 0.0004(12) 0.0009(12) 
C3 0.0042(15) 0.0302(18) 0.0171(16) -0.0016(13) 0.0003(12) 0.0000(12) 
C4 0.0078(15) 0.0313(18) 0.0147(16) 0.0000(13) -0.0020(12) 0.0025(13) 
C5 0.0110(15) 0.0282(18) 0.0151(16) 0.0025(13) -0.0003(12) 0.0026(13) 
C6 0.0102(16) 0.0274(18) 0.0202(18) -0.0015(13) -0.0026(13) -0.0014(13) 
C7 0.0210(18) 0.0289(19) 0.030(2) -0.0005(15) -0.0080(15) -0.0072(15) 
C8 0.0074(17) 0.041(2) 0.028(2) -0.0068(16) -0.0015(14) -0.0036(14) 
C9 0.0151(17) 0.0320(19) 0.0254(19) -0.0046(15) 0.0008(14) -0.0027(14) 
Cl1 0.0078(4) 0.0288(5) 0.0174(5) 0.0010(3) -0.0018(3) 0.0004(3) 
O3 0.0175(18) 0.031(2) 0.033(2) 0 -0.0010(15) 0 
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C10 0.0127(17) 0.037(2) 0.030(2) 0.0014(16) -0.0021(14) -0.0001(14) 
C11 0.0157(17) 0.036(2) 0.033(2) -0.0028(16) -0.0012(16) -0.0037(15) 
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Table S5. Bond Distances in Compound [Ni(dtbbpy)(H2O)4]Cl2, Å 
          
Ni1-O1 2.059(2)   Ni1-O1 2.059(2)   Ni1-O2 2.073(2) 
Ni1-O2 2.073(2)   Ni1-N1 2.075(3)   Ni1-N1 2.075(3) 
N1-C1 1.347(4)   N1-C5 1.343(4)   C1-C1 1.486(6) 
C1-C2 1.385(5)   C2-C3 1.397(5)   C3-C4 1.393(5) 
C3-C6 1.529(5)   C4-C5 1.386(5)   C6-C7 1.530(5) 
C6-C8 1.540(4)   C6-C9 1.540(5)   O3-C10 1.435(4) 
O3-C10 1.435(4)   C10-C11 1.505(5)   C11-C11 1.524(7) 
11-X,+Y,3/2-Z; 2-X,+Y,3/2-Z 
 
Table S6. Bond Angles in Compound [Ni(dtbbpy)(H2O)4]Cl2, ° 
          
O1-Ni1-O11 171.76(14)   O1-Ni1-O21 85.93(9)   O1-Ni1-O21 88.12(10) 
O1-Ni1-O2 88.12(10)   O1-Ni1-O2 85.93(9)   O1-Ni1-N11 100.41(10) 
O1-Ni1-N1 100.41(10)   O1-Ni1-N11 85.99(10)   O1-Ni1-N1 85.98(10) 
O2-Ni1-O21 87.53(14)   O2-Ni1-N11 170.46(10)   O2-Ni1-N1 170.46(10) 
O2-Ni1-N1 97.26(10)   O2-Ni1-N11 97.26(10)   N1-Ni1-N1 79.24(15) 
	  
	  
575 
C1-N1-Ni1 114.3(2)   C5-N1-Ni1 126.8(2)   C5-N1-C1 117.3(3) 
N1-C1-C1 114.91(18)   N1-C1-C2 122.5(3)   C2-C1-C1 122.6(2) 
C1-C2-C3 120.4(3)   C2-C3-C6 122.5(3)   C4-C3-C2 116.7(3) 
C4-C3-C6 120.6(3)   C5-C4-C3 119.6(3)   N1-C5-C4 123.5(3) 
C3-C6-C7 112.3(3)   C3-C6-C8 107.2(3)   C3-C6-C9 110.3(3) 
C7-C6-C8 108.8(3)   C7-C6-C9 108.7(3)   C9-C6-C8 109.4(3) 
C10-O3-C10 108.4(4)   O3-C10-C11 106.9(3)   C10-C11-C11 101.5(2) 
11-X,+Y,3/2-Z; 2-X,+Y,3/2-Z 
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Table S7. Hydrogen Bonds for [Ni(dtbbpy)(H2O)4]Cl2.  
 
D H A d(D-H)/Å d(H-A)/Å d(D-A)/Å D-H-A/° 
O1 H1a Cl11 0.838(2) 2.2683(8) 3.095(2) 169.09(17) 
O1 H1b Cl12 0.940(2) 2.3404(8) 3.104(2) 138.10(14) 
O2 H2a Cl13 0.816(2) 2.3486(8) 3.141(2) 164.06(17) 
O2 H2b Cl1 0.920(2) 2.3960(8) 3.254(2) 155.18(15) 
11-X,+Y,3/2-Z; 2-1/2+X,3/2-Y,1/2+Z; 31-X,+Y,1/2-Z 
 
 
This report has been created with Olex2 [6], compiled on 2016.05.11 svn.r3296 for 
OlexSys. 
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X-Ray crystallographic data for compound (3aR,5S,5aR,8aS,8bR)-5-
(Benzo[b]thiophen-2-yl)-2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-
b:4',5'-d]pyran (3lf) 
 
 
Compound 3lf, C19H22O5S, crystallizes in the orthorhombic space group P212121 
(systematic absences h00:  h=odd, 0k0:  k=odd and 00l:  l=odd) with a=5.63430(10)Å, 
b=17.0439(4)Å, c=18.3976(4)Å, V=1766.73(6)Å3, Z=4, and dcalc=1.363 g/cm3 . X-ray 
intensity data were collected on a Bruker APEXII [1] CCD area detector employing 
graphite-monochromated Mo-Kα radiation (λ=0.71073Å) at a temperature of 100K. 
Preliminary indexing was performed from a series of thirty-six 0.5° rotation frames with 
exposures of 10 seconds. A total of 4232 frames were collected with a crystal to detector 
distance of 37.4 mm, rotation widths of 0.5° and exposures of 10 seconds: 
 
scan type 2θ ω φ χ Frames 
  24.50 7.41 12.48 28.88 739 
  -23.00 334.21 44.72 73.66 727 
  -20.50 342.55 321.55 -73.06 542 
  -23.00 333.49 158.99 -70.01 69 
O
S
O
O
O
O
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scan type 2θ ω φ χ Frames 
  -25.50 330.51 47.91 -56.95 137 
  27.00 276.67 5.00 57.63 227 
  -23.00 315.83 12.48 28.88 739 
  19.50 59.55 348.71 -26.26 739 
  17.00 321.50 184.44 82.07 116 
  -10.50 306.95 272.07 99.72 80 
  17.00 321.08 318.36 83.36 117 
 
Rotation frames were integrated using SAINT [2], producing a listing of unaveraged F2 and 
σ(F2) values. A total of 76138 reflections were measured over the ranges 3.258 ≤ 2θ ≤ 55.2°, 
-7 ≤ h ≤ 7, -22 ≤ k ≤ 22, -23 ≤ l ≤ 23 yielding 4098 unique reflections (Rint = 0.0244). The 
intensity data were corrected for Lorentz and polarization effects and for absorption using 
SADABS [3] (minimum and maximum transmission 0.7252, 0.7456). The structure was 
solved by direct methods - SHELXS-97 [4]. Refinement was by full-matrix least squares 
based on F2 using SHELXL-2014 [5]. All reflections were used during refinement. The 
weighting scheme used was w=1/[σ2(Fo2 )+ (0.0372P)2 + 0.4474P] where P = (Fo2 + 2Fc2)/3. 
Non-hydrogen atoms were refined anisotropically and hydrogen atoms were refined using a 
riding model. Refinement converged to R1=0.0236 and wR2=0.0627 for 3997 observed 
reflections for which F > 4σ(F) and R1=0.0244 and wR2=0.0636 and GOF =1.032 for all 
4098 unique, non-zero reflections and 230 variables. The maximum Δ/σ in the final cycle of 
least squares was 0.001 and the two most prominent peaks in the final difference Fourier 
	  
	  
579 
were +0.26 and -0.20 e/Å3.  The Flack absolute structure parameter refined to a value of 
0.000(8) thus corroborating the assigned stereochemistry. 
Table S8 lists cell information, data collection parameters, and refinement data. 
Final positional and equivalent isotropic thermal parameters are given in Tables S9 and S10. 
Anisotropic thermal parameters are in Table S11 Tables S12 and S13 list bond distances and 
bond angles. Figure S3 is an ORTEP representation of the molecule with 50% probability 
thermal ellipsoids displayed. 
 
Figure S3. ORTEP drawing of the compound 3lf with 50% thermal ellipsoids. 
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Table S8.  Summary of Structure Determination of Compound 3lf 
 
Empirical formula  C19H22O5S  
Formula weight  362.42  
Temperature/K  100  
Crystal system  orthorhombic  
Space group  P212121  
a  5.63430(10)Å  
b  17.0439(4)Å  
c  18.3976(4)Å  
Volume  1766.73(6)Å3  
Z  4  
dcalc  1.363 g/cm3  
µ  0.210 mm-1  
F(000)  768.0  
Crystal size, mm  0.27 × 0.22 × 0.07 
2θ range for data collection      3.258 - 55.2°  
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Index ranges  -7 ≤ h ≤ 7, -22 ≤ k ≤ 22, -23 ≤ l ≤ 23  
Reflections collected  76138  
Independent reflections  4098[R(int) = 0.0244]  
Data/restraints/parameters  4098/0/230  
Goodness-of-fit on F2  1.032  
Final R indexes [I>=2σ (I)]  R1 = 0.0236, wR2 = 0.0627  
Final R indexes [all data]  R1 = 0.0244, wR2 = 0.0636  
Largest diff. peak/hole  0.26/-0.20 eÅ-3  
Flack parameter 0.000(8) 
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Table S9. Refined Positional Parameters for Compound 3lf 
Atom x y z U(eq) 
C1 0.6373(3) 0.50568(9) 0.51875(8) 0.0145(3) 
C2 0.7001(3) 0.42985(9) 0.47838(8) 0.0172(3) 
C3 0.5746(3) 0.35804(9) 0.51175(9) 0.0222(3) 
C4 0.4763(3) 0.37244(9) 0.58716(8) 0.0207(3) 
C5 0.3429(3) 0.45049(9) 0.59475(8) 0.0178(3) 
C6 0.5803(3) 0.4253(1) 0.69607(8) 0.0195(3) 
C7 0.4446(3) 0.37174(10) 0.39391(9) 0.0225(3) 
C8 0.7835(3) 0.46938(13) 0.73007(10) 0.0286(4) 
C9 0.4471(4) 0.37383(11) 0.74995(9) 0.0274(4) 
C10 0.2302(3) 0.40696(13) 0.35715(10) 0.0306(4) 
C11 0.5599(4) 0.30581(11) 0.35112(10) 0.0304(4) 
C12 0.6783(3) 0.57838(9) 0.47468(8) 0.0144(3) 
C13 0.8724(3) 0.62536(8) 0.47743(8) 0.0137(3) 
C14 0.8484(3) 0.69286(9) 0.42958(8) 0.0144(3) 
C15 1.0044(3) 0.75587(9) 0.41932(8) 0.0175(3) 
C16 0.9400(3) 0.81664(9) 0.37318(9) 0.0206(3) 
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C17 0.7226(3) 0.81538(10) 0.33700(9) 0.0211(3) 
C18 0.5653(3) 0.75346(9) 0.34553(8) 0.0191(3) 
C19 0.6295(3) 0.69260(9) 0.39259(8) 0.0153(3) 
O1 0.4194(2) 0.48015(7) 0.66282(6) 0.0193(2) 
O2 0.6695(2) 0.37960(7) 0.63673(6) 0.0219(3) 
O3 0.3764(3) 0.34537(7) 0.46493(7) 0.0282(3) 
O4 0.6157(2) 0.43222(7) 0.40557(6) 0.0217(3) 
O5 0.39104(19) 0.50437(6) 0.53894(6) 0.0162(2) 
S1 0.46110(7) 0.61115(2) 0.41498(2) 0.01748(9) 
 
Table S10. Positional Parameters for Hydrogens in Compound 3lf  
Atom x y z U(eq) 
H1 0.7355 0.5088 0.5639 0.019 
H2 0.8759 0.4218 0.4788 0.023 
H3 0.6822 0.3114 0.5116 0.03 
H4 0.3712 0.3279 0.602 0.028 
H5 0.1684 0.4401 0.5966 0.024 
H8a 0.8601 0.5023 0.6932 0.043 
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H8b 0.8991 0.432 0.7496 0.043 
H8c 0.7234 0.5026 0.7695 0.043 
H9a 0.3871 0.4063 0.7899 0.041 
H9b 0.5547 0.3338 0.7693 0.041 
H9c 0.3137 0.3483 0.7253 0.041 
H10a 0.1675 0.4498 0.387 0.046 
H10b 0.108 0.3666 0.3512 0.046 
H10c 0.2759 0.4274 0.3094 0.046 
H11a 0.6138 0.3259 0.304 0.046 
H11b 0.4443 0.2637 0.3434 0.046 
H11c 0.6961 0.2854 0.3783 0.046 
H13 1.0074 0.6154 0.507 0.018 
H15 1.153 0.757 0.4437 0.023 
H16 1.0451 0.8596 0.3662 0.027 
H17 0.6814 0.8577 0.3059 0.028 
H18 0.4184 0.7524 0.3202 0.025 
 
  
	  
	  
585 
Table S11. Refined Thermal Parameters (U's) for Compound 3lf 
Atom U11 U22 U33 U23 U13 U12 
C1 0.0155(7) 0.0154(7) 0.0127(6) 0.0013(5) -0.0005(6) 0.0007(6) 
C2 0.0235(8) 0.0155(7) 0.0126(7) 0.0002(5) 0.0006(6) 0.0022(6) 
C3 0.0363(10) 0.0141(7) 0.0163(7) -0.0002(6) 0.0001(7) -0.0014(7) 
C4 0.0313(8) 0.0157(7) 0.0150(7) 0.0041(6) -0.0004(7) -0.0036(6) 
C5 0.0187(7) 0.0211(7) 0.0136(7) 0.0041(6) 0.0011(6) -0.0029(6) 
C6 0.0225(8) 0.0236(8) 0.0124(7) 0.0028(6) 0.0005(6) 0.0044(7) 
C7 0.0314(9) 0.0208(8) 0.0152(7) -0.0028(6) 0.0003(7) -0.0021(7) 
C8 0.0239(8) 0.0431(11) 0.0187(8) -0.0027(8) -0.0016(7) -0.0001(8) 
C9 0.0338(9) 0.0306(9) 0.0176(7) 0.0084(6) 0.0027(8) 0.0037(8) 
C10 0.0280(9) 0.0404(11) 0.0234(9) -0.0018(8) 0.0012(7) 0.0029(8) 
C11 0.0425(11) 0.0230(8) 0.0257(8) -0.0083(7) -0.0042(8) 0.0033(8) 
C12 0.0179(7) 0.0155(7) 0.0097(6) -0.0001(5) 0.0000(5) 0.0030(6) 
C13 0.0169(6) 0.0136(7) 0.0106(6) -0.0020(5) 0.0024(5) -0.0001(5) 
C14 0.0170(7) 0.0145(6) 0.0115(6) -0.0013(5) 0.0011(5) 0.0011(6) 
C15 0.0211(7) 0.0172(7) 0.0142(7) -0.0022(5) 0.0000(6) -0.0027(6) 
C16 0.0288(8) 0.0154(7) 0.0177(7) -0.0001(6) 0.0036(7) -0.0041(6) 
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C17 0.0287(8) 0.0186(7) 0.0159(7) 0.0038(6) 0.0030(6) 0.0024(7) 
C18 0.0208(7) 0.0219(7) 0.0147(7) 0.0031(6) 0.0001(6) 0.0023(6) 
C19 0.0171(7) 0.0160(7) 0.0128(6) -0.0002(5) 0.0024(5) -0.0008(6) 
O1 0.0247(6) 0.0200(5) 0.0133(5) 0.0018(4) -0.0007(4) 0.0031(4) 
O2 0.0295(6) 0.0231(6) 0.0131(5) 0.0016(4) 0.0001(5) 0.0073(5) 
O3 0.0422(8) 0.0251(6) 0.0171(6) 0.0000(5) -0.0006(5) -0.0124(6) 
O4 0.0346(6) 0.0190(5) 0.0115(5) -0.0002(4) -0.0007(5) -0.0034(5) 
O5 0.0150(5) 0.0184(5) 0.0153(5) 0.0052(4) 0.0011(4) 0.0005(4) 
S1 0.01670(17) 0.01913(17) 0.01660(17) 0.00510(14) -0.00268(14) -0.00218(14) 
 
Table S12. Bond Distances in Compound 3lf, Å 
          
C1-C2 1.532(2)   C1-C12 1.499(2)   C1-O5 1.4363(19) 
C2-C3 1.541(2)   C2-O4 1.4221(18)   C3-C4 1.514(2) 
C3-O3 1.427(2)   C4-C5 1.534(2)   C4-O2 1.425(2) 
C5-O1 1.4176(19)   C5-O5 1.4038(18)   C6-C8 1.505(3) 
C6-C9 1.522(2)   C6-O1 1.4387(19)   C6-O2 1.4323(19) 
C7-C10 1.509(3)   C7-C11 1.518(2)   C7-O3 1.434(2) 
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C7-O4 1.428(2)   C12-C13 1.356(2)   C12-S1 1.7368(15) 
C13-C14 1.455(2)   C14-C15 1.401(2)   C14-C19 1.409(2) 
C15-C16 1.388(2)   C16-C17 1.394(3)   C17-C18 1.387(2) 
C18-C19 1.399(2)   C19-S1 1.7310(16)       
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Table S13. Bond Angles in Compound 3lf. ° 
          
C12-C1-C2 113.55(12)   O5-C1-C2 109.61(13)   O5-C1-C12 107.57(12) 
C1-C2-C3 111.77(13)   O4-C2-C1 110.82(13)   O4-C2-C3 104.15(13) 
C4-C3-C2 113.83(13)   O3-C3-C2 103.82(12)   O3-C3-C4 106.93(15) 
C3-C4-C5 113.78(13)   O2-C4-C3 108.70(14)   O2-C4-C5 103.99(12) 
O1-C5-C4 103.93(12)   O5-C5-C4 113.96(13)   O5-C5-O1 110.74(12) 
C8-C6-C9 113.09(14)   O1-C6-C8 109.36(14)   O1-C6-C9 109.92(14) 
O2-C6-C8 108.75(14)   O2-C6-C9 110.86(14)   O2-C6-O1 104.50(12) 
C10-C7-C11 113.86(15)   O3-C7-C10 108.58(15)   O3-C7-C11 110.80(14) 
O4-C7-C10 108.71(14)   O4-C7-C11 108.86(15)   O4-C7-O3 105.70(12) 
C1-C12-S1 119.95(12)   C13-C12-C1 126.34(14)   C13-C12-S1 113.69(11) 
C12-C13-C14 111.69(14)   C15-C14-C13 129.01(14)   C15-C14-C19 119.14(14) 
C19-C14-C13 111.78(14)   C16-C15-C14 119.38(15)   C15-C16-C17 120.69(15) 
C18-C17-C16 121.27(15)   C17-C18-C19 117.99(15)   C14-C19-S1 111.56(11) 
C18-C19-C14 121.53(15)   C18-C19-S1 126.90(13)   C5-O1-C6 109.60(12) 
C4-O2-C6 105.44(12)   C3-O3-C7 107.02(13)   C2-O4-C7 110.29(12) 
C5-O5-C1 112.69(11)   C19-S1-C12 91.27(8)       
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This report has been created with Olex2 [6], compiled on 2016.08.25 svn.r3337 for 
OlexSys. 
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1H and 13C NMR Spectra: 1,4-Dihydropyridines 
1H NMR (CDCl3, 500 MHz) of diethyl 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (6.1.1)  
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13C NMR (CDCl3, 126 MHz) of diethyl 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (6.1.1)  
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1H NMR (CDCl3, 500 MHz) of diethyl 4-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarboxylate (6.1.2)  
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13C NMR (CDCl3, 126 MHz) of diethyl 4-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,6-dimethyl-
1,4-dihydropyridine-3,5-dicarboxylate (6.1.2)  
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1H NMR (CDCl3, 500 MHz) of diethyl 4-cyclohexyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (6.1.3)  
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13C NMR (CDCl3, 126 MHz) of diethyl 4-cyclohexyl-2,6-dimethyl-1,4-dihydropyridine-
3,5-dicarboxylate (6.1.3)  
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1H NMR (CDCl3, 500 MHz) of diethyl 4-(cyclohex-3-en-1-yl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (6.1.4)  
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13C NMR (CDCl3, 126 MHz) of diethyl 4-(cyclohex-3-en-1-yl)-2,6-dimethyl-1,4-
dihydropyridine-3,5-dicarboxylate (6.1.4)  
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1H NMR (CDCl3, 500 MHz) of diethyl 4-(heptan-3-yl)-2,6-dimethyl-1,4-dihydropyridine-
3,5-dicarboxylate (6.1.5)  
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13C NMR (CDCl3, 126 MHz) of diethyl 4-(heptan-3-yl)-2,6-dimethyl-1,4-dihydropyridine-
3,5-dicarboxylate (6.1.5)  
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1H NMR (CDCl3, 500 MHz) of diethyl 2,6-dimethyl-4-(7-methyloct-6-en-3-yl)-1,4-
dihydropyridine-3,5-dicarboxylate (6.1.6)  
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13C NMR (CDCl3, 126 MHz) of diethyl 2,6-dimethyl-4-(7-methyloct-6-en-3-yl)-1,4-
dihydropyridine-3,5-dicarboxylate (6.1.6)  
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1H NMR (CDCl3, 500 MHz) of diethyl 2,6-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1,4-
dihydropyridine-3,5-dicarboxylate (6.1.7)  
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13C NMR (CDCl3, 126 MHz) of diethyl 2,6-dimethyl-4-(tetrahydro-2H-pyran-4-yl)-1,4-
dihydropyridine-3,5-dicarboxylate (6.1.7)  
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1H NMR (CDCl3, 500 MHz) of diethyl 4-benzyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (6.1.8)  
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13C NMR (CDCl3, 126 MHz) of diethyl 4-benzyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (6.1.8)  
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1H NMR (CDCl3, 400 MHz) of diethyl 4-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.9)  
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13C NMR (CDCl3, 101 MHz) of diethyl 4-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-2,6-
dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.9)  
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1H NMR (CDCl3, 500 MHz) of diethyl 4-(3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidin-
4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.10)  
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13C NMR (CDCl3, 126 MHz) of diethyl 4-(3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidin-
4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.10)  
 
 
 
 
 
 
 
 
 
 
	  
	  
611 
1H NMR (DMSO-d6, 400 MHz) of diethyl 4-(1-((tert-butoxycarbonyl)amino)-2-
phenylethyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.11)  
 
 
 
 
 
 
 
 
 
	  
	  
612 
13C NMR (DMSO-d6, 101 MHz) of diethyl 4-(1-((tert-butoxycarbonyl)amino)-2-
phenylethyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate (6.1.11)  
 
 
 
 
 
 
 
 
 
	  
	  
613 
1H NMR (CDCl3, 500 MHz) of diethyl 2,6-dimethyl-4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-1,4-dihydropyridine-
3,5-dicarboxylate (6.1.12)  
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13C NMR (CDCl3, 126 MHz) of diethyl 2,6-dimethyl-4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-1,4-dihydropyridine-
3,5-dicarboxylate (6.1.12)  
 
 
 
 
 
 
 
 
 
	  
	  
615 
1H NMR (CDCl3, 500 MHz) of 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarbonitrile (6.3.1)  
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13C NMR (CDCl3, 126 MHz) of 4-isopropyl-2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarbonitrile (6.3.2)  
 
  
 
 
 
 
 
 
 
	  
	  
617 
1H NMR (CDCl3, 500 MHz) of 4-isopropylbenzonitrile (6.2.1)  
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13C NMR (CDCl3, 126 MHz) of 4-isopropylbenzonitrile (6.2.1)  
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1H NMR (CDCl3, 500 MHz) of 2,2-dimethyl-4-(4-(trifluoromethyl)phenyl)-1,3-dioxolane 
(6.3.1)  
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13C NMR (CDCl3, 126 MHz) of 2,2-dimethyl-4-(4-(trifluoromethyl)phenyl)-1,3-dioxolane 
(6.3.1) 
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1H NMR (CDCl3, 500 MHz) of 2,2-dimethyl-4-(naphthalen-2-yl)-1,3-dioxolane (6.3.1)  
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13C NMR (CDCl3, 126 MHz) of 2,2-dimethyl-4-(naphthalen-2-yl)-1,3-dioxolane (6.3.2)  
 
 
 
 
 
 
 
 
 
	  
	  
623 
1H NMR (CDCl3, 500 MHz) of 2-(2,2-dimethyl-1,3-dioxolan-4-yl)-5-
(trifluoromethyl)pyridine (6.3.3)  
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13C NMR (CDCl3, 126 MHz) of 2-(2,2-dimethyl-1,3-dioxolan-4-yl)-5-
(trifluoromethyl)pyridine (6.3.3)  
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1H NMR (CDCl3, 500 MHz) of 2-(2,2-dimethyl-1,3-dioxolan-4-yl)thiazole (6.3.4)  
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13C NMR (CDCl3, 126 MHz) of 2-(2,2-dimethyl-1,3-dioxolan-4-yl)thiazole (6.3.4)  
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1H NMR (CDCl3, 500 MHz) of 4-(benzo[b]thiophen-2-yl)-2,2-dimethyl-1,3-dioxolane 
(6.3.5)  
 
 
 
 
 
 
 
 
 
 
	  
	  
628 
 
13C NMR (CDCl3, 126 MHz) of 4-(benzo[b]thiophen-2-yl)-2,2-dimethyl-1,3-dioxolane 
(6.3.5)  
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1H NMR (CDCl3, 500 MHz) of 5-(2,2-dimethyl-1,3-dioxolan-4-yl)thiophene-2-
carbaldehyde (6.3.6)  
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13C NMR (CDCl3, 126 MHz) of 5-(2,2-dimethyl-1,3-dioxolan-4-yl)thiophene-2-
carbaldehyde (6.3.6)  
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1H NMR (CDCl3, 500 MHz) of 1-(5-(2,2-dimethyl-1,3-dioxolan-4-yl)thiophen-2-yl)ethan-
1-one (6.3.7) 
 
 
 
 
 
 
 
 
 
	  
	  
632 
13C NMR (CDCl3, 126 MHz) of 1-(5-(2,2-dimethyl-1,3-dioxolan-4-yl)thiophen-2-yl)ethan-
1-one (6.3.7) 
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1H and 13C NMR Spectra: Scope of (Hetero)Aryl Bromides and Dihydropyridines 
1H NMR (CDCl3, 500 MHz) of 2-isopropylbenzo[b]thiophene (6.4.1)  
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13C NMR (CDCl3, 126 MHz) of 2-isopropylbenzo[b]thiophene (6.4.1) 
 
 
 
 
 
 
 
 
 
 
 
	  
	  
635 
1H NMR (CDCl3, 500 MHz) of ethyl 5-cyclohexylfuran-2-carboxylate (6.4.2)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
636 
13C NMR (CDCl3, 126 MHz) of ethyl 5-cyclohexylfuran-2-carboxylate (6.4.2)  
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1H NMR (CDCl3, 500 MHz) of 1-(5-cyclohexylthiophen-2-yl)ethan-1-one (6.4.3)  
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13C NMR (CDCl3, 126 MHz) of 1-(5-cyclohexylthiophen-2-yl)ethan-1-one (6.4.3)  
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1H NMR (CDCl3, 500 MHz) of 5-cyclohexylthiophene-2-sulfonamide (6.4.4)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
640 
13C NMR (CDCl3, 126 MHz) of 5-cyclohexylthiophene-2-sulfonamide (6.4.4)  
 
 
 
 
 
 
 
 
 
 
	  
	  
641 
1H NMR (CDCl3, 500 MHz) of 1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-carbonitrile (6.4.5)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
642 
13C NMR (CDCl3, 126 MHz) of 1',2',3',6'-tetrahydro-[1,1'-biphenyl]-4-carbonitrile (6.4.5)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
643 
1H NMR (CDCl3, 500 MHz) of 2-(cyclohex-3-en-1-yl)benzo[b]thiophene (6.4.6)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
644 
13C NMR (CDCl3, 126 MHz) of 2-(cyclohex-3-en-1-yl)benzo[b]thiophene (6.4.6)  
 
 
 
 
 
 
 
 
 
 
	  
	  
645 
1H NMR (CDCl3, 500 MHz) of 1-(5-(cyclohex-3-en-1-yl)thiophen-2-yl)ethan-1-one (6.4.7)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
646 
13C NMR (CDCl3, 126 MHz) of 1-(5-(cyclohex-3-en-1-yl)thiophen-2-yl)ethan-1-one (6.4.7)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
647 
1H NMR (CDCl3, 500 MHz) of 4-(heptan-3-yl)benzonitrile (6.4.8)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
648 
13C NMR (CDCl3, 126 MHz) of 4-(heptan-3-yl)benzonitrile (6.4.8)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
649 
1H NMR (CDCl3, 500 MHz) of 1-(5-(heptan-3-yl)thiophen-2-yl)ethan-1-one (6.4.9)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
650 
13C NMR (CDCl3, 126 MHz) of 1-(5-(heptan-3-yl)thiophen-2-yl)ethan-1-one (6.4.9)  
 
 
 
 
 
 
 
 
 
 
 
	  
	  
651 
1H NMR (CDCl3, 500 MHz) of 1-(5-(6-methylhept-5-en-2-yl)thiophen-2-yl)ethan-1-one 
(6.4.10)  
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13C NMR (CDCl3, 126 MHz) of 1-(5-(6-methylhept-5-en-2-yl)thiophen-2-yl)ethan-1-one 
(6.4.10)  
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1H NMR (CDCl3, 500 MHz) of 1-(5-(tetrahydro-2H-pyran-4-yl)thiophen-2-yl)ethan-1-one 
(6.4.11)  
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13C NMR (CDCl3, 126 MHz) of 1-(5-(tetrahydro-2H-pyran-4-yl)thiophen-2-yl)ethan-1-one 
(6.4.11)  
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1H NMR (CDCl3, 500 MHz) of 3-benzyl-5-chloropyridine (6.4.12)  
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13C NMR (CDCl3, 126 MHz) of 3-benzyl-5-chloropyridine (6.4.12)  
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1H NMR (CDCl3, 500 MHz) of tert-butyl 2-(3-acetylphenyl)pyrrolidine-1-carboxylate 
(6.4.13)  
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13C NMR (CDCl3, 126 MHz) of tert-butyl 2-(3-acetylphenyl)pyrrolidine-1-carboxylate 
(6.4.13)  
 
  
	  
	  
659 
1H NMR (CDCl3, 500 MHz) of tert-butyl 4-(4-cyanophenyl)-2,2-dimethyloxazolidine-3-
carboxylate (6.4.14)  
 
 
 
 
 
 
 
 
 
	  
	  
660 
13C NMR (CDCl3, 126 MHz) of tert-butyl 4-(4-cyanophenyl)-2,2-dimethyloxazolidine-3-
carboxylate (6.4.14)  
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1H NMR (CDCl3, 500 MHz) of tert-butyl (1-(4-cyanophenyl)-2-phenylethyl)carbamate 
(6.4.15)  
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13C NMR (CDCl3, 126 MHz) of tert-butyl (1-(4-cyanophenyl)-2-phenylethyl)carbamate 
(6.4.15) 
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1H and 13C NMR Spectra: Synthesis of Aryl-Containing Saccharides 
1H NMR (DMSO-d6, 500 MHz) of (3aR,5S,5aR,8aS,8bR)-5-(benzo[b]thiophen-2-yl)-
2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran (6.5.1)  
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13C NMR (DMSO-d6, 126 MHz) of (3aR,5S,5aR,8aS,8bR)-5-(benzo[b]thiophen-2-yl)-
2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran (6.5.1)  
 
 
 
 
 
 
 
 
 
	  
	  
665 
1H NMR (DMSO-d6, 500 MHz) of (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-((6-(6-
methylhept-5-en-2-yl)naphthalen-2-yl)oxy)tetrahydro-2H-pyran-3,4,5-triol (6.5.2)  
 
 
 
 
 
 
 
 
 
	  
	  
666 
13C NMR (DMSO-d6, 126 MHz) of (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-((6-(6-
methylhept-5-en-2-yl)naphthalen-2-yl)oxy)tetrahydro-2H-pyran-3,4,5-triol (6.5.2)  
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Chapter 7. Accessing Non-Classical Arylated Saccharides via Photoredox/Ni Dual Catalysis 
 
7.1 Introduction 
 The incorporation of saccharide derivatives into lead compounds represents an attractive 
way to diversify drug candidate scaffolds by modulating crucial parameters related to the in vivo 
efficacy of a therapeutic drug (e.g., solubility, membrane transport, pharmacodynamics or 
pharmacokinetics).1† Notably, “reverse aryl C-glycosides”2 comprise a class of saccharides that 
have proven to be efficient antibiotics,3 antitumor agents4 or inhibitors for diabetes.2d,5 These 
glycosides have the particularity of bearing an aromatic moiety directly attached to the 
carbohydrate through a C-C bond, differentiating them from the usual O-glycosides, thus leading 
to better stability to both enzymatic and acidic hydrolysis, while preserving excellent biological 
efficacy. 
    Several routes toward anomeric, arylated saccharides have been reported,2 such as Friedel-Crafts 
reactions or nucleophilic additions of organometallic reagents (e.g., organolithium or Grignard 
reagents) to suitable electrophiles. However, such methods suffer from serious drawbacks, 
including harsh acidic or basic conditions, low functional group tolerance, and undesired side-
products arising from elimination or epimerization processes.  
 Recently, the transition metal-catalyzed cross-coupling of in situ generated glycosyl 
radicals6 (from the corresponding glycosyl chloride or bromide) with organometallic reagents (aryl- 
or alkenylzinc and magnesium reagents) has emerged as one of the most efficient ways to access 
aryl C-saccharides (Figure 7.1). This transformation has been achieved in the presence of nickel,7 
 
 
† Reproduced in part from Dumoulin, A.; Matsui, J. K.; Gutierrez-Bonet, A.; Molander, G. A. Angew. 
Chem. Int. Ed. 2018, 57, 6614. 
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cobalt8 or iron9 catalysts, affording the desired saccharide derivatives in moderate to good yields. 
Alternatively, pyranosylstannanes could be coupled with aryl halides in the presence of a palladium 
catalyst.10 Despite these improvements, such reaction conditions remain limited in terms of 
functional group tolerance and operational simplicity as they involve highly reactive 
organometallic species that need to be freshly prepared and suffer from β-elimination.8a 
Furthermore, stoichiometric amounts of metal waste are generated. Finally, these processes rely on 
substitution reactions at the anomeric center, thus preventing the substrate from being further 
functionalized by traditional chemistry at the anomeric carbon. 
    In this context, the development of straightforward, modular, and operationally simple 
conditions to access C-arylated saccharides remains an unsolved challenge and, specifically, 
methods that would preserve the anomeric carbon to afford non-classical “reverse aryl C-
glycosides” are particularly scarce. Indeed, despite their attractive biological properties,11 few 
synthetic efforts have been carried out in this regard.12 
 
Figure 7.1. Previous routes accessing aryl monosaccharides. 
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 Other approaches toward the synthesis of “reverse aryl C-glycosides” have been reported, 
such as the [4+2] cycloaddition between Danishefsky’s dienes and aromatic aldehydes, yielding 
glycal derivatives,13 or the addition of organozinc reagents to 4α-epoxypyranosides (Figure 7.2).14 
However, these strategies are restricted to pyranoses, lack modularity, and require several extra 
steps to obtain the desired “reverse aryl C-glycoside.” 
 
Figure 7.2. Cycloaddition and ring-opening approaches targeting reverse aryl C-glycosides. 
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is directed to one of the two potential anomeric positions, one being masked by the DHP.12 
7.2 Reaction Desigan and Results 
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addition to being bench stable and easy to handle, these compounds tolerate high functionalization 
levels owing to the mild reaction conditions required for their preparation from the corresponding 
aldehyde. A wide range of 4-glycosyl-1,4-DHPs was accessed from commercially available 
pentose and hexose derivatives via deprotection and oxidation chemistry to form the aldehyde. 
Using Tripathi and coworker’s procedure, the monosaccharide DHPs were accessed via the 
reported acid-catalyzed condensation reaction.17 It is worth mentioning that this synthetic pathway 
accommodated a broad range of carbohydrate derivatives (e.g., ribonucleoside, furanoses and 
pyranoses). 
    Next, the feasibility of the photoredox/nickel cross-coupling reaction between DHPs and 
2-bromonaphthalene was studied by means of microscale high-throughput experimentation. 
Results from the screening revealed that the organic photocatalyst 4CzIPN (excited state Ered = 
+1.35 V vs SCE)18 was extremely efficient in oxidatively cleaving the DHP [Ered = +1.20 V vs 
SCE], delivering the desired glycosyl radical (Figure 7.3). Among the advantages of 4CzIPN 
compared to traditional iridium-based photocatalyst are its lower cost ($4.7/mmol vs 
$140.0/mmol),19 which provides significant benefit when it comes to industrial application. After 
further screening, the best yields were obtained in the presence of 2 mol % of 4-CzIPN 
photocatalyst, 5 mol % of NiBr2•dme and 7 mol % of dMeObpy as a ligand in acetone at room 
temperature for 24 h. As expected, control experiments showed that all parameters were essential 
for the transformation to proceed. 
    Next, the generality of the reaction with respect to the DHP derivative was explored. As 
illustrated in Figure 7.3, the reaction was remarkably tolerant of substitution in the saccharide 
scaffold, providing the desired products in moderate to high yields. Notably, good to excellent 
diastereoselectivity was observed for certain furanosyl units (7.3.1, 7.3.4, and 7.3.5), likely because 
of steric interactions with the adjacent substituent, an effect observed by Nakamura and coworkers 
in their recent iron-catalyzed arylation of halosugars.9 Excellent diastereoselectivity has also been 
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observed in the field of photoredox/Ni catalysis when 2-methylcyclopentyltrifluoroborate was 
coupled with aryl bromide, affording exclusively the trans product.19 
    The steric control on the L-arabinofuranose and D-xylofuranose derivatives was made 
evident when comparing the effect of the vicinal substituent, where small substituents (e.g., MeO 
and F, 7.3.2 and 7.3.3, respectively) afforded poor drs, whereas sterically encumbered, TBS-
protected moieties afforded excellent steric control (9:1 dr). D-Ribofuranosyl DHP afforded 
excellent dr. X-Ray crystallography confirmed the retention of configuration (7.3.7). Likewise, 
uridine-derived DHP afforded excellent diastereoselectivity, although in low yields; again, this 
highlights the prevalent role of steric interactions. Additionally, aryl pyranose 7.3.8 generated 
excellent dr with the aryl group cis to the dimethyl acetal protecting group (confirmed by X-ray 
crystallography). Not surprisingly, the more flexible radical leading to 7.3.9 afforded lower 
diastereoselectivity.6,20,21 Finally, the TBS protecting group choice allowed the formation of 
unprotected derivative 7.3.5 upon TBAF addition to the crude reaction mixture of 7.3.4. 
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Figure 7.3. Modulating monosaccharide backbone. 
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Figure 7.4. Demonstrating diversity with various aryl- and heteroaryl bromides. 
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Coupling with a steroid derivative (7.4.1) proved successful, thus offering a privileged substructure 
of use in medicinal chemistry.23 Recognizing the potential for late-stage functionalization, we 
introduced functional group-dense aryl bromides from Merck’s chemistry informer library 
containing drug-like motifs.24 A quinoxalinedione derivative, which is encountered in ionotropic 
glutamate receptor antagonists,25 exhibited good reactivity under optimized conditions to furnish 
pyranose product 7.5.2 with excellent diastereocontrol. Even the more complex 3-bromothiophene 
derivative bearing a guanidine motif, belonging to the family of aspartic protease inhibitors,26 
afforded the desired products in high yield (7.4.3). In addition, a furanosyl residue could be 
introduced into the loratadine scaffold (7.4.4) under the standard reaction conditions. 
 
Figure 7.5. Late-stage functionalization. 
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quenching with the DHP derivative [Ered = + 1.20 V vs SCE]. The resulting radical cation A rapidly 
fragments to generate an aromatized pyridine derivative along with the corresponding saccharyl 
radical B. This latter species would first add to the active Ni(0) catalyst, thus producing a Ni(I)-
saccharyl complex C that would undergo oxidative addition with the aryl bromide to afford the 
corresponding Ni(III) complex D.27 Subsequent reductive elimination would take place to yield the 
cross-coupling product 2 and a Ni(I) species E. This latter complex would then be reduced to Ni(0) 
F with the reduced form of the 4CzIPN photocatalyst (Ered = + 1.21 V vs SCE), thus regenerating 
both active catalysts for subsequent catalytic cycles. 
 
Figure 7.6. Proposed mechanism. 
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diastereoselectivity in the presence of the same saccharyl radical. Previous mechanistic studies 
suggest the high-valent Ni(III) species D ultimately dictates the observed diastereoselectivity after 
the irreversible reduction elimination;28 therefore, we sought to improve the lower drs by 
identifying suitable ligands. Bidentate and tridentate ligands were screened with both Ni(0) and 
Ni(II) species. Modifying the bipyridine backbone by replacing electron-donating methoxy groups 
with bulkier, less electron-rich, tert-butyl substituents afforded excellent diastereoselectivities, 
improving from 3.3:1 dr to >20:1, for example (7.7.2). Alternatively, the use of phenanthroline 
resulted in a >20:1 dr for hexose 1,4-dihydropyridine (7.7.3), whereas the previously successful 
dtbbpy showed no improvement. Although the subtleties dictating the diastereoselectivity remain 
elusive, it is clear that diastereoselectivities can be improved on a case-by-case basis, if needed, 
through effective screening efforts. Further mechanistic studies are ongoing to shed light on these 
ligand effects. 
  
Figure 7.7. Modulating diastereoselectivity. 
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precursors. The optimized conditions provide straightforward access to a wide variety of highly 
functionalized, arylated saccharides. Further studies were conducted to improve observed 
diastereoselectivities by targeting the diastereo-determining step, reductive elimination from the 
high-valent Ni(III) complex. This new strategy could find broad applications in the field of 
medicinal chemistry research, affording structurally novel materials that have been largely 
underexplored 
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(3aR,5S,6S,6aR)-6-(Benzyloxy)-2,2-dimethyl-5-(naphthalen-2-yl)tetrahydrofuro[2,3-d] 
[1,3]dioxole (7.3.1): Following General Procedure I using corresponding DHP (375.9 mg, 0.75 
mmol, 1.5 equiv), 2-bromonaphthalene (103.0 mg, 0.5 mmol, 1.0 equiv), 4-CzIPN (7.8 mg, 0.01 
mmol, 2 mol %), NiBr2·dme (7.7 mg, 0.025 mmol, 5 mol %), and dMeObpy (7.5 mg, 0.035 mmol, 
7 mol %) in anhydrous acetone (5.0 mL, 0.1 M). The product was purified by flash chromatography 
on silica gel (hexanes/EtOAc 0 to 10%, 10 to 30%) to afford a semi solid (154.2 mg, 82% yield). 
dr > 20:1 based on 1H NMR of the crude reaction mixture.  
1H NMR (500 MHz, CDCl3) δ 7.89 (s, 1H), 7.81 (d, J = 7.7 Hz, 3H), 7.48 (dd, J = 17.7, 7.8 Hz, 
3H), 7.33 (d, J = 19.5 Hz, 5H), 6.06 (s, 1H), 5.19 (s, 1H), 4.84 – 4.68 (m, 2H), 4.61 (d, J = 11.7 
Hz, 1H), 4.19 (s, 1H), 1.40 (s, 3H), 1.38 (s, 3H) ppm.  
13C NMR (126 MHz, CDCl3) δ 137.4, 137.0, 133.2, 133.0, 128.7, 128.2, 128.2, 128.2, 128.0, 127.8, 
126.3, 126.0, 124.8, 123.9, 114.0, 105.5, 88.3, 86.0, 84.8, 72.4, 27.3, 27.0 ppm.  
IR (neat, cm-1): 3060, 2936, 1455, 1382, 1074, 860.  
HRMS (EI+) calcd for C24H24O4 [M]+ 376.1675, found 376.1670. 
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(3aR,5R,6S,6aR)-6-Methoxy-2,2-dimethyl-5-(naphthalen-2-yl)tetrahydrofuro[2,3-d] 
[1,3]dioxole (7.3.2): Following General Procedure II using corresponding DHP (300.9 mg, 0.6 
mmol, 2.0 equiv), 2-bromonaphthalene (62.1 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 0.006 
mmol, 2 mol %), NiBr2·dme (9.2 mg, 0.03 mmol, 10 mol %), and dMeObpy (9.1 mg, 0.042 mmol, 
14 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 15%) to afford a white solid (40.0 mg, 44% 
yield). dr = 2:1 based on 1H NMR of the crude reaction mixture. mp = 68-70 °C. 1H NMR (500 
MHz, CDCl3, major diastereomer) δ 7.95 (s, 1H), 7.87 – 7.81 (m, 3H), 7.59 – 7.44 (m, 3H), 6.04 
(d, J = 4.0 Hz, 1H), 5.10 (d, J = 5.0 Hz, 1H), 4.71 (dd, J = 4.0, 1.5 Hz, 1H), 3.97 (dd, J = 4.5, 1.0 
Hz, 1H), 3.50 (s, 3H), 1.43 (s, 3H), 1.39 (s, 3H) ppm. 1H NMR (500 MHz, CDCl3, minor 
diastereomer) δ 7.92 (s, 1H), 7.87 – 7.81 (m, 3H), 7.59 – 7.44 (m, 3H), 6.16 (d, J = 3.5 Hz, 1H), 
5.44 (d, J = 3.0 Hz, 1H), 4.73 (d, J = 3.5 Hz, 1H), 3.91 (d, J = 3.0 Hz, 1H), 3.05 (s, 3H), 1.61 (s, 
3H), 1.41 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3, major diastereomer) δ 137.1, 133.3, 133.1, 
128.2, 128.2, 127.8, 126.3, 126.0, 124.9, 123.9, 113.9, 105.4, 90.6, 85.5, 84.8, 58.1, 27.4, 27.0 ppm. 
13C NMR (126 MHz, CDCl3, minor diastereomer) δ 137.1, 133.3, 133.2, 128.3, 128.2, 127.7, 126.1, 
125.9, 125.1, 123.9, 111.8, 105.0, 86.3, 82.9, 81.9, 58.6, 27.0, 26.4 ppm. IR (neat, cm-1): 2987, 
2934, 1373, 1382, 1315, 1193, 958. HRMS (EI+) calcd for C18H20O4 [M]+ 300.1362, found 
300.1350. 
 
 
(3aR,6S,6aS)-6-Fluoro-2,2-dimethyl-5-(naphthalen-2-yl)tetrahydrofuro[2,3-d][1,3]dioxole 
(7.3.3): Following General Procedure II using corresponding DHP (248.1 mg, 0.6 mmol, 2.0 
O
O
O
Me
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equiv), 2-bromonaphthalene (62.1 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 0.006 mmol, 2 mol 
%), NiBr2·dme (9.3 mg, 0.03 mmol, 10 mol %), and dMeObpy (9.1 mg, 0.042 mmol, 14 mol %) 
in anhydrous acetone (6.0 mL, 0.05 M). The two diastereomers were independently isolated by 
flash chromatography on silica gel (hexanes/EtOAc 0 to 5%) as crystalline white solids (25.1 mg, 
29% yield, dr = 6.7:1 for the major diastereomer, 12.9 mg, 15% yield, dr > 20:1 for the minor 
diastereomer. 44% combined yield). mp (minor) = 81-84 ºC, mp (major) = 90-94 ºC. dr = 1.5:1 
based on 1H NMR of the crude reaction mixture. 1H NMR (500 MHz, CDCl3, minor diastereomer) 
δ 7.97 (s, 1H), 7.90 – 7.80 (m, 3H), 7.54 (d, J = 8.5 Hz, 1H), 7.51 – 7.44 (m, 2H), 6.17 (d, J = 3.9 
Hz, 1H), 5.49 (d, J = 24.1 Hz, 1H), 5.29 (d, J = 50.1 Hz, 1H), 4.87 (dd, J = 14.7, 4.0 Hz, 1H), 1.31 
(s, 3H), 1.18 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3, minor diastereomer) δ 133.1, 133.0, 128.3, 
128.2, 127.8, 126.5, 126.2 (2C), 125.0, 123.7, 113.7, 106.0, 99.2 (d, J = 182.5 Hz), 86.1 (d, J = 
26.8 Hz), 84.7 (d, J = 32.0 Hz), 26.5, 26.3 ppm. 1H NMR (500 MHz, CDCl3, major diastereomer) 
δ 7.92 (s, 1H), 7.89 – 7.81 (m, 3H), 7.57 – 7.44 (m, 3H), 6.23 (d, J = 3.7 Hz, 1H), 5.45 (d, J = 29.4 
Hz, 1H), 5.06 (dd, J = 49.7, 1.8 Hz, 1H), 4.86 (dd, J = 10.1, 3.8 Hz, 1H), 1.61 (s, 3H), 1.41 (s, 3H) 
ppm. 13C NMR (126 MHz, CDCl3, major diastereomer) δ 133.4, 133.3, 131.3 (d, J = 3.7 Hz), 128.2, 
128.0, 127.9, 126.5, 126.3, 126.3, 124.9, 112.4, 105.0, 95.2 (d, J = 187.2 Hz), 83.0 (d, J = 32.8 Hz), 
81.6 (d, J = 19.2 Hz), 26.9, 26.4 ppm. 19F NMR (471 MHz, CDCl3) δ -183.14, -203.98 ppm. IR 
(neat, cm-1): 2960, 2924, 2850, 1374, 1119, 1053, 1001 (minor diastereomer), 2992, 2938, 1386, 
1374, 1217, 1163, 1079, 1020 (major diastereomer). HRMS (EI+) calcd for C18H20O4 [M]+ 
288.1156, found 288.1177. 
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tert-Butyl(((3aR,6S,6aR)-2,2-dimethyl-5-(naphthalen-2-yl)tetrahydrofuro[2,3-d][1,3]dioxol-
6-yl)oxy)dimethylsilane (7.3.4): Following General Procedure I using corresponding DHP (262.9 
mg, 0.5 mmol, 2.0 equiv), 2-bromonaphthalene (51.8 mg, 0.25 mmol, 1.0 equiv), 4-CzIPN (3.9 mg, 
0.005 mmol, 2 mol %), NiBr2·dme (3.9 mg, 0.00125 mmol, 5 mol %), and dMeObpy (3.8 mg, 
0.0175 mmol, 7 mol %) in anhydrous acetone (5.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 10%) to afford a yellow, viscous oil (40.9 mg, 
41% yield). dr = 9:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 MHz, CDCl3) 
δ 7.90 (s, 1H), 7.88 – 7.76 (m, 3H), 7.53 (d, J = 8.5 Hz, 1H), 7.49 – 7.42 (m, 2H), 6.02 (d, J = 4.0 
Hz, 1H), 4.97 (d, J = 4.9 Hz, 1H), 4.58 (d, J = 4.0 Hz, 1H), 4.32 (d, J = 4.9 Hz, 1H), 1.43 (s, 3H), 
1.37 (s, 3H), 0.90 (s, 9H), 0.05 (s, 3H), -0.03 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 136.8, 
133.2, 133.1, 128.2, 128.1, 127.8, 126.2, 125.9, 125.1, 124.0, 113.8, 105.1, 88.6, 87.1, 82.6, 27.5, 
27.2, 25.8, 18.1, -4.6, -4.8 ppm. IR (neat, cm-1): 2953, 2930, 2858, 1472, 1382, 1257, 1119, 1079, 
1017. HRMS (EI+) calcd for C23H32O4Si [M]+ 400.2070, found 400.2080. 
For the conformation elucidation of product 2d, a combination of DEPT 45, COSY, HMBC and 
HSQC experiments were taken to unequivocally assigned each proton and carbon signals. Next, 
coupled 13C NMR experiment allowed us to detect a 2JC3,H4 constant of 5.5 Hz. When compared 
this value with previous literature, a relative trans configuration between the OTBS and the 
naphthyl groups was established.1 
 
 
                                                      
1 Napolitano, J. G.; Gavín, J. A.; García, C.; Norte, M.; Fernández, J. J.; Hernández 
Daranas, A. Chem. Eur. J. 2011, 17, 6338. 
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(3aR,6S,6aR)-2,2-Dimethyl-5-(naphthalen-2-yl)tetrahydrofuro[2,3-d][1,3]dioxol-6-ol (7.3.5): 
Following General Procedure II using corresponding DHP (262.9 mg, 0.5 mmol, 2.0 equiv), 2-
bromonaphthalene (51.8 mg, 0.25 mmol, 1.0 equiv), 4-CzIPN (3.9 mg, 0.005 mmol, 2 mol %), 
NiBr2·dme (7.8 mg, 0.0025 mmol, 10 mol %), and dMeObpy (7.6 mg, 0.035 mmol, 14 mol %) in 
anhydrous acetone (4.0 mL, 0.05 M). After 24 h, a solution of TBAF (1.5 mL, 1.0 M in THF, 6.0 
equiv) was added dropwise at 0 °C. The reaction was allowed to stir for 5 h at rt, then quenched by 
addition of a saturated aq solution of NaHCO3 (15 mL). The aqueous layer was extracted with 
EtOAc (3 x 15 mL), the combined organic layers were dried (MgSO4) and concentrated under 
reduced pressure. The crude was purified by flash chromatography on silica gel (hexanes/EtOAc 0 
to 40%) to afford a crystalline solid (48.4 mg, 67% yield). dr > 20:1 based on 1H NMR of the crude 
reaction mixture. mp = 105-107 °C. 1H NMR (500 MHz, CDCl3) δ 7.92 (s, 1H), 7.87 – 7.70 (m, 
3H), 7.55 (dd, J = 8.6, 1.6 Hz, 1H), 7.50 – 7.36 (m, 2H), 6.04 (d, J = 4.1 Hz, 1H), 5.07 (d, J = 4.5 
Hz, 1H), 4.66 (dd, J = 4.1, 1.5 Hz, 1H), 4.46 (s, 1H), 2.67 (d, J = 4.0 Hz, 1H), 1.34 (s, 6H) ppm. 
13C NMR (126 MHz, CDCl3) δ 136.5, 133.2, 133.1, 128.3, 128.2, 127.8, 126.3, 126.1, 124.9, 123.9, 
113.8, 105.3, 88.0, 87.0, 81.3, 27.0, 26.9 ppm. IR (neat, cm-1): 3437, 2986, 2937, 1374, 1316, 1212, 
1070, 1014. HRMS (EI+) calcd for C17H18O4 [M]+ 286.1205, found 286.1201. 
 
 
(3aR,4R,6R,6aR)-4-Methoxy-2,2-dimethyl-6-(naphthalen-2-yl)tetrahydrofuro[3,4-
d][1,3]dioxole (7.3.6): Following General Procedure II using corresponding DHP (191.5 mg, 0.45 
mmol, 1.5 equiv), 2-bromonaphthalene (62.1 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 0.006 
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mmol, 2 mol %), NiBr2·dme (9.3 mg, 0.03 mmol, 10 mol %), and dMeObpy (9.1 mg, 0.042 mmol, 
14 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 10%) to afford a crystalline white solid (52.0 
mg, 58% yield). mp = 104-106 ºC. dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H 
NMR (500 MHz, CDCl3) δ 7.87 – 7.80 (m, 4H), 7.53 (d, J = 8.9 Hz, 1H), 7.50 – 7.45 (m, 2H), 5.41 
(s, 1H), 5.19 (s, 1H), 4.97 (dd, J = 5.9, 1.6 Hz, 1H), 4.72 (d, J = 6.0 Hz, 1H), 3.41 (s, 3H), 1.62 (s, 
3H), 1.38 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 138.0, 133.3, 133.0, 128.3, 128.2, 127.7, 
126.3, 126.1, 125.3, 124.4, 113.1, 110.2, 89.4, 86.0, 85.9, 55.6, 27.0, 25.4 ppm. IR (neat, cm-1): 
2949, 2927, 2854, 1456, 1370, 1199, 1082, 825. HRMS (EI+) calcd for C18H20O4 [M]+ 300.1362, 
found 300.1369. 
 
 
1-((3aR,6R,6aR)-2,2-Dimethyl-6-(naphthalen-2-yl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl) 
pyrimidine-2,4(1H,3H)-dione (7.3.7): Following General Procedure II using corresponding DHP 
(151.4 mg, 0.3 mmol, 1.0 equiv), 2-bromonaphthalene (124.2 mg, 0.6 mmol, 2.0 equiv), 4-CzIPN 
(4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (9.3 mg, 0.03 mmol, 10 mol %), and dMeObpy (9.1 
mg, 0.042 mmol, 14 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by 
flash chromatography on silica gel (CH2Cl2/MeOH 0 to 10%) to afford a white solid (27,4 mg, 24% 
yield). mp = 137-139 ºC. dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 
MHz, CDCl3) δ 9.13 (br s, 1H), 7.87 (d, J = 8.6 Hz, 1H), 7.85 – 7.80 (m, 3H), 7.52 (dd, J = 8.5, 1.5 
Hz, 1H), 7.51 – 7.45 (m, 2H), 7.27 (d, J = 5.2 Hz, 1H), 5.86 (d, J = 2.2 Hz, 1H), 5.75 (d, J = 8.0 
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Hz, 1H), 5.18 (d, J = 5.3 Hz, 1H), 5.11 (dd, J = 6.5, 2.2 Hz, 1H), 4.98 (t, J = 5.0 Hz, 1H), 1.70 (s, 
3H), 1.40 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 163.4, 150.0, 142.3, 135.5, 133.4, 133.2, 
128.9, 128.2, 127.9, 126.5, 126.4, 125.1, 123.5, 115.5, 102.9, 93.4, 87.6, 85.4, 84.4, 27.5, 25.6 ppm. 
IR (neat, cm-1): 3214, 3085, 2981, 2919, 1697, 1387, 1293, 1072. HRMS (ES+) calcd for 
C21H21N2O5 [M+H]+ 381.1450, found 381.1474. 
 
 
(3aR,5R,5aS,8aS,8bR)-2,2,7,7-Tetramethyl-5-(naphthalen-2-yl)tetrahydro-5H-bis 
([1,3]dioxolo)[4,5-b:4',5'-d]pyran (7.3.8): Following General Procedure I using corresponding 
DHP (216.7 mg, 0.45 mmol, 1.5 equiv), 2-bromonaphthalene (62.1 mg, 0.3 mmol, 1.0 equiv), 4-
CzIPN (4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy 
(4.5 mg, 0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified 
by flash chromatography on silica gel (hexanes/EtOAc 0 to 10%) to afford a white solid (95.1 mg, 
89% yield). mp = 122-124 ºC. dr = 9:1 based on 1H NMR of the crude reaction mixture. 1H NMR 
(500 MHz, CDCl3) δ 7.89 (s, 1H), 7.86 – 7.79 (m, 3H), 7.56 (d, J = 8.5 Hz, 1H), 7.49 – 7.42 (m, 
2H), 5.80 (d, J = 5.0 Hz, 1H), 5.09 (s, 1H), 4.78 (dd, J = 7.8, 2.2 Hz, 1H), 4.57 (dd, J = 7.8, 1.9 Hz, 
1H), 4.48 – 4.44 (m, 1H), 1.63 (s, 3H), 1.50 (s, 3H), 1.42 (s, 3H), 1.32 (s, 3H) ppm. 13C NMR (126 
MHz, CDCl3) δ 135.3, 133.3, 133.1, 128.2, 127.8, 127.7, 126.0, 125.8 (2C), 125.0, 109.4, 108.8, 
97.1, 74.0, 71.3, 70.9, 69.7, 26.4, 26.1, 25.1, 24.4 ppm. IR (neat, cm-1): 2988, 1381, 1372, 1253, 
1142, 1102, 963. HRMS (ES+) calcd for C21H24O5Na [M+Na]+ 379.1516, found 379.1520. 
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(2S,3R,4S,5R)-2,3,4,5-Tetramethoxy-6-(naphthalen-2-yl)tetrahydro-2H-pyran (7.3.9): 
Following General Procedure II using corresponding DHP (171.6 mg, 0.375 mmol, 1.5 equiv), 2-
bromonaphthalene (51.8 mg, 0.25 mmol, 1.0 equiv), 4-CzIPN (3.9 mg, 0.005 mmol, 2 mol %), 
NiBr2·dme (7.8 mg, 0.025 mmol, 10 mol %), dMeObpy (7.8 mg, 0.036 mmol, 14 mol %) in 
anhydrous acetone (5.0 mL, 0.05 M). The product was purified by flash chromatography on silica 
gel (hexanes/EtOAc 0 to 30%) to afford a colorless oil (56.8 mg, 68% yield).  dr = 4:1 based on 1H 
NMR of the crude reaction mixture. 1H NMR (500 MHz, CDCl3) δ 7.99 – 7.77 (m, 4H), 7.61 – 7.45 
(m, 3H), 4.96 (d, J = 3.6 Hz, 1H), 4.62 (d, J = 9.7 Hz, 1H), 3.66 (s, 3H), 3.65 (s, 1H), 3.60 (s, 3H), 
3.46 (s, 3H), 3.41 (dd, J = 9.6, 3.6 Hz, 1H), 3.20 (t, J = 9.3 Hz, 1H), 3.00 (s, 3H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 136.4, 133.5, 133.3, 128.3, 128.2, 127.8, 127.2, 126.3, 126.2, 125.2, 98.1, 
85.9, 83.4, 82.0, 73.1, 61.2, 60.6, 59.3, 55.5 ppm. (Only the signals corresponding to the major 
stereoisomer are reported). IR (neat, cm-1): 2930, 2831, 1444, 1158, 1126, 1094, 1067, 1048, 1030. 
HRMS (ES+) calcd for C19H24O5Na [M+Na]+ 355.1521, found 355.1526. 
 
 
4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-Tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d] 
pyran-5-yl)benzonitrile (2j): Following General Procedure I using corresponding DHP (216.7 
mg, 0.45 mmol, 1.5 equiv), 4-bromobenzonitrile (54.6 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 
mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 mg, 
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0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 10%) to afford a white solid (69.6 mg, 70% 
yield). mp = 89-91 ºC. dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (360 
MHz, CDCl3) δ 7.63 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.1 Hz, 2H), 5.70 (d, J = 5.0 Hz, 1H), 4.92 
(d, J = 1.3 Hz, 1H), 4.73 (dd, J = 7.8, 2.4 Hz, 1H), 4.45 – 4.40 (m, 2H), 1.56 (s, 3H), 1.42 (s, 3H), 
1.37 (s, 3H), 1.28 (s, 3H) ppm. 13C NMR (91 MHz, CDCl3) δ 143.3, 131.9 (2C), 127.7 (2C), 
119.0, 111.4 (2C), 109.7, 109.0, 96.9, 73.5, 71.1, 70.7, 69.1, 26.3, 26.0, 25.0, 24.3 ppm. IR (neat, 
cm-1): 2988, 2227, 1382, 1254, 1142, 1042, 974. HRMS (EI+) calcd for C17H18NO5 [M-CH3] 
316.1185, found 316.1195. 
 
 
4-((3aR,5R,6S,6aR)-6-(Benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl) 
benzonitrile (2k): Following General Procedure I using corresponding DHP (225.7 mg, 0.45 
mmol, 1.5 equiv), 4-bromobenzonitrile (54.6 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 0.006 
mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 mg, 0.021 
mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 10%) to afford a colorless oil (56.9 mg, 54% 
yield). dr = 9:1 based on 1H NMR of the crude reaction mixture. 1H NMR (360 MHz, CDCl3) δ 
7.61 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.5 Hz, 2H), 7.43 – 7.28 (m, 5H), 6.03 (d, J = 4.1 Hz, 1H), 
5.06 (d, J = 4.4 Hz, 1H), 4.75 (d, AB syst, J = 11.5 Hz, 1H), 4.74 (dd, J = 4.0, 0.7 Hz, 1H), 4.59 
(d, AB syst, J = 11.8 Hz, 1H), 4.05 (d, J = 4.4 Hz, 1H), 1.35 (s, 3H), 1.31 (s, 3H) ppm. 13C NMR 
(91 MHz, CDCl3) δ 145.2, 137.0, 132.2 (2C), 128.7 (2C), 128.3, 128.0 (2C), 126.4 (2C), 118.9, 
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113.9, 111.5, 105.7, 88.0, 85.4, 84.0, 72.4, 27.1, 26.8 ppm. IR (neat, cm-1): 2988, 2937, 2228, 
1609, 1455, 1383, 1308, 888. HRMS (ES+) calcd for C21H21NO4Na [M+Na]+ 374.1363, found 
374.1385. 
 
 
4-((3aR,5R,6S,6aR)-6-Methoxy-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl) 
benzonitrile (2l): Following General Procedure I using corresponding DHP (191.5 mg, 0.45 mmol, 
1.5 equiv), 4-bromobenzonitrile (54.6 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 0.006 mmol, 
2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 mg, 0.021 mmol, 7 mol 
%) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash chromatography on 
silica gel (hexanes/EtOAc 0 to 15%) to afford a colorless oil (49.5 mg, 60% yield). dr = 2:1 based 
on 1H NMR of the crude reaction mixture. 1H NMR (360 MHz, CDCl3, major diastereomer) δ 7.64 
(d, J = 8.4 Hz, 2H), 7.58 (d, J = 8.2 Hz, 2H), 5.99 (d, J = 4.1 Hz, 1H), 4.97 (d, J = 4.4 Hz, 1H), 
4.66 (dd, J = 4.1, 1.2 Hz, 1H), 3.85–3.82 (m, 1H), 3.48 (s, 3H), 1.35 (s, 3H), 1.32 (s, 3H) ppm. 1H 
NMR (360 MHz, CDCl3, minor diastereomer) δ 7.64 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.1 Hz, 2H), 
6.07 (d, J = 3.7 Hz, 1H), 5.28 (d, J = 3.1 Hz, 1H), 4.69 (d, J = 3.7 Hz, 1H), 3.84 (d, J = 3.2 Hz, 
1H), 3.10 (s, 3H), 1.56 (s, 3H), 1.38 (s, 3H) ppm. 13C NMR (91 MHz, CDCl3, major diastereomer) 
δ 141.4, 131.8 (2C), 127.7 (2C), 118.9, 111.9, 111.5, 105.0, 85.9, 82.3, 81.0, 58.3, 26.8, 26.2 ppm. 
IR (neat, cm-1): 2989, 2229, 1733, 1406, 1375, 1164 (major diastereomer), 2936, 2228, 1458, 1376, 
1286, 1223. HRMS (EI+) calcd for C14H14NO4 [M-CH3]+ 260.0923, found 260.0911. 
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(3aR,5R,5aS,8aS,8bR)-5-(3-Methoxyphenyl)-2,2,7,7-tetramethyltetrahydro-5H-bis 
([1,3]dioxolo) [4,5-b:4',5'-d]pyran (2m): Following General Procedure I using corresponding 
DHP (216.7 mg, 0.45 mmol, 1.5 equiv), 3-bromoanisole (44.3 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN 
(4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 
mg, 0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by 
flash chromatography on silica gel (hexanes/EtOAc 0 to 20%) to afford a colorless oil (74.5 mg, 
74% yield). dr = 9:1 based on 1H NMR of the crude reaction mixture. 1H NMR (360 MHz, CDCl3) 
δ 7.25 (t, J = 7.9 Hz, 1H), 7.03 – 6.94 (m, 2H), 6.82 (dd, J = 8.0, 2.3 Hz, 1H), 5.71 (d, J = 5.0 Hz, 
1H), 4.88 (d, J = 0.8 Hz, 1H), 4.72 (dd, J = 7.8, 2.3 Hz, 1H), 4.44 (dd, J = 7.8, 1.9 Hz, 1H), 4.40 
(dd, J = 5.0, 2.3 Hz, 1H), 3.81 (s, 3H), 1.57 (s, 3H), 1.47 (s, 3H), 1.38 (s, 3H), 1.31 (s, 3H) ppm. 
13C NMR (91 MHz, CDCl3) δ 159.5, 139.4, 129.1, 119.2, 113.3, 112.8, 109.4, 108.8, 97.1, 74.0, 
71.3, 70.9, 69.4, 55.3, 26.3, 26.1, 25.1, 24.4 ppm. IR (neat, cm-1): 2989, 1684, 1491, 1455, 1381, 
1287, 1252, 1102. HRMS (ES+) calcd for C18H24O6Na [M+Na]+ 359.1471, found 359.1476. 
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1-(4-((3aR,5S,6S,6aR)-6-(Benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-
yl)phenyl)-2,2,2-trifluoroethan-1-one (2n): Following General Procedure I using corresponding 
DHP (375.9 mg, 0.75 mmol, 1.5 equiv), 1-bromo-2-(trifluoromethyl)benzene (112.0 mg, 0.5 mmol, 
1.0 equiv), 4-CzIPN (7.8 mg, 0.01 mmol, 2 mol %), NiBr2·dme (7.7 mg, 0.025 mmol, 5 mol %), 
and dMeObpy (7.5 mg, 0.035 mmol, 7 mol %) in anhydrous acetone (5.0 mL, 0.1 M). The product 
was purified by flash chromatography on silica gel (hexanes/EtOAc 0 to 10%, 10 to 25%) to afford 
a semi solid (100.5 mg, 49% yield). dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H 
NMR (500 MHz, CDCl3) δ 7.42 (d, J = 8.3 Hz, 2H), 7.40 – 7.29 (m, 5H), 7.17 (d, J = 8.2 Hz, 2H), 
6.00 (d, J = 4.1 Hz, 1H), 5.00 (d, J = 4.8 Hz, 1H), 4.77 – 4.69 (m, 2H), 4.59 (d, J = 11.7 Hz, 1H), 
4.06 (d, J = 4.8 Hz, 1H), 1.36 (s, 6H) ppm. 13C NMR (126 MHz, CDCl3) δ 148.7, 138.4, 137.2, 
128.7, 128.2, 127.9, 127.4, 120.9, 114.0, 105.4, 100.1, 88.2, 85.8, 83.8, 72.3, 27.2, 27.0 ppm. IR 
(neat, cm-1): 2990, 1939, 1725, 1260, 1222, 1164. HRMS (EI+) calcd for C21H21F3O5 [M]+ 
410.1341, found 410.1367. 
 
 
4-(4-((3aR,5S,6S,6aR)-6-(Benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-
yl)phenyl)-4-oxobutanenitrile (2o): Following General Procedure I using corresponding DHP 
(225.6 mg, 0.45 mmol, 1.5 equiv), 2-bromo-1,4-dimethylbenzene (71.1 mg, 0.3 mmol, 1.0 equiv), 
4-CzIPN (4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and 
dMeObpy (4.5 mg, 0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product 
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was purified by flash chromatography on silica gel (hexanes/EtOAc 0 to 20%) to afford a clear oil 
(83.0 mg, 68% yield). dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 
MHz, CDCl3) δ 7.91 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.41 – 7.28 (m, 5H), 6.03 (s, 
1H), 5.08 (s, 1H), 4.74 (d, J = 11.8 Hz, 2H), 4.60 (d, J = 11.7 Hz, 1H), 4.09 (d, J = 15.6 Hz, 1H), 
3.36 (t, J = 7.3 Hz, 2H), 2.77 (t, J = 7.2 Hz, 2H), 1.35 (s, 3H), 1.33 (s, 3H) ppm. 13C NMR (126 
MHz, CDCl3) δ 195.0, 146.1, 137.1, 134.9, 128.7, 128.3, 128.2, 128.0, 126.2, 119.3, 113.9, 105.7, 
88.1, 85.5, 84.2, 72.3, 60.5, 53.9, 34.4, 29.4, 27.1, 26.8, 21.2, 14.3, 11.9 ppm. IR (neat, cm-1): 2937, 
1685, 1608, 1374, 1212, 1073. HRMS (EI+) calcd for C24H25NO5 [M]+ 407.1733, found 407.1714. 
 
4-((3aR,4R,6R,6aR)-6-(2,4-Dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,2-
dimethyltetrahydrofuro [3,4-d][1,3]dioxol-4-yl)benzonitrile (2p): Following General 
Procedure II using corresponding DHP (151.6 mg, 0.3 mmol, 1.0 equiv), 4-bromobenzonitrile 
(109.8 mg, 0.6 mmol, 2.0 equiv), 4-CzIPN (4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (9.3 mg, 
0.03 mmol, 10 mol %), and dMeObpy (9.1 mg, 0.042 mmol, 14 mol %) in anhydrous acetone 
(6.0 mL, 0.05 M). The product was purified by flash chromatography on silica gel 
(CH2Cl2/EtOAc 0 to 30%) to afford a white solid (50.1 mg, 47% yield). mp = 131-133 ºC. dr > 
20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (360 MHz, CDCl3) δ 9.54 (s, 1H), 
7.63 (d, J = 8.3 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 7.24 (s, 1H), 5.77 (d, J = 6.8 Hz, 1H), 5.67 (d, J 
= 1.4 Hz, 1H), 5.16 (dd, J = 6.4, 1.4 Hz, 1H), 5.00 (d, J = 5.5 Hz, 1H), 4.89 (t, J = 5.9 Hz, 1H), 
1.64 (s, 3H), 1.37 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 163.5, 150.0, 143.9, 143.2, 132.5 
(2C), 126.5 (2C), 118.8, 115.6, 112.1, 103.1, 95.0, 87.4, 85.7, 84.2, 27.5, 25.6 ppm. IR (neat, cm-
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1): 2989, 2228, 1632, 1612, 1421, 1156, 1018. HRMS (EI+) calcd for C17H14N3O5 [M-CH3]+ 
340.0933, found 340.0936. 
 
 
N-(4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-Tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran-5-yl)phenyl)acetamide (2q): Following General Procedure I using corresponding DHP 
(216.7 mg, 0.45 mmol, 1.5 equiv), N-acetyl-4-bromoaniline 2c (64.2 mg, 0.3 mmol, 1.0 equiv), 4-
CzIPN (4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy 
(4.5 mg, 0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified 
by flash chromatography on silica gel (hexanes/EtOAc 0 to 50%) to afford a white solid (44.6 mg, 
41% yield). mp = 204-206 ºC. dr = 9:1 based on 1H NMR of the crude reaction mixture. 1H NMR 
(360 MHz, CDCl3) δ 7.47 (d, J = 8.4 Hz, 2H), 7.41 (s, 1H), 7.34 (d, J = 8.4 Hz, 2H), 5.69 (d, J = 
5.0 Hz, 1H), 4.85 (s, 1H), 4.70 (dd, J = 7.8, 2.2 Hz, 1H), 4.43–4.34 (m, 2H), 2.12 (s, 3H), 1.56 (s, 
3H), 1.45 (s, 3H), 1.37 (s, 3H), 1.29 (s, 3H) ppm. 13C NMR (91 MHz, CDCl3) δ 168.4, 137.4, 133.7, 
127.7 (2C), 119.6 (2C), 109.4, 108.7, 97.0, 73.9, 71.2, 70.8, 69.2, 26.3, 26.1, 25.1, 24.7, 24.3 ppm. 
IR (neat, cm-1): 1667, 1604, 1535, 1411, 1381, 1142, 1040, 962. HRMS (ES+) calcd for 
C19H25NO6Na [M+Na]+ 386.1580, found 386.1583. 
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4,4,5,5-Tetramethyl-2-(4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-5H-bis 
([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)phenyl)-1,3,2-dioxaborolane (2r): Following General 
Procedure I using corresponding DHP (288.9 mg, 0.6 mmol, 2.0 equiv), (4-bromophenyl)-
pinacolborane (84.9 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 0.006 mmol, 2 mol %), 
NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 mg, 0.021 mmol, 7 mol %) in 
anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash chromatography on silica 
gel (hexanes/EtOAc 0 to 3%) to afford a white crystalline solid (75.4 mg, 58% yield). mp = 135-
137 °C. dr = 9:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 MHz, CDCl3) δ 
7.79 (d, J = 7.8 Hz, 2H), 7.40 (d, J = 7.8 Hz, 2H), 5.72 (d, J = 4.9 Hz, 1H), 4.91 (s, 1H), 4.71 (dd, 
J = 7.7, 1.9 Hz, 1H), 4.44 (dd, J = 7.8, 1.4 Hz, 1H), 4.39 (d, J = 2.4 Hz, 1H), 1.56 (s, 3H), 1.44 (s, 
3H), 1.37 (s, 3H), 1.33 (s, 12H), 1.27 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 141.0, 134.6 
(2C), 126.1 (2C), 111.2, 109.4, 108.7, 97.0, 83.8 (2C), 74.0, 71.2, 70.8, 69.6, 26.3, 26.0, 25.1, 25.0 
(4C), 24.4 ppm. 11B NMR (128.38 MHz, CDCl3) δ 30.7 (br,s). IR (neat, cm-1): 2980, 1399, 1358, 
1210, 1165, 1142, 1088, 1066. HRMS (ES+) calcd for (C23H33BO7Na, [M+Na]+) 454.2253, found 
454.2278. 
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(3aR,6S,6aR)-6-(Benzyloxy)-2,2-dimethyl-5-phenyltetrahydrofuro[2,3-d][1,3]dioxole (2s): 
Following General Procedure II using corresponding DHP (225.7 mg, 0.45 mmol, 1.5 equiv), 2-
bromobenzene (47.1 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 0.006 mmol, 2 mol %), 
NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 mg, 0.021 mmol, 7 mol %) in 
anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash chromatography on silica 
gel (hexanes/EtOAc 0 to 10%) to afford a colorless oil (29.7 mg, 30% yield). dr = 2.6:1 based on 
1H NMR of the crude reaction mixture. 1H NMR (500 MHz, CDCl3, major diastereomer) δ 7.42 
(d, J = 7.5 Hz, 2H), 7.38 – 7.27 (m, 8H), 6.00 (d, J = 4.1 Hz, 1H), 5.02 (d, J = 4.9 Hz, 1H), 4.74 
(d, J = 3.6 Hz, 1H), 4.70 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 11.7 Hz, 1H), 4.10 (d, J = 4.7 Hz, 1H), 
1.40 (s, 3H), 1.37 (s, 3H) ppm. 1H NMR (500 MHz, CDCl3, minor diastereoisomer) δ 7.44 – 7.31 
(m, 6H), 7.23 – 7.20 (m, 2H), 6.94 – 6.87 (m, 2H), 6.12 (d, J = 3.9 Hz, 1H), 5.28 (d, J = 3.0 Hz, 
1H), 4.71 (d, J = 3.7 Hz, 1H), 4.25 (d, J = 11.9 Hz, 1H), 4.08 (d, J = 12.0 Hz, 1H), 3.98 (d, J = 
3.1 Hz, 1H), 1.56 (s, 3H), 1.37 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3, major diastereomer) δ 
139.6, 137.4, 128.6 (2C), 128.4 (2C), 128.1, 127.9 (2C), 127.7, 126.0 (2C), 113.9, 105.3, 88.4, 
86.0, 84.4, 72.3, 27.3, 27.1 ppm. 13C NMR (126 MHz, CDCl3, minor diastereomer) δ 137.43, 
135.75, 128.4 (2C), 128.1 (2C), 127.8, 127.8, 127.7 (2C), 127.3 (2C), 111.7, 105.1, 83.6 (2C), 
81.9, 72.4, 27.0, 26.4 ppm. IR (neat, cm-1): 2930, 1724, 1498, 1455, 1374, 1071, 1020 (major 
diastereomer), 2981, 2923, 2854, 1724, 1454, 1075 (minor diastereomer). HRMS (EI+) calcd for 
C19H19O4 [M-CH3] 311.1283, found 311.1305. 
 
(3aR,5S,6S,6aR)-6-(Benzyloxy)-5-(2,5-dimethylphenyl)-2,2-dimethyltetrahydrofuro[2,3-d] 
[1,3] dioxole (2t): Following General Procedure I using corresponding DHP (225.6 mg, 0.45 
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mmol, 1.5 equiv), 2-bromo-1,4-dimethylbenzene (54.6 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 
mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 mg, 
0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 20%) to afford a clear oil (46.8 mg, 44% 
yield). dr = 7.3:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 MHz, CDCl3) δ 
7.41 (s, 1H), 7.32 (dt, J = 14.2, 7.3 Hz, 5H), 7.01 (t, J = 8.3 Hz, 2H), 6.00 (d, J = 4.2 Hz, 1H), 
5.20 (d, J = 4.9 Hz, 1H), 4.74 (d, J = 4.1 Hz, 1H), 4.68 (d, J = 11.6 Hz, 1H), 4.51 (d, J = 11.5 Hz, 
1H), 4.08 (d, J = 4.9 Hz, 1H), 2.30 (s, 3H), 2.26 (s, 3H), 1.57 (s, 3H), 1.40 (s, 3H) ppm. 13C NMR 
(126 MHz, CDCl3) δ 137.4, 137.2, 135.4, 132.4, 130.4, 128.6, 128.4, 128.1, 127.9, 126.9, 113.9, 
105.5, 88.2, 85.6, 83.4, 72.3, 27.3, 27.0, 21.3, 19.1 ppm. IR (neat, cm-1): 3581, 2941, 1455, 1214, 
1074, 864. HRMS (EI+) calcd for C22H26O4 [M]+ 354.1831, found 354.1856. 
 
 
3-Chloro-5-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-
b:4',5'-d]pyran-5-yl)pyridine (2u): Following General Procedure I using corresponding DHP 
(216.7 mg, 0.45 mmol, 1.5 equiv), 3-bromo-5-chloropyridine (57.7 mg, 0.3 mmol, 1.0 equiv), 4-
CzIPN (4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy 
(4.5 mg, 0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified 
by flash chromatography on silica gel (hexanes/EtOAc 0 to 30%) to afford a colorless foam (45.1 
mg, 44% yield). dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (360 MHz, 
CDCl3) δ 8.47 (d, J = 7.0 Hz, 2H), 7.75 (t, J = 1.7 Hz, 1H), 5.68 (d, J = 5.0 Hz, 1H), 4.90 (d, J = 
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1.3 Hz, 1H), 4.73 (dd, J = 7.8, 2.4 Hz, 1H), 4.43–4.36 (m, 2H), 1.57 (s, 3H), 1.45 (s, 3H), 1.37 (s, 
3H), 1.29 (s, 3H) ppm. 13C NMR (91 MHz, CDCl3) δ 147.9, 146.2, 135.1, 135.0, 129.8, 109.8, 
109.1, 96.9, 73.3, 71.1, 70.7, 67.4, 26.3, 26.0, 25.0, 24.3 ppm. IR (neat, cm-1): 2980, 2929, 1424, 
1382, 1372, 1142, 1024, 1000. HRMS (ES+) calcd for C16H21ClNO5 [M+H]+ 342.1108, found 
342.1093. 
 
 
 
5-((3aR,5S,6S,6aR)-6-(Benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl) 
picolinonitrile (2v): Following General Procedure I using corresponding DHP (225.6 mg, 0.45 
mmol, 1.5 equiv), 5-bromopicolinonitrile (54.6 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 
0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 mg, 0.021 
mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 20%) to afford a clear oil (73.9 mg, 70% 
yield). dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 MHz, CDCl3) δ 
8.71 – 8.68 (m, 1H), 7.84 (ddd, J = 8.1, 2.2, 1.0 Hz, 1H), 7.66 – 7.60 (m, 1H), 7.36 (q, J = 7.3, 6.6 
Hz, 5H), 6.04 (d, J = 4.1 Hz, 1H), 5.10 (d, J = 4.2 Hz, 1H), 4.78 – 4.74 (m, 2H), 4.59 (d, J = 11.8 
Hz, 1H), 4.07 (dd, J = 4.3, 1.3 Hz, 1H), 1.34 (s, 3H), 1.27 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
148.9, 139.5, 136.7, 134.3, 133.0, 128.9, 128.5, 128.1, 128.0, 117.3, 114.0, 106.6, 105.9, 87.5, 
85.2, 82.3, 72.5, 61.6, 27.5, 27.0, 26.6, 25.0, 14.4 ppm. IR (neat, cm-1): 2987, 2938, 1720, 1455, 
1374, 1212, 1075. HRMS (EI+) calcd for C20H20N2O4 [M]+ 352.1423, found 352.1450. 
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2-(4-((3aR,5S,6S,6aR)-6-(Benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-
yl)phenyl) -1,3,4-oxadiazole (2w): Following General Procedure II using the corresponding 
DHP (225.7 mg, 0.45 mmol, 1.5 equiv), aryl bromide 2e (66.9 mg, 0.3 mmol, 1.0 equiv), 4-
CzIPN (4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and 
dMeObpy (4.5 mg, 0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product 
was purified by flash chromatography on silica gel (hexanes/EtOAc 0 to 10%) to afford a 
colorless oil (29.7 mg, 30% yield). dr = 2.6:1 based on 1H NMR of the crude reaction mixture. 1H 
NMR (500 MHz, CDCl3, major diastereomer) δ 7.42 (d, J = 7.5 Hz, 2H), 7.38 – 7.27 (m, 8H), 
6.00 (d, J = 4.1 Hz, 1H), 5.02 (d, J = 4.9 Hz, 1H), 4.74 (d, J = 3.6 Hz, 1H), 4.70 (d, J = 11.6 Hz, 
1H), 4.59 (d, J = 11.7 Hz, 1H), 4.10 (d, J = 4.7 Hz, 1H), 1.40 (s, 3H), 1.37 (s, 3H) ppm. 1H NMR 
(500 MHz, CDCl3, minor diastereoisomer) δ 7.44 – 7.31 (m, 6H), 7.23 – 7.20 (m, 2H), 6.94 – 
6.87 (m, 2H), 6.12 (d, J = 3.9 Hz, 1H), 5.28 (d, J = 3.0 Hz, 1H), 4.71 (d, J = 3.7 Hz, 1H), 4.25 (d, 
J = 11.9 Hz, 1H), 4.08 (d, J = 12.0 Hz, 1H), 3.98 (d, J = 3.1 Hz, 1H). 
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1-(5-((3aR,5R,6R,6aR)-6-(Benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl) 
thiophen-2-yl)ethan-1-one (2x): Following General Procedure I using corresponding DHP (225.6 
mg, 0.45 mmol, 1.5 equiv), 1-(5-bromothiophen-2-yl)ethan-1-one (61.1 mg, 0.3 mmol, 1.0 equiv), 
4-CzIPN (4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and 
dMeObpy (4.5 mg, 0.021 mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product 
was purified by flash chromatography on silica gel (hexanes/EtOAc 0 to 20%) to afford a yellow 
oil (87.5 mg, 78% yield). dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 
MHz, CDCl3) δ 7.55 (d, J = 3.8 Hz, 1H), 7.34 (m, 5H), 7.03 (d, J = 3.8 Hz, 1H), 5.99 (d, J = 4.0 
Hz, 1H), 5.19 (d, J = 4.1 Hz, 1H), 4.75 – 4.68 (m, 2H), 4.61 (d, J = 11.6 Hz, 1H), 4.18 (d, J = 4.1 
Hz, 1H), 2.53 (s, 3H), 1.35 (s, 6H) ppm. 13C NMR (126 MHz, CDCl3) δ 190.8, 152.2, 143.6, 136.9, 
132.4, 128.8, 128.3, 128.0, 125.6, 114.2, 106.6, 105.8, 88.2, 85.6, 81.5, 72.6, 29.9, 27.1, 26.9, 26.9 
ppm. IR (neat, cm-1): 2987, 2937, 1722, 1663, 1251, 1214, 1073, 855. HRMS (EI+) calcd for 
C20H22O5S [M]+ 374.1188, found 374.1203. 
 
 
(3aR,5S,5aR,8aS,8bR)-5-(Benzo[b]thiophen-2-yl)-2,2,7,7-tetramethyltetrahydro-5H-bis 
([1,3]dioxolo)[4,5-b:4',5'-d]pyran (2y): Following General Procedure II using corresponding 
DHP (216.7 mg, 0.45 mmol, 1.5 equiv), aryl bromide 2e (66.9 mg, 0.3 mmol, 1.0 equiv), 4-
CzIPN (4.7 mg, 0.006 mmol, 2 mol %), NiBr2·dme (9.2 mg, 0.03 mmol, 10 mol %), and 
dMeObpy (9.1 mg, 0.042 mmol, 14 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product 
was purified by flash chromatography on silica gel (hexanes/EtOAc 0 to 20%) to afford a clear oil 
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(76.1 mg, 70% yield). dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 
MHz, CDCl3) δ 8.46 (s, 1H), 8.15 – 8.02 (m, 2H), 7.57 (d, J = 8.3 Hz, 2H), 5.29 (d, J = 2.3 Hz, 
1H), 5.16 (s, 1H), 4.87 (dd, J = 6.0, 2.2 Hz, 1H), 4.68 (d, J = 5.9 Hz, 1H), 3.40 (s, 3H), 1.59 (s, 
3H), 1.37 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 164.8, 152.8, 145.1, 127.4, 127.2, 123.0, 113.4, 
110.4, 88.8, 86.0, 85.9, 55.9, 27.1, 25.5. IR (neat, cm-1): 2988, 2937, 1719, 1617, 1558, 1516, 
1498, 1458, 1374, 1211, 1104. HRMS (EI+) calcd for C15H15N2O5 [M-CH3]+ 303.0981, found 
303.0957.  
 
 
tert-Butyl(((3aR,5R,6R,6aR)-2,2-dimethyl-5-(5-methylthiophen-2-yl)tetrahydrofuro[2,3-
d][1,3] dioxol-6-yl)oxy)dimethylsilane (2z): Following General Procedure I using using 
corresponding DHP (262.9 mg, 0.5 mmol, 2.0 equiv), 2-bromo-5-methylthiophene (44.3 mg 0.25 
mmol, 1.0 equiv), 4-CzIPN (3.9 mg, 0.005 mmol, 2 mol %), NiBr2·dme (3.9 mg, 0.00125 mmol, 5 
mol %), and dMeObpy (3.8 mg, 0.0175 mmol, 7 mol %) in anhydrous acetone (5.0 mL, 0.05 M). 
The product was purified by flash chromatography on silica gel (hexanes/EtOAc 0 to 10%) to afford 
a colorless foam (42.8 mg, 46% yield). dr = 1.8:1 based on 1H NMR of the crude reaction mixture. 
1H NMR (500 MHz, CDCl3) δ 6.80 (d, J = 3.3 Hz, 1H), 6.63 – 6.52 (m, 1H), 5.91 (d, J = 4.0 Hz, 
1H), 4.91 (d, J = 4.4 Hz, 1H), 4.51 (dd, J = 4.1, 1.5 Hz, 1H), 4.34 (dd, J = 4.4, 1.4 Hz, 1H), 2.45 
(s, 3H), 1.42 (s, 3H), 1.35 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.01 (s, 3H) ppm. 13C NMR (126 
MHz, CDCl3) δ 140.1, 140.0, 125.3, 124.6, 113.8, 105.1, 88.4, 84.1, 82.5, 27.3, 27.2, 25.8 (3C), 
18.1, 15.5, 0.1, -4.8 ppm. (Only the signals corresponding to the major stereoisomer are reported). 
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IR (neat, cm-1): 2929, 2857, 1471, 1382, 1373, 1254, 1213, 1119, 1017, 837. HRMS (ES+) calcd 
for C12H16O4S [M-TBS]+ 256.0769, found 256.0764. 
 
 
 
(8R,9S,13S,14S)-13-Methyl-3-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-5H-bis 
([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta 
[a]phenanthren-17-one (3a): Following General Procedure II using corresponding DHP (216.7 
mg, 0.45 mmol, 1.5 equiv), estrone derivative2 (57.7 mg, 0.3 mmol, 1.0 equiv), 4-CzIPN (4.7 mg, 
0.006 mmol, 2 mol %), NiBr2·dme (4.6 mg, 0.015 mmol, 5 mol %), and dMeObpy (4.5 mg, 0.021 
mmol, 7 mol %) in anhydrous acetone (6.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 20%) to afford a slightly yellow solid (60.8 
mg, 42% yield). mp = 70-72 ºC. dr = 8:1 based on 1H NMR of the crude reaction mixture. 1H 
NMR (360 MHz, CDCl3) δ 7.28 (d, J = 8.2 Hz, 1H), 7.20 (d, J = 8.2 Hz, 1H), 7.12 (s, 1H), 5.70 
(d, J = 5.0 Hz, 1H), 4.84 (s, 1H), 4.71 (dd, J = 7.9, 2.3 Hz, 1H), 4.44 (dd, J = 7.9, 1.8 Hz, 1H), 
4.39 (dd, J = 5.0, 2.3 Hz, 1H), 2.93 (dd, J = 8.7, 3.9 Hz, 2H), 2.56 – 2.37 (m, 2H), 2.34 – 2.24 (m, 
1H), 2.19 – 1.92 (m, 4H), 1.68 – 1.58 (m, 2H), 1.57 – 1.41 (m, 10H), 1.37 (s, 3H), 1.31 (s, 3H), 
0.90 (s, 3H) ppm. 13C NMR (91 MHz, CDCl3) δ 190.9, 139.0, 136.2, 135.3, 127.5, 125.2, 124.4, 
109.4, 108.7, 97.1, 72.9, 71.3, 70.9, 69.3, 50.7, 48.1, 44.5, 38.2, 36.0, 31.8, 29.6, 26.7, 26.3, 26.1, 
                                                      
2 Prepared following the littérature porcedure from the corresponding triflate: Pan, J.; 
Wang, X.; Zhang, Y.; Buchwald, S. L. Org. Lett. 2011, 13, 4974. 
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25.8, 25.1, 24.4, 21.7, 14.0 ppm. IR (neat, cm-1): 2987, 2931, 1736, 1380, 1372, 1209, 1100, 
1066, 997. HRMS (EI+) calcd for C29H38O6 [M]+ 482.2668, found 482.2667. 
 
 
Methyl 2-(2,3-Dioxo-9-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-5H-bis ([1,3] 
dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-2,3,6,7-tetrahydro-1H,5H-pyrido[1,2,3-de]quinoxalin-5-
yl) acetate (3b): Following General Procedure II using corresponding DHP (72.2 mg, 0.15 mmol, 
1.5 equiv), the heteroaryl bromide (35.3 mg, 0.1 mmol, 1.0 equiv), 4-CzIPN (1.5 mg, 0.002 mmol, 
2 mol %), NiBr2·dme (3.1 mg, 0.01 mmol, 10 mol %), and dMeObpy (3.0 mg, 0.014 mmol, 14 mol 
%) in anhydrous acetone (2.0 mL, 0.05 M). The product was purified by flash chromatography on 
silica gel (hexane/EtOAc/MeOH 6/3/1) to afford a white solid (26.7 mg, 53% yield). mp = 93-
95 ºC. dr = 9:1 based on 1H NMR of the crude reaction mixture. 1H NMR (360 MHz, CDCl3) 
mixture of rotamers: δ 11.50 (br s, 1H), 7.18 – 7.07 (m, 2H), 5.69 (dd, J = 4.8, 3.3 Hz, 1H), 5.44 – 
5.31 (m, 1H), 4.92 (s, 1H), 4.74 (td, J = 7.6, 2.2 Hz, 1H), 4.57 (dd, J = 7.9, 1.7 Hz, 0.5H, rot.1), 
4.48 (dd, J = 7.9, 1.7 Hz, 0.5H, rot.2), 4.41 – 4.35 (m, 1H), 3.70 (br s, 3H), 3.06 – 2.90 (m, 1H), 
2.89 – 2.69 (m, 2H), 2.58 – 2.47 (m, 1H), 2.28 (br s, 1H), 2.04 – 1.83 (m, 1H), 1.57 (s, 1.5H, rot.1), 
1.56 (s, 1.5H, rot.2), 1.50 (s, 1.5H, rot.1), 1.46 (s, 1.5H, rot.2), 1.36 (s, 3H), 1.32 (s, 1.5H, rot.1), 
1.29 (s, 1.5H, rot.2) ppm. 13C NMR (91 MHz, CDCl3) mixture of rotamers: δ 170.6, 155.5/155.0 
(rot.1/rot.2), 154.2, 134.4, 124.6/124.5 (rot.1/rot.2), 124.4, 123.4/123.2 (rot.1/rot.2), 122.1/121.9 
(rot.1/rot.2), 112.9/112.8 (rot.1/rot.2), 109.6/109.5 (rot.1/rot.2), 109.0, 96.9, 73.9, 71.1, 70.8, 
68.6/68.5 (rot.1/rot.2), 52.1, 48.0/47.9 (rot.1/rot.2), 35.3, 26.4, 26.1, 25.0, 24.3, 23.3, 22.0/21.8 
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(rot.1/rot.2) ppm. IR (neat, cm-1): 2980, 2901, 1696, 1674, 1326, 1256, 1165, 1101, 1064. HRMS 
(ES+) calcd for C25H31N2O9 [M+H]+ 503.2030, found 503.2046. 
 
 
tert-Butyl ((R,Z)-1,4-Dimethyl-6-oxo-4-(4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyl 
tetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)thiophen-2-yl) tetrahydro 
pyrimidin-2(1H)-ylidene)carbamate (3c): Following General Procedure II using corresponding 
DHP (72.2 mg, 0.15 mmol, 1.5 equiv), the heteroaryl bromide (35.3 mg, 0.1 mmol, 1.0 equiv), 4-
CzIPN (1.5 mg, 0.002 mmol, 2 mol %), NiBr2·dme (3.1 mg, 0.01 mmol, 10 mol %), and dMeObpy 
(3.0 mg, 0.014 mmol, 14 mol %) in anhydrous acetone (2.0 mL, 0.05 M). The product was purified 
by flash chromatography on silica gel (hexane/EtOAc/acetone 85:10:5) to afford a yellow oil (51.8 
mg, 94% yield). dr = 4:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 MHz, 
CDCl3) δ 10.28 (br s, 1H), 7.20 (s, 1H), 6.97 (d, J = 1.2 Hz, 1H), 5.61 (d, J = 5.0 Hz, 1H), 4.82 (s, 
1H), 4.66 (dd, J = 7.8, 2.3 Hz, 1H), 4.36 – 4.30 (m, 2H), 3.25 (s, 3H), 3.12 (d, J = 16.2 Hz, 1H), 
2.88 (d, J = 16.2 Hz, 1H), 1.74 (s, 3H), 1.55 (s, 3H), 1.51 (s, 9H), 1.47 (s, 3H), 1.35 (s, 3H), 1.31 
(s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 167.5, 163.9, 157.6, 147.4, 138.6, 124.3, 122.7, 109.5, 
108.8, 96.9, 80.0, 73.3, 71.1, 70.7, 66.7, 53.3, 45.9, 30.0, 28.6, 28.3 (3C), 26.4, 26.1, 25.0, 24.5 
ppm. IR (neat, cm-1): 2989, 1713, 1640, 1597, 1269, 1251, 1157, 1066, 997. HRMS (ES+) calcd 
for C26H38N3O8S [M+H]+ 552.2380, found 552.239 
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Ethyl 4-(3-((3aR,5S,6S,6aR)-6-(Benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-
yl)-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-
carboxylate (3d): Following General Procedure I using corresponding DHP (225.6 mg, 0.45 
mmol, 3.0 equiv), ethyl 4-(3-bromo-8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-
b]pyridin-11-ylidene)piperidine-1-carboxylate (69.0 mg, 0.15 mmol, 1.0 equiv), 4-CzIPN (2.3 mg, 
0.006 mmol, 2 mol %), NiBr2·dme (2.3 mg, 0.015 mmol, 5 mol %), and dMeObpy (2.3 mg, 0.021 
mmol, 7 mol %) in anhydrous acetone (3.0 mL, 0.05 M). The product was purified by flash 
chromatography on silica gel (hexanes/EtOAc 0 to 60%) to afford a light yellow oil (78.5 mg, 83% 
yield). dr > 20:1 based on 1H NMR of the crude reaction mixture. 1H NMR (500 MHz, CDCl3, 
major diastereomer) δ 8.42 (s, 1H), 7.52 – 7.41 (m, 1H), 7.32 – 7.27 (m, 5H), 7.19 – 7.10 (m, 3H), 
5.98 (d, J = 4.1 Hz, 1H), 4.96 (dd, J = 9.4, 4.7 Hz, 1H), 4.75 – 4.67 (m, 2H), 4.58 – 4.53 (m, 1H), 
4.14 (q, J = 7.2 Hz, 2H), 4.04 (dd, J = 17.3, 4.8 Hz, 1H), 3.79 (d, J = 14.9 Hz, 2H), 3.41 – 3.28 (m, 
2H), 3.12 (ddt, J = 14.3, 10.0, 5.2 Hz, 2H), 2.79 (dddd, J = 15.1, 11.1, 8.2, 3.9 Hz, 2H), 2.48 (t, J 
= 13.1 Hz, 1H), 2.40 – 2.25 (m, 3H), 1.35 (s, 6H), 1.26 (d, J = 7.1 Hz, 3H) ppm. 13C NMR (126 
MHz, CDCl3, mixture of rotamers) δ 155.6, 139.6, 138.9, 138.7, 137.8, 137.7, 137.0 (2C), 133.2, 
130.7, 130.6, 129.1 (2C), 128.8 (2C), 128.7 (2C), 128.6 (2C), 128.4, (2C), 128.3 (2C), 128.2 (2C), 
128.1, 128.1, 128.0, 127.7 (2C), 127.6, 126.4, 114.1, 114.0, 111.9, 105.5, 105.3, 87.7, 87.5, 85.7, 
85.6, 82.4 (2C), 82.0 (2C), 75.7, 73.6, 72.9, 72.4 (2C), 72.2, 71.5, 61.6, 61.5, 44.9, 44.8, 31.7 (3C), 
30.9, 30.7, 29.9, 27.3 (2C), 26.9, 26.5, 14.8, 14.4, 14.3, 0.2. IR (neat, cm-1): 2931, 1696, 1445, 
O
O
O
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 706 
1383, 1229, 1074, 769, 699. HRMS (ES+) calcd for C36H40ClN2O6 [M+H]+ 631.2575, found 
631.2589. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 707 
1H NMR (CDCl3, 500 MHz) of (3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-dimethyl-5-(naphthalen-
2-yl)tetrahydrofuro[2,3-d] [1,3]dioxole (7.3.1) 
 
  
 708 
13C NMR (126 MHz, CDCl3) of (3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-dimethyl-5-(naphthalen-
2-yl)tetrahydrofuro[2,3-d] [1,3]dioxole (7.3.1) 
 
 
  
 709 
1H NMR (CDCl3, 500 MHz) of (3aR,5R,6S,6aR)-6-methoxy-2,2-dimethyl-5-(naphthalen-2-
yl)tetrahydrofuro[2,3-d] [1,3]dioxole (7.3.2) 
 
 
 
  
 710 
13C NMR (126 MHz, CDCl3) of (3aR,5R,6S,6aR)-6-methoxy-2,2-dimethyl-5-(naphthalen-2-
yl)tetrahydrofuro[2,3-d] [1,3]dioxole (7.3.3) 
 
 
 
  
 711 
1H NMR (CDCl3, 500 MHz) of (3aR,6S,6aS)-6-Fluoro-2,2-dimethyl-5-(naphthalen-2-yl) 
tetrahydrofuro[2,3-d][1,3]dioxole (7.3.3) 
 
 
 712 
13C NMR (126 MHz, CDCl3) of (3aR,6S,6aS)-6-Fluoro-2,2-dimethyl-5-(naphthalen-2-yl) 
tetrahydrofuro[2,3-d][1,3]dioxole (7.3.3) 
 
 
 713 
19F NMR (471 MHz, CDCl3) of (3aR,6S,6aS)-6-Fluoro-2,2-dimethyl-5-(naphthalen-2-yl) 
tetrahydrofuro[2,3-d][1,3]dioxole (7.3.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 714 
1H NMR (CDCl3, 500 MHz) of tert-Butyl(((3aR,6S,6aR)-2,2-dimethyl-5-(naphthalen-2-
yl)tetrahydrofuro[2,3-d][1,3]dioxol-6-yl)oxy)dimethylsilane (7.3.4) 
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 715 
13C NMR (126 MHz, CDCl3) of tert-Butyl(((3aR,6S,6aR)-2,2-dimethyl-5-(naphthalen-2-
yl)tetrahydrofuro[2,3-d][1,3]dioxol-6-yl)oxy)dimethylsilane (7.3.4) 
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 716 
1H NMR (CDCl3, 500 MHz) of (3aR,6S,6aR)-2,2-dimethyl-5-(naphthalen-2-
yl)tetrahydrofuro[2,3-d][1,3]dioxol-6-ol (7.3.5) 
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 717 
13C NMR (CDCl3, 126 MHz) of (3aR,6S,6aR)-2,2-dimethyl-5-(naphthalen-2-
yl)tetrahydrofuro[2,3-d][1,3]dioxol-6-ol (7.3.5) 
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 718 
1H NMR (CDCl3, 500 MHz) of (3aR,4R,6R,6aR)-4-Methoxy-2,2-dimethyl-6-(naphthalen-2-
yl)tetrahydrofuro[3,4-d][1,3]dioxole (7.3.6) 
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 719 
13C NMR (126 MHz, CDCl3) of (3aR,4R,6R,6aR)-4-Methoxy-2,2-dimethyl-6-(naphthalen-2-
yl)tetrahydrofuro[3,4-d][1,3]dioxole (7.3.6) 
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 720 
1H NMR (CDCl3, 500 MHz) of 1-((3aR,4R,6R,6aR)-2,2-dimethyl-6-(naphthalen-2-yl) 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl) pyrimidine-2,4(1H,3H)-dione (7.3.7) 
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 721 
13C NMR (126 MHz, CDCl3) of 1-((3aR,4R,6R,6aR)-2,2-dimethyl-6-(naphthalen-2-yl) 
tetrahydrofuro[3,4-d][1,3]dioxol-4-yl) pyrimidine-2,4(1H,3H)-dione (7.3.7) 
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 722 
1H NMR (CDCl3, 500 MHz) of (3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyl-5-(naphthalen-2-
yl)tetrahydro-5H-bis ([1,3]dioxolo)[4,5-b:4',5'-d]pyran (7.3.8) 
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 723 
13C NMR (126 MHz, CDCl3) of (3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyl-5-(naphthalen-2-
yl)tetrahydro-5H-bis ([1,3]dioxolo)[4,5-b:4',5'-d]pyran (7.3.8) 
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 724 
1H NMR (CDCl3, 500 MHz) of (2S,3R,4S,5R)-2,3,4,5-tetramethoxy-6-(naphthalen-2-
yl)tetrahydro-2H-pyran (7.3.9) 
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 725 
13C NMR (CDCl3, 126 MHz) of (2S,3R,4S,5R)-2,3,4,5-tetramethoxy-6-(naphthalen-2-
yl)tetrahydro-2H-pyran (7.3.9) 
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 726 
1H NMR (CDCl3, 360 MHz) of 4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-5H-
bis([1,3]dioxolo)[4,5-b:4',5'-d] pyran-5-yl)benzonitrile (7.4.1) 
 
 
  
 727 
13C NMR (CDCl3, 91 MHz) of of 4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-
5H-bis([1,3]dioxolo)[4,5-b:4',5'-d] pyran-5-yl)benzonitrile (7.4.1) 
 
  
 728 
1H NMR (CDCl3, 360 MHz) of 
4-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro [2,3-d] 
[1,3]dioxol-5-yl)benzonitrile (7.4.2) 
 
 
  
 729 
13C NMR (CDCl3, 91 MHz) of 
4-((3aR,5R,6S,6aR)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro [2,3-d] 
[1,3]dioxol-5-yl)benzonitrile (7.4.2) 
 
 
  
 730 
1H NMR (CDCl3, 360 MHz) of 4-((3aR,5R,6S,6aR)-6-methoxy-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl) benzonitrile (7.4.3) 
 
 
  
 731 
13C NMR (CDCl3, 91 MHz) of 4-((3aR,5R,6S,6aR)-6-methoxy-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl) benzonitrile (7.4.3) 
 
  
 732 
1H NMR (CDCl3, 360 MHz) of (3aR,5R,5aS,8aS,8bR)-5-(3-methoxyphenyl)-2,2,7,7-
tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran (7.4.4) 
 
 
  
 733 
13C NMR (CDCl3, 91 MHz) of (3aR,5R,5aS,8aS,8bR)-5-(3-methoxyphenyl)-2,2,7,7-
tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran (7.4.4) 
 
 
 
  
 734 
1H NMR (CDCl3, 500 MHz) of 1-(4-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl)phenyl)-2,2,2-trifluoroethan-1-one (7.4.5) 
 
  
 735 
13C NMR (CDCl3, 126 MHz) of 1-(4-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl)phenyl)-2,2,2-trifluoroethan-1-one (7.4.5) 
 
 
  
 736 
1H NMR (CDCl3, 500 MHz) of 4-(4-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl)phenyl)-4-oxobutanenitrile (7.4.6) 
 
 
 
  
 737 
13C NMR (CDCl3, 126 MHz) of 4-(4-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl)phenyl)-4-oxobutanenitrile (7.4.6) 
 
 
  
 738 
1H NMR (CDCl3, 360 MHz) of 4-((3aR,4R,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)benzonitrile (7.4.7) 
 
  
 739 
13C NMR (CDCl3, 126 MHz) of 4-((3aR,4R,6R,6aR)-6-(2,4-dioxo-3,4-dihydropyrimidin-
1(2H)-yl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)benzonitrile (7.4.7) 
 
 
 
  
 740 
1H NMR (CDCl3, 360 MHz) of N-(4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-
5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)phenyl)acetamide (7.4.8) 
 
 
  
 741 
13C NMR (CDCl3, 91 MHz) of N-(4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-tetramethyltetrahydro-
5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)phenyl)acetamide (7.4.8) 
 
  
 742 
1H NMR (CDCl3, 360 MHz) of 4,4,5,5-tetramethyl-2-(4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis ([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)phenyl)-1,3,2-
dioxaborolane (7.4.9) 
 
  
 743 
13C NMR (CDCl3, 91 MHz) of 4,4,5,5-tetramethyl-2-(4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis ([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)phenyl)-1,3,2-
dioxaborolane (7.4.9) 
 
 
  
 744 
11B NMR (CDCl3, 128.38 MHz) of 4,4,5,5-tetramethyl-2-(4-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis ([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)phenyl)-1,3,2-
dioxaborolane (7.4.9) 
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 745 
1H NMR (CDCl3, 500 MHz) of tert-b 1H NMR (CDCl3, 500 MHz) of (3aR,6S,6aR)-6-
(Benzyloxy)-2,2-dimethyl-5-phenyltetrahydrofuro [2,3-d][1,3]dioxole (7.4.10) 
 
 
 746 
13C NMR (CDCl3, 126 MHz) of (3aR,6S,6aR)-6-(Benzyloxy)-2,2-dimethyl-5-
phenyltetrahydrofuro [2,3-d][1,3]dioxole (7.4.10) 
 
 
 747 
1H NMR (CDCl3, 500 MHz) of (3aR,5S,6S,6aR)-6-(benzyloxy)-5-(2,5-dimethylphenyl)-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxole (7.4.11) 
 
 
  
 748 
13C NMR (CDCl3, 126 MHz) of (3aR,5S,6S,6aR)-6-(benzyloxy)-5-(2,5-dimethylphenyl)-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxole (7.4.11) 
 
  
 749 
1H NMR (CDCl3, 360 MHz) of 3-chloro-5-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)pyridine (7.4.12) 
 
 
 
 750 
13C NMR (CDCl3, 91 MHz) of 3-chloro-5-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)pyridine (7.4.12) 
 
  
 751 
1H NMR (CDCl3, 500 MHz) of 5-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl) picolinonitrile (7.4.13) 
 
  
 752 
13C NMR (CDCl3, 126 MHz) of 5-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl) picolinonitrile (7.4.13) 
 
  
 753 
1H NMR (CDCl3, 500 MHz) of 2-(4-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl)phenyl) -1,3,4-oxadiazole (7.4.14) 
 
 
  
 754 
13C NMR (CDCl3, 126 MHz) of 2-(4-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl)phenyl) -1,3,4-oxadiazole (7.4.14) 
 
  
 755 
1H NMR (CDCl3, 500 MHz) of 1-(5-((3aR,5R,6R,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl) thiophen-2-yl)ethan-1-one (7.4.15) 
 
  
 756 
13C NMR (CDCl3, 126 MHz) of 1-(5-((3aR,5R,6R,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro [2,3-d][1,3]dioxol-5-yl) thiophen-2-yl)ethan-1-one (7.4.15) 
 
  
 757 
1H NMR (CDCl3, 500 MHz) of 2-(4-((3aR,4S,6R,6aR)-6-methoxy-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)phenyl)-1,3,4-oxadiazole (7.4.16) 
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 758 
13C NMR (CDCl3, 126 MHz) of 2-(4-((3aR,4S,6R,6aR)-6-methoxy-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)phenyl)-1,3,4-oxadiazole (7.4.16) 
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 759 
utyl(((3aR,5R,6R,6aR)-2,2-dimethyl-5-(5-methylthiophen-2-yl)tetrahydrofuro[2,3-d][1,3] 
dioxol-6-yl)oxy)dimethylsilane (7.4.17) 
 
 
 
  
 760 
13C NMR (CDCl3, 126 MHz) of tert-butyl(((3aR,5R,6R,6aR)-2,2-dimethyl-5-(5-
methylthiophen-2-yl)tetrahydrofuro[2,3-d][1,3] dioxol-6-yl)oxy)dimethylsilane (7.4.17) 
 
 
  
 761 
1H NMR (CDCl3, 360 MHz) of (8R,9S,13S,14S)-13-methyl-3-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-
6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (7.5.1) 
 
 
  
 762 
13C NMR (CDCl3, 91 MHz) of (8R,9S,13S,14S)-13-methyl-3-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-
6,7,8,9,11,12,13,14,15,16-decahydro-17H-cyclopenta[a]phenanthren-17-one (7.5.1) 
 
 
 
 
 
  
 763 
1H NMR (CDCl3, 360 MHz) of methyl 2-(2,3-dioxo-9-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis ([1,3] dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-2,3,6,7-tetrahydro-
1H,5H-pyrido[1,2,3-de]quinoxalin-5-yl) acetate (7.5.2) 
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 764 
13C NMR (CDCl3, 91 MHz) of methyl 2-(2,3-dioxo-9-((3aR,5R,5aS,8aS,8bR)-2,2,7,7-
tetramethyltetrahydro-5H-bis ([1,3] dioxolo)[4,5-b:4',5'-d]pyran-5-yl)-2,3,6,7-tetrahydro-
1H,5H-pyrido[1,2,3-de]quinoxalin-5-yl) acetate (7.5.2) 
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 765 
1H NMR (CDCl3, 500 MHz) of tert-butyl ((R,Z)-1,4-dimethyl-6-oxo-4-(4-
((3aR,5R,5aS,8aS,8bR) -2,2,7,7-tetramethyl tetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran-5-yl)thiophen-2-yl) tetrahydro pyrimidin-2(1H)-ylidene)carbamate (7.5.3) 
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 766 
13C NMR (CDCl3, 126 MHz) of tert-butyl ((R,Z)-1,4-dimethyl-6-oxo-4-(4-
((3aR,5R,5aS,8aS,8bR) -2,2,7,7-tetramethyl tetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran-5-yl)thiophen-2-yl) tetrahydro pyrimidin-2(1H)-ylidene)carbamate (7.5.3) 
 
 
 
  
3c
O
O
O
O
O
SNH
N
O
N
O
O
Me
 767 
1H NMR (CDCl3, 500 MHz) of ethyl 4-(3-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-8-chloro-5,6-dihydro-11H-
benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate (7.5.4) 
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 768 
13C NMR (CDCl3, 126 MHz) of ethyl 4-(3-((3aR,5S,6S,6aR)-6-(benzyloxy)-2,2-
dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)-8-chloro-5,6-dihydro-11H-
benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate (7.5.4e) (mixture of 
rotamers) 
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